Therapeutic Groups

| Alimentary Tract and Metabolism | . 3 |
|--|-----|
| Blood and Blood Forming Organs | 44 |
| Cardiovascular System | 75 |
| Dermatologicals | 106 |
| Genito-Urinary System | 112 |
| Hormone Preparations | 117 |
| nfections | 131 |
| Musculoskeletal System | |
| Nervous System | 233 |
| Oncology Agents and Immunosuppressants | 266 |
| Respiratory System and Allergies | 465 |
| Sensory Organs | 479 |
| /arious | |
| Special Foods | 487 |
| /accines | 511 |
| ndex of form numbers | 538 |
| ndex of titles | 541 |
| | |

Alimentary Tract and Metabolism

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|-------------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Calcium carbonate | |
| | |

Prerequisites (tick box where appropriate)

O Only when prescribed for patients unable to swallow calcium carbonate tablets or where calcium carbonate tablets are inappropriate.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Budesonide

| | | Crohn's disease (tick boxes where appropriate) |
|----|-------|---|
| an | O | Mild to moderate ileal, ileocaecal or proximal Crohn's disease |
| | | O Diabetes |
| | or | O Cushingoid habitus |
| | or | O Osteoporosis where there is significant risk of fracture |
| | or | O Severe acne following treatment with conventional corticosteroid therapy |
| | or | O History of severe psychiatric problems associated with corticosteroid treatment |
| | or | O History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high |
| | or | O Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated) |
| | | Collagenous and lymphocytic colitis (microscopic colitis) (tick box where appropriate) |
| Ο | Patie | ent has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies |
| | | Gut Graft versus Host disease (tick box where appropriate) |
| Ο | Patie | ent has gut Graft versus Host disease following allogenic bone marrow transplantation |

Page 6

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIB | ER | | | PATIENT: |
|-------|-----------------|----------|----------|---|---|
| Name: | | | | | Name: |
| Ward: | | | | | NHI: |
| Bude | son | ide | - con | tinued | |
| Re-as | sess | men | it requi | rrhotic autoimmune hepatitis red after 6 months oxes where appropriate) | |
| | (| С | Patier | nt has autoimmune hepatitis* | |
| | and (and | С | Patier | nt does not have cirrhosis | |
| | | | Ο | Diabetes | |
| | | or or | 0 | Cushingoid habitus | |
| | | or | Ο | Osteoporosis where there is significant risk of fracture | |
| | | | Ο | Severe acne following treatment with conventional cortic | osteroid therapy |
| | | or | Ο | History of severe psychiatric problems associated with c | orticosteroid treatment |
| | | or | | History of major mental illness (such as bipolar affective causing relapse is considered to be high | disorder) where the risk of conventional corticosteroid treatment |
| | | - | Ο | Relapse during pregnancy (where conventional corticost | eroids are considered to be contraindicated) |
| | | or | Ο | Adolescents with poor linear growth (where conventional | corticosteroid use may limit further growth) |
| Note: | India | catio | ns ma | rked with * are unapproved indications. | |
| Re-as | sess | men | t requi | on-cirrhotic autoimmune hepatitis red after 6 months | |
| Prere | ` | | | ox where appropriate) | |
| | ד ל | reatr | ment r | emains appropriate and the patient is benefitting from the | treatment |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CR | IBER | PATIENT: |
|-----------------|-----|---|----------|
| Name | : | | Name: |
| Ward: | | | NHI: |
| Rani | tid | ine | |
| INITI. Prere | | ON isites (tick boxes where appropriate) | |
| | ~ | O For continuation use | |
| | or | O Routine prevention of allergic reactions. | |
| \subseteq | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|----------|
| Name: | Name: |
| Ward: | NHI: |
| Omeprazole - Tab dispersible 10 mg and 20 mg | |
| INITIATION | |
| Prerequisites (tick box where appropriate) | |
| O Only for use in tube-fed patients | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|-------------------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| L-ornithine L-aspartate | |

INITIATION

Prerequisites (tick box where appropriate)

()For patients with chronic hepatic encephalopathy who have not responded to treatment with, or are intolerant to lactulose, or where lactulose is contraindicated

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|----------|
| Name: | Name: |
| Ward: | NHI: |
| Rifaximin | |
| | |
| Prerequisites (tick box where appropriate) | |

 $m O\,$ For patients with hepatic encephalopathy despite an adequate trial of maximum tolerated doses of lactulose

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|----------|
| Name: | Name: |
| Ward: | NHI: |
| Diazoxide | |
| INITIATION Prerequisites (tick box where appropriate) | |
| m O~ For patients with confirmed hypoglycaemia caused by hyperinsulinis | m |

Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|-------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Dulaglutide | |

| (or | J f | or c | ontinuation use |
|---------|-----|------|---|
| | and | С | Patient has type 2 diabetes |
| | and | С | Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of all of the following funded blood glucose lowering agents for a period of least 6 months, where clinically appropriate: empagliflozin, metformin, and vildagliptin |
| | unu | | O Patient is Māori or any Pacific ethnicity* |
| | | or | O Patient has pre-existing cardiovascular disease or risk equivalent (see note a)* |
| | | or | O Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator* |
| | | or | O Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult* |
| | | or | O Patient has diabetic kidney disease (see note b)* |

Note: * Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.

- a) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.
- Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three b) samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m2 in the presence of diabetes, without alternative cause identified.
- Funded GLP-1a treatment is not to be given in combination with (empagliflozin / empagliflozin with metformin hydrochloride) unless receiving C) (empagliflozin or empagliflozin in combination with metformin hydrochloride) for the treatment of heart failure.

Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|-------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Liraglutide | |

| or | 0 | For c | ontinuation use |
|----|-----|-------|---|
| • | and | 0 | Patient has type 2 diabetes |
| | and | 0 | Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of all of the following funded blood glucose lowering agents for a period of least 6 months, where clinically appropriate: empagliflozin, metformin, and vildagliptin |
| | | | O Patient is Māori or any Pacific ethnicity* |
| | | or | O Patient has pre-existing cardiovascular disease or risk equivalent (see note a)* |
| | | or | O Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator* |
| | | | O Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult* |
| | | or | O Patient has diabetic kidney disease (see note b)* |

- Note: * Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.
- a) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.
- Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three b) samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m2 in the presence of diabetes, without alternative cause identified.
- Funded GLP-1a treatment is not to be given in combination with (empagliflozin / empagliflozin with metformin hydrochloride) unless receiving C) (empagliflozin or empagliflozin in combination with metformin hydrochloride) for the treatment of heart failure.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Empagliflozin; Empagliflozin with metformin hydrochloride

| \bigcap | | | |
|-----------|---|---|-------|
| and | Patient has heart failure | | |
| | Patient is in NYHA functional class II or III or IV | | |
| and | | | |
| | O Patient has a documented left ventricular ejection fraction (LVEF) of less the | han or equal to 40% | |
| no | | | |
| | \odot An ECHO is not reasonably practicable, and in the opinion of the treating p | practitioner the patient would benefit from tre | atmen |

INITIATION – Type 2 Diabetes

Prerequisites (tick boxes where appropriate)

| | or | O f | or continuation use |
|----|----------|------------|--|
| | or | Ор | atient has previously had an initial approval for a GLP-1 agonist |
| | | and (| O Patient has type 2 diabetes |
| | | unu | O Patient is Māori or any Pacific ethnicity* |
| | | | or O Patient has pre-existing cardiovascular disease or risk equivalent (see note a)* |
| | | | or O Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator* |
| | | | O Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult* |
| | | | O Patient has diabetic kidney disease (see note b)* |
| | | and (| Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of at least one blood-glucose lowering agent (e.g. metformin, vildagliptin, or insulin) for at least 3 months |
| No | te: * Cr | riteria ir | ntended to describe patients at high risk of cardiovascular or renal complications of diabetes. |
| a) | corona | ry inter | ardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous vention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart lial hypercholesterolaemia. |
| b) | | | ey disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m2 in the presence of diabetes, without alternative cause. |
| c) | | | agliflozin / empagliflozin with metformin hydrochloride] treatment is not to be given in combination with a funded GLP-1 unless receiving / empagliflozin with metformin hydrochloride] for the treatment of heart failure. |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|--|---|--|
| Name: | Name: | |
| Vard: NHI: | | |
| Ursodeoxycholic acid | | |
| INITIATION – Alagille syndrome or progressive familial intrahepatic chol Prerequisites (tick boxes where appropriate) | estasis | |
| O Patient has been diagnosed with Alagille syndrome or O Patient has progressive familial intrahepatic cholestasis | | |
| INITIATION – Chronic severe drug induced cholestatic liver injury Prerequisites (tick boxes where appropriate) | | |
| O Patient has chronic severe drug induced cholestatic liver injury and O Cholestatic liver injury not due to Total Parenteral Nutrition (TF and O Treatment with ursodeoxycholic acid may prevent hospital adm | PN) use in adults | |
| INITIATION – Primary biliary cholangitis Prerequisites (tick boxes where appropriate) O Primary biliary cholangitis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative by liver biopsy and O Patient not requiring a liver transplant (bilirubin > 100 umol/l; decompensated cirrhosis | | |
| INITIATION – Pregnancy Prerequisites (tick box where appropriate) O Patient diagnosed with cholestasis of pregnancy | | |
| INITIATION – Haematological transplant Prerequisites (tick boxes where appropriate) | | |
| O Patient at risk of veno-occlusive disease or has hepatic impair cell or bone marrow transplantation and O Treatment for up to 13 weeks | ment and is undergoing conditioning treatment prior to allogenic stem | |
| INITIATION – Total parenteral nutrition induced cholestasis Prerequisites (tick boxes where appropriate) | | |
| Paediatric patient has developed abnormal liver function as inc and D Liver function has not improved with modifying the TPN compo | | |
| INITIATION – prevention of sinusoidal obstruction syndrome Prerequisites (tick box where appropriate) O The individual has leukaemia/lymphoma and requires prophylaxis for syndrome | r medications/therapies with a high risk of sinusoidal obstruction | |

| Signed: Date: | |
|---------------|--|
|---------------|--|

Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|----------|
| Name: | Name: |
| Ward: | NHI: |
| Methylnaltrexone bromide | |
| NITIATION – Opioid induced constipation | |
| Prerequisites (tick boxes where appropriate) | |

()The patient is receiving palliative care and Oral and rectal treatments for opioid induced constipation are ineffective \bigcirc or \bigcirc Oral and rectal treatments for opioid induced constipation are unable to be tolerated

INITIATION – Opioid induced constipation outside of palliative care

Re-assessment required after 14 days

Prerequisites (tick boxes where appropriate)

 \bigcirc and and

Individual has opioid induced constipation

Oral and rectal treatments for opioid induced constipation, including bowel-cleansing preparations, are ineffective or inappropriate

Mechanical bowel obstruction has been excluded

I confirm that the above details are correct:

Signed: Date:

 \bigcirc

and ()

HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|----------|
| Name: | Name: |
| Ward: | NHI: |
| sodium picosulfate | |
| INITIATION Prerequisites (tick boxes where appropriate) | |

The patient is a child with problematic constipation despite an adequate trial of other oral pharmacotherapies including macrogol where practicable

The patient would otherwise require a high-volume bowel cleansing preparation

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESC | RIBER | PATIENT: | |
|-------|-------|----------|--|
| Name: | | Name: | |
| Ward: | | NHI: | |

Betaine

()

| Re-a | | mer | ent required after 12 months s (tick boxes where appropriate) |
|------|-------|-----|--|
| and | | | scribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Health Hospital. |
| | and | 0 | The patient has a confirmed diagnosis of homocystinuria |
| | | or | O A cystathionine beta-synthase (CBS) deficiency |
| | | or | A 5,10-methylene-tetrahydrofolate reductase (MTHFR) deficiency |
| | and | | O A disorder of intracellular cobalamin metabolism |
| | | 0 | An appropriate homocysteine level has not been achieved despite a sufficient trial of appropriate vitamin supplementation |
| | ITINU | | ON |

Re-assessment required after 12 months **Prerequisites** (tick box where appropriate)

O Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

The treatment remains appropriate and the patient is benefiting from treatment

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Levocarnitine | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a neurologist, metabolic physician or metabolic disorders dietitian, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|---|
| Name: | Name: |
| Ward: | NHI: |
| Sodium phenylbutyrate | |
| INITIATION Re-assessment required after 12 months Prerequisites (tick box where appropriate) | |
| | ordance with a protocol or guideline that has been endorsed by the Health |

For the chronic management of a urea cycle disorder involving a deficiency of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase

CONTINUATION

()

and \bigcirc

and

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

The treatment remains appropriate and the patient is benefiting from treatment

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Biotin | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a metabolic physician or metabolic disorders dietitian, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|-----------------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Pyridoxal-5-phosphate | | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a neurologist, metabolic physician or metabolic disorders dietitian, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Galsulfase

| Re-a | | nt required after 12 months |
|------------|--------|---|
| Prero (| \sim | (tick boxes where appropriate) cribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Health |
| and | | lospital. |
| | and | The patient has been diagnosed with mucopolysaccharidosis VI |
| | 01 | O Diagnosis confirmed by demonstration of N-acetyl-galactosamine-4-sulfatase (arylsulfatase B) deficiency confirmed by either enzyme activity assay in leukocytes or skin fibroblasts |
| | | O Detection of two disease causing mutations and patient has a sibling who is known to have mucopolysaccharidosis VI |
| Re-a | | DN ht required after 12 months (tick boxes where appropriate) |
| (and | | cribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Health lospital. |
| | and | The treatment remains appropriate for the patient and the patient is benefiting from treatment |
| | | Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates |
| | and | Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by Enzyme Replacement Therapy (ERT) |

O Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT

Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Alglucosidase Alfa

INITIATION Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and () The patient is aged up to 24 months at the time of initial application and has been diagnosed with infantile Pompe disease and () Diagnosis confirmed by documented deficiency of acid alpha-glucosidase by prenatal diagnosis using chorionic villus biopsies and/or cultured amniotic cells or Documented deficiency of acid alpha-glucosidase, and urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides or Documented deficiency of acid alpha-glucosidase, and documented molecular genetic testing indicating a disease-causing mutation in the acid alpha-glucosidase gene (GAA gene) or Documented urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides, and molecular genetic testing indicating a disease-causing mutation in the GAA gene and) Patient has not required long-term invasive ventilation for respiratory failure prior to starting enzyme replacement therapy (ERT) and ()Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by ERT or might be reasonably expected to compromise a response to ERT and Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks

| | ITINUA ssessn | TION nent required after 12 months |
|----------|------------------|---|
| Prer | equisit | es (tick boxes where appropriate) |
| (and | | escribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Health Z Hospital. |
| | |) The treatment remains appropriate for the patient and the patient is benefiting from treatment |
| | and and | Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates |
| | and (and | D Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by ERT |
| | and | Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT |
| | (and | There is no evidence of life threatening progression of respiratory disease as evidenced by the needed for > 14 days of invasive ventilation |
| | | D There is no evidence of new or progressive cardiomyopathy |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Idursulfase

| Re-a | | men | t required after 24 weeks (tick boxes where appropriate) |
|---|---------------|-----|---|
| Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and | | | |
| | (and | 0 | The patient has been diagnosed with Hunter Syndrome (mucopolysacchardosis II) |
| | unu | or | Diagnosis confirmed by demonstration of iduronate 2-sulfatase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts Detection of a disease causing mutation in the iduronate 2-sulfatase gene |
| | and (| 0 | Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with idursulfase would be bridging treatment to transplant |
| an | (and (| 0 | Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT) Idursulfase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 weeks post-HSCT) at doses no greater than 0.5 mg/kg every week |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Laronidase

| INITIAT | | | |
|----------|---------------|-----|--|
| Re-asse | essn | nen | t required after 24 weeks |
| Prerequ | uisit | tes | (tick boxes where appropriate) |
| O and | | | ribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Health ospital. |
| a | (nd | C | The patient has been diagnosed with Hurler Syndrome (mucopolysacchardosis I-H) |
| | | or | O Diagnosis confirmed by demonstration of alpha-L-iduronidase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts |
| | | | O Detection of two disease causing mutations in the alpha-L-iduronidase gene and patient has a sibling who is known to have Hurler syndrome |
| a | nd | | |
| |) | C | Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with laronidase would be bridging treatment to transplant |
| | nd (nd | C | Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT) |
| | (| C | Laronidase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 post-HSCT) at doses no greater than 100 units/kg every week |
| | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Taliglucerase alfa

| | ΙΑΤΙΟ | | | |
|--|--------|---|---|--|
| Re-assessment required after 12 months | | | | |
| Prer | equi | sites | (tick boxes where appropriate) | |
| and | | Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | |
| | anc | 0 | The patient has a diagnosis of symptomatic type 1 or type 3* Gaucher disease confirmed by the demonstration of specific deficiency of glucocerebrosidase in leukocytes or cultured skin fibroblasts, and genotypic analysis | |
| ar | | 0 I | Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by enzyme replacement therapy (ERT) or the disease might be reasonably expected to compromise a response to ERT | |
| | | or | O Patient has haematological complications of Gaucher disease | |
| | | or | O Patient has skeletal complications of Gaucher disease | |
| | | or | m O Patient has significant liver dysfunction or hepatomegaly attributable to Gaucher disease | |
| | | or | O Patient has reduced vital capacity from clinically significant or progressive pulmonary disease due to Gaucher disease | |
| | | | O Patient is a child and has experienced growth failure with significant decrease in percentile linear growth over a 6-12 month period | |
| | anc | 0 | Taliglucerase alfa is to be administered at a dose no greater than 30 unit/kg every other week rounded to the nearest whole vial (200 units) | |
| Note | e: Ind | icatio | n marked with * is an unapproved indication | |
| CONTINUATION Re-assessment required after 3 years Prerequisites (tick boxes where appropriate) | | | | |
| and | | | ribed by, or recommended by a metabolic physician or any relevant practitioner on the recommendation of a metabolic physician, or in dance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | |
| | | 0 | Patient has demonstrated a symptomatic improvement and has maintained improvements in the main symptom or symptoms for which therapy was started | |
| | anc | 0 | Patient has demonstrated a clinically objective improvement or no deterioration in haemoglobin levels, platelet counts and liver and spleen size | |
| | anc | Ο | RRadiological (MRI) signs of bone activity performed at two years since initiation of treatment, and five yearly thereafter, demonstrate no deterioration shown by the MRI, compared with MRI taken immediately prior to commencement of therapy or adjusted dose | |
| | anc | Ο | Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT | |
| | ant | 0 | Patient is adherent with regular treatment and taliglucerase alfa is to be administered at a dose no greater than 30 unit/kg every other week rounded to the nearest whole vial (200 units) | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Sapropterin dihydrochloride

| INITIATION | | | | |
|---|--|---|--|--|
| Re-assessment required after 1 month Prerequisites (tick boxes where appropriate) | | | | |
| | - - | | | |
| (and | | escribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Health Hospital. | | |
| O Patient has phenylketonuria (PKU) and is pregnant or actively planning to become pregnant | | | | |
| and Treatment with sapropterin is required to support management of PKU during pregnancy and Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg and | | | | |
| | | | | Sapropterin to be used alone or in combination with PKU dietary management Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery |
| | | | | |
| | | | | |
| Re-a | CONTINUATION Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | |
| | and | Following the initial one-month approval, the patient has demonstrated an adequate response to a 2 to 4 week trial of sapropterin with a clinically appropriate reduction in phenylalanine levels to support management of PKU during pregnancy On subsequent renewal applications, the patient has previously demonstrated response to treatment with sapropterin and maintained adequate phenylalanine levels to support management of PKU during pregnancy Patient continues to be pregnant and treatment with sapropterin will not continue after delivery Patient is actively planning a pregnancy and this is the first renewal for treatment with sapropterin | | |
| | | O Treatment with sapropterin is required for a second or subsequent pregnancy to support management of their PKU during pregnancy | | |
| and O Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg and O Sapropterin to be used alone or in combination with PKU dietary management and | | | | |
| O Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and become pregnant) and treatment will be stopped after delivery | | | | |
| | | | | |

and

HOSPITAL MEDICINES LIST **RESTRICTIONS CHECKLIST**

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|---|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |
| Carglumic Acid | | | |
| INITIATION Prerequisites (tick box where appropriate) | | | |

()Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

O For the acute in-patient treatment of organic acidaemias as an alternative to haemofiltration

Page 30

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|--|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |
| Coenzyme Q10 | | | |
| INITIATION Re-assessment required after 6 months Prerequisites (tick box where appropriate) O Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and O The patient has a suspected inborn error of metabolism that may respond to coenzyme Q10 supplementation | | | |
| CONTINUATION Re-assessment required after 24 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and O The patient has a confirmed diagnosis of an inborn error of metabolism that responds to coenzyme Q10 supplementation O The treatment remains appropriate and the patient is benefiting from treatment | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|---|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |
| Riboflavin | | | |
| INITIATION Re-assessment required after 6 months Prerequisites (tick box where appropriate) O Prescribed by, or recommended by a metabolic physician or neurologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and O The patient has a suspected inborn error of metabolism that may respond to riboflavin supplementation | | | |
| CONTINUATION Re-assessment required after 24 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a metabolic physician or neurologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and O The patient has a confirmed diagnosis of an inborn error of metabolism that responds to riboflavin supplementation O The treatment remains appropriate and the patient is benefiting from treatment | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|---|--|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Taurine | | |
| INITIATION Re-assessment required after 6 months Prerequisites (tick box where appropriate) O Prescribed by, or recommended by a metabolic physician, or in acconnected by a metabolic physician. and O The patient has a suspected specific mitochondrial disorder that may | rdance with a protocol or guideline that has been endorsed by the Health y respond to taurine supplementation | |
| CONTINUATION Re-assessment required after 24 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and O The patient has a confirmed diagnosis of a specific mitochondrial disorder which responds to taurine supplementation O The treatment remains appropriate and the patient is benefiting from treatment | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | | PATIENT: |
|---|---|----------|
| Name: | | Name: |
| Ward: | | NHI: |
| Trientine | | |
| INITIATION Prerequisites (tick boxes where appropriate) O Patient has confirmed Wilson disease and O Treatment with D-penicillamine has been trialled and discontinued because the person has experienced intolerable side effects or has not received sufficient benefit and Treatment with zinc has been trialled and discontinued because the person has experienced intolerable side effects or has not received sufficient benefit, or zinc is considered clinically inappropriate as the person has symptomatic liver disease and requires copper chelation | | |
| | received sufficient benefit, or zinc is considered clinically inapp | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | SCRIBER | PATIENT: | |
|--|---|----------|--|
| Name | 5: | Name: | |
| Ward | : | NHI: | |
| Сор | per chloride | | |
| Re-a | ATION – Moderate to severe burns ssessment required after 3 months | | |
| Prerequisites (tick boxes where appropriate) | | | |
| | O Patient has been hospitalised with moderate to severe burns | | |
| | O Treatment is recommended by a National Burns Unit specialis | t | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|--|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |
| Ferric carboxymaltose | | | |
| INITIATION Prerequisites (tick box where appropriate) | | | |
| O Treatment with oral iron has proven ineffective or is clinically inappro | ppriate | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | SCRIBER | PATIENT: |
|--|---|----------|
| Name | e: | Name: |
| Ward | k | NHI: |
| Sele | nium | |
| | IATION – Moderate to severe burns assessment required after 3 months | |
| Prerequisites (tick boxes where appropriate) | | |
| | O Patient has been hospitalised with moderate to severe burns | |
| | O Treatment is recommended by a National Burns Unit specialis | t |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|--------------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |
| Sodium hyaluronate | | | |

INITIATION

Prerequisites (tick box where appropriate)

()Prescribed by, or recommended by an otolaryngologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

| I confirm that the | above details | are correct: |
|--------------------|---------------|--------------|
|--------------------|---------------|--------------|

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRI | BER | | PATIENT: |
|-----------------|------|------|--|----------|
| Name | : | | | Name: |
| Ward: | | | | NHI: |
| Multi | vita | amir | is - Cap | |
| INITI. Prere | | | (tick boxes where appropriate) | |
| | | 0 | Patient has cystic fibrosis with pancreatic insufficiency | |
| | or | Ο | Patient is an infant or child with liver disease or short gut synd | rome |
| | or | 0 | Patient has severe malabsorption syndrome | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|----------|
| Name: | Name: |
| Ward: | NHI: |
| Multivitamins – Powder | |
| INITIATION Prerequisites (tick box where appropriate) | |
| O Patient has inborn errors of metabolism | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESC | RIB | ER | | | PATIENT: |
|---------|-------|---------------|-------------|--|-------------------|
| Name: | | | | | Name: |
| Ward: . | | | | | NHI: |
| Multiv | itar | nin | and | mineral supplement | |
| Prereq | sessr | ment tes (| tick b | ired after 3 months boxes where appropriate) nt was admitted to hospital with burns | |
| a | | or or | 0 0 0 | Burn size is greater than 15% of total body surface area Burn size is greater than 10% of BSA for mid-dermal or o Nutritional status prior to admission or dietary intake is p | deep dermal burns |

or

HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|----------|
| Name: | Name: |
| Ward: | NHI: |
| Multivitamin renal | |
| INITIATION Prerequisites (tick boxes where appropriate) | |

 \bigcirc The patient has chronic kidney disease and is receiving either peritoneal dialysis or haemodialysis

The patient has chronic kidney disease grade 5, defined as patient with an estimated glomerular filtration rate of < 15 ml/min/1.73m² body surface area (BSA)

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | SCRIE | BER | PATIENT: | |
|------|-------|------|--|---------|
| Name | e: | | Name: | |
| Ward | : | | NHI: | |
| Alph | a to | сор | heryl acetate | |
| | | | Cystic fibrosis (tick boxes where appropriate) | |
| | and | 0 | Cystic fibrosis patient | |
| | | or | Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate the patient | ate for |
| | equis | ites | Osteoradionecrosis (tick box where appropriate) e treatment of osteoradionecrosis | |
| | | | Other indications (tick boxes where appropriate) | |
| | and | 0 | Infant or child with liver disease or short gut syndrome | |
| | and | 0 | Requires vitamin supplementation | |
| | | | O Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck) | |
| | | or | O The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriation | ate for |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |

Alpha tocopheryl

| | | Cystic fibrosis (tick boxes where appropriate) |
|----------|------|--|
| (and | С | Cystic fibrosis patient |
| | or | O Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) |
| | | O The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient |
| equis | ites | Disteoradionecrosis (tick box where appropriate) e treatment of osteoradionecrosis |
| | | Other indications (tick boxes where appropriate) |
| (and | С | Infant or child with liver disease or short gut syndrome |
| and (| С | Requires vitamin supplementation |
| | or | O Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck) |
| | | O The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient |

Blood and Blood Forming Organs

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |

Epoetin beta

| and |) Patie | ent in chronic renal failure |
|-----|---------|--|
| and |) Haer | moglobin is less than or equal to 100g/L |
| anu | | |
| | an | O Patient does not have diabetes mellitus |
| | | O Glomerular filtration rate is less than or equal to 30ml/min |
| | or | |
| | | O Patient has diabetes mellitus |
| | an | O Glomerular filtration rate is less than or equal to 45ml/min |

INITIATION – myelodysplasia*

| Re-assessment | t required | after 1 | 12 months | ; |
|---------------|------------|---------|-----------|---|
| | | | | |

Prerequisites (tick boxes where appropriate)

| and | Patient has a confirmed diagnosis of myelodysplasia (MDS) |
|-----------------|--|
| and | Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent |
| | Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS) |
| and O | Other causes of anaemia such as B12 and folate deficiency have been excluded |
| and O and | Patient has a serum epoetin level of < 500 IU/L |
| 0 | The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week |

CONTINUATION – myelodysplasia*

Re-assessment required after 2 months
Prerequisites (tick boxes where appropriate)
O
The patient's transfusion requirement continues to be reduced with epoetin treatment
and
O
Transformation to acute myeloid leukaemia has not occurred
and
O
The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|--------------------|
| Name: | Name: |
| Ward: | NHI: |
| Epoetin beta - continued | |
| INITIATION – all other indications Prerequisites (tick boxes where appropriate) | |
| Haematologist | |
| O For use in patients where blood transfusion is not a viable trea | atment alternative |
| and *Note: Indications marked with * are unapproved indications | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |

Epoetin alfa

| C | Patient in | chronic renal failure | |
|-----------------|------------|---|--|
| and C and | Haemoglo | obin is less than or equal to 100g/L | |
| | and | Patient does not have diabetes mellitus Glomerular filtration rate is less than or equal to 30ml/min | |
| c | or and | Patient has diabetes mellitus Glomerular filtration rate is less than or equal to 45ml/min | |

INITIATION – myelodysplasia*

and

and

and

and

and

and

Re-assessment required after 2 months

Prerequisites (tick boxes where appropriate)

| | \sim | | |
|---|--------|---|-----|
| (| \cup | Patient has a confirmed diagnosis of myelodysplasia (| MDS |

Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent

O Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS)

 $\odot~$ Other causes of anaemia such as B12 and folate deficiency have been excluded

 ${\sf O}\,$ Patient has a serum epoetin level of < 500 IU/L

The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week

CONTINUATION – myelodysplasia*

Re-assessment required after 12 months
Prerequisites (tick boxes where appropriate)

O The patient's transfusion requirement continues to be reduced with epoetin treatment and

O Transformation to acute myeloid leukaemia has not occurred

The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | | |
|---|-------------|--|--|--|
| Name: | Name: | | | |
| Ward: | NHI: | | | |
| Epoetin alfa - continued | | | | |
| INITIATION – all other indications | | | | |
| Prerequisites (tick box where appropriate) | | | | |
| O Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | | |
| O For use in patients where blood transfusion is not a viable treatment | alternative | | | |
| Note: Indications marked with * are unapproved indications | | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | | | | PATIENT: |
|--------------------|------|-------|--|---|
| Name | e: | | | Name: |
| Ward | : | | | NHI: |
| Apro | otin | in | | |
| INITI Prer (| | Preso | (tick boxes where appropriate) cribed by, or recommended by a cardiac anaesthetist, or in according on the second second second second second | ordance with a protocol or guideline that has been endorsed by the Health |
| and | | 0 | Paediatric patient undergoing cardiopulmonary bypass procec | lure |
| | or | 0 | Adult patient undergoing cardiac surgical procedure where the effects of the drug | e significant risk of massive bleeding outweighs the potential adverse |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | | | | | PATIENT: | |
|--|---|----|-------------|--|---|--|
| Name: | | | | | Name: | |
| Ward: | | | | | NHI: | |
| Eltro | Eltrombopag | | | | | |
| Re-a | Hospital. | | | uired after 6 weeks boxes where appropriate) | ce with a protocol or guideline that has been endorsed by the Health NZ | |
| | anc | Ο | | ent has had a splenectomy immunosuppressive therapies have been trialled and fail | ed after therapy of 3 months each (or 1 month for rituximab) | |
| | | or | 0 0 0 | | s per microlitre and has evidence of significant mucocutaneous bleeding 000 platelets per microlitre and has evidence of active bleeding 000 platelets per microlitre | |
| Re-a | INITIATION – idiopathic thrombocytopenic purpura - preparation for splenectomy Re-assessment required after 6 weeks Prerequisites (tick box where appropriate) O Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and O The patient requires eltrombopag treatment as preparation for splenectomy | | | | | |
| Re-a Prero (and | CONTINUATION – idiopathic thrombocytopenic purpura - post-splenectomy Re-assessment required after 12 months Prerequisites (tick box where appropriate) O Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and O The patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required Note: Response to treatment is defined as a platelet count of > 30,000 platelets per microlitre | | | | | |
| INITIATION - idiopathic thrombocytopenic purpura contraindicated to splenectomy Re-assessment required after 3 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and | | | | | | |
| | anc | Ο | | Patient has immune thrombocytopenic purpura* with a | n to splenectomy for clinical reasons ed after therapy of 3 months each (or 1 month for rituximab) platelet count of less than or equal to 20,000 platelets per microliter platelet count of 20,000 to 30,000 platelets per microlitre and significant | |

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | | | | |
|--|---|--|--|--|--|--|
| Name: | Name: | | | | | |
| Ward: | NHI: | | | | | |
| Eltrombopag - continued | | | | | | |
| CONTINUATION – idiopathic thrombocytopenic purpura contraindicated Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) | e with a protocol or guideline that has been endorsed by the Health NZ ins e initial approval period elets per microlitre on treatment | | | | | |
| Hospital. and Two immunosuppressive therapies have been trialled and faile and O Patient has severe aplastic anaemia with a platelet count or | | | | | | |
| and Hospital. | ee with a protocol or guideline that has been endorsed by the Health NZ t 20,000 platelets per microlitre above baseline during the initial approval during the initial approval period | | | | | |
| Platelet transfusion independence for a minimum of 8 weeks c | luring the initial approval period | | | | | |

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|----------|
| Name: | Name: |
| Ward: | NHI: |
| Aluminium chloride | |
| INITIATION Prerequisites (tick box where appropriate) | |
| O For use as a haemostatis agent | |

and ()

HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Emicizumab | |

INITIATION - Severe Haemophilia A with or without FVIII inhibitors

Prerequisites (tick boxes where appropriate)

()Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and

Patient has severe congenital haemophilia A with a severe bleeding phenotype (endogenous factor VIII activity less than or equal to 2%)

Emicizumab is to be administered at a dose of no greater than 3 mg/kg weekly for 4 weeks followed by the equivalent of 1.5 mg/kg weekly

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | | |
|--------------|----------|--|--|--|
| Name: | Name: | | | |
| Ward: | NHI: | | | |
| Idarucizumab | | | | |
| | | | | |

INITIATION

Prerequisites (tick box where appropriate)

()For the reversal of the anticoagulant effects of dabigatran when required in situations of life-threatening or uncontrolled bleeding, or for emergency surgery or urgent procedures

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|---|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Moroctocog alfa [Recombinant factor VIII] | | |

INITIATION

Prerequisites (tick box where appropriate)

For patients with haemophilia. Rare Clinical Circumstances Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group, subject to criteria ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|---|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Octocog alfa [Recombinant factor VIII] (Advate) | | |

INITIATION

Prerequisites (tick box where appropriate)

()For patients with haemophilia. Preferred Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|----------|
| Name: | Name: |
| Ward: | NHI: |
| Octocog alfa [Recombinant factor VIII] (Kogenate FS) | |

INITIATION

Prerequisites (tick box where appropriate)

For patients with haemophilia. Rare Clinical Circumstances Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group, subject to criteria ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|---------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Nonacog gamma | | |

INITIATION

Prerequisites (tick box where appropriate)

()For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|--|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Rurioctocog alfa pegol [Recombinant factor VIII] | | |
| | | |

INITIATION

Prerequisites (tick box where appropriate)

For patients with haemophilia A receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|-------------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Eftrenonacog alfa | | |

INITIATION

Prerequisites (tick box where appropriate)

For patients with haemophilia B receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|---|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Factor eight inhibitor bypassing fraction | | |

INITIATION

Prerequisites (tick box where appropriate)

For patients with haemophilia. Preferred Brand of bypassing agent for > 14 days predicted use. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group ()

Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|--------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Eptacog alfa | | |

INITIATION

Prerequisites (tick box where appropriate)

()For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group. Rare Clinical Circumstances Brand of bypassing agent for > 14 days predicted use. Access to funded treatment for > 14 days predicted use is by named patient application to the Haemophilia Treaters Group, subject to access criteria

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CR | IBER | PATIENT: |
|--|--|---|----------|
| Name | : | | Name: |
| Ward: | | | NHI: |
| Bival | iru | ıdin | |
| INITI Prere | | ON isites (tick boxes where appropriate) | |
| | O For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance or | | |
| O For use in patients undergoing endovascular procedures | | | |
| \subseteq | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|----------|
| Name: | Name: |
| Ward: | NHI: |
| Danaparoid | |
| INITIATION Prerequisites (tick box where appropriate) | |

O For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCR | IBER | PATIENT: |
|---|---|----------|
| Name: | | Name: |
| Ward: | | NHI: |
| Defibrotide | | |
| INITIATION Prerequisites (tick box where appropriate) | | |
| 0 | Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | |
| and | Patient has moderate or severe sinusoidal obstruction syndrome as a result of chemotherapy or regimen-related toxicities | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|--|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Fondaparinux sodium | | |
| INITIATION Prerequisites (tick box where appropriate) | | |

O For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance

and ()

HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|--|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Lysine acetylsalicylate | | |
| | | |
| Prerequisites (tick boxes where appropriate) | | |

 \bigcirc For use when an immediate antiplatelet effect is required prior to an urgent interventional neuro-radiology or interventional cardiology procedure

Administration of oral aspirin would delay the procedure

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | ł | PATIENT: |
|--|---|----------|
| Name: | | Name: |
| Ward: | | NHI: |
| Eptifibatide | | |
| INITIATION Prerequisites (tick boxes where appropriate) O For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention or O For use in patients with definite or strongly suspected intra-coronary thrombus on coronary angiography or O For use in patients with definite or strongly suspected intra-coronary thrombus on coronary angiography or O For use in patients undergoing intra-cranial intervention | | |

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRI | BER | PATIENT: | |
|--------------|-------------------------------------|---|--|
| Name: | | Name: | |
| Ward: | | NHI: | |
| Ticagre | lor | | |
| 0 | i sites (Restri an ST | ick box where appropriate) eted to treatment of acute coronary syndromes specifically for patients who have recently (within the last 60 days) been diagnosed wit elevation or a non-ST-elevation acute coronary syndrome, and in whom fibrinolytic therapy has not been given in the last 24 hours an olanned | |
| Re-asses | ssment | rombosis prevention neurological stenting required after 12 months ick boxes where appropriate) | |
| | or | Patient has had a neurological stenting procedure* in the last 60 days Patient is about to have a neurological stenting procedure performed* | |
| and | d or | O Patient has demonstrated clopidogrel resistance using the P2Y12 (VerifyNow) assay or another appropriate platelet function assay and requires antiplatelet treatment with ticagrelor | |
| | | O Clopidogrel resistance has been demonstrated by the occurrence of a new cerebral ischemic event O Clopidogrel resistance has been demonstrated by the occurrence of transient ischemic attack symptoms referable to the stent. | |
| Re-asses | isites | A – thrombosis prevention neurological stenting required after 12 months ick boxes where appropriate) Patient is continuing to benefit from treatment | |
| and | - | Treatment continues to be clinically appropriate | |
| Re-asses | ssment | ercutaneous coronary intervention with stent deployment required after 12 months ick boxes where appropriate) | |
| and | d | Patient has undergone percutaneous coronary intervention | |
| and | | Patient has had a stent deployed in the previous 4 weeks Patient is clopidogrel-allergic** | |
| | | ent thrombosis ick box where appropriate) | |
| 0 | Patier | has experienced cardiac stent thrombosis whilst on clopidogrel | |
| Re-asses | ssment | yocardial infarction required after 1 week ick box where appropriate) | |
| 0 | For sh | ort term use while in hospital following ST-elevated myocardial infarction | |
| I confirm th | hat the | above details are correct: | |

| Signed: | Date: |
|---------|-----------|

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| | | |

Ticagrelor - continued

Note: Indications marked with * are unapproved indications. Note: Note: ** Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBI | ER | PATIENT: |
|---------------------------|---|--|
| Name: | | Name: |
| Ward: | | NHI: |
| Plerixafor | r | |
| Re-assessr Prerequisit | I – Autol ment req tes (tick rescriber ospital. D Pati Pati | logous stem cell transplant uired after 3 days boxes where appropriate) d by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ ent is to undergo stem cell transplantation ent has not had a previous unsuccessful mobilisation attempt with plerixafor O Patient is undergoing G-CSF mobilisation O Has a suboptimal peripheral blood CD34 count of less than or equal to 10 × 10 ⁶ /L on day 5 after 4 days of G-CSF or O Efforts to collect > 1 × 10 ⁶ CD34 cells/kg have failed after one apheresis procedure O Patient is undergoing chemotherapy and G-CSF mobilisation Ind O Has rising white blood cell counts of > 5 × 10 ⁹ /L |
| | | O Has a suboptimal peripheral blood CD34 count of less than or equal to 10 × 10 ⁶ /L or O Efforts to collect > 1 × 10 ⁶ CD34 cells/kg have failed after one apheresis procedure or O The peripheral blood CD34 cell counts are decreasing before the target has been received |
| | or O | A previous mobilisation attempt with G-CSF or G-CSF plus chemotherapy has failed |

Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|---------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Pegfilgrastim | | |

INITIATION

Prerequisites (tick box where appropriate)

O For prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than or equal to 5%*) Note: *Febrile neutropenia risk greater than or equal to 5% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Filgrastim | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a haematologist or oncologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | | |
|---|----------|--|--|--|
| Name: | Name: | | | |
| Ward: | NHI: | | | |
| Sodium chloride – Inj | | | | |
| INITIATION Prerequisites (tick box where appropriate) | | | | |
| O For use in flushing of in-situ vascular access devices only | | | | |

Cardiovascular System

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | SCRI | BER | | PATIENT: |
|--------------------------------|------|--------|--|-----------------|
| Name | e: | | | Name: |
| Ward: | : | | | NHI: |
| Capt | opr | il - C | Dral liq 5 mg per ml | |
| INITI Prero | | | (tick boxes where appropriate) | |
| | | Ο | For use in children under 12 years of age | |
| O For use in tube-fed patients | | | For use in tube-fed patients | |
| | or | 0 | For management of rebound transient hypertension following | cardiac surgery |

and

and \bigcirc

HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | SCRIB | ER | | PATIENT: |
|------|---|-------|---|----------|
| Name | ə: | | | Name: |
| Ward | : | | | NHI: |
| Sacı | ubitri | il wi | ith valsartan | |
| | IATIOI equis | | (tick boxes where appropriate) | |
| | and | О | Patient has heart failure | |
| | | or | O Patient is in NYHA/WHO functional class II | |
| | O Patient is in NYHA/WHO functional class III | | O Patient is in NYHA/WHO functional class III | |
| | | or | O Patient is in NYHA/WHO functional class IV | |

| | Ο | Patient has a documented left ventricular ejection fraction (LV | VEF) of les | ss than or equa | al to 35% | |
|----|---|---|-------------|-----------------|-----------|--|
| or | _ | | | | | |

O An ECHO is not reasonably practical, and in the opinion of the treating practitioner the patient would benefit from treatment

Patient is receiving concomitant optimal standard chronic heart failure treatments

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|----------|
| Name: | Name: |
| Ward: | NHI: |
| Adenosine - Inj 3 mg per ml, 10 ml vial | |
| INITIATION Prerequisites (tick box where appropriate) | |
| O For use in cardiac catheterisation, electrophysiology and MRI | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |
| Ajmaline | | | |
| | | | |

Prerequisites (tick box where appropriate)

()Prescribed by, or recommended by a cardiologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIB | ER | | PATIENT: |
|----------------|---|----|--|---|
| Name | : | | | Name: |
| Ward: | | | | NHI: |
| lvabı | adir | ne | | |
| INITI Prere | | | (tick boxes where appropriate) | |
| | (and | С | Patient is indicated for computed tomography coronary angiog | raphy |
| | O Patient has a heart rate of greater than 70 beats per minute while taking a maximally tolerated dose of beta blocker O Patient is unable to tolerate beta blockers | | | ute while taking a maximally tolerated dose of beta blocker |
| | | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|----------|
| Name: | Name: |
| Ward: | NHI: |
| Midodrine | |
| INITIATION Prerequisites (tick box where appropriate) | |
| O Patient has disabling orthostatic hypotension not due to drugs | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---------------------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Nicardipine hydrochloride | |
| | |

| Prer | | | where appropriate) |
|----------|----|----------------|---|
| (and | С | | r recommended by an anaesthetist, intensivist, cardiologist or paediatric cardiologist, or in accordance with a protocol or is been endorsed by the Health NZ Hospital. |
| | | O Patient has | s hypertension requiring urgent treatment with an intravenous agent |
| | or | O Patient has | s excessive ventricular afterload |
| | or | O Patient is a | awaiting or undergoing cardiac surgery using cardiopulmonary bypass |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIB | ER | | | PATIENT: |
|--|-----------------|----|---------|--|---|
| Name | : | | | | Name: |
| Ward: | | | | | NHI: |
| Eple | reno | ne | | | |
| | ATION equisi | - | (tick k | poxes where appropriate) | |
| Patient has heart failure with ejection fraction less than 40% O Patient is intolerant to optimal dosing of spironolactone | | | | | |
| | | | 0 | | |
| | | or | 0 | Patient has experienced a clinically significant adverse e | ffect while on optimal dosing of spironolactone |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Tabaantaa | |

Tolvaptan

INITIATION - autosomal dominant polycystic kidney disease Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a renal physician or any relevant practitioner on the recommendation of a renal physician, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and O Patient has a confirmed diagnosis of autosomal dominant polycystic kidney disease and O Patient has an estimated glomerular filtration rate (eGFR) of greater than or equal to 25 ml/min/1.73 m² at treatment initiation or O Patient's disease is rapidly progressing, with a decline in eGFR of greater than or equal to 2.5 mL/min/1.73 m² per year over a five-year period

CONTINUATION – autosomal dominant polycystic kidney disease Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a renal physician or any relevant practitioner on the recommendation of a renal physician, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and O Patient has not developed end-stage renal disease, defined as an eGFR of less than 15 mL/min/1.73 m² Patient has not undergone a kidney transplant

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |

Rosuvastatin

| INITIATION – cardiovascular disease risk Prerequisites (tick boxes where appropriate) | | |
|---|---|--|
| | O Patient is considered to be at risk of cardiovascular disease and O Patient is Māori or any Pacific ethnicity | |
| | or | Patient has a calculated risk of cardiovascular disease of at least 15% over 5 years LDL cholesterol has not reduced to less than 1.8 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin |
| | | I – familial hypercholesterolemia tes (tick boxes where appropriate) |
| Patient has familial hypercholesterolemia (defined as a Dutch Lipid Criteria score greater than or equal to 6) and D LDL cholesterol has not reduced to less than 1.8 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin | | |
| | | I – established cardiovascular disease tes (tick boxes where appropriate) |
| | | or O Patient has proven coronary artery disease (CAD) or O Patient has proven peripheral artery disease (PAD) or O Patient has experienced an ischaemic stroke |
| and LDL cholesterol has not reduced to less than 1.4 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin | | |
| | | I – recurrent major cardiovascular events tes (tick boxes where appropriate) |
| | and | Patient has experienced a recurrent major cardiovascular event (defined as myocardial infarction, ischaemic stroke, coronary revascularisation, hospitalisation for unstable angina) in the last 2 years |

LDL cholesterol has not reduced to less than 1.0 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|---|
| Name: | Name: |
| Ward: | NHI: |
| Levosimendan | |
| INITIATION – Heart transplant Prerequisites (tick boxes where appropriate) O For use as a bridge to heart transplant, in patients who have be or or O For the treatment of heart failure following heart transplant | een accepted for transplant |
| INITIATION – Heart failure Prerequisites (tick box where appropriate) | |
| O Prescribed by, or recommended by a cardiologist or intensivist, or in Health NZ Hospital. | accordance with a protocol or guideline that has been endorsed by the |

O For the treatment of severe acute decompensated heart failure that is non-responsive to dobutamine

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PATIENT: |
|----------|
| Name: |
| NHI: |
| |
| |
| |
| |
| |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | | | | PATIENT: |
|--|--|--|--------------------------------|----------|
| Name: | | | Name: | |
| Ward: | | | NHI: | |
| Hydı | Hydralazine hydrochloride - Tab 25 mg | | | |
| INITI Prer | | | (tick boxes where appropriate) | |
| | O For the treatment of refractory hypertension | | | |
| or Sor the treatment of heart failure, in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitor and/or angiotensin receptor blockers | | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESC | RIBER | PATIENT: | | |
|--|--|---|--|--|
| Name: | | Name: | | |
| Ward: . | | NHI: | | |
| bosen | tan | | | |
| INITIATION – PAH monotherapy Re-assessment required after 6 months | | | | |
| Prereq | uisites (tick boxes where appropriate) | | | |
| and | Prescribed by, or recommended by a respiratory specialist, cardiologial a respiratory specialist, cardiologist or rheumatologist, or in accordated Hospital. | gist, rheumatologist or any relevant practitioner on the recommendation of nce with a protocol or guideline that has been endorsed by the Health NZ | | |
| | - | | | |

| י ב | Hospit | aı. | |
|--------|----------|------------|---|
| and | | Patie | nt has pulmonary arterial hypertension (PAH)* |
| and | Ο | PAH | is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications |
| and | O | PAH | is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV |
| | | | O PAH has been confirmed by right heart catheterisation |
| | | an | O A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair) |
| | | an | O A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg |
| | | an | O Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm ⁻⁵) |
| | | | O PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) † |
| | | | O Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool** |
| | | | O Patient has PAH other than idiopathic / heritable or drug-associated type |
| | or or | 0 | Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease |
| | | 0 | Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures |
| and | | ~ | |
| | and | \bigcirc | Bosentan is to be used as PAH monotherapy |
| | | or | O Patient has experienced intolerable side effects on sildenafil |
| | | or | O Patient has an absolute contraindication to sildenafil |
| | | | O Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease |
| 1 | | | |

Signed: Date:

Page 90

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBEF | 2 | PATIENT: |
|-------------------|-----------|---|
| Name: | | Name: |
| Ward: | | NHI: |
| bosentan - | continu | ed |
| | ent requi | ual therapy red after 6 months oxes where appropriate) |
| O Pres a re | scribed | by, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of y specialist, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ |
| Ο | Patie | nt has pulmonary arterial hypertension (PAH)* |
| and and and | PAH i | s in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications |
| and | PAH | s in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV |
| 0 | 0 | A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair) A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵) PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) † Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool** Patient has PAH other than idiopathic / heritable or drug-associated type |
| and | | |
| a | or | Bosentan is to be used as part of PAH dual therapy O Patient has tried a PAH monotherapy (sildenafil) for at least three months and has experienced an inadequate therapeutic response to treatment according to a validated risk stratification tool** O Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would likely benefit from initial dual therapy |

| Signed: | Date: |
|---------|-------|
|---------|-------|

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| Name: | |
|--|---|
| Ward: NHI: | |
| | |
| bosentan - continued | |
| INITIATION – PAH triple therapy Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) Prescribed by, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist, or in accordance with a protocol or guideline that has been endorsed by the Health N: Hospital. and Patient has pulmonary arterial hypertension (PAH)* and PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications and PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV and and PAH has been confirmed by right heart catheterisation and PAH has been confirmed by right heart catheterisation and A mean pulmonary artery pressure (PCWP) less than or equal to 15 mmHg and Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm ⁻⁵) and PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) † or Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool** | (dyn s cm ⁻⁵) ost or nitric oxide, as es) † |
| or Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disease Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures and Bosentan is to be used as part of PAH triple therapy Patient is on the lung transplant list Or Patient is presenting in NYHA/WHO functional class IV Or Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool** Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario | ajor complication of the |

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCR | IBER | PATIENT: |
|---------|--|---|
| Name: | | Name: |
| Ward: | | NHI: |
| bosenta | an - continued | |
| | UATION ssment required after 2 years isites (tick box where appropriate) | |
| and | | gist, rheumatologist or any relevant practitioner on the recommendation of nce with a protocol or guideline that has been endorsed by the Health NZ |
| O | Patient is continuing to derive benefit from bosentan treatment accord | rding to a validated PAH risk stratification tool** |

| Note: † The European Respiratory Journal Guidelines can be found here: 2022 ECS/ERS Guidelines for the | 16 |
|---|----|
| diagnosis and treatment of pulmonary hypertension PAH | |
| ** the requirement to use a validated risk stratification tool to determine insufficient response applies to adult | s |
| Determining insufficient response in children does not require use of a validated PAH risk stratification tool, whe | re |
| currently no such validated tools exist for PAH risk stratification in children. | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Ambrisentan

| Re-a | NITIATION – PAH monotherapy Re-assessment required after 6 months | | | | | |
|----------|--|----------|--------|---|--|--|
| Prer | equis | ites (t | ick bo | exes where appropriate) | | |
| (and | а | | ratory | by, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of r specialist, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ | | |
| | (and | D f | Patier | t has pulmonary arterial hypertension (PAH) | | |
| | (and | F C | PAH is | s in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications | | |
| | (and | J F | PAH i | s in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV | | |
| | | | and | O PAH has been confirmed by right heart catheterisation | | |
| | | | and | O A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair) | | |
| | | | and | O A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg | | |
| | | | and | O Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm ⁻⁵) | | |
| | | | | O PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) † | | |
| | | | | O Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool** | | |
| | | | | O Patient has PAH other than idiopathic / heritable or drug-associated type | | |
| | | or or | | Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease | | |
| | | | | Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures | | |
| | and | | О | Ambrisentan is to be used as PAH monotherapy | | |
| | | and | | O Patient has experienced intolerable side effects with both sildenafil and bosentan | | |
| | | | or | O Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease) | | |
| | | | or | O Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease | | |
| | | | _ | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIBI | ER | | PATIENT: |
|-----------------------|---|--|---|---|
| Name | ame: Name: | | | |
| Nard: | | | | NHI: |
| ۱mb | risen | ntan | - con | inued |
| INITI Re-as | ATION ssessr equisit O Pi a | I – PA ment i tes (ti respii lospita | AH du requir ick bo bed b ratory al. Patien PAH is | In the appropriate of months ease where appropriate) t, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of specialist, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ has pulmonary arterial hypertension (PAH) in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV PAH has been confirmed by right heart catheterisation A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair) A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm ⁻⁵) PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) † |
| | and | or or (and | O I | Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool** Patient has PAH other than idiopathic / heritable or drug-associated type atient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung isorders including chronic neonatal lung disease atient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the ontan circulation requiring the minimising of pulmonary/venous filling pressures Patient has tried bosentan (either as PAH dual therapy Patient has not experienced an acceptable response to treatment according to a validated risk stratification tool** Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease) Patient is presenting in NYHA/WHO functional class III or IV, and would benefit from initial dual therapy in the opinion of the treating clinician and has an absolute or relative contraindication to bosentan (e.g. due to current liver disease or use of a combined oral contraceptive) |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| RESCRIBER | PATIENT: | | |
|---|---|--|--|
| ame: | me: Name: | | |
| /ard: | NHI: | | |
| mbrisenta | n - continued | | |
| Re-assessmer Prerequisites Prese ares Hosp and and and | PAH triple therapy t required after 6 months (tick boxes where appropriate) pribed by, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of piratory specialist, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ ital. Patient has pulmonary arterial hypertension (PAH) PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV | | |
| and or or | PAH has been confirmed by right heart catheterisation A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair) A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵) PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) † Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool** Patient has PAH other than idiopathic / heritable or drug-associated type Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disease Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures | | |
| and | Ambrisentan is to be used as PAH triple therapy Patient is on the lung transplant list Patient is presenting in NYHA/WHO functional class IV and Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease) Patient has tried PAH dual therapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool** Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario | | |

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|--|
| Name: | Name: |
| Ward: | NHI: |
| Ambrisentan - continued | |
| | gist, rheumatologist or any relevant practitioner on the recommendation of nce with a protocol or guideline that has been endorsed by the Health NZ nt according to a validated PAH risk stratification tool** |
| Note: † The European Respiratory Journal Guidelines can be found here: diagnosis and treatment of pulmonary hypertension PAH ** the requirement to use a validated risk stratification tool to determine ins Determining insufficient response in children does not require use of a validat currently no such validated tools exist for PAH risk stratification in children. | ufficient response applies to adults. |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| | |

sildenafil (Vedafil)

| 0 | Patient has Raynaud's phenomenon |
|-----|---|
| and | Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene) |
| and | Patient is following lifestyle management (proper body insulation, avoidance of cold exposure, smoking cessation support, avoidance of sympathomimetic drugs) |
| and | Patient has persisting severe symptoms despite treatment with calcium channel blockers and nitrates (unless contraindicated or not tolerated) |

O Prescribed by, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

| and | | | | |
|-----|-----|--|--------|---|
| | and | O Patient has pulmonary arterial hypertension (PAH)* | | |
| | (| Э ғ | PAH is | in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications |
| | and | ЭF | PAH is | in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV |
| | and | | | |
| | | | and | O PAH is confirmed by right heart catheterisation |
| | | | (| O A mean pulmonary artery pressure (PAPm) of greater than 20 mmHg |
| | | | and | O A pulmonary capillary wedge pressure (PCWP) that is less than or equal to 15 mmHg |
| | | | and | $ m O$ Pulmonary vascular resistance (PVR) of at least 2 Wood Units or at least 160 International Units (dyn s cm $^{-5}$) |
| | | | anu | PAH is non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) † |
| | | | | Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool** |
| | | | | O Patient has PAH other than idiopathic / heritable or drug-associated type |
| | | or (| | Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disease |
| | | or (| | Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | RESCRIBER PATIENT: | | | | |
|-------|---|-------|---|--|--|
| Name | : | | Name: | | |
| Ward: | | | | | |
| silde | nafi | I (Ve | edafil) - continued | | |
| | INITIATION – tablets other conditions Prerequisites (tick boxes where appropriate) | | | | |
| | or (| 0 | For use in weaning patients from inhaled nitric oxide | | |
| | or (| 0 | For perioperative use in cardiac surgery patients For use in intensive care as an alternative to nitric oxide | | |
| | or (| 0 | For use in the treatment of erectile dysfunction secondary to spinal cord injury in patients being treated in a spinal unit | | |
| | | | njection (tick boxes where appropriate) | | |
| | (and | 0 | For use in the treatment of pulmonary hypertension in infants or children being treated in paediatric intensive care units and neonatal intensive care units when the enteral route is not accessible | | |
| | | | O For perioperative use following cardiac surgery | | |
| | | or | O For use in persistent pulmonary hypertension of the newborn (PPHN) | | |
| | | | O For use in congenital diaphragmatic hernia | | |
| | | | | | |

Note: † The European Respiratory Journal Guidelines can be found here: 2022 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension PAH ** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where

currently no such validated tools exist for PAH risk stratification in children.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Epoprostenol

| Re-a | ssess | smen | AH dual therapy required after 6 months ick boxes where appropriate) |
|----------|------------|----------|--|
| (and | á | | ibed by, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of ratory specialist, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ al. |
| | | Ο | Patient has pulmonary arterial hypertension (PAH) |
| | and | Ο | PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications |
| | and and | Ο | PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class III or IV |
| | | | O PAH has been confirmed by right heart catheterisation |
| | | | A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair) |
| | | | A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg |
| | | | A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm ⁻⁵) and |
| | | | PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) † |
| | | | O Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool** |
| | | | O Patient has PAH other than idiopathic / heritable or drug-associated type |
| | | or or | Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures |
| | and | | |
| | | an | O Epoprostenol is to be used as part of PAH dual therapy with either sildenafil or an endothelin receptor antagonist |
| | | an | O Patient is presenting in NYHA/WHO functional class IV |
| | | an | O Patient has tried a PAH monotherapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool |

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting | . For more details, refer to Section H of the Pharmaceutical |
|---|--|
| Schedule. For community funding, see the Special Authority Criteria. | |

| PRESCRIBER | PATIENT: |
|---|--|
| Name: | Name: |
| Ward: | NHI: |
| Epoprosteno | - continued |
| INITIATION – PA Re-assessment Prerequisites (t O Prescri a respi Hospita and O F and O F | AH triple therapy required after 6 months ick boxes where appropriate) ibed by, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of ratory specialist, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ |
| or or and and | Patient has PAH other than idiopathic / heritable or drug-associated type Patient has palliated single ventricle congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures Epoprostenol is to be used as PAH triple therapy Patient is on the lung transplant list Patient is presenting in NYHA/WHO functional class IV Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario |

Page 101

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCR | IBER | PATIENT: | |
|--------|--|---|--|
| Name: | | Name: | |
| Ward: | | NHI: | |
| Epopro | stenol - continued | | |
| | UATION ssment required after 2 years isites (tick box where appropriate) | | |
| and | | gist, rheumatologist or any relevant practitioner on the recommendation of nce with a protocol or guideline that has been endorsed by the Health NZ | |
| | Patient is continuing to derive benefit from epoprostenol treatment a | ccording to a validated PAH risk stratification tool | |

| Note: † The European Respiratory Journal Guidelines can be found here: 2022 ECS/ERS Guidelines fo | or the |
|---|--------|
| diagnosis and treatment of pulmonary hypertension PAH | |
| ** the requirement to use a validated risk stratification tool to determine insufficient response applies to ac | dults. |
| Determining insufficient response in children does not require use of a validated PAH risk stratification tool, w | here |
| currently no such validated tools exist for PAH risk stratification in children. | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIE | BER | P | ATIENT: |
|-------------------------------------|--|---|--|
| Name: | | N | ame: |
| Vard: | | N | HI: |
| oprost | | | |
| INITIATIO Re-assess Prerequis | DN – P sment sites (Presc a resp Hospi | piratory specialist, cardiologist or rheumatologist, or in accordance ital. Patient has pulmonary arterial hypertension (PAH) PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical class PAH is in New York Heart Association/World Health Organization O PAH has been confirmed by right heart catheterisatic and O A mean pulmonary artery pressure (PAPm) greater t and O A pulmonary capillary wedge pressure (PCWP) less and O A pulmonary vascular resistance greater than 2 Woo and O PAH has been demonstrated to be non-respon defined in the 2022 ECS/ERS Guidelines for P O Patient has not experienced an acceptable res risk stratification tool** O Patient has PAH other than idiopathic / heritable | n (NYHA/WHO) functional class II, III or IV nn han 20 mmHg (unless peri Fontan repair) than or equal to 15 mmHg d Units or greater than 160 International Units (dyn s cm ⁻⁵) sive in vasoreactivity assessment using iloprost or nitric oxide, as AH (see note below for link to these guidelines) † ponse to calcium antagonist treatment, according to a validated |
| and | or | disorders including severe chronic neonatal lung disease O Patient has palliated single ventricle congenital heart disea Fontan circulation requiring the minimising of pulmonary/ve | se and elevated pulmonary pressures or a major complication of the enous filling pressures |
| and | • | O Iloprost is to be used as PAH monotherapy | |
| | and | | Idenafil and both the funded endothelin receptor antagonists (i.e. |

Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to endothelin receptor antagonists

or

 \bigcirc

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | | | | PATIENT: |
|------------|-------------------------------------|---|---|---|
| Name: Na | | | | Name: |
| Ward: | | | | NHI: |
| llopr | ost - c | contii | nued | |
| Re-a | ssessm equisite D Pre a re | ent r es (ti escril espir spita | equin ck bo bed k atory II. | red after 6 months oxes where appropriate) by, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of or specialist, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ of the has pulmonary arterial hypertension (PAH) |
| | С |) Р | AH is | s in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications |
| | and C and |) Р | AH is | s in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV |
| | | or (or (| С | A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair) A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵) |
| | and | (and | Or | Iloprost is to be used as PAH dual therapy with either sildenafil or an endothelin receptor antagonist Patient has an absolute contraindication to or has experienced intolerable side effects on sildenafil Patient has an absolute or relative contraindication to or experienced intolerable side effects with a funded endothelin receptor antagonist |
| | Ĩ | and | or | Patient has tried a PAH monotherapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool** Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would benefit from initial dual therapy |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIB | ER | | | | PATIENT: |
|---------------|-------------------------------------|--|---|--|--|---|
| Name | Name: Name: | | | | | |
| Ward: | | | | | | NHI: |
| llopr | ost - | conti | inued | | | |
| INITI Re-a | ATION ssessi equisi P a | h - PA ment tes (t rescri respi lospita | AH trij requin ick bo ibed b ratory al. Patient PAH is | ed a xes y, or spe t has in (| Fifter 6 wher r recc cialis s pulr A roup A rr A p A p | py imonths e appropriate) mmended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of t, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ nonary arterial hypertension (PAH) ot 1, 4 or 5 of the WHO (Venice 2003) clinical classifications York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV I has been confirmed by right heart catheterisation nean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair) ulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg ulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm ⁻⁵) PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) † Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool** Patient has PAH other than idiopathic / heritable or drug-associated type |
| | and | or or and | | disor Patie Font | rders ant ha an cin ost is Pat Pat | a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung including severe chronic neonatal lung disease and elevated pulmonary pressures or a major complication of the culation requiring the minimising of pulmonary/venous filling pressures to be used as PAH triple therapy ent is on the lung transplant list ent is presenting in NYHA/WHO functional class IV Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool** |
| | | | | | | Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCR | BER | PATIENT: | | | | |
|---|---|----------|--|--|--|--|
| Name: | | Name: | | | | |
| Ward: | | NHI: | | | | |
| lloprost | - continued | | | | | |
| | UATION ssment required after 2 years isites (tick box where appropriate) | | | | | |
| O Prescribed by, or recommended by a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | | | | |
| and | Patient is continuing to derive benefit from iloprost treatment according to a validated PAH risk stratification tool | | | | | |

Note: † The European Respiratory Journal Guidelines can be found here: <u>2022 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension PAH</u> ** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

Dermatologicals

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | | |
|--|----------|--|--|--|
| Name: | Name: | | | |
| Ward: | NHI: | | | |
| Mafenide acetate | | | | |
| INITIATION Prerequisites (tick box where appropriate) | | | | |
| O For the treatment of burns patients | | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBE | 3 | PATIENT: | | |
|-----------------------------|---|----------|--|--|
| Name: | | Name: | | |
| Ward: | | NHI: | | |
| Betametha | sone valerate with clioquinol | | | |
| INITIATION Prerequisites | s (tick boxes where appropriate) | | | |
| | For the treatment of intertrigo | | | |
| or O | For continuation use | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Pimecrolimus | |
| | |

| Prer | equisites | (tick boxes where appropriate) |
|----------|-----------|---|
| (and | | cribed by, or recommended by a dermatologist, paediatrician or ophthalmologist, or in accordance with a protocol or guideline that has been rsed by the Health NZ Hospital. |
| | O | Patient has atopic dermatitis on the eyelid |
| | | Patient has at least one of the following contraindications to topical corticosteroids: periorificial dermatitis, rosacea, documented epidermal atrophy, documented allergy to topical corticosteroids, cataracts, glaucoma, or raised intraocular pressure |

Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|----------------------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Ta ana lina an Oin Incan I | |

Tacrolimus Ointment

(

INITIATION

and

Prerequisites (tick boxes where appropriate)

()Prescribed by, or recommended by a dermatologist or paediatrician, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

 \bigcirc Patient has atopic dermatitis on the face and

Patient has at least one of the following contraindications to topical corticosteroids: periorificial dermatitis, rosacea, documented epidermal atrophy or documented allergy to topical corticosteroids

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--------------------------------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Methyl aminolevulinate hydrochloride | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a dermatologist or plastic surgeon, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Genito-Urinary System

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|-------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Terbutaline | |
| | |

Prerequisites (tick box where appropriate)

()Prescribed by, or recommended by an obstetrician, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIBI | ER | | PATIENT: |
|-----------------|----------|----|---|------------------------------|
| Name: | : | | | Name: |
| Ward: | | | | NHI: |
| Finas | sterio | de | | |
| INITI/ Prere | | | tick boxes where appropriate) | |
| | (and | С | Patient has symptomatic benign prostatic hyperplasia | |
| | | | $O\ $ The patient is intolerant of non-selective alpha blockers a | or these are contraindicated |
| | | or | O Symptoms are not adequately controlled with non-select | tive alpha blockers |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|-------------------------|
| Name: | Name: |
| Ward: | NHI: |
| Tamsulosin | |
| INITIATION Prerequisites (tick boxes where appropriate) | |
| O Patient has symptomatic benign prostatic hyperplasia | |
| The patient is intolerant of non-selective alpha blockers or the | ese are contraindicated |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|------------------------------|
| Name: | Name: |
| Ward: | NHI: |
| Potassium citrate | |
| INITIATION Prerequisites (tick boxes where appropriate) | |
| O The patient has recurrent calcium oxalate urolithiasis | |
| O The patient has had more than two renal calculi in the two yes | ars prior to the application |

Hormone Preparations

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|----------|
| Name: | Name: |
| Ward: | NHI: |
| Oxandrolone - Tab 2.5 mg | |
| INITIATION Prerequisites (tick box where appropriate) | |
| O For the treatment of burns patients | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCR | IBER | PATIENT: |
|----------------|---|--|
| Name: | | Name: |
| Ward: | | NHI: |
| Cinacal | cet | |
| Re-asse | ON – parathyroid carcinoma or calciphylaxis ssment required after 6 months isites (tick boxes where appropriate) Prescribed by, or recommended by a nephrologist or endocrinolog the Health NZ Hospital. | gist, or in accordance with a protocol or guideline that has been endorsed by |
| | O The patient has been diagnosed with a parathyroid ca and O The patient has persistent hypercalcaemia (serum ca treatments including sodium thiosulfate (where appro and O The patient is symptomatic | lcium greater than or equal to 3 mmol/L) despite previous first-line |
| or | and | alcific uraemic arteriolopathy) s) hypercalcaemia (serum calcium greater than or equal to 3 mmol/L) s first-line treatments including bisphosphonates and sodium thiosulfate |
| | UATION – parathyroid carcinoma or calciphylaxis isites (tick boxes where appropriate) Prescribed by, or recommended by a nephrologist or endocrinolog the Health NZ Hospital. | gist, or in accordance with a protocol or guideline that has been endorsed by |
| an | The patient's serum calcium level has fallen to < 3mmol/L The patient has experienced clinically significant symptom in the patient has experienced adenomas unless these have been been been been been been been be | |
| | ON – primary hyperparathyroidism isites (tick boxes where appropriate) | |
| an an an | or O Patient has hypercalcaemia of more than 3 mmol/L v O Patient has hypercalcaemia of more than 2.85 mmol/ O Surgery is not feasible or has failed | L with symptoms |

I confirm that the above details are correct:

Signed: Date:

or ()

HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESC | RIBE | R | | PATIENT: |
|--------|------|---------|--|---|
| Name: | | | | Name: |
| Ward: | | | | NHI: |
| Cinaca | alce | t - c | ontinued | |
| | | | condary or tertiary hyperparathyroidism equired after 6 months | |
| | | | ck boxes where appropriate) | |
| | | (| ${\cal O}$ Patient has tertiary hyperparathyroidism and markedly e | levated parathyroid hormone (PTH) with hypercalcaemia |
| | | or (| O Patient has symptomatic secondary hyperparathyroidisn | n and elevated PTH |

| Residual parathyroid tissue has not been localised despite repeat unsuccessful parathyroid explorations |
|---|
| |
| Parathyroid tissue is surgically inaccessible |
| Parathyroid surgery is not feasible |
| condary or tertiary hyperparathyroidism |
| ed after 12 months xes where appropriate) |
| ed at |

hormone (PTH) level to support ongoing cessation of treatment has not been reached

The patient has not received a kidney transplant and trial of withdrawal of cinacalcet is clinically inappropriate

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|----------|
| Name: | Name: |
| Ward: | NHI: |
| Cabergoline | |
| INITIATION Prerequisites (tick boxes where appropriate) | |
| O Inhibition of lactation | |
| O Patient has hyperprolactinemia | |
| O Patient has acromegaly | |
| Note: Indication marked with * is an unapproved indication. | |

| RS1826 - Somatropin | |
|---|-----|
| | |
| Prader-Willi syndrome - INITIATION | 126 |
| Prader-Willi syndrome - CONTINUATION | 126 |
| Turner syndrome - INITIATION | 123 |
| Turner syndrome - CONTINUATION | 124 |
| Adults and adolescents - INITIATION | 127 |
| Adults and adolescents - CONTINUATION | |
| Growth hormone deficiency in children - INITIATION | 123 |
| Growth hormone deficiency in children - CONTINUATION | 123 |
| Short stature due to chronic renal insufficiency - INITIATION | 125 |
| Short stature due to chronic renal insufficiency - CONTINUATION | |
| Short stature without growth hormone deficiency - INITIATION | |
| Short stature without growth hormone deficiency - CONTINUATION | 124 |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIBER | PATIENT: | |
|----------------|---|--|--|
| Name | lame: Name: | | |
| Ward: | /ard: NHI: | | |
| Soma | atropin | | |
| INITI Re-as | ATION – growth hormone deficiency in children ssessment required after 12 months equisites (tick boxes where appropriate) Prescribed by, or recommended by an endocrinologist or paediatric en- endorsed by the Health NZ Hospital. Growth hormone deficiency causing symptomatic hypoglycaemic cardiomyopathy, hepatic dysfunction) and diagnosed with GH < life, or from samples during established hypoglycaemia (whole b or Height velocity < 25th percentile for age; and adjusted for standards of Tanner and Davies (1985) and O A current bone age is < 14 years (female patients) or < 16 and O Peak growth hormone value of < 5.0 mcg per litre in response who are 5 years or older, GH testing with sex steroid primi and O If the patient has been treated for a malignancy, they should other the standards of the patient has been treated for a malignancy, they should other the standards of the patient has been treated for a malignancy, they should other the patient has been treated for a malignancy of the standards of the patient has been treated for a malignancy they should other the patient has been treated for a malignancy they should other the patient has been treated for a malignancy they should other the patient has been treated for a malignancy they should other the patient has been treated for a malignancy they should other the patient has been treated for a malignancy they should other the patient has been treated for a malignancy they should other the patient has been treated for a malignancy they should other the patient has been treated for a malignancy they should other the patient has been treated for a malignancy they should other the patient has been treated for a malignancy the patient of the patient has been treated for a malignancy the patient for the patient has been treated for a malignancy the patient has been treated for a malignancy the patient for the patient has been treated for a malignancy the patient for the patient has been treated for a malignancy the p | bone age/pubertal status if appropriate over 6 or 12 months using the years (male patients) inse to two different growth hormone stimulation tests. In children ng is required Id be disease free for at least one year based upon follow-up lignancy, unless there are strong medical reasons why this is either | |
| Re-as | TINUATION – growth hormone deficiency in children ssessment required after 12 months equisites (tick boxes where appropriate) | | |
| and | endorsed by the Health NZ Hospital. O A current bone age is 14 years or under (female patients) or 16 and O Height velocity is greater than or equal to 25th percentile for age hormone treatment, as calculated over six months using the star and O Height velocity is greater than or equal to 2.0 cm per year, as ca and | (adjusted for bone age/pubertal status if appropriate) while on growth adards of Tanner and Davis (1985) | |
| Re-as | ATION – Turner syndrome ssessment required after 12 months equisites (tick boxes where appropriate) Prescribed by, or recommended by an endocrinologist or paediatric en endorsed by the Health NZ Hospital. The patient has a post-natal genotype confirming Turner Syndro and | docrinologist, or in accordance with a protocol or guideline that has been | |

O Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985)

O A current bone age is < 14 years

I confirm that the above details are correct:

and

| Signed: | Date: |
|---------|-------|
|---------|-------|

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|---|---|--|
| Name: | | |
| Nard: NHI: | | |
| Somatropin - continued | | |
| CONTINUATION – Turner syndrome Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by an endocrinologist or paediatric endorsed by the Health NZ Hospital. and | ndocrinologist, or in accordance with a protocol or guideline that has been | |
| | | |
| and endorsed by the Health NZ Hospital. The patient's height is more than 3 standard deviations below th or delay and Height velocity is < 25th percentile for age (adjusted for bone age using the standards of Tanner and Davies(1985) and A current bone age is < 14 years (female patients) or < 16 year and | ndocrinologist, or in accordance with a protocol or guideline that has been he mean for age or for bone age if there is marked growth acceleration ge/pubertal status if appropriate), as calculated over 6 to 12 months rs (male patients) alignancy or recognized severe skeletal dysplasia) and is not receiving | |
| CONTINUATION – short stature without growth hormone deficiency Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by an endocrinologist or paediatric endorsed by the Health NZ Hospital. and | ndocrinologist, or in accordance with a protocol or guideline that has been | |
| Height velocity is greater than or equal to 50th percentile (adjus 12 months using the standards of Tanner and Davies (1985) and Height velocity is greater than or equal to 2 cm per year as calc and Current bone age is 14 years or under (female patients) or 16 yeard | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIBE | R | PATIENT: |
|------|-------------|---|--|
| Name | lame: Name: | | Name: |
| Ward | | | NHI: |
| Som | atropi | in - continued | |
| | - | - short stature due to chronic renal insufficiency | |
| | | ent required after 12 months es (tick boxes where appropriate) | |
| Fier | | | |
| and | | escribed by, or recommended by an endocrinologist, paediatric er paediatric endocrinologist, or in accordance with a protocol or gui | ndocrinologist or renal physician on the recommendation of a endocrinologist ideline that has been endorsed by the Health NZ Hospital. |
| | and |) The patient's height is more than 2 standard deviations below | the mean |
| | C | Height velocity is < 25th percentile (adjusted for bone age/pub standards of Tanner and Davies (1985) | pertal status if appropriate) as calculated over 6 to 12 months using the |
| | and | A current bone age is to 14 years or under (female patients) o | r to 16 years or under (male patients) |
| | and |) The patient is metabolically stable, has no evidence of metabolically stable. | olic bone disease and absence of any other severe chronic disease |
| | and | The patient is under the supervision of a specialist with experi | tise in renal medicine |
| | | O The patient has a GFR less than or equal to 30 ml/min/ creatinine (umol/l × 40 = corrected GFR (ml/min/1.73 m | 1.73 m ² as measured by the Schwartz method (Height(cm)/plasma ²) in a child who may or may not be receiving dialysis |
| | | \sim | eived < 5mg/ m ² /day of prednisone or equivalent for at least 6 months |
| | | | |
| | | FION – short stature due to chronic renal insufficiency ent required after 12 months | |
| | | es (tick boxes where appropriate) | |
| (| | escribed by, or recommended by an endocrinologist, paediatric er paediatric endocrinologist, or in accordance with a protocol or gui | ndocrinologist or renal physician on the recommendation of a endocrinologist ideline that has been endorsed by the Health NZ Hospital. |
| and | | | |
| | C | Height velocity is greater than or equal to 50th percentile (adjulation 12 months using the standards of Tanner and Davies (1985) | usted for bone age/pubertal status if appropriate) as calculated over 6 to |
| | and | Height velocity is greater than or equal to 2 cm per year as ca | Iculated over six months |
| | and | A current bone age is 14 years or under (female patients) or 1 | 6 years or under (male patients) |
| | and | No serious adverse effect that the patients specialist consider | s is likely to be attributable to growth hormone has occurred |
| | and | No malignancy has developed after growth hormone therapy | was commenced |
| | and | The patient has not experienced significant biochemical or me | etabolic deterioration confirmed by diagnostic results |
| | and | The patient has not received renal transplantation since starting | ng growth hormone treatment |
| | and | If the patient requires transplantation, growth hormone prescribe made after transplantation based on the above criteria | ption should cease before transplantation and a new application should |

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting | . For more details, refer to Section H of the Pharmaceutical |
|---|--|
| Schedule. For community funding, see the Special Authority Criteria. | |

| PRESCRIBER | PATIENT: | | |
|---|---|--|--|
| Name: | me: Name: | | |
| Ward: | | | |
| Somatropin | - continued | | |
| Re-assessmer Prerequisites O Pres | Prader-Willi syndrome tt required after 12 months (tick boxes where appropriate) cribed by, or recommended by an endocrinologist or paediatric endocrinologist, or in accordance with a protocol or guideline that has been irsed by the Health NZ Hospital. | | |
| and and | The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria The patient is aged six months or older | | |
| and | A current bone age is < 14 years (female patients) or < 16 years (male patients) Sleep studies or overnight oximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon | | |
| or | O The patient is aged two years or older and O There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months O The patient is aged between six months and two years and a thorough upper airway assessment is planned to be undertaken prior to treatment commencement and at six to 12 weeks following treatment initiation | | |
| Re-assessmer Prerequisites O Pres | DN – Prader-Willi syndrome ht required after 12 months (tick boxes where appropriate) cribed by, or recommended by an endocrinologist or paediatric endocrinologist, or in accordance with a protocol or guideline that has been prised by the Health NZ Hospital. | | |
| and O and O | Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985) | | |
| and and | Height velocity is greater than or equal to 2 cm per year as calculated over six months A current bone age is 14 years or under (female patients) or 16 years or under (male patients) | | |
| and and | No serious adverse effect that the patient's specialist con siders is likely to be attributable to growth hormone treatment has occurred No malignancy has developed after growth hormone therapy was commenced The patient has not developed type II diabetes or uncontrolled obesity as defined by BMI that has increased by greater than or equal | | |
| | to 0.5 standard deviations in the preceding 12 months | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | | | PATIENT: | |
|----------------|---------------|----------------|---|---|
| Name | : | | | Name: |
| Ward: | | | | NHI: |
| Soma | atro | pin | - continued | |
| Re-as | ssess | smen | dults and adolescents t required after 12 months (tick boxes where appropriate) | |
| and | | | ribed by, or recommended by an endocrinologist or paediatric or sed by the Health NZ Hospital. | endocrinologist, or in accordance with a protocol or guideline that has been |
| | and | | The patient has a medical condition that is known to cause gro treatment of a pituitary tumour) | wth hormone deficiency (e.g. surgical removal of the pituitary for |
| | | Ο | The patient has undergone appropriate treatment of other horn | nonal deficiencies and psychological illnesses |
| | and and | Ο | The patient has severe growth hormone deficiency (see notes) | |
| | and | Ο | The patient's serum IGF-I is more than 1 standard deviation be | slow the mean for age and sex |
| | ana | 0 | The patient has poor quality of life, as defined by a score of 16 growth hormone deficiency (QoL-AGHDA®) | or more using the disease-specific quality of life questionnaire for adult |
| equal Patie | to 3 nts w | mcg /ith or | per litre during an adequately performed insulin tolerance test ne or more additional anterior pituitary hormone deficiencies an | ficiency is defined as a peak serum growth hormone level of less than or (ITT) or glucagon stimulation test. d a known structural pituitary lesion only require one test. Patients with sts, of which, one should be ITT unless otherwise contraindicated. Where |

isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of less than or equal to 0.4 mcg per litre. The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until it is within 1 standard deviation of the mean normal value for age and sex; and

The dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

| I confirm that the above details are correc | t: |
|---|----|
|---|----|

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. | For more details, refer to Section H of the Pharmaceutical |
|--|--|
| Schedule. For community funding, see the Special Authority Criteria. | |

| PRES | CRIE | CRIBER PATIENT: | | |
|-------|-----------------------|---|---|--|
| Name: | : | Name: | | |
| Ward: | | | NHI: | |
| Soma | atro | pin - con | tinued | |
| Re-as | ssess equis D F | sment requ i ites (tick b Prescribed | dults and adolescents ired after 12 months ioxes where appropriate) by, or recommended by an endocrinologist or paediatric endocrinologist, or in accordance with a protocol or guideline that has been by the Health NZ Hospital. | |
| anu | | and and | The patient has been treated with somatropin for < 12 months There has been an improvement in the Quality of Life Assessment defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA®) score from baseline | |
| | | and | Serum IGF-I levels have increased to within ±1SD of the mean of the normal range for age and sex The dose of somatropin does not exceed 0.7 mg per day for male patients, or 1 mg per day for female patients | |
| | or | | | |
| | | and and and and | The patient has been treated with somatropin for more than 12 months The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA® score on treatment (other than due to obvious external factors such as external stressors) Serum IGF-I levels have continued to be maintained within ±1SD of the mean of the normal range for age and sex (other than for obvious external factors) The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients | |
| | or | | | |
| | | and and and | The patient has had a Special Authority approval for somatropin for childhood deficiency in children and no longer meets the renewal criteria under this indication The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses The patient has severe growth hormone deficiency (see notes) | |
| | | and and and | The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex | |
| | | | The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®) | |
| equal | l to 3 | mcg per lit | ses of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or irre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test. more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with | |

isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of less than or equal to 0.4 mcg per litre. The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until the serum IGF-I is within 1 standard deviation of the mean normal value for age and sex; and

The dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|----------------------------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Liothyronine sodium - Tab 20 mcg | |
| | |

Prerequisites (tick box where appropriate)

m O~ For a maximum of 14 days' treatment in patients with thyroid cancer who are due to receive radioiodine therapy

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|---------------|
| Name: | Name: |
| Ward: | . NHI: |
| Propylthiouracil | |
| INITIATION Prerequisites (tick boxes where appropriate) | |
| O The patient has hyperthyroidism | |
| The patient is intolerant of carbimazole or carbimazole is co | ntraindicated |

Infections

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|-----------------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Streptomycin sulphate | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Amikacin | |
| | |

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Page 134

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Tobramycin | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|----------|
| Name: | Name: |
| Ward: | NHI: |
| Tobramycin Solution for inhalation 60 mg per ml, 5 ml | |
| INITIATION Prerequisites (tick box where appropriate) | |
| O Patient has cystic fibrosis | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|----------|
| Name: | Name: |
| Ward: | NHI: |
| Tobramcyin | |
| INITIATION Prerequisites (tick box where appropriate) | |
| O For addition to orthopaedic bone cement | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|-------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Paromomycin | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or gastroenterologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--------------------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Imipenem with cilastatin | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Ertapenem | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Meropenem | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Page 141

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|----------------------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Ceftazidime with avibactam | |
| | |

| requisite | es (| (tick boxes where appropriate) |
|-----------|------|---|
| and | | Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital |
| | | O Proven infection with a carbapenem-resistant micro-organism, based on microbiology report |
| | or | O Probable infection with a carbapenem-resistant micro-organism, based on assessment by a clinical microbiologist or infectious disease specialist. |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | | | |
|-------------|----------|--|--|--|--|
| Name: | Name: | | | | |
| Ward: | NHI: | | | | |
| Ceftazadime | | | | | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | | | |
|------------|----------|--|--|--|--|
| Name: | Name: | | | | |
| Ward: | NHI: | | | | |
| Cefepime | | | | | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Page 144

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | SCRIBER | PATIENT: | | | | | |
|--|---|----------------------------|--|--|--|--|--|
| Name | 2 | Name: | | | | | |
| Ward | | NHI: | | | | | |
| Ceftaroline | | | | | | | |
| INITIATION – multi-resistant organisn salvage therapy Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has | | | | | | | |
| and | been endorsed by the Health NZ Hospital. | | | | | | |
| | O For patients where alternative therapies have failed or O For patients who have a contraindication or hypersensitivity to | standard surrout therapies | | | | | |
| | • To patients who have a contraindication of hypersensitivity to | standard current merapies | | | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|----------|
| Name: | Name: |
| Ward: | NHI: |
| Roxithromycin tab dispersible 50 mg | |
| INITIATION Prerequisites (tick box where appropriate) | |
| O Only for use in patients under 12 years of age | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|---|---|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Clarithromycin | | |
| INITIATION – Tab 250 mg and oral liquid Prerequisites (tick boxes where appropriate) O Atypical mycobacterial infection or O or Helicobacter pylori eradication | stance or intolerance to standard pharmaceutical agents | |
| O Prophylaxis of infective endocarditis associated with surgical of | or dental procedures if amoxicillin is contra-indicated | |
| INITIATION – Tab 500 mg Prerequisites (tick box where appropriate) O Helicobacter pylori eradication | | |
| INITIATION – Infusion Prerequisites (tick boxes where appropriate) | | |

or O Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents

O Community-acquired pneumonia

Atypical mycobacterial infection

 \bigcirc

or

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. | For more details, refer to Section H of the Pharmaceutical |
|--|--|
| Schedule. For community funding, see the Special Authority Criteria. | |

| PRESCRIBER | PATIENT: | |
|--|--|--|
| Name: | | |
| Ward: | NHI: | |
| Azithromycin | | |
| INITIATION – bronchiolitis obliterans syndrome, cystic fibrosis and atyp Prerequisites (tick boxes where appropriate) | ical Mycobacterium infections | |
| Patient has received a lung transplant, stem cell transplant or bone marrow transplant and requires treatment for bronchiolitis obliterans syndrome* Patient has received a lung transplant and requires prophylaxis for bronchiolitis obliterans syndrome* Patient has cystic fibrosis and has chronic infection with Pseudomonas aeruginosa or Pseudomonas related gram negative organisms* Patient has an atypical Mycobacterium infection Note: Indications marked with * are unapproved indications | | |
| INITIATION – non-cystic fibrosis bronchiectasis* Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a respiratory specialist or paediatrician, or in accordance with a protocol or guideline that has been | | |
| and endorsed by the Health NZ Hospital. O For prophylaxis of exacerbations of non-cystic fibrosis bronch and O Patient is aged 18 and under and O Patient has had 3 or more exacerbations of their bronch or O Patient has had 3 acute admissions to hospital for treate | | |
| Note: Indications marked with * are unapproved indications. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis will be subsidised in the community. | | |
| CONTINUATION – non-cystic fibrosis bronchiectasis* Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a respiratory specialist or paedia endorsed by the Health NZ Hospital. and O The patient has completed 12 months of azithromycin treatment and O Following initial 12 months of treatment, the patient has not re- | | |
| and The patient will not receive more than a total of 24 months' az Note: Indications marked with * are unapproved indications. A maximum of 2 in the community. | ically inappropriate to stop treatment ithromycin cumulative treatment (see note) | |
| INITIATION – other indications Re-assessment required after 5 days Prerequisites (tick box where appropriate) | | |

O For any other condition

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|----------|
| Name: | Name: |
| Ward: | NHI: |
| Azithromycin - continued | |
| CONTINUATION – other indications Re-assessment required after 5 days Prerequisites (tick box where appropriate) | |
| O For any other condition | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|----------------------------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Ticarcillin with clavulanic acid | | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|------------------------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Piperacillin with tazobactam | | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Page 151

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Ciprofloxacin | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Moxifloxacin

| | | DN – Mycobacterium infection sites (tick boxes where appropriate) |
|-----|----------|---|
| and | | Prescribed by, or recommended by an infectious disease specialist, clinical microbiologist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. |
| | | Active tuberculosis |
| | | O Documented resistance to one or more first-line medications or O Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with nor O the second-line agents |
| | | or O Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications |
| | | O Significant documented intolerance and/or side effects following a reasonable trial of first-line medications |
| | or or | O Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated O Patient is under five years of age and has had close contact with a confirmed multi-drug resistant tuberculosis case |
| | equi: | DN – Pneumonia sites (tick boxes where appropriate) Prescribed by, or recommended by an infectious disease specialist or clinical microbiologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. |
| | or | O Immunocompromised patient with pneumonia that is unresponsive to first-line treatment |
| | | O Pneumococcal pneumonia or other invasive pneumococcal disease highly resistant to other antibiotics |
| | | DN – Penetrating eye injury sites (tick box where appropriate) |
| and | | Prescribed by, or recommended by an ophthalmologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. |
| anu | 0 | Five days treatment for patients requiring prophylaxis following a penetrating eye injury |
| | | DN – Mycoplasma genitalium sites (tick boxes where appropriate) |
| | and | O Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium and is symptomatic |
| | une | O Has tried and failed to clear infection using azithromycin |
| | | O Has laboratory confirmed azithromycin resistance |
| | and | d O Treatment is only for 7 days |

| Signed: | | Date: | |
|---------|--|-------|--|
|---------|--|-------|--|

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|---|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |
| Moxifloxacin - continued | | | |
| INITIATION – severe delayed beta-lactam allergy Prerequisites (tick box where appropriate) | | | |
| O Prescribed by, or recommended by an infectious disease specialist or clinical microbiologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | |

O Individual has a history of severe delayed beta-lactam allergy

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|-------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Tigecycline | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Daptomycin | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Lincomycin | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Linezolid | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Sulphadiazine | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or maternal-foetal medicine specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|-------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Teicoplanin | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Fosfomycin | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Page 161

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Pivmecillinam | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Vancomycin | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|----------------------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Aztreonam, Chloramphenicol | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|-------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Clindamycin | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Fusidic acid | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|---|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |
| Colistin sulphomethate [Colestimethate] | | | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|---------------------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Ketoconazole - Tab 200 mg | | |

INITIATION

Prerequisites (tick box where appropriate)

()Prescribed by, or recommended by an oncologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |

Amphotericin B - Inj (liposomal) 50 mg vial

INITIATION

and

and

Prerequisites (tick boxes where appropriate) () Prescribed by, or recommended by a clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

| | \bigcirc | Proven or probable invasive fungal infection, to be prescribed under an established protocol | |
|----|------------|--|--|
| or | | | |

()Possible invasive fungal infection

A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be () appropriate

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|---------------------------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Amphotericin B - Inj 50 mg vial | | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|-------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Fluconazole | | |

INITIATION

Prerequisites (tick box where appropriate)

()Prescribed by, or recommended by a consultant, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Itraconazole | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical immunologist, clinical microbiologist, dermatologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

| July 2023 |) | RESTRICTION | 5 CHECKLIST |
|---|--------|---|---|
| | | st to determine if a patient meets the restrictions for funding in th ommunity funding, see the Special Authority Criteria. | e hospital setting. For more details, refer to Section H of the Pharmaceutical |
| PRESCR | IBER | | PATIENT: |
| Name: | | | Name: |
| Ward: | | | NHI: |
| Voricon | nazole | e | |
| | | Proven or probable aspergillus infection (tick boxes where appropriate) | |
| O and | | cribed by, or recommended by a clinical microbiologist, haemato line that has been endorsed by the Health NZ Hospital. | ologist or infectious disease specialist, or in accordance with a protocol or |
| an | | Patient is immunocompromised | |
| | \sim | Patient has proven or probable invasive aspergillus infection | |
| | | Possible aspergillus infection (tick boxes where appropriate) | |
| and | | cribed by, or recommended by a clinical microbiologist, haemato line that has been endorsed by the Health NZ Hospital. | ologist or infectious disease specialist, or in accordance with a protocol or |
| | - | Patient is immunocompromised | |
| O Patient has possible invasive aspergillus infection | | | |
| an | \sim | A multidisciplinary team (including an infectious disease physic | cian) considers the treatment to be appropriate |
| | | | |
| | | Resistant candidiasis infections and other moulds (tick boxes where appropriate) | |
| O | | cribed by, or recommended by a clinical microbiologist, haemato line that has been endorsed by the Health NZ Hospital. | ologist or infectious disease specialist, or in accordance with a protocol or |
| an | - | Patient is immunocompromised | |
| | | O Patient has fluconazole resistant candidiasis | |
| | or | O Patient has mould strain such as Fusarium spp. and Sce | edosporium spp |
| an | \sim | A multidisciplinary team (including an infectious disease physic | cian or clinical microbiologist) considers the treatment to be appropriate |
| | | | |
| Re-asses | ssment | nvasive fungal infection prophylaxis t required after 6 months (tick boxes where appropriate) | |
| O and | | cribed by, or recommended by any relevant practitioner, or in accospital. | cordance with a protocol or guideline that has been endorsed by the Health |
| an | - | The patient is at risk of invasive fungal infection | |
| all | or | O Voriconazole is prescribed by, or recommended by a have paediatric haematologist or paediatric oncologist | ematologist, transplant physician, infectious disease specialist, |
| | | | I or guideline that has been endorsed by the Health New Zealand - Te s a greater than 10% risk of invasive fungal infection (IFI) |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| r the Health | | |
|---|--|--|
| and O The patient is at risk of invasive fungal infection | | |
| | | |
| d - Te | | |
| | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| D | |

Posaconazole

| INITIATION Re-assessment required after 6 weeks |
|--|
| Prerequisites (tick boxes where appropriate) |
| O Prescribed by, or recommended by a haematologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. |
| O Patient has acute myeloid leukaemia or |
| O Patient is planned to receive a stem cell transplant and is at high risk for aspergillus infection |
| Patient is to be treated with high dose remission induction therapy or re-induction therapy |
| CONTINUATION Re-assessment required after 6 weeks Prerequisites (tick boxes where appropriate) |
| O Prescribed by, or recommended by a haematologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. |
| Patient has previously received posaconazole prophylaxis during remission induction therapy |
| O Patient is to be treated with high dose remission re-induction therapy or |
| O Patient is to be treated with high dose consolidation therapy or |
| O Patient is receiving a high risk stem cell transplant |
| |
| INITIATION – Invasive fungal infection prophylaxis Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) |
| O Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. |
| The patient is at risk of invasive fungal infection |
| O Posaconazole is prescribed by, or recommended by a haematologist, transplant physician, infectious disease specialist, paediatric haematologist or paediatric oncologist |
| Prescribing posaconazole is in accordance with a protocol or guideline that has been endorsed by the Health New Zealand - Te Whatu Ora Hospital in the specific settings where there is a greater than 10% risk of invasive fungal infection (IFI) |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIB | BER | | | PATIENT: |
|-------|-----------------------|-----------------------|-------------------|--|---|
| Name | : | | | | Name: |
| Ward: | | | | | NHI: |
| Posa | con | azo | le - a | continued | |
| Re-as | ssess equis D F | i tes Presc | t requ (tick b | | cordance with a protocol or guideline that has been endorsed by the Health |
| | and | Ο | The p | patient is at risk of invasive fungal infection | |
| | | or | ł | Posaconazole is prescribed by, or recommended by a hap paediatric haematologist or paediatric oncologist | ematologist, transplant physician, infectious disease specialist, |
| | | | 0 | | ol or guideline that has been endorsed by the Health New Zealand - Te s a greater than 10% risk of invasive fungal infection (IFI) |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|-------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Flucytosine | | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|-------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |
| Caspofungin | | | |

| Prerequisites (tick boxes where appropriate) | | | | |
|--|---|--|---|--|
| and | С | Prescribed by, or recommended by a clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | |
| | O Proven or probable invasive fungal infection, to be prescribed under an established protocol or | | | |
| | | and | Possible invasive fungal infection | |
| | | 0 | A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|-------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Clofazimine | | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, dermatologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Dapsone | | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, dermatologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|-------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Cycloserine | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---------------------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Isoniazid with rifampicin | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, dermatologist, paediatrician, public health physician or internal medicine physician, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Pyrazinamide | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Rifampicin | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, dermatologist, internal medicine physician, paediatrician or public health physician, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Page 184

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PATIENT: |
|--|
| Name: |
| NHI: |
| |
| ed the individual case and recommends bedaquiline as part of the |
| |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Isoniazid | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, dermatologist, paediatrician, public health physician or internal medicine physician, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Rifabutin | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, gastroenterologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--------------------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Ethambutol hydrochloride | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--------------------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Para-aminosalicylic Acid | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Protionamide | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|-------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Albendazole | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Page 191

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Ivermectin | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, dermatologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------------------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Artemether with lumefantrine | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Artesunate | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|----------|
| Name: | Name: |
| Ward: | NHI: |
| Atovaquone with proguanil hydrochloride | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|-----------------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Chloroquine phosphate | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, dermatologist, infectious disease specialist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--------------------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Mefloquine hydrochloride | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, dermatologist, infectious disease specialist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|-------------------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Pentamidine isethionate | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|----------------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Primaguine phosphate | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Pyrimethamine | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist or maternal-foetal medicine specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|-------------------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Quinine dihydrochloride | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|-----------------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Sodium stibogluconate | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Spiramycin | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a maternal-foetal medicine specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Nitazoxanide | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | ł | PATIENT: |
|----------------|---|---|
| Name: | | Name: |
| Ward: | | NHI: |
| Non-Nucleo | oside Reverse Transcriptase Inhibitors | |
| | Confirmed HIV s (tick box where appropriate) | |
| O Pati | ent has confirmed HIV infection | |
| | Prevention of maternal transmission s (tick boxes where appropriate) | |
| or O | Prevention of maternal foetal transmission Treatment of the newborn for up to eight weeks | |
| | Post-exposure prophylaxis following exposure to HIV s (tick boxes where appropriate) Treatment course to be initiated within 72 hours post exposu | Jre |
| | unknown or detectable viral load greater than 200 cop | tive vaginal intercourse with a known HIV positive person with an ies per ml |
| O | O Patient has had non-consensual intercourse and the c required | th a known HIV positive person |
| O | $\hat{}$ | erson from a high HIV prevalence country or risk group whose HIV status |
| Note: Refer to | o local health pathways or the Australasian Society for HIV, Vir | al Hepatitis and Sexual Health Medicine clinical guidelines for PEP (https://www.ashn |
| Prerequisites | Percutaneous exposure s (tick box where appropriate) ent has percutaneous exposure to blood known to be HIV posi | tive |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | | | | PATIENT: |
|--------------------------|---------|--------|--|---|
| Name: | Name: | | | Name: |
| Ward: | | | | NHI: |
| Nucleosi | de F | Reve | rse Transcriptase Inhibitors | |
| INITIATION Prerequisi | | | med HIV ox where appropriate) | |
| Ор | atien | t has | confirmed HIV infection | |
| | | | ntion of maternal transmission oxes where appropriate) | |
| or (| | | ention of maternal foetal transmission ment of the newborn for up to eight weeks | |
| Prerequisi | ites (| tick b | xposure prophylaxis following exposure to HIV oxes where appropriate) ment course to be initiated within 72 hours post exposur | e |
| and | or | 0 | Patient has had condomless anal intercourse or reception unknown or detectable viral load greater than 200 copie | ve vaginal intercourse with a known HIV positive person with an is per ml |
| | or | 0 0 | | a known HIV positive person nician considers that the risk assessment indicates prophylaxis is |
| | or | 0 | required Patient has had condomless anal intercourse with a per is unknown | son from a high HIV prevalence country or risk group whose HIV status |
| Note: Refe | er to l | ocal | nealth pathways or the Australasian Society for HIV, Viral | Hepatitis and Sexual Health Medicine clinical guidelines for PEP (https://www.ashn |
| Prerequisi | tes (| tick b | aneous exposure ox where appropriate) percutaneous exposure to blood known to be HIV positi | ve |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCR | IBER | | | PATIENT: |
|----------|---------|---------|---|---|
| Name: | | | | Name: |
| Ward: | | | | NHI: |
| Proteas | se Inł | nibit | ors | |
| | | | rmed HIV pox where appropriate) | |
| 0 | Patie | nt has | s confirmed HIV infection | |
| | | | ntion of maternal transmission boxes where appropriate) | |
| or | 0 0 | | ention of maternal foetal transmission tment of the newborn for up to eight weeks | |
| | | | exposure prophylaxis following exposure to HIV poxes where appropriate) | |
| an | d | Trea | tment course to be initiated within 72 hours post exposur | e |
| | | 0 | Patient has had condomless anal intercourse or reception unknown or detectable viral load greater than 200 copies | ve vaginal intercourse with a known HIV positive person with an s per ml |
| | or | Ο | Patient has shared intravenous injecting equipment with | a known HIV positive person |
| | or | 0 | Patient has had non-consensual intercourse and the clin required | nician considers that the risk assessment indicates prophylaxis is |
| | or | 0 | Patient has had condomless anal intercourse with a per is unknown | son from a high HIV prevalence country or risk group whose HIV status |
| Note: Re | efer to | local | health pathways or the Australasian Society for HIV, Viral | Hepatitis and Sexual Health Medicine clinical guidelines for PEP (https://www.ash |
| | isites | (tick I | taneous exposure box where appropriate) s percutaneous exposure to blood known to be HIV positi | /e |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| RESCRIBER | 1 | PATIENT: |
|----------------|--|---|
| lame: | | Name: |
| Vard: | | NHI: |
| strand Trar | nsfer Inhibitors | |
| | Confirmed HIV s (tick box where appropriate) | |
| O Pati | ent has confirmed HIV infection | |
| | Prevention of maternal transmission s (tick boxes where appropriate) | |
| or O | Prevention of maternal foetal transmission Treatment of the newborn for up to eight weeks | |
| Prerequisites | Post-exposure prophylaxis following exposure to HIV s (tick boxes where appropriate) Treatment course to be initiated within 72 hours post expos | ure |
| and | unknown or detectable viral load greater than 200 cor | ptive vaginal intercourse with a known HIV positive person with an bies per ml |
| 0 | O Patient has had non-consensual intercourse and the required | ith a known HIV positive person |
| 0 | \sim | erson from a high HIV prevalence country or risk group whose HIV status |
| Note: Refer to | o local health pathways or the Australasian Society for HIV, Vi | ral Hepatitis and Sexual Health Medicine clinical guidelines for PEP (https://www.asl |
| Prerequisites | Percutaneous exposure s (tick box where appropriate) ent has percutaneous exposure to blood known to be HIV pos | itive |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Ledipasvir with sofosbuvir

Note: Only for use in patients with approval by the Hepatitis C Treatment Panel (HepCTP). Applications will be considered by HepCTP at its regular meetings and approved subject to eligibility according to the Access Criteria (set out in Section B of the Pharmaceutical Schedule).

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Cidofovir | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist, infectious disease specialist, otolaryngologist or oral surgeon, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|------------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |
| Foscarnet sodium | | | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | | |
|-------------|----------|--|--|--|
| Name: | Name: | | | |
| Ward: | NHI: | | | |
| Ganciclovir | | | | |

INITIATION

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. ()

| | | list to determine if a patient meets the restrictions for funding community funding, see the Special Authority Criteria. | in the hospital setting . For more details, refer to Section H of the Pharmaceutical |
|-------|------------------------------|---|--|
| PRES | CRIBER | 3 | PATIENT: |
| Name: | | | Name: |
| Ward: | | | NHI: |
| Valga | nciclo | ovir | |
| Re-as | sessme quisites | Transplant cytomegalovirus prophylaxis ent required after 3 months s (tick box where appropriate) ient has undergone a solid organ transplant and requires val | ganciclovir for CMV prophylaxis |
| Re-as | sessme | ION – Transplant cytomegalovirus prophylaxis ent required after 3 months s (tick boxes where appropriate) | |
| | or | CMV prophylaxis Patient is to receive a maximum of 90 days of valga Patient has received pulse methylprednisolone for a prophylaxis | received anti-thymocyte globulin and requires valganciclovir therapy for inciclovir prophylaxis following anti-thymocyte globulin acute rejection and requires further valganciclovir therapy for CMV inciclovir prophylaxis following pulse methylprednisolone |
| Re-as | sessme quisites) Pres | Lung transplant cytomegalovirus prophylaxis ent required after 12 months s (tick boxes where appropriate) scribed by, or recommended by a relevant specialist, or in ac spital. | ccordance with a protocol or guideline that has been endorsed by the Health NZ |
| | and or and | Patient has undergone a lung transplant O The donor was cytomegalovirus positive and the parent of the recipient is cytomegalovirus positive Patient has a high risk of CMV disease | tient is cytomegalovirus negative |
| | | - Cytomegalovirus in immunocompromised patients s (tick boxes where appropriate) | |
| | and oi | m O Patient has rapidly rising plasma CMV DNA in abse | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|---|
| Name: | Name: |
| Ward: | NHI: |
| Emtricitabine with tenofovir disoproxil | |
| INITIATION – Confirmed HIV | |
| Prerequisites (tick box where appropriate) | |
| O Patient has confirmed HIV infection | |
| INITIATION – Prevention of maternal transmission Prerequisites (tick boxes where appropriate) | |
| O Prevention of maternal foetal transmission | |
| O Treatment of the newborn for up to eight weeks | |
| INITIATION – Post-exposure prophylaxis following non-occupational exp | posure to HIV |
| Prerequisites (tick boxes where appropriate) | |
| O Treatment course to be initiated within 72 hours post exposure | |
| O Patient has had unprotected receptive anal intercourse | with a known HIV positive person |
| O Patient has shared intravenous injecting equipment with | a known HIV positive person |
| O Patient has had non-consensual intercourse and the clin required | nician considers that the risk assessment indicates prophylaxis is |
| INITIATION – Percutaneous exposure Prerequisites (tick box where appropriate) O Patient has percutaneous exposure to blood known to be HIV positive | /e |
| INITIATION – Pre-exposure prophylaxis Re-assessment required after 24 months Prerequisites (tick boxes where appropriate) | |
| O Patient has tested HIV negative, does not have signs or symp | toms of acute HIV infection and has been assessed for HIV seroconversion |
| O The Practitioner considers the patient is at elevated risk of HIV | / exposure and use of PrEP is clinically appropriate |
| Note: Refer to local health pathways or the Australasian Society for HIV, Viral | Hepatitis and Sexual Health Medicine clinical guidelines (https://ashm.org.au/HIV/F |
| CONTINUATION – Pre-exposure prophylaxis Re-assessment required after 24 months Prerequisites (tick boxes where appropriate) | |
| | toms of acute HIV infection and has been assessed for HIV seroconversion |
| The Practitioner considers the patient is at elevated risk of HIV | / exposure and use of PrEP is clinically appropriate |
| Note: Refer to local health pathways or the Australasian Society for HIV, Viral | Hepatitis and Sexual Health Medicine clinical guidelines (https://ashm.org.au/HIV/F |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCR | IBER | PATIENT: |
|---------------------|---|----------|
| Name: . | | Name: |
| Ward: | | NHI: |
| Oseltar | nivir | |
| INITIATI Prerequ | ON iisites (tick boxes where appropriate) | |
| | O Only for hospitalised patient with known or suspected influenza | a |
| or | a Health NZ Hospital approved infections control plan | |
| | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | SCR | IBER | PATIENT: | |
|--|-----|--|----------|--|
| Name | e: | | Name: | |
| Ward: | | | NHI: | |
| Zanamivir - Powder for inhalation 5 mg | | | | |
| INITIATION Prerequisites (tick boxes where appropriate) | | | | |
| | | O Only for hospitalised patient with known or suspected influenza | a | |
| | or | O For prophylaxis of influenza in hospitalised patients as part of a Health NZ Hospital approved infections control plan | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|---------------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |
| COVID-19 treatments | | | |

INITIATION

Prerequisites (tick box where appropriate)

Only if patient meets access criteria (as per https://pharmac.govt.nz/covid-oral-antivirals). Note the supply of treatment is via Pharmac's approved distribution process. Refer to the Pharmac website for more information about this and stock availability ()

Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Remdesivir | |

INITIATION – Treatment of mild to moderate COVID-19

Prerequisites (tick box where appropriate)

 \bigcirc Only if patient meets access criteria (as per https://pharmac.govt.nz/covid-oral-antivirals). Note the supply of treatment is via Pharmac's approved distribution process. Refer to the Pharmac website for more information about this and stock availability

INITIATION – COVID-19 in hospitalised patients Re-assessment required after 5 doses Prerequisites (tick boxes where appropriate) () Patient is hospitalised with confirmed (or probable) symptomatic COVID-19 and Patient is considered to be at high risk of progression to severe disease and Patient's symptoms started within the last 7 days and Patient does not require, or is not expected to require, mechanical ventilation and Not to be used in conjunction with other funded COVID-19 antiviral treatments and Treatment not to exceed five days

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|----------|
| Name: | Name: |
| Ward: | NHI: |
| Interferon gamma | |
| INITIATION Prerequisites (tick box where appropriate) | |
| m O Patient has chronic granulomatous disease and requires interferon g | gamma |

RS1827 - Pegylated interferon alfa-2a

| Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior - INITIATION Chronic hepatitis C - genotype 1 infection - CONTINUATION Chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver tran - INITIATION | 220 <mark>splant</mark> |
|---|----------------------------|
| Chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV - INITIATION | 221 |
| Myeloproliferative disorder or cutaneous T cell lymphoma - INITIATION Myeloproliferative disorder or cutaneous T cell lymphoma - CONTINUATION | 222 |
| Ocular surface squamous neoplasia - INITIATION | 222 |
| Post-allogenic bone marrow transplant - INITIATION Post-allogenic bone marrow transplant - CONTINUATION | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Pegylated interferon alfa-2a

| INITIATION – Chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant Re-assessment required after 48 weeks |
|---|
| Prerequisites (tick boxes where appropriate) |
| O Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection |
| O Patient has chronic hepatitis C and is co-infected with HIV |
| O Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant |
| Note: Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure. Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml. |
| CONTINUATION – Chronic hepatitis C - genotype 1 infection Re-assessment required after 48 weeks |
| Prerequisites (tick boxes where appropriate) |
| O Prescribed by, or recommended by a gastroenterologist, infectious disease specialist or general physician, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. |
| O Patient has chronic hepatitis C, genotype 1 and |
| O Patient has had previous treatment with pegylated interferon and ribavirin and |
| O Patient has responder relapsed |
| O Patient was a partial responder |
| And O Patient is to be treated in combination with boceprevir |
| INITIATION – Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior Re-assessment required after 48 weeks |
| Prerequisites (tick boxes where appropriate) |
| O Prescribed by, or recommended by a gastroenterologist, infectious disease specialist or general physician, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. |
| O Patient has chronic hepatitis C, genotype 1 and |
| Patient has had previous treatment with pegylated interferon and ribavirin and |
| O Patient has responder relapsed |
| or O Patient was a partial responder |
| O Patient received interferon treatment prior to 2004 |
| And O Patient is to be treated in combination with boceprevir |

HOSPITAL MEDICINES LIST

| July 2 | n RS182 2025 | 27 | RESTRICTIONS CHECKLIST | Page 22 |
|--------|-----------------|---|--|--|
| | | st to determine if a patient meets the rest community funding, see the Special Auth | | For more details, refer to Section H of the Pharmaceutical |
| PRES | SCRIBER | | PATIENT: | |
| Name |): | | Name: | |
| Ward | : | | NHI: | |
| Peg | lated ir | nterferon alfa-2a - continued | | |
| | | Chronic hepatitis C - genotype 2 or 3 at required after 6 months | infection without co-infection with HIV | |
| | | (tick box where appropriate) | | |
| | O Patie | nt has chronic hepatitis C, genotype 2 o | r 3 infection | |
| and | | Patient has been endorsed by the Hea Patient has confirmed Hepatitis B infec Patient is Hepatitis B treatment-naive ALT > 2 times Upper Limit of Normal HBV DNA < 10 log10 IU/mI O HBeAg positive O Serum HBV DNA greater than or moderate fibrosis) | Ith NZ Hospital. tion (HBsAg positive for more than 6 month | general physician, or in accordance with a protocol or Is) Dosis (greater than or equal to Metavir Stage F2 or |
| | and | Compensated liver disease | | |
| | and | No continuing alcohol abuse or intraver | nous drug use | |
| | O | Not co-infected with HCV, HIV or HDV | | |

O No history of hypersensitivity or contraindications to pegylated interferon

INITIATION – myeloproliferative disorder or cutaneous T cell lymphoma Re-assessment required after 12 months

O Neither ALT nor AST > 10 times upper limit of normal

Prerequisites (tick boxes whe

| Prerequisites | (tick boxes | where | appropriat | e) |
|---------------|-------------|-------|------------|----|
| | | | | |

and

and

| or | O | Patient has a myeloproliferative disorder* |
|----|-----------|--|
| | and O and | Patient is intolerant of hydroxyurea |
| | 0 | Treatment with anagrelide and busulfan is not clinically appropriate |
| or | 0 | Patient has a myeloproliferative disorder |
| | and | Patient is pregnant, planning pregnancy or lactating |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|--|
| | |
| | Name: |
| Ward: | NHI: |
| Pegylated interferon alfa-2a - continued | |
| CONTINUATION – myeloproliferative disorder or cutaneous T cell lymp Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) | homa |
| O No evidence of disease progression and O The treatment remains appropriate and patient is benefitting | from treatment |
| and O Patient has a cutaneous T cell lymphoma* | |
| or O Patient has a myeloproliferative disorder* | |
| or | atment with anagrelide and busulfan remains clinically inappropriate |
| O Patient is pregnant, planning pregnancy or | lactating |
| Note: Indications marked with * are unapproved indications | |
| Re-assessment required after 12 months Prerequisites (tick box where appropriate) O Prescribed by, or recommended by an ophthalmologist, or in accor Hospital. and O Patient has ocular surface squamous neoplasia* | dance with a protocol or guideline that has been endorsed by the Health NZ |
| CONTINUATION – ocular surface squamous neoplasia Re-assessment required after 12 months Prerequisites (tick box where appropriate) | |
| O Prescribed by, or recommended by an ophthalmologist, or in accor Hospital. | dance with a protocol or guideline that has been endorsed by the Health NZ |
| O The treatment remains appropriate and patient is benefitting from t Note: Indications marked with * are unapproved indications | reatment |
| INITIATION – post-allogenic bone marrow transplant Re-assessment required after 3 months Prerequisites (tick box where appropriate) O Patient has received an allogeneic bone marrow transplant* and has | as evidence of disease relapse |
| CONTINUATION – post-allogenic bone marrow transplant Re-assessment required after 3 months Prerequisites (tick box where appropriate) | |
| O Patient is responding and ongoing treatment remains appropriate Note: Indications marked with * are unapproved indications | |
| | |

Signed: Date:

Musculoskeletal System

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|----------|
| Name: | Name: |
| Ward: | NHI: |
| Edrophonium chloride | |
| INITIATION Prerequisites (tick box where appropriate) | |
| ${igodoldoldoldoldoldoldoldoldoldoldoldoldol$ | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Denosumab

| (and | С | The | patient has established osteoporosis |
|----------|-------------|------------|---|
| | | 0 | History of one significant osteoporotic fracture demonstrated radiologically, with a documented T-Score less than or equal to -2.5, that incorporates BMD measured using dual-energy x-ray absorptiometry (DEXA) |
| | or | Ο | History of one significant osteoporotic fracture, demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of logistical, technical or pathophysiological reasons |
| | or | Ο | History of two significant osteoporotic fractures demonstrated radiologically |
| | or | Ο | Documented T-Score less than or equal to -3.0 |
| | or | 0 | A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm that incorporates BMD measured using DEXA |
| nd | \subseteq | | |
| | or | Ο | Bisphosphonates are contraindicated because the patient's creatinine clearance or eGFR is less than 35 mL/min |
| | •. | Ο | The patient has experienced at least two symptomatic new fractures or a BMD loss greater than 2% per year, after at least 12 months' continuous therapy with a funded antiresorptive agent |
| | or | 0 | Bisphosphonates result in intolerable side effects |
| | or | \bigcirc | Intravenous bisphosphonates cannot be administered due to logistical or technical reasons |

INITIATION – Hypercalcaemia

Prerequisites (tick boxes where appropriate)



Patient has hypercalcaemia of malignancy

Patient has severe renal impairment

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Raloxifene

| | | (tick boxes where appropriate) |
|----|---|---|
| or | 0 | History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Notes) |
| | 0 | History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age |
| or | Ο | History of two significant osteoporotic fractures demonstrated radiologically |
| or | Ο | Documented T-Score greater than or equal to -3.0 (see Notes) |
| or | Ο | A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes) |
| or | Ο | Patient has had a Special Authority approval for zoledronic acid (Underlying cause - Osteoporosis) or has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019 |

Note:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for raloxifene funding.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| | |

Teriparatide

| | IATION Issessmen | t required after 18 months |
|------|---------------------|---|
| Prer | equisites | (tick boxes where appropriate) |
| | and | The patient has severe, established osteoporosis |
| | and | The patient has a documented T-score less than or equal to -3.0 (see Notes) |
| | and | The patient has had two or more fractures due to minimal trauma |
| | 0 | The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes) |

Note:

- a) The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- b) Antiresorptive agents and their adequate doses for the purposes of this restriction are defined as: alendronate sodium tab 70 mg or tab 70 mg with colecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.
- c) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|-------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Rasburicase | |
| | |

INITIATION

Prerequisites (tick box where appropriate)

()Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Febuxostat

| (| С | Patie | ent has been diagnosed with gout |
|-----|----|------------|--|
| and | | | |
| | | 0 | The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose |
| | or | Ο | The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose |
| | or | 0 | The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains |
| | or | ~ | greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note) |
| | | \bigcirc | The patient has previously had an initial Special Authority approval for benzbromarone for treatment of gout. |

INITIATION – Tumour lysis syndrome Re-assessment required after 6 weeks

Prerequisites (tick boxes where appropriate)

O Prescribed by, or recommended by a haematologist or oncologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

O Patient is scheduled to receive cancer therapy carrying an intermediate or high risk of tumour lysis syndrome and

O Patient has a documented history of allopurinol intolerance

CONTINUATION – Tumour lysis syndrome

Re-assessment required after 6 weeks **Prerequisites** (tick box where appropriate)

()

and

Prescribed by, or recommended by a haematologist or oncologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

The treatment remains appropriate and patient is benefitting from treatment

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| | |

Sugammadex

| INITI Prere | | | (tick boxes where appropriate) |
|----------------|----------|---|--|
| | or | 0 | Patient requires reversal of profound neuromuscular blockade following rapid sequence induction that has been undertaken using rocuronium (i.e. suxamethonium is contraindicated or undesirable) |
| | or | Ο | Severe neuromuscular degenerative disease where the use of neuromuscular blockade is required |
| | | Ο | Patient has an unexpectedly difficult airway that cannot be intubated and requires a rapid reversal of anaesthesia and neuromuscular blockade |
| | or or | Ο | The duration of the patient's surgery is unexpectedly short |
| | | Ο | Neostigmine or a neostigmine/anticholinergic combination is contraindicated (for example the patient has ischaemic heart disease, morbid obesity or COPD) |
| | or | 0 | Patient has a partial residual block after conventional reversal |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|----------|
| Name: | Name: |
| Ward: | NHI: |
| Etoricoxib | |
| INITIATION Prerequisites (tick box where appropriate) | |
| O For in-vivo investigation of allergy only | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Capsaicin | |
| | |

Prerequisites (tick box where appropriate)

O Patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated

Nervous System

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|---|
| Name: | Name: |
| Ward: | NHI: |
| Riluzole | |
| INITIATION Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a neurologist or respiratory speci by the Health NZ Hospital. | alist, or in accordance with a protocol or guideline that has been endorsed |
| The patient has amyotrophic lateral sclerosis with disease dura and The patient has at least 60 percent of predicted forced vital cap and The patient has not undergone a tracheostomy and The patient has not experienced respiratory failure and | |

or O The patient is able to use upper limbs

The patient is ambulatory

 \bigcirc The patient is able to swallow

CONTINUATION

Re-assessment required after 18 months

()

Prerequisites (tick boxes where appropriate)

| O The patient has not undergone a tracheostomy | | | patient has not undergone a tracheostomy |
|--|----|-------|---|
| and (and | С | The p | patient has not experienced respiratory failure |
| and | | 0 | The patient is ambulatory |
| | or | Ο | The patient is able to use upper limbs |
| | or | Ο | The patient is able to swallow |

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|----------|
| Name: | Name: |
| Ward: | NHI: |
| Sucrose | |
| INITIATION Prerequisites (tick box where appropriate) | |
| O For use in neonatal patients only | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIBER | | PATIENT: | | |
|------|--------------------|--|------------------------------|--|--|
| Name | : | | Name: | | |
| Ward | | | NHI: | | |
| Meth | oxyflur | ane | | | |
| | ATION equisites | (tick boxes where appropriate) | | | |
| |) and | Patient is undergoing a painful procedure with an expected du | ration of less than one hour | | |
| | Ö | O Only to be used under supervision by a medical practitioner or nurse who is trained in the use of methoxyflurane | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|-------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Paracetamol | |

INITIATION

Prerequisites (tick box where appropriate)

()Intravenous paracetamol is only to be used where other routes are unavailable or impractical, or where there is reduced absorption. The need for IV paracetamol must be re-assessed every 24 hours

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|----------|
| Name: | Name: |
| Ward: | NHI: |
| Capsaicin | |
| INITIATION Prerequisites (tick box where appropriate) | |
| O For post-herpetic neuralgia or diabetic peripheral neuropathy | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Vigabatrin

| Re-a | | men | equired after 15 months ck boxes where appropriate) | | |
|----------------------|-----------------|--------------------------------|--|--|--|
| | | O Patient has infantile spasms | | | |
| Patient has epilepsy | | | | | |
| | | | O Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents or | | |
| | | | O Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents | | |
| | | or | O Patient has tuberous sclerosis complex | | |
| | and | | | | |
| | | | O Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter) | | |
| | | or | O It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields | | |
| \subseteq | | | | | |
| | NTINU requis | | ck boxes where appropriate) | | |
| | and | 0 | he patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life | | |
| | | or | Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin | | |

O It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|--|
| Name: | Name: |
| Ward: | NHI: |
| Lacosamide | |
| INITIATION Re-assessment required after 15 months Prerequisites (tick boxes where appropriate) | |
| | erienced unacceptable side effects from, optimal treatment with all of the ny two of carbamazepine, lamotrigine, and phenytoin sodium (see Note) |
| Note: Those of childbearing potential are not required to trial phenytoin sodiul required to trial sodium valproate. | m, sodium valproate, or topiramate. Those who can father children are not |

CONTINUATION

Prerequisites (tick box where appropriate)

() Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|-------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Ctivinontal | |

Stiripentol

and

()

| INITIATION Re-assessment required after 6 months Prereguisites (tick boxes where appropriate) |
|--|
| O Prescribed by, or recommended by a paediatric neurologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and |
| Patient has confirmed diagnosis of Dravet syndrome Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet |
| Note: Those of childbearing potential are not required to trial sodium valproate or topiramate. Those who can father children are not required to trial sodium valproate. |
| CONTINUATION Prerequisites (tick box where appropriate) |

O Prescribed by, or recommended by a paediatric neurologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

Patient continues to benefit from treatment as measured by reduced seizure frequency from baseline

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--------------------------------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Hyoscine hydrobromide - Patch 1.5 mg | |
| | |

Prerequisites (tick boxes where appropriate) ()Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease where the patient cannot tolerate or does not adequately respond to oral anti-nausea agents or Control of clozapine-induced hypersalivation where trials of at least two other alternative treatments have proven ineffective or ()For treatment of post-operative nausea and vomiting where cyclizine, droperidol and a 5HT3 antagonist have proven ineffective, are not tolerated or are contraindicated

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Aprepitant | | |
| | | |

Prerequisites (tick box where appropriate)

O Patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Paliperidone

| sses | smer | | uired after 12 months poxes where appropriate) |
|------|------|--------|---|
| or | 0 | | patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection or aripiprazole ot injection |
| | an | O d | The patient has schizophrenia or other psychotic disorder The patient has been unable to adhere to treatment using oral atypical antipsychotic agents |
| | an | d O | The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months |
| | | | |

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

The initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection \bigcirc

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|---|
| Name: | Name: |
| Ward: | NHI: |
| Paliperidone palmitate | |
| INITIATION Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) | liperidone once-monthly depot injection |
| CONTINUATION Re-assessment required after 12 months Prerequisites (tick box where appropriate) O The initiation of paliperidone depot injection has been associated wincorresponding period of time prior to the initiation of an atypical antiparticle | |
| | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Olanzapine | |
| | |

CONTINUATION Re-assessment required after 12 months Prerequisites (tick box where appropriate)

 \bigcirc The initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Risperidone

| Prerec | | | | uired after 12 months boxes where appropriate) |
|--------|----|----|---|---|
| C | or | 0 | | patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection or aripiprazole t injection |
| | | an | O | The patient has schizophrenia or other psychotic disorder |
| | | an | Ο | The patient has not been able to adhere to treatment using oral atypical antipsychotic agents |
| | | | 0 | The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months |

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

The initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection \bigcirc

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Aripiprazole

| | or | O The patient has had an initial Special Authority approval for risperidone depot injection or paliperidone depot injection or olanzapine depot injection |
|----|----|---|
| | | O The patient has schizophrenia or other psychotic disorder |
| | | and O The patient has received treatment with oral atypical antipsychotic agents but has been unable to adhere |
| | | The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months |
| or | 0 | Patient has been unable to access olanzapine depot injection due to supply issues with olanzapine depot injection, or otherwise would have been initiated on olanzapine depot injection but has been unable to due to supply issues with olanzapine depot injection. (see Note below for the olanzapine Special Authority criteria for new olanzapine depot injection patients prior to 1 April 2024) |

- All of the following:
 - The patient has schizophrenia; and
 - The patient has tried but has not been able to adhere with treatment using oral atypical antipsychotic agents; and
 - The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

and

HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|--|
| Name: | Name: |
| Ward: | NHI: |
| Diazepam | |
| INITIATION Prerequisites (tick box where appropriate) | |
| O Prescribed by, or recommended by a relevant specialist, or in accord Hospital. | dance with a protocol or guideline that has been endorsed by the Health NZ |

Only for use in children where diazepam tablets are not appropriate

| SCRIBER | | PATIENT: |
|---|--|---|
| e: | | Name: |
| I: | | NHI: |
| tiple Scler | rosis | |
| teriflunomic assessment r requisites (ti O Prescri NZ Hos | de required after 12 months ick boxes where appropriate) bed by, or recommended by any relevant practitioner, o | latiramer acetate, interferon beta-1-alpha, interferon beta-1-beta, natalizum |
| and | Diagnosis of multiple sclerosis (MS) meets the M neurologist Patient has an EDSS score between 0 - 6.0 | cDonald 2017 diagnostic criteria for MS and has been confirmed by a |
| and (and | O Patient has had at least one significant attack of I | MS in the previous 12 months or two significant attacks in the past 24 months |
| | and Each significant attack is associated with cl experienced symptoms(s)/sign(s) and Each significant attack has lasted at least cl attack (where relevant) and | by the applying neurologist or general physician (the patient may not g the attack, but the neurologist/physician must be satisfied that the clinical haracteristic new symptom(s)/sign(s) or substantially worsening of previously one week and has started at least one month after the onset of a previous d from the effects of general fatigue; and is not associated with a fever (T> |
| | System scores by at least 1 point | ugh to change either the EDSS or at least one of the Kurtze Functional paroxysmal symptom of multiple sclerosis (tonic seizures/spasms, ptom) |
| and (and | Evidence of new inflammatory activity on an MRI | scan within the past 24 months MRI scanning (in criterion 5 immediately above) is a gadolinium enhancing |
| | or O A sign of that new inflammatory activity of a sign of that new inflammatory activity is a or | |
| | O A sign of that new inflammatory is a T2 les | ion with associated local swelling |
| | O A sign of that new inflammatory activity is a recent attack that occurred within the last 2 | a prominent T2 lesion that clearly is responsible for the clinical features of a years |
| | $\overline{\mathbf{O}}$ | new T2 lesions compared with a previous MRI scan |

()

and

HOSPITAL MEDICINES LIST **RESTRICTIONS CHECKLIST**

Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Multiple Sclerosis - continued

CONTINUATION - Multiple Sclerosis - dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1-alpha, interferon beta-1-beta, natalizumab and teriflunomide

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

Patient has had an EDSS score of 0 to 6.0 (inclusive) with or without the use unilateral or bilateral aids at any time in the last six months (ie the patient has walked 100 metres or more with or without aids in the last six months) Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| SCRIBER | PATIENT: |
|---|--|
| ə: | Name: |
| : | NHI: |
| iple Sclerosis | |
| assessment required a requisites (tick boxes | |
| and Patie | nosis of multiple sclerosis (MS) meets the McDonald 2017 diagnostic criteria for MS and has been confirmed by a ologist ent has an EDSS score between 0 – 6.0 ent has had at least one significant attack of MS in the previous 12 months or two significant attacks in the past 24 months |
| and and and and and and and or | Each significant attack must be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the attack, but the neurologist/physician must be satisfied that the clinical features were characteristic) Each significant attack is associated with characteristic new symptom(s)/sign(s) or substantially worsening of previously experienced symptoms(s)/sign(s) Each significant attack has lasted at least one week and has started at least one month after the onset of a previous attack (where relevant) Each significant attack can be distinguished from the effects of general fatigue; and is not associated with a fever (T> 37.5°C) O Each significant attack is severe enough to change either the EDSS or at least one of the Kurtze Functional System scores by at least 1 point |
| and | O Each significant attack is a recurrent paroxysmal symptom of multiple sclerosis (tonic seizures/spasms, trigeminal neuralgia, Lhermitte's symptom) ence of new inflammatory activity on an MRI scan within the past 24 months A sign of that new inflammatory activity on MRI scanning (in criterion 5 immediately above) is a gadolinium enhancing lesion |
| or or or or | A sign of that new inflammatory activity is a lesion showing diffusion restriction A sign of that new inflammatory is a T2 lesion with associated local swelling A sign of that new inflammatory activity is a prominent T2 lesion that clearly is responsible for the clinical features of a recent attack that occurred within the last 2 years A sign of that new inflammatory activity is new T2 lesions compared with a previous MRI scan |

| Use this checklist to determine if a patient meets the restrictions for funding in t Schedule. For community funding, see the Special Authority Criteria. | he hospital setting . For more details, refer to Section H of the Pharmaceutical |
|---|---|
| PRESCRIBER | PATIENT: |
| Name: | Name: |
| Ward: | NHI: |
| Multiple Sclerosis - continued | |
| CONTINUATION – Multiple Sclerosis - ocrelizumab | |
| Prerequisites (tick box where appropriate) | |
| O Prescribed by, or recommended by any relevant practitioner, or in a NZ Hospital. | ccordance with a protocol or guideline that has been endorsed by the Health |
| | |
| INITIATION – Primary Progressive Multiple Sclerosis Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by any relevant practitioner, or in an NZ Hospital. | ccordance with a protocol or guideline that has been endorsed by the Health |
| | |
| | |
| CONTINUATION – Primary Progressive Multiple Sclerosis Prerequisites (tick box where appropriate) | |
| O Prescribed by, or recommended by any relevant practitioner, or in a NZ Hospital. | ccordance with a protocol or guideline that has been endorsed by the Health |
| \sim | ime in the last six months (ie patient has walked 20 metres with bilateral |

| Signed: Date: | |
|---------------|--|
|---------------|--|

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | | |
|--|--|--|--|--|
| Name: | Name: | | | |
| Ward: | NHI: | | | |
| Melatonin | | | | |
| INITIATION – insomnia secondary to neurodevelopmental disorder Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) | | | | |
| O Prescribed by, or recommended by a psychiatrist, paediatrician, neu guideline that has been endorsed by the Health NZ Hospital. | urologist or respiratory specialist, or in accordance with a protocol or | | | |
| | somnia secondary to a neurodevelopmental disorder (including, but not activity disorder) | | | |
| O Behavioural and environmental approaches have been tried or are inappropriate | | | | |
| O Funded modified-release melatonin is to be given at doses no and | O Funded modified-release melatonin is to be given at doses no greater than 10 mg per day | | | |
| O Patient is aged 18 years or under | | | | |
| CONTINUATION – insomnia secondary to neurodevelopmental disorder Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a psychiatrist, paediatrician, neu guideline that has been endorsed by the Health NZ Hospital. | urologist or respiratory specialist, or in accordance with a protocol or | | | |
| O Patient is aged 18 years or under | | | | |
| | unded modified-release melatonin (clinician determined) discontinuation within the past 12 months and has had a recurrence of | | | |
| and Funded modified-release melatonin is to be given at doses no | o greater than 10 mg per day | | | |
| INITIATION – insomnia where benzodiazepines and zopicione are contra Prerequisites (tick boxes where appropriate) | aindicated | | | |
| O Patient has insomnia and benzodiazepines and zopiclone are and O For in-hospital use only | e contraindicated | | | |

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |

Nusinersen

| | ATION | |
|-------|------------|--|
| Re-a | ssessmer | nt required after 12 months |
| Prere | equisites | (tick boxes where appropriate) |
| | and and | Patient has genetic documentation of homozygous SMN1 gene deletion, homozygous SMN1 point mutation, or compound heterozygous mutation Patient is 18 years of age or under |
| | or | O Patient has experienced the defined signs and symptoms of SMA type I, II or IIIa prior to three years of age |
| | | O Patient is pre-symptomatic |
| | | O Patient has three or less copies of SMN2 |
| | | |
| Re-a | | DN at required after 12 months (tick boxes where appropriate) |
| |) and | There has been demonstrated maintenance of motor milestone function since treatment initiation |
| | 0 | Patient does not require invasive permanent ventilation (at least 16 hours per day), in the absence of a potentially reversible cause while being treated with nusinersen |
| | and | Nusinersen not to be administered in combination other SMA disease modifying treatments or gene therapy |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |

Risdiplam

| | sessmer | nt required after 12 months (tick boxes where appropriate) |
|--------|---------|--|
| | O | Patient has genetic documentation of homozygous SMN1 gene deletion, homozygous SMN1 point mutation, or compound heterozygous mutation |
| | | Patient is 18 years of age or under |
| | or | O Patient has experienced the defined signs and symptoms of SMA type I, II or IIIa prior to three years of age |
| | | O Patient is pre-symptomatic and O Patient has three endow endow endow endow |
| | | Patient has three or less copies of SMN2 |
| Re-ass | | DN Int required after 12 months (tick boxes where appropriate) |
| | | There has been demonstrated maintenance of motor milestone function since treatment initiation |
| | 0 | Patient does not require invasive permanent ventilation (at least 16 hours per day), in the absence of a potentially reversible cause while being treated with risdiplam |
| Ĩ | | Risdiplam not to be administered in combination other SMA disease modifying treatments or gene therapy |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |

Modafinil

| INITIATION – Narcolepsy Prerequisites (tick boxes where appropriate) | | | | | | | |
|---|---|---|--|--|--|--|--|
| | | Prescribed by, or recommended by a neurologist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | | | |
| | O The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more and | | | | | | |
| | | or | O The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods O The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations | | | | |
| | and | or | An effective dose of a listed formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerable side effects Methylphenidate and dexamphetamine are contraindicated | | | | |
| or | (and | C C | Patient meets the Hospital Restriction criteria for methylphenidate hydrochloride for narcolepsy Patient is unable to access methylphenidate hydrochloride presentations due to an out of stock (see note) | | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |

Lisdexamfetamine dimesilate

INITIATION

Prerequisites (tick boxes where appropriate)

()Prescribed by, or recommended by a paediatrician or psychiatrist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and

| | (and | С | ADHD | 0 (Attention Deficit and Hyperactivity Disorder) |
|---|----------|---|--|---|
| Diagnosed according to DSM-V or ICD 11 criteria | | | | osed according to DSM-V or ICD 11 criteria |
| | | | | Patient is taking a currently subsidised formulation of atomoxetine or methylphenidate hydrochloride (extended-release and has not received sufficient benefit or has experienced intolerable side effects |
| | | | Patient is taking a currently subsidised formulation of dexamfetamine sulfate (immediate-release) which has not been effective due to significant administration and/or treatment adherence difficulties | |
| | | or O Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-rel | | There is significant concern regarding the risk of diversion or abuse of immediate release dexamfetamine sulfate |
| | | | | Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-release or sustained release) which has not been effective due to significant administration and/or treatment adherence difficulties |
| | or | | 0 | There is significant concern regarding the risk of diversion or abuse of immediate release methylphenidate hydrochloric |
| | | | and | O Patient would have been prescribed a subsidised formulation of methylphenidate hydrochloride (extended-release) but has been unable to access due to supply issues with methylphenidate hydrochloride (extended-release) |
| | | | and | O Other alternative stimulant presentations (methylphenidate or dexamfetamine) are not appropriate |

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | | | |
|---|---|--|--|--|--|
| Name: | Name: | | | | |
| Ward: | NHI: | | | | |
| Methylphenidate hydrochloride | | | | | |
| INITIATION – ADHD (immediate-release and sustained-release formulat Prerequisites (tick box where appropriate) | ions) | | | | |
| Health NZ Hospital. | O Prescribed by, or recommended by a paediatrician or psychiatrist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | | |
| Patient has ADHD (Attention Deficit and Hyperactivity Disorder), di | agnosed according to DSM-IV or ICD 10 criteria | | | | |
| INITIATION – Narcolepsy (immediate-release and sustained-release for Prerequisites (tick box where appropriate) | nulations) | | | | |
| by the Health NZ Hospital. | cialist, or in accordance with a protocol or guideline that has been endorsed | | | | |
| O Patient suffers from narcolepsy | | | | | |
| INITIATION – Extended-release and modified-release formulations Prerequisites (tick boxes where appropriate) | | | | | |
| O Prescribed by, or recommended by a paediatrician or psychiatrist, o Health NZ Hospital. | or in accordance with a protocol or guideline that has been endorsed by the | | | | |
| Patient has ADHD (Attention Deficit and Hyperactivity Disord | er), diagnosed according to DSM-IV or ICD 10 criteria | | | | |
| O Patient is taking a currently listed formulation of methyl has not been effective due to significant administration | phenidate hydrochloride (immediate-release or sustained-release) which and/or compliance difficulties | | | | |
| | ion or abuse of immediate-release methylphenidate hydrochloride | | | | |
| INITIATION – Narcolepsy* (extended-release only) Prerequisites (tick box where appropriate) | | | | | |

O Prescribed by, or recommended by a neurologist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

O Patient suffers from narcolepsy

and

Note: *narcolepsy is not a registered indication for Concerta or Ritalin LA.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCR | IBER | PATIENT: | | |
|---|--|---|--|--|
| Name: . | | Name: | | |
| Ward: | | NHI: | | |
| Dexam | phetamine sulphate | | | |
| | ON – ADHD isites (tick box where appropriate) | | | |
| O Prescribed by, or recommended by a paediatrician or psychiatrist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | | |
| and | Patient has ADHD (Attention Deficit and Hyperactivity Disorder), dia | gnosed according to DSM-IV or ICD 10 criteria | | |
| | INITIATION – Narcolepsy | | | |
| Prerequ | isites (tick box where appropriate) | | | |
| O Prescribed by, or recommended by a neurologist or respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | | |
| and | O Patient suffers from narcolepsy | | | |

Page 261

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|---------------------------|
| Name: | Name: |
| Ward: | NHI: |
| Rivastigmine | |
| INITIATION Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) O The patient has been diagnosed with dementia and O The patient has experienced intolerable nausea and/or vomiting | ng from donepezil tablets |
| CONTINUATION Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) O The treatment remains appropriate and O The patient has demonstrated a significant and sustained beneficial | efit from treatment |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|---|
| Name: | Name: |
| Ward: | NHI: |
| Naltrexone hydrochloride | |
| INITIATION – Alcohol dependence Prerequisites (tick boxes where appropriate) | |
| O Patient is currently enrolled, or is planned to be enrolled, in a and O Naltrexone is to be prescribed by, or on the recommendation of | recognised comprehensive treatment programme for alcohol dependence of, a physician working in an Alcohol and Drug Service |
| INITIATION – Constipation Prerequisites (tick box where appropriate) O For the treatment of opioid-induced constipation | |
| | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRI | BER | | PATIENT: |
|-----------------|------|-------|--|---|
| Name | : | | | Name: |
| Ward: | | | | NHI: |
| Nico | tine | e | | |
| INITI. Prere | | sites | (tick boxes where appropriate) For perioperative use in patients who have a 'nil by mouth' inst | ruction |
| | or | 0 | For use within mental health inpatient units | |
| | or | 0 | Patient would be admitted to a mental health inpatient unit, but | t is unable to due to COVID-19 self-isolation requirement |
| | | 0 | For acute use in agitated patients who are unable to leave the | hospital facilities |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| | | |

Varenicline

| ITIATION rerequisites (tick boxes where appropriate) | | | |
|---|---|---|--|
| | 0 | Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking | |
| and | 0 | The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring | |
| | O The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy | | |
| | or | O The patient has tried but failed to quit smoking using bupropion or nortriptyline | |
| and | Ο | The patient has not had a Special Authority for varenicline approved in the last 6 months | |
| | | Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this | |
| | Ο | The patient is not pregnant | |
| and | Ο | The patient will not be prescribed more than 12 weeks' funded varenicline in a 12 month period | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|---|
| Name: | Name: |
| Ward: | NHI: |
| Buprenorphine with naloxone | |
| INITIATION – Detoxification Prerequisites (tick boxes where appropriate) O Patient is opioid dependent and O Patient is currently engaged with an opioid treatment service a and O Prescriber works in an opioid treatment service approved by the | |
| INITIATION – Maintenance treatment Prerequisites (tick boxes where appropriate) | |
| O Patient is opioid dependent | |
| Patient will not be receiving methadone and | |
| O Patient is currently enrolled in an opioid substitution treatment | program in a service approved by the Ministry of Health |
| O Prescriber works in an opioid treatment service approved by the | he Ministry of Health |

Oncology Agents and Immunosuppressants

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|---|--|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Bendamustine I | hydrochloride | |
| INITIATION – CLL* Prerequisites (tick and Pati and Ben | * boxes where appropriate) e patient has chronic lymphocytic leukaemia requiring treatment ient has ECOG performance status 0-2 ndamustine is to be administered at a maximum dose of 100 mg/m ² on days 1 and 2 every 4 weeks for a maximum of 6 cycles | |
| Note: Indication ma (SLL). | arked with a * includes indications that are unapproved. 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma | |
| Re-assessment req Prerequisites (tick | Ilent, Low-grade lymphomas quired after 9 months a boxes where appropriate) e patient has indolent low grade NHL requiring treatment ient has ECOG performance status of 0-2 | |
| or a or | Patient is treatment naive Bendamustine is to be administered for a maximum of 6 cycles (in combination with rituximab when CD20+) Patient is refractory to or has relapsed within 12 months of a rituximab containing combined chemo-immunotherapy regimen Bendamustine is to be administered in combination with obinutuzumab for a maximum of 6 cycles | |
| | Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+) Patient has had a rituximab treatment-free interval of 12 months or more Bendamustine is to be administered as monotherapy for a maximum of 6 cycles in rituximab refractory patients | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|---|
| Name: | Name: |
| Ward: | NHI: |
| Bendamustine hydrochloride - continued | |
| CONTINUATION – Indolent, Low-grade lymphomas Re-assessment required after 9 months | |
| Prerequisites (tick boxes where appropriate) | |
| O Patient is refractory to or has relayed within 12 months | of rituximab in combination with bendamustine |

| | and O Bendamustine is to be administered in combination with obinutuzumab for a maximum of 6 cycles | | |
|-------|---|--|------------------------------------|
| | • | Patients have not received a bendamustine regimen within the last 12 months | |
| | | Bendamustine is to be administered for a maximum of 6 cycles in relapsed rituximab when CD20+) | d patients (in combination with |
| | | O Patient has had a rituximab treatment-free interval of 12 months or more | |
| | | or O Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles | s in rituximab refractory patients |
| Note: | 'ind | dolent, low-grade lymphomas' includes follicular, mantle cell, marginal zone and lymphoplasmacytic/ | Waldenström's macroglobulinaemia. |
| Re-as | ssess | DN – Hodgkin's lymphoma* esement required after 6 months isites (tick boxes where appropriate) | |
| | and | O Patient has Hodgkin's lymphoma requiring treatment | |
| | | O Patient has a ECOG performance status of 0-2 | |

Patient has a ECOG performance status of 0-2
 and
 Patient has received one prior line of chemotherapy
 and
 Patient's disease relapsed or was refractory following prior chemotherapy
 and

O Bendamustine is to be administered in combination with gemcitabine and vinorelbine (BeGeV) at a maximum dose of no greater than 90 mg/m2 twice per cycle, for a maximum of four cycles

Note: Indications marked with * are unapproved indications.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| | | |

Azacitidine

| INITIATION Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) | | |
|--|--|--|
| O The individual has intermediate or high risk MDS based on an internationally recognised scoring system O The individual has chronic myelomonocytic leukaemia (based on an intermediate or high risk score from an internationally recognised scoring system or 10%-29% marrow blasts without myeloproliferative disorder) O The individual has acute myeloid leukaemia according to World Health Organisation (WHO) Classification | | |
| and O The individual has an estimated life expectancy of at least 3 months | | |
| CONTINUATION Re-assessment required after 12 months Prerequisites (tick box where appropriate) | | |
| O No evidence of disease progression | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|---|
| Name: | Name: |
| Ward: | NHI: |
| Mercaptopurine | |
| INITIATION Re-assessment required after 12 months Prerequisites (tick box where appropriate) O Prescribed by, or recommended by a paediatric haematologist or pa been endorsed by the Health NZ Hospital. and O The patient requires a total dose of less than one full 50 mg tablet pa | ediatric oncologist, or in accordance with a protocol or guideline that has er day |
| CONTINUATION Re-assessment required after 12 months Prerequisites (tick box where appropriate) O Prescribed by, or recommended by a paediatric haematologist or pa been endorsed by the Health NZ Hospital. and O The patient requires a total dose of less than one full 50 mg tablet p | ediatric oncologist, or in accordance with a protocol or guideline that has er day |

Page 271

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |

Venetoclax

| | | relapsed/refractory chronic lymphocytic leukaemia t required after 7 months |
|------|-----------|--|
| Prer | equisites | (tick boxes where appropriate) |
| | Ο | Individual has chronic lymphocytic leukaemia requiring treatment |
| | and | Individual has received at least one prior therapy for chronic lymphocytic leukaemia |
| | and | Individual has not previously received funded venetoclax |
| | and | The individual's disease has relapsed |
| | and | Venetoclax to be used in combination with six 28-day cycles of rituximab commencing after the 5-week dose titration schedule with venetoclax |
| | and | Individual has an ECOG performance status of 0-2 |

CONTINUATION - relapsed/refractory chronic lymphocytic leukaemia

Re-assessment required after 6 months

()

and

Prerequisites (tick boxes where appropriate)

Treatment remains clinically appropriate and the individual is benefitting from and tolerating treatment

Venetoclax is to be discontinued after a maximum of 24 months of treatment following the titration schedule unless earlier discontinuation is required due to disease progression or unacceptable toxicity

| Re-as | sessmer | previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation* nt required after 6 months (tick boxes where appropriate) |
|-------|-----------|--|
| | Ο | Individual has previously untreated chronic lymphocytic leukaemia |
| | and O and | There is documentation confirming that the individual has 17p deletion by FISH testing or TP53 mutation by sequencing |
| | | Individual has an ECOG performance status of 0-2 |

CONTINUATION – previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation* Re-assessment required after 6 months

Prerequisites (tick box where appropriate)

O No evidence of disease progression

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL)* and B-cell prolymphocytic leukaemia (B-PLL)*. Indications marked with * are unapproved indications

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIB | ER | | | PATIENT: |
|-------|--|------|---------|---|---|
| Name | : | | | | Name: |
| Ward: | | | | | NHI: |
| Vene | tocl | ax - | conti | nued | |
| Re-a | ssess | ment | t requi | usly untreated acute myeloid leukaemia ired after 6 months oxes where appropriate) | |
| | (or | С | The i | ndividual is currently on treatment with venetoclax and me | et all remaining special authority criteria prior to commencing treatment |
| | | and | 0 | Individual has previously untreated acute myeloid leukae Classification | emia (see note a), according to World Health Organization (WHO) |
| | | | Ο | Venetoclax not to be used in combination with standard | intensive remission induction chemotherapy |
| | O Venetoclax to be used in combination with azacitidine or low dose cytarabine | | | | |

CONTINUATION – previously untreated acute myeloid leukaemia Re-assessment required after 6 months

Prerequisites (tick box where appropriate)

O No evidence of disease progression Note:

a) 'Acute myeloid leukaemia' includes myeloid sarcoma*

b) Indications marked with * are Unapproved indications

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESC | RIBER | PATIENT: |
|-------|-------|----------|
| Name: | | Name: |
| Ward: | | NHI: |

Olaparib

| | essr | nent | t requir | red a | iter 12 months where appropriate) |
|-----|-------------------|--------------|----------|--------|--|
| and | | resc ospi | | oy, or | recommended by a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ |
| a | ind | ~ | | | a high-grade serous* epithelial ovarian, fallopian tube, or primary peritoneal cancer cumentation confirming pathogenic germline BRCA1 or BRCA2 gene mutation |
| a | Ind | | and | Ο | Patient has newly diagnosed, advanced disease Patient has received one line** of previous treatment with platinum-based chemotherapy Patient's disease must have experienced a partial or complete response to the first-line platinum-based regimen |
| | | or | and | | Patient has received at least two lines** of previous treatment with platinum-based chemotherapy Patient has platinum sensitive disease defined as disease progression occurring at least 6 months after the last dose of the penultimate line** of platinum-based chemotherapy Patient's disease must have experienced a partial or complete response to treatment with the immediately preceding platinum-based regimen Patient has not previously received funded olaparib treatment |
| а | ind ind ind | | Treatn | nenti | will be commenced within 12 weeks of the patient's last dose of the immediately preceding platinum-based regimen to be administered as maintenance treatment not to be administered in combination with other chemotherapy |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIB | ER | PATIENT: |
|-------|-----------------------------|-------------|--|
| Name: | | | Name: |
| Ward: | | | NHI: |
| Olapa | arib | - <i>co</i> | ntinued |
| Re-as | ssessi quisi | men ites | N – Ovarian cancer required after 12 months (tick boxes where appropriate) ribed by, or recommended by a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ tal. |
| and | (and | С | Treatment remains clinically appropriate and patient is benefitting from treatment |
| | | or | No evidence of progressive disease Evidence of residual (not progressive) disease and the patient would continue to benefit from treatment in the clinician's opinion |
| | and (and (and | С С | Treatment to be administered as maintenance treatment Treatment not to be administered in combination with other chemotherapy |
| | | or | Patient has received one line** of previous treatment with platinum-based chemotherapy Documentation confirming that the patient has been informed and acknowledges that the funded treatment period of olaparib will not be continued beyond 2 years if the patient experiences a complete response to treatment and there is no radiological evidence of disease at 2 years |
| | | | O Patient has received at least two lines** of previous treatment with platinum-based chemotherapy |

Note: *Note "high-grade serous" includes tumours with high-grade serous features or a high-grade serous component **A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|--|
| Name: | Name: |
| Ward: | NHI: |
| Ibrutinib | |
| INITIATION – chronic lymphocytic leukaemia (CLL) Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) Individual has chronic lymphocytic leukaemia (CLL) requiring and Individual has not previously received funded ibrutinib and Individual has not previously received funded ibrutinib and Ibrutinib is to be used as monotherapy | therapy |
| O There is documentation confirming that the individ | lual has 17p deletion or TP53 mutation |

Individual has experienced intolerable side effects with venetoclax in combination with rituximab regimen

Individual has experienced intolerable side effects with venetoclax monotherapy

Individual has received at least one prior immunochemotherapy for CLL

| CONTINUATION – chronic lymphocytic leukaemia | (CLL) | |
|--|-------|--|
| Re-assessment required after 12 months | | |

Individual's CLL has relapsed

Prerequisites (tick box where appropriate)

and

and

and

()

or

or

()

No evidence of clinical disease progression

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL) and B-cell prolymphocytic leukaemia (B-PLL)*. Indications marked with * are Unapproved indications.

O Individual's CLL is refractory to or has relapsed following a venetoclax regimen

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |

Niraparib

| | essme | nt required after 6 months (tick boxes where appropriate) |
|------------------|-------|---|
| a a a a | | Patient has advanced high-grade serous* epithelial ovarian, fallopian tube, or primary peritoneal cancer Patient has received at least one line** of treatment with platinum-based chemotherapy Patient has experienced a partial or complete response to the preceding treatment with platinum-based chemotherapy Patient has not previously received funded treatment with a PARP inhibitor O Treatment will be commenced within 12 weeks of the patient's last dose of the preceding platinum-based regimen O Patient commenced treatment with niraparib prior to 1 May 2024 Treatment to be administered as maintenance treatment Treatment not to be administered in combination with other chemotherapy |
| Prereq | essme | nt required after 6 months (tick boxes where appropriate) No evidence of progressive disease Treatment to be administered as maintenance treatment Treatment not to be administered in combination with other chemotherapy O Treatment with niraparib to cease after a total duration of 36 months from commencement |

Note: * "high-grade serous" includes tumours with high-grade serous features or a high-grade serous component. **A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments

| Use this checklist to determine if a patient meets the restrictions for funding i Schedule. For community funding, see the Special Authority Criteria. | in the hospital setting . For more details, refer to Section H of the Pharmaceutical |
|---|---|
| PRESCRIBER | PATIENT: |
| Name: | Name: |
| Ward: | NHI: |
| Lenalidomide | |
| INITIATION – Plasma cell dyscrasia Prerequisites (tick boxes where appropriate) | |
| O Prescribed by, or recommended by any relevant practitioner, or in NZ Hospital. | n accordance with a protocol or guideline that has been endorsed by the Health |
| O Patient has plasma cell dyscrasia, not including Waldenstro and O Patient is not refractory to prior lenalidomide use | öm macroglobulinaemia, requiring treatment |
| INITIATION – Myelodysplastic syndrome Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by any relevant practitioner, or in NZ Hospital. | n accordance with a protocol or guideline that has been endorsed by the Health |
| and Patient has low or intermediate-1 risk myelodysplastic sync a deletion 5q cytogenetic abnormality and Patient has transfusion-dependent anaemia | drome (based on IPSS or an IPSS-R score of less than 3.5) associated with |
| | n accordance with a protocol or guideline that has been endorsed by the Health |
| ANZ Hospital. | |

and

and

()

and

HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|---|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |
| Pomalidomide | | | |
| INITIATION – Relapsed/refractory plasma cell dyscrasia Re-assessment required after 6 months | | | |

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

O Patient has relapsed or refractory plasma cell dyscrasia, not including Waldenström macroglobulinaemia, requiring treatment

Patient has not received prior funded pomalidomide

CONTINUATION - Relapsed/refractory plasma cell dyscrasia

Re-assessment required after 12 months

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

Patient has no evidence of disease progression

| PRESCRIBER | PATIENT: |
|--|--|
| Name: | Name: |
| Ward: | NHI: |
| Temozolomide | |
| INITIATION – gliomas Re-assessment required after 12 months Prerequisites (tick box where appropriate) | |
| O Patient has a glioma | |
| CONTINUATION – gliomas Re-assessment required after 12 months Prerequisites (tick box where appropriate) O Treatment remains appropriate and patient is benefitting fro | om treatment |
| INITIATION – Neuroendocrine tumours Re-assessment required after 9 months Prerequisites (tick boxes where appropriate) | |
| Patient has been diagnosed with metastatic or unresand Temozolomide is to be given in combination with capand Temozolomide is to be used in 28 day treatment cycl per day Temozolomide to be discontinued at disease progresand | ecitabine es for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m ² |
| CONTINUATION – Neuroendocrine tumours Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) | |
| O No evidence of disease progression and O The treatment remains appropriate and the patient is | benefitting from treatment |
| | |
| INITIATION – ewing's sarcoma Re-assessment required after 9 months Prerequisites (tick box where appropriate) | |
| O Patient has relapse or refractory Ewing's sarcoma | |
| CONTINUATION – ewing's sarcoma Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) | |
| O No evidence of disease progression and | benefitting from treatment |

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|----------|
| Name: | Name: |
| Ward: | NHI: |
| Thalidomide | |
| INITIATION Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) | |

 \bigcirc The patient has plasma cell dyscrasia, not including Waldenström macroglobulinaemia, requiring treatment

The patient has erythema nodosum leprosum

CONTINUATION

or

Prerequisites (tick box where appropriate)

O Patient has obtained a response from treatment during the initial approval period Note: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|-----------------------------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Bortezomib | | |
| NITIATION – plasma cell dyscrasia | | |

Prerequisites (tick box where appropriate)

m O The patient has plasma cell dyscrasia, not including Waldenström macroglobulinaemia, requiring treatment

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|--|
| Name: | Name: |
| Ward: | NHI: |
| Pegaspargase | |
| INITIATION – Newly diagnosed ALL Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) O The patient has newly diagnosed acute lymphoblastic leukaen | nia |
| and O Pegaspargase to be used with a contemporary intensive multi | |
| INITIATION – Relapsed ALL Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) | |
| O The patient has relapsed acute lymphoblastic leukaemia and O Pegaspargase to be used with a contemporary intensive multi | -agent chemotherapy treatment protocol |
| INITIATION – Lymphoma Re-assessment required after 12 months Prerequisites (tick box where appropriate) O Patient has lymphoma requiring L-asparaginase containing protocol | (e.g. SMILE) |
| O Patient has lymphoma requiring L-asparaginase containing protocol | (e.g. SMILE) |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESC | RIBER | PATIENT: |
|-------|-------|----------|
| Name: | | Name: |
| Ward: | | NHI: |
| | | |

Nilotinib

| INITIATION Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) | | |
|---|---------|--|
| (and | | Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. |
| | and | O Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, high risk chronic phase, or in chronic phase |
| | | O Patient has documented CML treatment failure* with a tyrosine kinase inhibitor (TKI) |
| | | O Patient has experienced treatment limiting toxicity with a tyrosine kinase inhibitor (TKI) precluding further treatment |
| | and | O Maximum nilotinib dose of 800 mg/day |
| | and | O Subsidised for use as monotherapy only |
| Note | : *trea | atment failure as defined by Leukaemia Net Guidelines. |
| Re-a | ssess | ATION ment required after 6 months ites (tick boxes where appropriate) |
| (and | | Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. |
| | and | O Lack of treatment failure while on nilotinib as defined by Leukaemia Net Guidelines |
| | and | O Nilotinib treatment remains appropriate and the patient is benefiting from treatment |
| | and | O Maximum nilotinib dose of 800 mg/day |
| | and | O Subsidised for use as monotherapy only |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Ruxolitinib

| INITIATION Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) | | | | |
|---|--|---------------|---|--|
| (and | | Preso Hosp | cribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ ital. | |
| O The patient has primary myelofibrosis or post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis and | | | The patient has primary myelofibrosis or post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis | |
| | A classification of risk of intermediate-2 or high-risk myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS | | | |
| | | | A classification of risk of intermediate-1 myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS and | |
| | | | O Patient has severe disease-related symptoms that are resistant, refractory or intolerant to available therapy | |
| | and | 0 | A maximum dose of 20 mg twice daily is to be given | |
| CONTINUATION | | | | |

Re-assessment required after 12 months **Prerequisites** (tick boxes where appropriate)

and

The treatment remains appropriate and the patient is benefiting from treatment

A maximum dose of 20 mg twice daily is to be given

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|---|
| Name: | Name: |
| Ward: | NHI: |
| Alectinib | |
| INITIATION Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) | -small cell lung cancer < tyrosine kinase gene rearrangement using an appropriate ALK test |
| CONTINUATION Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) O No evidence of progressive disease according to RECIST crite and O The patient is benefitting from and tolerating treatment | eria |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Palbociclib (Ibrance)

| | (and | С | Patient has unresectable locally advanced or metastatic breast cancer |
|----|-----------------|---------------|--|
| | | С | There is documentation confirming disease is hormone-receptor positive and HER2-negative |
| | and (and | С | Patient has an ECOG performance score of 0-2 |
| | | or | O Disease has relapsed or progressed during prior endocrine therapy |
| | | | O Patient is amenorrhoeic, either naturally or induced, with endocrine levels consistent with a postmenopausal or without menstrual-potential state |
| | | | Patient has not received prior systemic treatment for metastatic disease |
| | and (and | С С | Treatment must be used in combination with an endocrine partner Patient has not received prior funded treatment with a CDK4/6 inhibitor |
| or | | | |
| | and | \mathcal{O} | Patient has an active Special Authority approval for ribociclib |
| | and (| С | Patient has experienced a grade 3 or 4 adverse reaction to ribociclib that cannot be managed by dose reductions and requires treatment discontinuation |
| | (| С | Treatment must be used in combination with an endocrine partner |
| | and (| С | There is no evidence of progressive disease since initiation of ribociclib |

Prerequisites (tick boxes where appropriate)

Ο

and \bigcirc Treatment must be used in combination with an endocrine partner

There is no evidence of progressive disease since initiation of palbociclib

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |

Ribociclib

| | C | Patient has unresectable locally advanced or metastatic breast cancer |
|----|-----|---|
| | and | There is documentation confirming disease is hormone-receptor positive and HER2-negative |
| | and | Patient has an ECOG performance score of 0-2 |
| | | O Disease has relapsed or progressed during prior endocrine therapy |
| | | Patient is amenorrhoeic, either naturally or induced, with endocrine levels consistent with a postmenopausal or without menstrual-potential state |
| | | O Patient has not received prior systemic endocrine treatment for metastatic disease |
| | and | Treatment to be used in combination with an endocrine partner |
| | and | Patient has not received prior funded treatment with a CDK4/6 inhibitor |
| or | C | Patient has an active Special Authority approval for palbociclib |
| | and | Patient has experienced a grade 3 or 4 adverse reaction to palbociclib that cannot be managed by dose reductions and requires treatment discontinuation |
| | C | Treatment must be used in combination with an endocrine partner |
| | and | There is no evidence of progressive disease since initiation of palbociclib |

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

| O |
|--------|
| and |
| \cup |

D Treatment must be used in combination with an endocrine partner

There is no evidence of progressive disease since initiation of ribociclib

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |

Lenvatinib

| or | O Patient is currently on treatment with lenvatinib and met all remaining criteria prior to commencing treatment | | | |
|--|--|--|---|---|
| | and | O The patient has locally advanced or metastatic differentiated thyroid cancer | | |
| | | | 0 | Patient must have symptomatic progressive disease prior to treatment |
| | | or | 0 | Patient must progressive disease at critical anatomical sites with a high risk of morbidity or mortality where local control cannot be achieved by other measures |
| | and | \sim | | |
| O A lesion without iodine uptake in a RAI scan | | A lesion without iodine uptake in a RAI scan | | |
| | | or | Ο | Receiving cumulative RAI greater than or equal to 600 mCi |
| | | or | Ο | Experiencing disease progression after a RAI treatment within 12 months |
| | | or | Ο | Experiencing disease progression after two RAI treatments administered within 12 months of each other |
| and Patient has thyroid stimulating hormone (TSH) adequately supressed | | ent has thyroid stimulating hormone (TSH) adequately supressed | | |
| | and | \bigcirc | | |
| Patient is not a candidate for radiotherapy with curative intent and Surgery is clinically inappropriate | | | | |
| | | | | and |

Prerequisites (tick box where appropriate)

O There is no evidence of disease progression

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|--|---|--|
| Name: | Name: | |
| Vard: NHI: | | |
| Lenvatinib - continued | | |
| INITIATION – unresectable hepatocellular carcinoma Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) | | |
| Patient has unresectable hepatocellular carcinoma Patient has preserved liver function (Childs-Pugh A) and Transarterial chemoembolisation (TACE) is unsuitable Patient has an ECOG performance status of 0-2 Patient has not received prior systemic therapy for their or Patient has not received prior systemic therapy for their or Patient has experienced treatment-limiting toxicity and No disease progression since initiation of atezolizit CONTINUATION – unresectable hepatocellular carcinoma Re-assessment required after 6 months Prerequisites (tick box where appropriate) O There is no evidence of disease progression | from treatment with atezolizumab with bevacizumab | |
| INITIATION – renal cell carcinoma Re-assessment required after 4 months Prerequisites (tick boxes where appropriate) | | |
| O The patient has metastatic renal cell carcinoma and The disease is of predominant clear-cell histology and The patient has documented disease progression follow and The patient has an ECOG performance status of 0-2 and Lenvatinib is to be used in combination with everolimus or Patient has received funded treatment with nivolumab for and Patient has experienced treatment limiting toxicity from t and Lenvatinib is to be used in combination with everolimus or There is no evidence of disease progression | or the second line treatment of metastatic renal cell carcinoma | |
| Re-assessment required after 4 months Prerequisites (tick box where appropriate) O There is no evidence of disease progression | | |
| I confirm that the above details are correct: | | |

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |

Osimertinib

| INITIATION – NSCLC – first line Re-assessment required after 4 months Prerequisites (tick boxes where appropriate) |
|--|
| O Patient has locally advanced or metastatic, incurable, non-squamous non-small cell lung cancer (NSCLC) |
| O Patient is treatment naïve |
| or O Patient has received prior treatment in the adjuvant setting and/or while awaiting EGFR results or |
| O The patient has discontinued gefitinib or erlotinib due to intolerance and |
| O The cancer did not progress while on gefitinib or erlotinib |
| and O There is documentation confirming that the cancer expresses activating mutations of EGFR and |
| O Patient has an ECOG performance status 0-3 and |
| O Baseline measurement of overall tumour burden is documented clinically and radiologically |
| CONTINUATION – NSCLC – first line Re-assessment required after 6 months Prerequisites (tick box where appropriate) O Response to or stable disease with treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period |
| INITIATION – NSCLC – second line Re-assessment required after 4 months Prerequisites (tick boxes where appropriate) |
| O Patient has locally advanced or metastatic, incurable, non-squamous non-small cell lung cancer (NSCLC) |
| and O Patient has an ECOG performance status 0-3 and |
| O The patient must have received previous treatment with erlotinib or gefitinib |
| O There is documentation confirming that the cancer expresses T790M mutation of EGFR following progression on or after erlotinib or gefitinib |
| and O The treatment must be given as monotherapy |
| and O Baseline measurement of overall tumour burden is documented clinically and radiologically |
| |

CONTINUATION – NSCLC – second line Re-assessment required after 6 months

()

Prerequisites (tick box where appropriate)

Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|------------------------------|
| Name: | Name: |
| Ward: | NHI: |
| Axitinib | |
| INITIATION Re-assessment required after 4 months Prerequisites (tick boxes where appropriate) | e previous line of treatment |
| The patient has ECOG performance status of 0-2 | |
| CONTINUATION Re-assessment required after 4 months Prerequisites (tick box where appropriate) | |

 \mathbf{O} No evidence of disease progression.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Crizotinib | |

| Re-a | | at required after 6 months (tick boxes where appropriate) |
|------|----------|--|
| | and | Patient has locally advanced or metastatic, unresectable, non-squamous non-small cell lung cancer |
| | Ο | There is documentation confirming that the patient has a ROS1 rearrangement using an appropriate ROS1 test |
| | and | Patient has ECOG performance score of 0-3 |
| | and | Baseline measurement of overall tumour burden is documented clinically and radiologically |
| | TINUATIO | DN |

Re-assessment required after 6 months Prerequisites (tick boxes where appropriate)

> and \bigcirc

 \bigcirc Response to treatment has been determined by comparable radiological assessment following the most recent treatment period

No evidence of disease progression.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| | |

Dabrafenib

| INITIATION – stage III or IV resected melanoma - adjuvant Re-assessment required after 4 months Prereguisites (tick boxes where appropriate) | | | |
|---|--|--|--|
| Prerequisites (lick boxes where appropriate) | | | |
| O Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | |
| O The individual is currently on treatment with dabrafenib and trametinib and met all remaining criteria prior to commencing treatment | | | |
| O The individual has resected stage IIIB, IIIC, IIID or IV melanoma (excluding uveal) (see note a) or | | | |
| O The individual has received neoadjuvant treatment with a PD-1/PD-L1 inhibitor and | | | |
| Adjuvant treatment with dabrafenib is required | | | |
| and O The individual has not received prior funded systemic treatment in the adjuvant setting for stage IIIB, IIIC, IIID or IV melanoma and | | | |
| O Treatment must be adjuvant to complete surgical resection | | | |
| O Treatment must be initiated within 13 weeks of surgical resection, unless delay is necessary due to post-surgery recovery (see note b) | | | |
| and O The individual has a confirmed BRAF mutation and | | | |
| Dabrafenib must be administered in combination with trametinib | | | |
| The individual has ECOG performance score 0-2 | | | |
| Note: | | | |
| a) Stage IIIB, IIIC, IIID or IV melanoma defined as per American Joint Committee on Cancer (AJCC) 8th Edition | | | |

b) Initiating treatment within 13 weeks of complete surgical resection means 13 weeks after resection (primary or lymphadenectomy)

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting . For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria. | | | |
|--|--|--|---|
| PRESCRIE | BER | | PATIENT: |
| Name: | | | Name: |
| Ward: | Ward: NHI: | | |
| Dabrafer | nib - cont | inued | |
| Re-assess Prerequis | sment requ sites (tick b | | ccordance with a protocol or guideline that has been endorsed by the Health |
| | and and and | No evidence of disease recurrence Dabrafenib must be administered in combination with tra Treatment to be discontinued at signs of disease recurre any systemic neoadjuvant treatment | ametinib ence or at completion of 12 months' total treatment course, including |
| or | and and and and and and | The individual has received adjuvant treatment with a BI The individual has metastatic or unresectable melanoma The individual meets initiation criteria for dabrafenib for The individual has received adjuvant treatment with a BI The individual has received a BRAF/MEK inhibitor for un | a (excluding uveal) stage III or IV unresectable or metastatic melanoma RAF/MEK inhibitor |
| | Ō | The individual meets continuation criteria for dabrafenib | for unresectable or metastatic melanoma |

| | | | letermine if a patient meets the restrictions for funding in the hospital setting . For more details, refer to Section H of the Pharmaceutical unity funding, see the Special Authority Criteria. |
|---|---|--|---|
| PRES | CRIB | ER | PATIENT: |
| Name | : | | Name: |
| Ward: | | | |
| Dabra | afen | ib - con | tinued |
| Re-as | ssess quisi | ment req tes (tick | ectable or metastatic melanoma uired after 4 months boxes where appropriate) I by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health |
| and | N | | |
| | or | J The | individual is currently on treatment with dabrafenib and trametinib and met all remaining criteria prior to commencing treatment |
| | | and | The individual has metastatic or unresectable melanoma (excluding uveal) stage III or IV |
| | | 0 | Baseline measurement of overall tumour burden is documented clinically and radiologically |
| | The individual has ECOG performance score 0-2 | | |
| | | | The individual has confirmed BRAF mutation |
| and O Dabrafenib must be administered in combination with trametinib and | | Dabrafenib must be administered in combination with trametinib | |
| | | | O The individual has been diagnosed in the metastatic or unresectable stage III or IV setting |
| | | 0 | m O The individual did not receive treatment in the adjuvant setting with a BRAF/MEK inhibitor |
| | | | O The individual received treatment in the adjuvant setting with a BRAF/MEK inhibitor and |
| | | | O The individual did not experience disease recurrence while on treatment with that BRAF/MEK inhibitor |
| | | | The individual did not experience disease recurrence within six months of completing adjuvant treatment with a BRAF/MEK inhibitor |
| | | | |
| CONTINUATION – unresectable or metastatic melanoma Re-assessment required after 4 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | |
| | | or O | The individual's disease has had a complete response to treatment |
| | | or O | The individual's disease has had a partial response to treatment |

O The individual has stable disease with treatment

Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period

I confirm that the above details are correct:

and

 \bigcirc

| Signed: | Date: |
|---------|-------|
|---------|-------|

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Trametinib | |

INITIATION - stage III or IV resected melanoma - adjuvant Re-assessment required after 4 months Prerequisites (tick boxes where appropriate) Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and The individual is currently on treatment with dabrafenib and trametinib and met all remaining criteria prior to commencing treatment or The individual has resected stage IIIB, IIIC, IIID or IV melanoma (excluding uveal) (see note a) or () The individual has received neoadjuvant treatment with a PD-1/PD-L1 inhibitor and () Adjuvant treatment with trametinib is required and The individual has not received prior funded systemic treatment in the adjuvant setting for stage IIIB, IIIC, IIID or IV melanoma and Treatment must be adjuvant to complete surgical resection and Treatment must be initiated within 13 weeks of surgical resection, unless delay is necessary due to post-surgery recovery (see note b) and The individual has a confirmed BRAF mutation and Trametinib must be administered in combination with dabrafenib and The individual has ECOG performance score 0-2 Note: a) Stage IIIB, IIIC, IIID or IV melanoma defined as per American Joint Committee on Cancer (AJCC) 8th Edition

b) Initiating treatment within 13 weeks of complete surgical resection means 13 weeks after resection (primary or lymphadenectomy)

I confirm that the above details are correct:

Signed: Date:

| | | letermine if a patient meets the restrictions for funding in t unity funding, see the Special Authority Criteria. | he hospital setting . For more details, refer to Section H of the Pharmaceutical |
|---|-----------------------------|--|---|
| PRESCRI | BER | | PATIENT: |
| Name: | | | Name: |
| Ward: | | | NHI: |
| Trametir | nib - conti | inued | |
| Re-asses Prerequis | sment requ sites (tick b | | ccordance with a protocol or guideline that has been endorsed by the Health |
| | and and O | No evidence of disease recurrence Trametinib must be administered in combination with da Treatment to be discontinued at signs of disease recurr any systemic neoadjuvant treatment | ubrafenib ence or at completion of 12 months' total treatment course, including |
| and O The individual has meta and | | The individual has received adjuvant treatment with a B The individual has metastatic or unresectable melanom The individual meets initiation criteria for trametinib for t | a (excluding uveal) stage III or IV |
| or | and and and | The individual has received adjuvant treatment with a B The individual has received a BRAF/MEK inhibitor for u The individual meets continuation criteria for trametinib | nresectable or metastatic melanoma |

| | | ermine if a patient meets the restrictions for funding in the hospital setting . For more details, refer to Section H of the Pharm ity funding, see the Special Authority Criteria. | aceutical |
|---|--------------------------------|--|-----------|
| PRESC | RIBER | PATIENT: | |
| Name: | | Name: | |
| Ward: | | NHI: | |
| Trame | etinib - a | led | |
| Re-ass | sessment quisites (t | ctable or metastatic melanoma ed after 4 months xes where appropriate) y, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the | Health |
| and | NZ Ho | | |
| | or O 1 | dividual is currently on treatment with dabrafenib and trametinib and met all remaining criteria prior to commencing treatment | t |
| | and | The individual has metastatic or unresectable melanoma (excluding uveal) stage III or IV Baseline measurement of overall tumour burden is documented clinically and radiologically The individual has ECOG performance score 0-2 | |
| | and and and | The individual has confirmed BRAF mutation | |
| | | The individual has been diagnosed in the metastatic or unresectable stage III or IV setting The individual did not receive treatment in the adjuvant setting with a BRAF/MEK inhibitor | |
| | | The individual received treatment in the adjuvant setting with a BRAF/MEK inhibitor and The individual did not experience disease recurrence while on treatment with that BRAF/MEK inhibitor and The individual did not experience disease recurrence within six months of completing adjuvant treatment with a BRAF/MEK inhibitor | |
| CONTINUATION - unresectable or metastatic melanoma Re-assessment required after 4 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and O The individual's disease has had a complete response to treatment | | | |
| | or | The individual's disease has had a partial response to treatment | |

O The individual has stable disease with treatment

Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period

I confirm that the above details are correct:

and

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Dasatinib

| INITIATION Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) | | | |
|--|--|--|--|
| O Prescribed by, or recommended by a haematologist or any relevant practitioner on the recommendation of a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | |
| O The patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis or accelerated phase O The patient has a diagnosis of Philadelphia chromosome-positive acute lymphoid leukaemia (Ph+ ALL) | | | |
| or O The patient has a diagnosis of CML in chronic phase and | | | |
| Patient has documented treatment failure* with imatinib Patient has experienced treatment-limiting toxicity with imatinib precluding further treatment with imatinib Patient has high-risk chronic-phase CML defined by the Sokal or EURO scoring system | | | |
| CONTINUATION Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) | | | |
| O Prescribed by, or recommended by a haematologist or any relevant practitioner on the recommendation of a haematologist , or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | |
| <pre>O Lack of treatment failure while on dasatinib* and O Dasatinib treatment remains appropriate and the patient is benefiting from treatment</pre> | | | |
| Nater theotheont follows for OML on defined by Louise Met Originalized | | | |

Note: *treatment failure for CML as defined by Leukaemia Net Guidelines.

Page 301

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| - • • • • | |

Erlotinib

| INITIATION Re-assessment required after 4 months Prerequisites (tick boxes where appropriate) | | | |
|---|--------|---|--|
| and | 0 0 | Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC) There is documentation confirming that the disease expresses activating mutations of EGFR | |
| | or | Patient is treatment naive Patient has received prior treatment in the adjuvant setting and/or while awaiting EGFR results The patient has discontinued osimertinib or getitinib due to intolerance and The cancer did not progress while on osimertinib or gefitinib | |

CONTINUATION

Re-assessment required after 6 months

Prerequisites (tick box where appropriate)

O Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|---|--|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |
| Sunitinib | | | |
| INITIATION – RCC Re-assessment required after 4 months Prerequisites (tick boxes where appropriate) | | | |
| and O The patient has not previously received funded sunitinib | | | |
| CONTINUATION - RCC Re-assessment required after 4 months Prerequisites (tick box where appropriate) O No evidence of disease progression | | | |
| INITIATION – GIST Re-assessment required after 3 months Prerequisites (tick boxes where appropriate) | | | |
| And The patient has unresectable or metastatic malignant gastrointer and O The patient's disease has progressed following treatment or O The patient has documented treatment-limiting intolerance | with imatinib | | |
| CONTINUATION – GIST Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) | | | |
| The patient has responded to treatment or has stable disease as follows: | s determined by Choi's modified CT response evaluation criteria as | | |
| O The patient has had a complete response (disappearance or O The patient has had a partial response (a decrease in siz (HU) of 15% or more on CT and no new lesions and no c | e of 10% or more or decrease in tumour density in Hounsfield Units bvious progression of non-measurable disease) e two above) and does not have progressive disease and no | | |
| and O The treatment remains appropriate and the patient is benefiting | from treatment | | |
| CONTINUATION – GIST pandemic circumstances Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) | | | |
| O The patient has unresectable or metastatic malignant gastrointe and O The patient is clinically benefiting from treatment and continued | | | |

O Sunitinib is to be discontinued at progression

The regular renewal requirements cannot be met due to COVID-19 constraints on the health sector

I confirm that the above details are correct:

and

and

 \bigcirc

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Sunitinib - continued

Note: GIST - It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of 10% or more and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|--|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Lapatinib | | |
| INITIATION Prerequisites (tick box where appropriate) O For continuation use only | | |
| CONTINUATION Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) | | |
| The patient has metastatic breast cancer expressing HER-2 IF and The cancer has not progressed at any time point during the pro- and Lapatinib not to be given in combination with trastuzumab and Lapatinib to be discontinued at disease progression | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |

Pazopanib

| | Ment required after 3 months tes (tick boxes where appropriate) |
|----------------------|--|
| | O The patient has metastatic renal cell carcinoma of predominantly clear cell histology |
| | O The patient is treatment naive |
| | O The patient has only received prior cytokine treatment |
| | and O The patient has an ECOG performance score of 0-2 and |
| | The patient has intermediate or poor prognosis defined as: |
| | O Lactate dehydrogenase level > 1.5 times upper limit of normal or O Haemoglobin level < lower limit of normal |
| | or O Corrected serum calcium level > 10 mg/dL (2.5 mmol/L) |
| | O Interval of < 1 year from original diagnosis to the start of systemic therapy or |
| | O Karnofsky performance score of less than or equal to 70 or O 2 or more sites of organ metastasis |
| or | |
| | O The patient has metastatic renal cell carcinoma |
| | and O The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance |
| | and O The cancer did not progress whilst on sunitinib and |
| | O Pazopanib to be used for a maximum of 3 months |
| CONTINU Re-assess | ATION ment required after 3 months |

Prerequisites (tick box where appropriate)

O No evidence of disease progression

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |

Gefitinib

| | N sment required after 4 months ites (tick boxes where appropriate) O Patient has locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC) |
|-----|---|
| and | or O Patient is treatment naive or O Patient has received prior treatment in the adjuvant setting and/or while awaiting EGFR results or O The view of the set of the |
| and | \sim |
| | There is documentation confirming that disease expresses activating mutations of EGFR ATION sment required after 6 months ites (tick box where appropriate) |

O Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|--|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |
| Dexrazoxane | | | |
| INITIATION Brazaguiaitas (tick bayos whore appropriate) | | | |
| Drerequisites (tick beyon where expression) | | | |

| Fier | cquisi | 103 | (lick boxes where appropriate) |
|----------|-----------------|-----|---|
| (and | | | cribed by, or recommended by a medical oncologist, paediatric oncologist, haematologist or paediatric haematologist, or in accordance with tocol or guideline that has been endorsed by the Health NZ Hospital. |
| | (and | С | Patient is to receive treatment with high dose anthracycline given with curative intent |
| | (| С | Based on current treatment plan, patient's cumulative lifetime dose of anthracycline will exceed 250mg/m2 doxorubicin equivalent or greater |
| | and (and | С | Dexrazoxane to be administered only whilst on anthracycline treatment |
| | anu | _ | O Treatment to be used as a cardioprotectant for a child or young adult |
| | | or | O Treatment to be used as a cardioprotectant for secondary malignancy |
| l | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |

Abiraterone acetate

| INITIATION Re-assessment required after 6 months Prereguisites (tick boxes where appropriate) | | | | |
|---|--------|---|--|--|
| O and | Presc | cribed by, or recommended by a medical oncologist, radiation oncologist or urologist, or in accordance with a protocol or guideline that has endorsed by the Health NZ Hospital. | | |
| and | C | Patient has prostate cancer | | |
| and | C t | Patient has metastases | | |
| and | C t | Patient's disease is castration resistant | | |
| | | O Patient is symptomatic | | |
| | | and O Patient has disease progression (rising serum PSA) after second line anti-androgen therapy and | | |
| | | O Patient has ECOG performance score of 0-1 | | |
| | | O Patient has not had prior treatment with taxane chemotherapy | | |
| | or | O Patient's disease has progressed following prior chemotherapy containing a taxane | | |
| | | O Patient has ECOG performance score of 0-2 | | |
| | | O Patient has not had prior treatment with abiraterone | | |
| | | | | |

CONTINUATION

and

and

and

)

| Re-assessmen | t required after 6 months | |
|---------------|--------------------------------|--|
| Prereauisites | (tick boxes where appropriate) | |

| \circ | Prescribed by, or recommended by a medical oncologist, radiation oncologist or urologist, or in accordance with a protocol or guideline that has |
|---------|--|
| and | been endorsed by the Health NZ Hospital. |
| | 2 |

|) | Significant decrease | in serum | PSA from | haseli | ne |
|---|----------------------|-------------|----------|---------|-----|
| / | Significant decrease | III Seruill | | Daseili | 116 |

No evidence of clinical disease progression

No initiation of taxane chemotherapy with abiraterone

The treatment remains appropriate and the patient is benefiting from treatment

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|---------------------------------------|
| Name: | Name: |
| Ward: | NHI: |
| Abiraterone acetate - continued | |
| CONTINUATION – pandemic circumstances Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) | |
| The patient is clinically benefiting from treatment and continue | ed treatment remains appropriate |
| O Abiraterone acetate to be discontinued at progression | |
| No initiation of taxane chemotherapy with abiraterone | |
| and The regular renewal requirements cannot be met due to COVI | D-19 constraints on the health sector |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Fulvestrant

| Re-a | | ent required after 6 months s (tick boxes where appropriate) |
|------|------------|--|
| and | | scribed by, or recommended by a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ apital. |
| | and and | Patient has oestrogen-receptor positive locally advanced or metastatic breast cancer Patient has disease progression following prior treatment with an aromatase inhibitor or tamoxifen for their locally advanced or metastatic disease |
| | and | Treatment to be given at a dose of 500 mg monthly following loading doses Treatment to be discontinued at disease progression |

CONTINUATION

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

| and | 0 | Prescribed by, or recommended by a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the He Hospital. | ncologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ | |
|-----|----|---|--|--|
| | | O Treatment remains appropriate and patient is benefitting from treatment | | |
| | an | O Treatment to be given at a dose of 500 mg monthly | | |
| | an | nd | | |

O No evidence of disease progression

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |

Long-acting Somatostatin Analogues

| | INITIATION – Malignant bowel obstruction Prerequisites (tick boxes where appropriate) | | | |
|------|--|-------|--|--|
| | and | 0 | The patient has nausea* and vomiting* due to malignant bowel obstruction* | |
| | and | 0 | Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has not been successful | |
| | anu | Ο | Treatment to be given for up to 4 weeks | |
| Note | : Indie | catio | ns marked with * are unapproved indications | |
| Re-a | ssess | men | acromegaly It required after 3 months (tick boxes where appropriate) | |
| | and | Ο | The patient has acromegaly | |
| | | | O Treatment with surgery and radiotherapy is not suitable or was unsuccessful | |
| | | or | O Treatment is for an interim period while awaiting the beneficial effects of radiotherapy | |
| | and | 0 | Treatment with a dopamine agonist has been unsuccessful | |

CONTINUATION – acromegaly

Prerequisites (tick box where appropriate)

O Without reassessment for applications where IGF1 levels have decreased since starting treatment

Note: In patients with acromegaly, treatment should be discontinued if IGF1 levels have no decreased 3 months after treatment. In patients treated with radiotherapy treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following treatment withdrawal for at least 4 weeks.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| ESCRIB | BER | | PATIENT: |
|---------|-----------|-------|---|
| ne: | | | Name: |
| rd: | | | |
| ng-act | ting S | Som | matostatin Analogues - continued |
| | | | r indications boxes where appropriate) |
| (or | 0 v | /IPoi | omas and glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery |
| | (and | Ο | Gastrinoma |
| | | | O Surgery has been unsuccessful |
| | | or | $^{ m r}$ O Patient has metastatic disease after treatment with H2 antagonist or proton pump inhibitors has been unsuccessful |
| or | \square | | |
| | (and | Ο | Insulinomas |
| | (| Ο | Surgery is contraindicated or has not been successful |
| or | | Tor n | pre-operative control of hypoglycaemia and for maintenance therapy |

O Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis) and

O Disabling symptoms not controlled by maximal medical therapy

INITIATION – pre-operative acromegaly

or

Re-assessment required after 12 months

| Prere | equisites | (tick boxes where appropriate) |
|-------|-----------|---|
| | 0 | Patient has acromegaly |
| | and | Patient has a large pituitary tumour, greater than 10 mm at its widest |
| | and | Patient is scheduled to undergo pituitary surgery in the next six months |
| Note: | Indicatio | ns marked with * are unapproved indications |
| | | of a long-acting somatostatin analogue in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will not be Special Authority |

| Signed: | | Date: | |
|---------|--|-------|--|
|---------|--|-------|--|

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | P | ATIENT: |
|--|---------------------------------------|---------|
| Name: | N | ame: |
| Ward: | N | НІ: |
| Aminolevulinic acid hydrochloride | | |
| INITIATION – high grade malignant glioma Prerequisites (tick boxes where appropriate) | | |
| And Patient has newly diagnosed, | untreated, glioblastoma multiforme | |
| \sim | vant to fluorescence-guided resection | in |
| O Patient's tumour is amenable | to complete resection | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIB | ER | РАТ | IENT: |
|-------|----------|--------------|---|---|
| Name | : | | Nar | e: |
| Ward: | | | NHI | |
| Tacro | olimu | ıs | | |
| | | tes (| organ transplant recipients (tick boxes where appropriate) | |
| | or (| | For use in organ transplant recipients The individual is receiving induction therapy for an organ transplant | |
| | | | non-transplant indications* (tick boxes where appropriate) | |
| and | | resc ospi | cribed by, or recommended by any specialist, or in accordance with a ital. | protocol or guideline that has been endorsed by the Health NZ |
| | (and | C | Patient requires long-term systemic immunosuppression | |
| | | | O Ciclosporin has been trialled and discontinued treatment beca | ause of unacceptable side effects or inadequate clinical response |
| | | or | O Patient is a child with nephrotic syndrome* | |
| Note | e: Indi | catio | ons marked with * are unapproved indications | |

RS2062 - Etanercept

| Arthritis - rheumatoid - INITIATION Arthritis - rheumatoid - CONTINUATION | |
|--|--|
| Adult-onset Still's disease - INITIATION | |
| Adult-onset Still's disease - CONTINUATION Ankylosing spondylitis - INITIATION | |
| Ankylosing spondylitis - CONTINUATION Oligoarticular course juvenile idiopathic arthritis - INITIATION | |
| Oligoarticular course juvenile idiopathic arthritis - CONTINUATION | |
| Polyarticular course juvenile idiopathic arthritis - INITIATION Polyarticular course juvenile idiopathic arthritis - CONTINUATION | |
| Psoriatic arthritis - INITIATION | |
| Psoriatic arthritis - CONTINUATION Pyoderma gangrenosum - INITIATION | |
| Pyoderma gangrenosum - CONTINUATION Severe chronic plaque psoriasis - CONTINUATION | |
| Severe chronic plaque psoriasis, prior TNF use - INITIATION | |
| Severe chronic plaque psoriasis, treatment-naive - INITIATION Undifferentiated spondyloarthritis - INITIATION | |
| Undifferentiated spondyloarthritis - CONTINUATION | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | SCRIBER PATIENT: | | | | |
|------|------------------|-------------------------------------|----------------------|---|--|
| Name | ne: Name: | | | | |
| Ward | : | | | NHI: | |
| Etan | nerce | ept | | | |
| Re-a | assess requis | sment sites (t Prescri | requ ick b bed | cular course juvenile idiopathic arthritis ed after 6 months xes where appropriate) y, or recommended by a rheumatologist or named specialist, or in accordance with a protocol or guideline that has been endorsed n NZ Hospital. | |
| unu | | and | Cor | The patient has had an initial Special Authority approval for adalimumab for polyarticular course juvenile idiopathic arthritis JIA) O The patient has experienced intolerable side effects from adalimumab O The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for polyarticular course JIA | |
| | or | and | O O or | To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance Patient has had polyarticular course JIA for 6 months duration or longer At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose) Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose) Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate | |
| | | | _ | | |
| Re-a | assess requis | sment sites (t Prescri | requ ick b bed | Iyarticular course juvenile idiopathic arthritis ed after 6 months xes where appropriate) y, or recommended by a rheumatologist or named specialist, or in accordance with a protocol or guideline that has been endorsed n NZ Hospital. | |
| | and | i | | Tent is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or ance Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in obysician's global assessment from baseline | |
| | | or | С | On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | SCRIE | BER | | PATIENT: | | |
|------|--|------------------------|------------------------|---|--|--|
| Name | : | | | Name: | | |
| Ward | | | | | | |
| Etan | erce | ept-c | ontir | ued | | |
| Re-a | ssess equis | sment re sites (tio | equi ck bo bed l | ticular course juvenile idiopathic arthritis ed after 6 months exes where appropriate) by, or recommended by a rheumatologist or named specialist, or in accordance with a protocol or guideline that has been endorsed h NZ Hospital. | | |
| | | and | | The patient has had an initial Special Authority approval for adalimumab for oligoarticular course juvenile idiopathic arthritis (JIA) O The patient has experienced intolerable side effects from adalimumab O The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for oligoarticular course JIA | | |
| | or | and | | To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance Patient has had oligoarticular course JIA for 6 months duration or longer | | |
| | | | or or | At least 2 active joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose) Moderate or high disease activity (cJADAS10 score greater than 1.5) with poor prognostic features after a 3-month trial of methotrexate (at the maximum tolerated dose) High disease activity (cJADAS10 score greater than 4) after a 6-month trial of methotrexate | | |
| Re-a | CONTINUATION – oligoarticular course juvenile idiopathic arthritis Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a rheumatologist or named specialist, or in accordance with a protocol or guideline that has been endorsed | | | | | |

by the Health NZ Hospital.

Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance

Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baselinee

On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline

()

or

 \bigcirc

and

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| RESCRI | BER | | PATIENT: |
|----------|--|--------------------------------|---|
| ame: | | | Name: |
| ard: | | | NHI: |
| anerce | ept - a | conti | nued |
| rerequis | sment sites (t | requ ick b ibed | tis - rheumatoid ired after 6 months ioxes where appropriate) by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ |
| | and | 0 | The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis |
| | una | or | O The patient has experienced intolerable side effects |
| | | | O The patient has received insufficient benefit to meet the renewal criteria for rheumatoid arthritis |
| or | and and and and | O O O or | Patient has had rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance Patient has tried and not responded to at least three months of methotrexate at a maximum tolerated dose (unless contraindicated) Patient has tried and not responded to at least three months of methotrexate in combination with sulfasalazine and hydroxychloroquit sulphate at maximum tolerated doses (unless contraindicated) Patient has tried and not responded to at least three months of methotrexate in combination with sulfasalazine and hydroxychloroquit sulphate at maximum tolerated doses (unless contraindicated) Patient has tried and not responded to at least three months of methotrexate in combination with the maximum tolerated dose of ciclosporin Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with methotrexate Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen joints Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip |
| rerequis | sment sites (t Prescri NZ Hos | requ ick b ibed spita | arthritis - rheumatoid ired after 2 years loxes where appropriate) by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health I. ment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or |
| and | . ii | | Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician |

| (and | | | ribed ospita | by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health I. |
|----------|----------|----|-----------------|---|
| | (and | 0 | | ment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or brance |
| | | or | 0 | Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician |
| | | | Ο | On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician |
| | and (| 0 | Etane | ercept to be administered at doses no greater than 50 mg every 7 days |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | | | | | | | F | PATIENT: |
|---|--|-------------------|------|----------------------------------|--|---|---|---|
| Name: . | ne: | | | | | | N | Name: |
| Ward: | rd: | | | | | | N | NHI: |
| Etaner | tanercept - continued | | | | | | | |
| INITIATION – ankylosing spondylitis Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Hospital. and | | | | | | e with a protocol or guideline that has been endorsed by the Health NZ | | |
| | | and | | The p | atient has had | an initial Special Author | ity approval fo | or adalimumab for ankylosing spondylitis |
| | | | or | 0 0 | - | | | from adalimumab alimumab to meet the renewal criteria for adalimumab for |
| 01 | | and and and | | Patie Patie Patie drugs | nt has low back nt has bilateral nt's ankylosing ; (NSAIDs), in c | pain and stiffness that sacroiliitis demonstrated spondylitis has not resp | is relieved by o d by plain radio onded adequa | s present for more than six months exercise but not by rest ographs, CT or MRI scan ately to treatment with two or more non-steroidal anti-inflammatory ndicated, while patient was undergoing at least 3 months of a regular |
| | | | or | O O Bath | Bath Ankylosir 4 cm and lumb Patient has lim gender (see N | ng Spondylitis Metrology par side flexion measure itation of chest expansion otes) | r Index (BASM ement of less the set on by at least | n the sagittal and the frontal planes as determined by the following II) measures: a modified Schober's test of less than or equal to han or equal to 10 cm (mean of left and right) 2.5 cm below the average normal values corrected for age and All of at least 6 on a 0-10 scale |
| measure | Note: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment. Average normal chest expansion corrected for age and gender: | | | | | | | |
| | | - | ge | | Male | Female | | |
| | | 18 | 8-24 | Ļ | 7.0 cm | 5.5 cm | | |
| | | 2 | 5-34 | Ļ | 7.5 cm | 5.5 cm | | |
| | | 3 | 5-44 | ŀ | 6.5 cm | 4.5 cm | | |
| | | 4 | 5-54 | Ļ | 6.0 cm | 5.0 cm | | |
| | | 5! | 5-64 | L | 5.5 cm | 4.0 cm | | |

65-74

75+

4.0 cm

3.0 cm

Signed: Date:

4.0 cm

2.5 cm

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|--|
| Name: | Name: |
| Ward: | NHI: |
| Etanercept - continued | |
| And Hospital. And Following 12 weeks' initial treatment and for subsequent renew points from pre-treatment baseline on a 10 point scale, or an in and Physician considers that the patient has benefited from treatment and Etanercept to be administered at doses no greater than 50 mg | ent and that continued treatment is appropriate |
| INITIATION – psoriatic arthritis Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a rheumatologist, or in accordan Hospital. and O The patient has had an initial Special Authority approval and O The patient has had an initial Special Authority approval | ce with a protocol or guideline that has been endorsed by the Health NZ for adalimumab or secukinumab for psoriatic arthritis |
| O The patient has experienced intolerable side effect or O The patient has received insufficient benefit from a adalimumab or secukinumab for psoriatic arthritis | ts from adalimumab or secukinumab |
| Patient has had severe active psoriatic arthritis for six m Patient has tried and not responded to at least three moweekly or a maximum tolerated dose | nths of oral or parenteral methotrexate at a dose of at least 20 mg |
| or | ed and active disease in at least 15 swollen, tender joints ed and active disease in at least four joints from the following: wrist, |
| or O Patient has an elevated erythrocyte sedimentation | 15 mg/L measured no more than one month prior to the date of this rate (ESR) greater than 25 mm per hour y receiving prednisone therapy at a dose of greater than 5 mg per day |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIB | ER | | | PATIENT: | | |
|--|---|------|---------|--|---|--|--|
| Name | : | | | | Name: | | |
| Ward: | /ard: | | | | | | |
| Etan | erce | pt - | - conti | nued | | | |
| Re-a | CONTINUATION – psoriatic arthritis Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) | | | | | | |
| O Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | | | | | |
| | and | or | 0 | clinically significant response to treatment in the opinion The patient demonstrates at least a continuing 30% impr response to prior etanercept treatment in the opinion of t | rovement in active joint count from baseline and a clinically significant he treating physician | | |
| | O Etanercept to be administered at doses no greater than 50 mg every 7 days | | | | | | |
| INITIATION – severe chronic plaque psoriasis, prior TNF use Re-assessment required after 4 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | | | | | |
| and | and (| | The p | patient has had an initial Special Authority approval for ad | alimumab for severe chronic plaque psoriasis | | |
| | | | 0 | The patient has experienced intolerable side effects from | adalimumab | | |
| | | or | 0 | The patient has received insufficient benefit from adalimuplaque psoriasis | umab to meet the renewal criteria for adalimumab for severe chronic | | |
| | and O Patient must be reassessed for continuation after 3 doses | | | | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIE | BER | | | PATIENT: | | | |
|---|--|---|---|--|---|--|--|--|
| Name | : | | | | Name: | | | |
| Ward | | | | | NHI: | | | |
| Etan | tanercept - continued | | | | | | | |
| | | | | chronic plaque psoriasis, treatment-naive red after 4 months | | | | |
| | | | | oxes where appropriate) | | | | |
| O Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by t Hospital. | | | | e with a protocol or guideline that has been endorsed by the Health NZ | | | | |
| | (| | | Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis | | | | |
| | | been present for at least 6 months from the time of initial | or palm of a hand or sole of a foot, where the plaque or plaques have I diagnosis | | | | | |
| | | or | 0 | | aque psoriasis where the plaques or lesions have been present for at a Dermatology Life Quality Index (DLQI) score greater than 10 | | | |
| | treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than cessation of each prior treatment course | | | | | | | |
| | | | treatr | PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior atment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following station of each prior treatment course | | | | |
| | and | 0 | The n | nost recent PASI or DLQI assessment is no more than 1 | month old at the time of initiation | | | |
| while | Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand, foot, genital or flexural areas at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very | | | | | | | |

face, hand, foot, genital or flexural areas at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and for the face, palm of a hand or sole of a foot the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |

Etanercept - continued

CONTINUATION – severe chronic plaque psoriasis Re-assessment required after 6 months Prerequisites (tick boxes where appropriate)

| | | and | Patient had "whole body" severe chronic plaque psoriasis at the start of treatment | |
|------------|------------------------|-----------|---|--|
| | | | O Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-etanercept treatment baseline value or | |
| | | | O Following each prior etanercept treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value | |
| | or | | | |
| | | and | Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment | |
| | | | O Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values | |
| | | | O Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline value | |
| | or | | | |
| | | and | Patient had severe chronic localised genital or flexural plaque psoriasis at the start of treatment | |
| | | | O The patient has experienced a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value or | |
| | | | O Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing etanercept | |
| | | | | |
| and | \frown | Etanerce | ept to be administered at doses no greater than 50 mg every 7 days | |
| | | | | |
| NITIATIO | N – py | oderma/ | a gangrenosum | |
| Prerequis | sites (t | ick boxe | es where appropriate) | |
| \bigcirc | Drooor | ibod by | or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ | |
| | Hospit | | or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ | |
| and | - | | | |
| | | Patient h | as pyoderma gangrenosum* | |
| and | | | | |
| and | á | | has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, rine, or methotrexate) and not received an adequate response | |
| | O A maximum of 8 doses | | | |

Note: Indications marked with * are unapproved indications.

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. | For more details, refer to Section H of the Pharmaceutical |
|--|--|
| Schedule. For community funding, see the Special Authority Criteria. | |

| PRESCRIBER | PATIENT: | | | | | | | |
|--|---|--|--|--|--|--|--|--|
| Name: | Name: | | | | | | | |
| Ward: | NHI: | | | | | | | |
| Etanercept - continued | Etanercept - continued | | | | | | | |
| CONTINUATION – pyoderma gangrenosum Prerequisites (tick boxes where appropriate) | or in accordance with a protocol or guideline that has been endorsed by the Health NZ | | | | | | | |
| Hospital. and O The patient has had an initial Speci or O The patient has been started on too and O The patient has experienced intoler | or in accordance with a protocol or guideline that has been endorsed by the Health NZ ial Authority approval for etanercept for adult-onset Still's disease (AOSD) cilizumab for AOSD in a Health NZ Hospital | | | | | | | |
| or O Patient diagnosed with AOSD according t | to the Yamaguchi criteria (J Rheumatol 1992;19:424-430) least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal thotrexate | | | | | | | |
| CONTINUATION – adult-onset Still's disease Re-assessment required after 6 months Prerequisites (tick box where appropriate) O Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | | | | | | |

O The patient has a sustained improvement in inflammatory markers and functional status

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | SCRIB | BER | | PATIENT: |
|------|-------------------------------|-----------------------|----------------------------|--|
| Name | e: | | | |
| Ward | : | | | NHI: |
| Etan | erce | pt | cont | inued |
| Re-a | issess equis O F | i tes Presc | t requ (tick b ribed | erentiated spondyloarthritis ired after 6 months poxes where appropriate) by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ |
| and | (and | Hosp O O | Patie wrist Patie | Int has undifferentiated peripheral spondyloarthritis* with active peripheral joint arthritis in at least four joints from the following: below, knee, ankle, and either shoulder or hip Int has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a |
| | and (| 0 | | mum tolerated dose ont has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day (or maximum tolerated) |
| | and | 0 | Patie | ent has tried and not responded to at least three months of leflunomide at a dose of up to 20 mg daily (or maximum tolerated dose) |
| | | or | 0 | Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application |
| | | or | 0 | Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour measured no more than one month prior to the date of this application |
| | | | 0 | ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months |
| Note | : India | catio | ns ma | arked with * are unapproved indications. |
| Re-a | issess | men | t requ | indifferentiated spondyloarthritis ired after 6 months poxes where appropriate) |
| | | or | 0 | Applicant is a rheumatologist |
| | | | 0 | Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment |
| | and | or | 0 | Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician |
| | | | \mathbf{O} | The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician |
| | and | Ο | Etan | ercept to be administered at doses no greater than 50 mg dose every 7 days |

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Bevacizumab

INITIATION – Recurrent Respiratory Papillomatosis Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) Prescribed by, or recommended by an otolaryngologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and () Maximum of 6 doses and The patient has recurrent respiratory papillomatosis and () The treatment is for intra-lesional administration **CONTINUATION – Recurrent Respiratory Papillomatosis** Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) () Prescribed by, or recommended by an otolaryngologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and () Maximum of 6 doses and The treatment is for intra-lesional administration and ()There has been a reduction in surgical treatments or disease regrowth as a result of treatment **INITIATION** – ocular conditions Prerequisites (tick boxes where appropriate)

O Ocular neovascularisation or

Exudative ocular angiopathy

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|----------|
| Name: | Name: |
| Ward: | NHI: |
| Ranibizumab | |
| INITIATION – Wet Age Related Macular Degeneration | |

| O f | ites (tick boxes where appropriate) Prescribed by, or recommended by an ophthalmologist or nurse practitioner, or in accordance with a protocol or guideline that has been Indorsed by the Health NZ Hospital. |
|-----|--|
| | O Wet age-related macular degeneration (wet AMD) |
| | or O Polypoidal choroidal vasculopathy |
| | or O Choroidal neovascular membrane from causes other than wet AMD |
| | and |
| | O The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab or |
| | O There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart |
| | and O There is no structural damage to the central fovea of the treated eye |
| | and O Patient has not previously been treated with aflibercept for longer than 3 months |
| or | |
| (| O Patient has current approval to use aflibercept for treatment of wAMD and was found to be intolerant to aflibercept within 3 months |
| | ATION – Wet Age Related Macular Degeneration ment required after 12 months |
| | ites (tick boxes where appropriate) |
| | Prescribed by, or recommended by an ophthalmologist or nurse practitioner, or in accordance with a protocol or guideline that has been indorsed by the Health NZ Hospital. |

I confirm that the above details are correct:

()

and

and

Signed: Date:

Documented benefit must be demonstrated to continue

Patient's vision is 6/36 or better on the Snellen visual acuity score

There is no structural damage to the central fovea of the treated eye

RS2124 - Infliximab

| Crohn's disease (adults) - INITIATION | |
|--|-----|
| Crohn's disease (adults) - CONTINUATION | |
| Crohn's disease (children) - INITIATION | |
| Crohn's disease (children) - CONTINUATION | |
| Graft vs host disease - INITIATION | |
| Inflammatory bowel arthritis (axial) - INITIATION | |
| Inflammatory bowel arthritis (axial) - CONTINUATION | |
| Inflammatory bowel arthritis (peripheral) - INITIATION | |
| Inflammatory bowel arthritis (peripheral) - CONTINUATION | 340 |
| Pulmonary sarcoidosis - INITIATION | |
| Acute fulminant ulcerative colitis - INITIATION | |
| Ankylosing spondylitis - INITIATION | |
| Ankylosing spondylitis - CONTINUATION | |
| Chronic ocular inflammation - INITIATION | |
| Chronic ocular inflammation - CONTINUATION | |
| Fistulising Crohn's disease - INITIATION | |
| Fistulising Crohn's disease - CONTINUATION | |
| Fulminant ulcerative colitis - CONTINUATION | |
| Immune checkpoint inhibitor toxicity in malignancy* - INITIATION | |
| Immune checkpoint inhibitor toxicity in malignancy* - CONTINUATION | |
| Neurosarcoidosis - INITIATION | |
| Neurosarcoidosis - CONTINUATION | |
| Plaque psoriasis - INITIATION | |
| Plaque psoriasis - CONTINUATION | |
| Psoriatic arthritis - INITIATION | |
| Psoriatic arthritis - CONTINUATION | |
| Pyoderma gangrenosum - INITIATION | |
| Pyoderma gangrenosum - CONTINUATION | |
| Rheumatoid arthritis - INITIATION | |
| Rheumatoid arthritis - CONTINUATION | |
| Severe Behcet's disease - INITIATION | |
| Severe Behcet's disease - CONTINUATION | |
| Severe ocular inflammation - INITIATION | |
| Severe ocular inflammation - CONTINUATION | |
| Ulcerative colitis - INITIATION | |
| Ulcerative colitis - CONTINUATION | |
| | |

and

and

| Form RS2124 July 2025 | RESTRICTIONS CHECKLIST | Page 329 |
|---|--|------------------------------------|
| Use this checklist to determine if a patient meets th Schedule. For community funding, see the Special | e restrictions for funding in the hospital setting . For more details, refer I Authority Criteria. | to Section H of the Pharmaceutical |
| PRESCRIBER | PATIENT: | |
| Name: | Name: | |
| Ward: | NHI: | |
| Infliximab | | |
| INITIATION – Graft vs host disease Prerequisites (tick box where appropriate) O Patient has steroid-refractory acute grafted | t vs. host disease of the gut | |
| INITIATION – rheumatoid arthritis Re-assessment required after 4 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a rhe Hospital. | eumatologist, or in accordance with a protocol or guideline that has bee | en endorsed by the Health NZ |
| | | |

m The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis

The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept

Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept

) Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance

CONTINUATION – rheumatoid arthritis Re-assessment required after 6 months

()

or

Prerequisites (tick boxes where appropriate)

Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and

| (| Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance |
|-----|--|
| and | |

Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician

The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician

Infliximab to be administered at doses no greater than 3 mg/kg every 8 weeks

INITIATION – ankylosing spondylitis

or

()

and

Re-assessment required after 3 months

Prerequisites (tick boxes where appropriate)

| and | | Pres Hosp | | by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ |
|-----|-----|--------------|-----|---|
| | and | 0 | The | patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis |
| | | or | Ο | The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept |
| | | | Ο | Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis |

I confirm that the above details are correct:

| Signed: Date: | |
|---------------|--|
|---------------|--|

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIBER | | PATIENT: |
|--------|-----------------------|---|---|
| Name: | : | | Name: |
| Ward: | | | NHI: |
| Inflix | imab - | continued | |
| Re-as | ssessmer | ON – ankylosing spondylitis nt required after 6 months s (tick boxes where appropriate) | |
| and | ~ | scribed by, or recommended by a rheumatologist, or in accordan | ce with a protocol or guideline that has been endorsed by the Health NZ |
| | O | Following 12 weeks of infliximab treatment, BASDAI has impro or by 50%, whichever is less | oved by 4 or more points from pre-infliximab baseline on a 10 point scale, |
| | Ο | Physician considers that the patient has benefited from treatm | ent and that continued treatment is appropriate |
| | and | Infliximab to be administered at doses no greater than 5 mg/kg | g every 6-8 weeks |
| Re-as | ssessmer equisites | | ce with a protocol or guideline that has been endorsed by the Health NZ |
| and | and or | The patient has had an initial Special Authority approval for ad O The patient has experienced intolerable side effects from | lalimumab and/or etanercept and/or secukinumab for psoriatic arthritis in a reasonable trial of adalimumab and/or etanercept and/or secukinumab and/or etanercept and/or secukinumab, the patient did not meet the or secukinumab for psoriatic arthritis. |
| Re-as | ssessmer equisites | pital. | ce with a protocol or guideline that has been endorsed by the Health NZ s at least a 50% decrease in active joint count from baseline and a |
| | and | r o v r | rovement in active joint count from baseline and a clinically significant |
| | 0 | Infliximab to be administered at doses no greater than 5 mg/kg | g every 8 weeks |
| | | | |

Page 331

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|----------|
| Name: | Name: |
| Ward: | NHI: |
| Infliximab - continued | |
| INITIATION – severe ocular inflammation | |

| | (and | С | The patient has had an initial Special Authority approval for adalimumab for severe ocular inflammation |
|-----|----------|---------------|---|
| | | | O The patient has experienced intolerable side effects from adalimumab |
| | | or | O The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe ocular inflammation |
| or | | ~ | |
| | and | \mathcal{O} | Patient has severe, vision-threatening ocular inflammation requiring rapid control |
| and | | | O Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms |
| | | or | O Patient developed new inflammatory symptoms while receiving high dose steroids |
| | | or | O Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms |
| | | _ | |

| | | Ο | The patient has had a good clinical response following 3 initial doses |
|------|----|--------|---|
| | or | 0 | Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria $< \frac{1}{2}$ + anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema) |
| | or | 0 | Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old |
| Noto | Δt | rial w | ithdrawal should be considered after every 24 months of stability unless the patient is deemed to have extremely high risk of irreversible |

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|--|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |
| Infliximab - continued | | | |
| INITIATION – chronic ocular inflammation Re-assessment required after 4 months | | | |
| Prerequisites (tick boxes where appropriate) | | | |

| | and | | ine p | patient has had an initial Special Authority approval for adalimumab for chronic ocular inflammation |
|----|----------|---------------|----------------|--|
| | | _ | Ο | The patient has experienced intolerable side effects from adalimumab |
| | | or | | The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for chronic ocular inflammation |
| or | | | | |
| | | | | |
| | (| С | Patier loss | nt has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision |
| | (and | C | loss | |
| | (and |) or | loss | nt has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective |
| | (and | Cor | loss | |
| | (and | C or or | loss O O | Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective |

CONTINUATION – chronic ocular inflammation

Re-assessment required after 12 months

| Prerequisites (t | tick boxes where | appropriate) |
|------------------|------------------|--------------|
|------------------|------------------|--------------|

| | | 0 | The patient has had a good clinical response following 3 initial doses | | | |
|--|--|---|--|--|--|--|
| | or or | 0 | Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema) | | | |
| | 0. | 0 | Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old | | | |
| | Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn. | | | | | |
| INITIATION – Pulmonary sarcoidosis Prerequisites (tick boxes where appropriate) | | | | | | |
| | O Patient has life-threatening pulmonary sarcoidosis that is refractory to other treatments and | | | | | |

O Treatment is to be prescribed by, or has been recommended by, a physician with expertise in the treatment of pulmonary sarcoidosis

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIBE | PATIENT: |
|-------------------|---------------------|--|
| Name | : | Name: |
| Ward: | | NHI: |
| Inflix | imab | - continued |
| Re-as | ssessme equisite | Crohn's disease (adults) ent required after 6 months s (tick boxes where appropriate) |
| and | | scribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health Hospital. |
| | and | Patient has active Crohn's disease |
| | o | O Patient has a CDAI score of greater than or equal to 300, or HBI score of greater than or equal to 10 |
| | o | O Patient has extensive small intestine disease affecting more than 50 cm of the small intestine r |
| | o | O Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection r |
| | | O Patient has an ileostomy or colostomy, and has intestinal inflammation |
| | and | Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and corticosteroids |
| Prere (and |) Pre | s (tick boxes where appropriate) scribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health Hospital. |
| | o | CDAI score has reduced by 100 points from the CDAI score, or HBI score has reduced by 3 points, from when the patient was initiated on infliximab |
| | o | CDAI score is 150 or less, or HBI is 4 or less |
| | | O The patient has demonstrated an adequate response to treatment but CDAI score and/or HBI score cannot be assessed |
| | and | Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle |
| Re-as | ssessme | Crohn's disease (children) ent required after 6 months s (tick boxes where appropriate) |
| and | | scribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health Hospital. |
| | and | Paediatric patient has active Crohn's disease |
| | o | O Patient has a PCDAI score of greater than or equal to 30 |
| | | O Patient has extensive small intestine disease |
| | and | Patient has tried but experienced an inadequate response to, or intolerable side effects from, prior therapy with immunomodulators and corticosteroids |

| | _ |
|---------|-------|
| Signed: | Date: |

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. | For more details, refer to Section H of the Pharmaceutical |
|--|--|
| Schedule. For community funding, see the Special Authority Criteria. | |

| PRESC | RIBER | PATIENT: | | |
|------------------|----------------------------|---|-------|--|
| Name: | | Name: | Name: | |
| Ward: | | NHI: | | |
| Inflixir | mab - | tinued | | |
| Re-ass Prereq | sessmen quisites | - Crohn's disease (children) quired after 2 years < boxes where appropriate) ed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Hea ital. | alth | |
| and | or or and | PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab PCDAI score is 15 or less The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed liximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for | | |
| | | to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen eks after completing the last re-induction cycle | | |
| Re-ass | sessmen quisites | Ilising Crohn's disease quired after 6 months < boxes where appropriate) ed by, or recommended by a gastroenterologist, or in accordance with a protocol or guideline that has been endorsed by the Health N | NZ | |
| a | o and | tient has confirmed Crohn's disease | | |
| | or | Patient has one or more complex externally draining enterocutaneous fistula(e) Patient has one or more rectovaginal fistula(e) | | |
| | or | Patient has complete peri-anal fistula | | |
| Re-ass | sessmen quisites | - fistulising Crohn's disease quired after 2 years < boxes where appropriate) ed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Hea ital. | alth | |
| | or | The number of open draining fistulae have decreased from baseline by at least 50% There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain | | |
| | 0 | liximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen eks after completing the last re-induction cycle | | |

| | checklist to determine if a patient meets the restrictions for funding in the e. For community funding, see the Special Authority Criteria. | the hospital setting . For more details, refer to Section H of the Pharmaceutical |
|------------------|---|--|
| PRESC | RIBER | PATIENT: |
| Name: | | Name: |
| Ward: | | NHI: |
| Inflixir | nab - continued | |
| Re-ass Prereq | FION – acute fulminant ulcerative colitis essment required after 6 weeks uisites (tick boxes where appropriate) Prescribed by, or recommended by a gastroenterologist, or in accor Hospital. | rdance with a protocol or guideline that has been endorsed by the Health NZ |
| and | Patient has acute, fulminant ulcerative colitis Ind Treatment with intravenous or high dose oral corticosteroids | nas not been successful |
| Re-ass Prereq | NZ Hospital. O Where maintenance treatment is considered appropriate, infl reassessed every 6 months Infliximab to be administered at doses up to 5 mg/kg every 8 | accordance with a protocol or guideline that has been endorsed by the Health iximab should be used in combination with immunomodulators and weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for timent for re-induction. Another re-induction may be considered sixteen |
| Re-ass Prereq | NZ Hospital. Patient has active ulcerative colitis and O Patients SCCAI is greater than or equal to 4 or O Patients PUCAI score is greater than or equal to 20 and | rable side effects from, prior therapy with immunomodulators and |

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | PRESCRIBER | | | PATIENT: |
|-------|---------------------------------|--|------------------------|--|
| Name | Name: | | | Name: |
| Ward | : | | | NHI: |
| nflix | kimal | b - cc | ontini | Jed |
| Re-a | issess equis i O F | ment i ites (ti | requi ick b bed | Icerative colitis ired after 2 years oxes where appropriate) by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health I. |
| | and (| | | The SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on infliximab The PUCAI score has reduced by 30 points or more from the PUCAI score when the patient was initiated on infliximab mab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen |
| Re-a | issess equis i O F | N – pla ment i ites (ti Prescri | aque requi ick b | s after completing the last re-induction cycle psoriasis ired after 3 doses oxes where appropriate) by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ |
| and | F | and | or | Patient has had an initial Special Authority approval for adalimumab, etanercept or secukinumab for severe chronic plaque psoriasis O Patient has experienced intolerable side effects from adalimumab, etanercept or secukinumab O Patient has received insufficient benefit from adalimumab, etanercept or secukinumab to meet the renewal criteria for adalimumab, etanercept or secukinumab to received insufficient benefit from adalimumab, etanercept or secukinumab to meet the renewal criteria for adalimumab, etanercept or secukinumab for severe chronic plaque psoriasis |
| | or | | or | Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis Patient has severe chronic localised genital or flexural plaque psoriasis where the plaques or lesions have been present for at least 6 months from the time of initial diagnosis. Patient has severe chronic localised genital or flexural plaque psoriasis where the plaques or lesions have been present for at least 6 months from the time of initial diagnosis, and with a Dermatology Life Quality Index (DLQI) score greater than 10 |
| | | | | Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course The most recent PASI assessment is no more than 1 month old at the time of initiation |

face, hand, foot, genital or flexural areas at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and for the face, palm of a hand or sole of a foot the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

| Signed: D | Date: |
|-----------|-------|
|-----------|-------|

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Infliximab - continued

| | and | O Patient had "whole body" severe chronic plaque psoriasis at the start of treatment |
|----|-----|--|
| | | O Following each prior infliximab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-infliximab treatment baseline value |
| or | and | O Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment |
| | | Following each prior infliximab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values Following each prior infliximab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-infliximab treatment baseline value |
| or | and | O Patient had severe chronic localised genital or flexural plaque psoriasis at the start of treatment |
| | anu | O The patient has experienced a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value O Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing infliximab |

Prerequisites (tick boxes where appropriate) ()Prescribed by, or recommended by a neurologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and \bigcirc Biopsy consistent with diagnosis of neurosarcoidosis and Patient has CNS involvement ()and \bigcirc Patient has steroid-refractory disease and () IV cyclophosphamide has been tried or

O Treatment with IV cyclophosphamide is clinically inappropriate

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|---|
| Name: | Name: |
| Ward: | NHI: |
| Infliximab - continued | |
| CONTINUATION – neurosarcoidosis Re-assessment required after 18 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a neurologist, or in Hospital. and or O A withdrawal period has been tried and the patie or O A withdrawal period has been considered I and O There has been a marked reduction in pre- and O There has been an improvement in N or O Marked improvement in other sympton | but would not be clinically appropriate dnisone dose MRI appearances |
| INITIATION – severe Behcet's disease Re-assessment required after 4 months Prerequisites (tick boxes where appropriate) | s significantly impacting the patient's quality of life (see Notes) |
| or or | eumatologic and/or mucocutaneous symptoms and has not responded adequately to |
| and O The patient is experiencing significant loss of qua | ality of life |
| measured using an appropriate quality of life scale such as theb) Treatments appropriate for the particular symptoms are those | e that are considered standard conventional treatments for these symptoms, for example ocular symptoms; azathioprine, steroids, thalidomide, interferon alpha and ciclosporin for |
| CONTINUATION – severe Behcet's disease Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) | I treatment with measurably improved quality of life |

O Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks

I confirm that the above details are correct:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | | |
|--|--|--|--|--|
| Name: | Name: | | | |
| Vard: NHI: | | | | |
| Infliximab - continued | | | | |
| and Hospital. | e with a protocol or guideline that has been endorsed by the Health NZ Iuding a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, | | | |
| CONTINUATION – pyoderma gangrenosum Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a dermatologist, or in accordance Hospital. and O Patient has shown clinical improvement and O Patient continues to require treatment and O A maximum of 8 doses | e with a protocol or guideline that has been endorsed by the Health NZ | | | |
| by a physiotherapist and | e | | | |
| CONTINUATION – Inflammatory bowel arthritis (axial) Re-assessment required after 2 years Prerequisites (tick box where appropriate) O Where treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10-point scale, or an improvement in BASDAI of 50%, whichever is less | | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIE | IBER PATIENT: | | | | | |
|--|---|--|--|--|--|--|
| Name: | ame: Name: | | | | | |
| Ward: | Vard: NHI: | | | | | |
| Inflixima | ab - continued | | | | | |
| INITIATIO Re-assess | ON - Inflammatory bowel arthritis (peripheral) ssment required after 6 months isites (tick boxes where appropriate) Patient has a diagnosis of active ulcerative colitis or active Crohn's disease Patient has active arthritis in at least four joints from the following: hip, knee, ankle, subtalar, tarsus, forefoot, wrist, elbow, shoulder, sternoclavicular Patient has tried and not experienced a response to at least three months of methotrexate or azathioprine at a maximum tolerated dose (unless contraindicated) Patient has tried and not experienced a response to at least three months of sulfasalazine at a maximum tolerated dose (unless contraindicated) | | | | | |
| CONTINUATION – Inflammatory bowel arthritis (peripheral) Re-assessment required after 2 years Prerequisites (tick boxes where appropriate) | | | | | | |
| or | Following initial treatment, patient has experienced at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician Patient has experienced at least a continuing 30% improvement in active joint count from baseline in the opinion of the treating physician | | | | | |
| INITIATION - immune checkpoint inhibitor toxicity in malignancy* Re-assessment required after 4 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and O The individual requires treatment for moderate to severe autoimmune toxicity following immune checkpoint inhibitor treatment for malignancy and O The individual has received insufficient benefit from use of corticosteroids and | | | | | | |
| Re-assess Prerequise and and | ssment required after 4 months isites (tick boxes where appropriate) Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by th NZ Hospital. O The individual requires treatment for moderate to severe autoimmune toxicity following immune checkpoint inhibitor treatment for malignancy The individual has received insufficient benefit from use of corticosteroids | | | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|---|--|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |
| Infliximab - continued | | | |
| CONTINUATION – immune checkpoint inhibitor toxicity in malig Re-assessment required after 4 months Prerequisites (tick boxes where appropriate) | gnancy* | | |
| O Prescribed by, or recommended by any relevant practition NZ Hospital. | er, or in accordance with a protocol or guideline that has been endorsed by the Health | | |
| O The individual has shown clinical improvement and and | ongoing treatment is required | | |
| O Infliximab is to be administered at up to 5mg/kg for \mathfrak{u} | up to a total of 8 doses | | |
| Note: Indications marked with * are unapproved indications. | | | |

I confirm that the above details are correct:

RS2125 - Tocilizumab

| Rheumatoid Arthritis - INITIATION | |
|---|--|
| Rheumatoid Arthritis - CONTINUATION | |
| Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept) - INITIATION | |
| Adult-onset Still's disease - INITIATION | |
| Adult-onset Still's disease - CONTINUATION | |
| Cytokine release syndrome - INITIATION | |
| Idiopathic multicentric Castleman's disease - INITIATION | |
| Idiopathic multicentric Castleman's disease - CONTINUATION | |
| Immune checkpoint inhibitor toxicity in malignancy* - INITIATION | |
| Immune checkpoint inhibitor toxicity in malignancy* - CONTINUATION | |
| Moderate to severe COVID-19 - INITIATION | |
| Polyarticular juvenile idiopathic arthritis - INITIATION | |
| Polyarticular juvenile idiopathic arthritis - CONTINUATION | |
| Previous use - INITIATION | |
| Systemic juvenile idiopathic arthritis - INITIATION | |
| Systemic juvenile idiopathic arthritis - CONTINUATION | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Tocilizumab

| Re-a | ssess | ment rec | vine release syndrome uired after 3 doses boxes where appropriate) | |
|----------|-------|---|--|--|
| | (| The patient has developed grade 3 or 4 cytokine release syndrome associated with the administration of blinatumomab for the treatment of acute lymphoblastic leukaemia Tocilizumab is to be administered at doses no greater than 8 mg/kg IV for a maximum of 3 doses (if less than 30kg, maximum of 12 mg/kg) | | |
| | or | and and | The patient is enrolled in the Malaghan Institute of Medical Research ENABLE trial programme The patient has developed CRS or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) following CAR T-Cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma Tocilizumab is to be administered according to the consensus guidelines for CRS or ICANS for CAR T-cell therapy at doses no greater than 8 mg/kg IV for a maximum of 3 doses | |
| Re-a | ssess | ment rec | ous use uired after 6 months boxes where appropriate) | |
| (and | | Prescribe NZ Hospi | d by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health al. | |
| | and | O Pat | ent was being treated with tocilizumab prior to 1 February 2019 | |
| | | or C | Rheumatoid arthritis Systemic juvenile idiopathic arthritis | |
| | | or or | Adult-onset Still's disease | |
| | | or | Polyarticular juvenile idiopathic arthritis | |
| | | | Idiopathic multicentric Castleman's disease | |

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting . For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria. | | | | | | | |
|--|-----------------------|--------------------------------|---|---|--|--|--|
| PRES | PRESCRIBER PATIENT: | | | | | | |
| Name | : | | Name: | | | | |
| Ward | | | NHI: | | | | |
| Toci | izun | nab | ontinued | _ | | | |
| Re-a | ssess equis C F | smen s ites Presc | Imatoid Arthritis (patients previously treated with adalimumab or etanercept) juired after 6 months boxes where appropriate) d by, or recommended by a rheumatologist or Practitioner on the recommendation of a rheumatologist, or in accordance with a r guideline that has been endorsed by the Health NZ Hospital. e patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis | | | | |
| | and | or | The patient has experienced intolerable side effects from adalimumab and/or etanercept The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis | | | | |
| | and | or | The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor | | | | |
| | | | m O The patient has been started on rituximab for rheumatoid arthritis in a Health NZ Hospital nd | | | | |

The patient has experienced intolerable side effects from rituximab

At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis

Ο

 \bigcirc

or

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIB | ER | | PATIENT: | | |
|--|--|-------------|------------|---|--|--|
| Name | ıme: Name: | | | | | |
| Ward | ard: NHI: | | | | | |
| Toci | izum | nab | - cor | ntinued | | |
| Re-a | ssessi | men | t requ | natoid Arthritis ired after 6 months | | |
| Prer | equisi | tes | (tick b | poxes where appropriate) | | |
| (and | | | | by, or recommended by a rheumatologist or Practitioner on the recommendation of a rheumatologist, or in accordance with a guideline that has been endorsed by the Health NZ Hospital. | | |
| | (| С | | nt has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic linated peptide (CCP) antibody positive) for six months duration or longer | | |
| | and (and | C | Tocili | zumab is to be used as monotherapy | | |
| | | or | Ο | Treatment with methotrexate is contraindicated | | |
| | | U | Ο | Patient has tried and did not tolerate oral and/or parenteral methotrexate | | |
| | and | | | | | |
| | | | \bigcirc | Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of ciclosporin alone or in combination with another agent | | |
| | | or | 0 | Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent | | |
| | and | | | | | |
| | | or | 0 | Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints | | |
| | | | 0 | Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip | | |
| | and | \subseteq | _ | | | |
| | | or | 0 | Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application | | |
| | | | 0 | C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months | | |
| | | | | | | |
| Re-a | INITIATION – systemic juvenile idiopathic arthritis Re-assessment required after 6 months | | | | | |
| Prer | ~ | | | poxes where appropriate) | | |
| (and | | | | by, or recommended by a rheumatologist or Practitioner on the recommendation of a rheumatologist, or in accordance with a guideline that has been endorsed by the Health NZ Hospital. | | |
| | (and | С | Patie | nt diagnosed with systemic juvenile idiopathic arthritis | | |
| Patient has tried and not responded to a reasonable trial of all of the following, either alone or in combination: oral or parenteral methotrexate; non-steroidal anti-inflammatory drugs (NSAIDs); and systemic corticosteroids | | | | | | |

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | SCRIE | BER | | PATIENT: | | |
|------|---|-------------------------------------|-----------------------|--|--|--|
| Name | e: | | | Name: | | |
| Ward | : | | | | | |
| Госі | lizun | nab - | - con | inued | | |
| Re-a | issess equis | sment sites (t Prescri | requ ick b ibed | nset Still's disease red after 6 months oxes where appropriate) oy, or recommended by a rheumatologist or Practitioner on the recommendation of a rheumatologist, or in accordance with a guideline that has been endorsed by the Health NZ Hospital. | | |
| | O The patient has had an initial Special Authority approval for adalimumab and/or etanercept for adult-onset Still's disease (AOSD) or O The patient has been started on tocilizumab for AOSD in a Health NZ Hospital | | | | | |
| | | and | or | O The patient has experienced intolerable side effects from adalimumab and/or etanercept O The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for AOSD | | |
| | | and | 0 0 0 | Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430) Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate Patient has persistent symptoms of disabling poorly controlled and active disease | | |
| Re-a | issess equis O F | sment sites (t Prescri | requ ick b ibed | icular juvenile idiopathic arthritis red after 4 months boxes where appropriate) by, or recommended by a rheumatologist or Practitioner on the recommendation of a rheumatologist, or in accordance with a guideline that has been endorsed by the Health NZ Hospital. | | |
| | | and | 0 | The patient has had an initial Special Authority approval for both etanercept and adalimumab for polyarticular course juvenile idiopathic arthritis (JIA) The patient has experienced intolerable side effects, or has received insufficient benefit from, both etanercept and adalimumab | | |
| | or | and | 0 0 | Treatment with a tumour necrosis factor alpha inhibitor is contraindicated Patient has had polyarticular course JIA for 6 months duration or longer To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance | | |
| | | and | or or | At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose) Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose) Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate | | |

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. | For more details, refer to Section H of the Pharmaceutical |
|--|--|
| Schedule. For community funding, see the Special Authority Criteria. | |

| PRESCRIBER | PATIENT: |
|---|--|
| Name: | Name: |
| Ward: | NHI: |
| Tocilizumab - continued | |
| INITIATION – idiopathic multicentric Castleman's disease Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a haematologist, rheumatologis or in accordance with a protocol or guideline that has been endorse and O Patient has severe HHV-8 negative idiopathic multicentric Ca and O Treatment with an adequate trial of corticosteroids has proven | stleman's disease |
| O Tocilizumab to be administered at doses no greater than 8 m | g/kg IV every 3-4 weeks |
| INITIATION – moderate to severe COVID-19 Re-assessment required after 1 dose Prerequisites (tick boxes where appropriate) | |
| Patient has confirmed (or probable) COVID-19 and Oxygen saturation of < 92% on room air, or requiring supplen and Patient is receiving adjunct systemic corticosteroids, or system and Tocilizumab is to be administered at doses no greater than 8n Tocilizumab is not to be administered in combination with bar | mic corticosteroids are contraindicated mg/kg IV for a maximum of one dose |
| and protocol or guideline that has been endorsed by the Health NZ Hos O Following 6 months' initial treatment, the patient has at least significant response to treatment in the opinion of the physicial | a 50% decrease in active joint count from baseline and a clinically an east a continuing 30% improvement in active joint count from baseline and |
| and protocol or guideline that has been endorsed by the Health NZ Hos | hieved at least an American College of Rheumatology paediatric 30% |

| Forn July 2 | n RS2125 025 | HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST | Page 34 |
|----------------|--|--|-----------------------------------|
| | his checklist to determine if a patient meets the relation of the second s | estrictions for funding in the hospital setting . For more details, refer to uthority Criteria. | o Section H of the Pharmaceutical |
| PRES | CRIBER | PATIENT: | |
| Name | 2: | Name: | |
| Ward | | NHI: | |
| Toci | izumab - continued | | |
| Re-a | protocol or guideline that has been endorse | natologist or Practitioner on the recommendation of a rheumatologist, ed by the Health NZ Hospital. n inflammatory markers and functional status | or in accordance with a |
| Re-a | TINUATION – polyarticular juvenile idiopathio ssessment required after 6 months equisites (tick boxes where appropriate) | c arthritis | |
| (and | Prescribed by, or recommended by a rheun protocol or guideline that has been endorse | natologist or Practitioner on the recommendation of a rheumatologist, ed by the Health NZ Hospital. | |
| | or physician's global assessment O On subsequent reapplications, | treatment, the patient has at least a 50% decrease in active joint cou from baseline the patient demonstrates at least a continuing 30% improvement in a sician's global assessment from baseline | |
| | | | |
| Re-a | TINUATION – idiopathic multicentric Castlerr ssessment required after 12 months equisites (tick box where appropriate) | nan's disease | |
| (and | or in accordance with a protocol or guidelin | natologist, rheumatologist or Practitioner on the recommendation of a ne that has been endorsed by the Health NZ Hospital. In patient has a sustained improvement in inflammatory markers and fu | |
| Re-a | ATION – immune checkpoint inhibitor toxicit ssessment required after 4 months equisites (tick boxes where appropriate) | y in malignancy* | |
| (and | Prescribed by, or recommended by any rele | evant practitioner, or in accordance with a protocol or guideline that ha | as been endorsed by the Health |
| | O The individual requires treatment for | moderate to severe autoimmune toxicity following immune checkpoin | t inhibitor treatment for |

The individual has received insufficient benefit from use of corticosteroids \bigcirc

m O Tocilizumab is to be administered at a maximum dose of 8 mg/kg fortnightly

I confirm that the above details are correct:

malignancy

and

and

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|---|
| Name: | Name: |
| Ward: | NHI: |
| Tocilizumab - continued | |
| CONTINUATION – immune checkpoint inhibitor toxicity in malignancy* Re-assessment required after 4 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by any relevant practitioner, or in ac NZ Hospital. | ccordance with a protocol or guideline that has been endorsed by the Health |
| The individual has shown clinical improvement and ongoing transformed and Tocilizumab is to be administered at a maximum dose of 8 mg | |
| Note: Indications marked with * are unapproved indications. | |

I confirm that the above details are correct:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|----------------------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Omalizumab | |
| INITIATION – severe asthma | |

| 0 | | cribed by, or recommended by a clinical immunologist or respiratory specialist, or in accordance with a protocol or guideline that has been rsed by the Health NZ Hospital. |
|-----|----|---|
| an | O | Patient must be aged 6 years or older |
| an | Ο | Patient has a diagnosis of severe asthma |
| an | Ο | Past or current evidence of atopy, documented by skin prick testing or RAST |
| an | | Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/ml at baseline |
| | | Proven adherence with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1,600 mcg per day or fluticasone propionate 1,000 mcg per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 mcg bd or eformoterol 12 mcg bd) for at least 12 months, unless contraindicated or not tolerated |
| an | or | O Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated |
| | | O Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral steroids |
| an | Ο | Patient has an Asthma Control Test (ACT) score of 10 or less |
| all | Ö | Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 26 weeks after the first dose to assess response to treatment |

Re-assessment required after 6 months

and \bigcirc

Prerequisites (tick boxes where appropriate)

 \bigcirc Prescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and

An increase in the Asthma Control Test (ACT) score of at least 5 from baseline Ο

A reduction in the maintenance oral corticosteroid dose or number of exacerbations of at least 50% from baseline

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|---|
| Name: | Name: |
| Ward: | NHI: |
| Omalizumab - continued | |
| INITIATION – severe chronic spontaneous urticaria Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a clinical immunologist or dermendorsed by the Health NZ Hospital. and | natologist, or in accordance with a protocol or guideline that has been |
| Patient must be aged 12 years or older | |
| O Patient is symptomatic with Urticaria Activity Sca and O Patient has a Dermatology life quality index (DL | |
| and | |
| or ⁶ weeks | |
| and | |
| O Treatment to be stopped if inadequate response* follow | wing 4 doses |
| Complete response* to 6 doses of omalizumab | |
| | ررح |
| CONTINUATION – severe chronic spontaneous urticaria Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a clinical immunologist or derm | natologist, or in accordance with a protocol or guideline that has been |
| endorsed by the Health NZ Hospital. | |
| O Patient has previously had a complete response* to 6 doses or | of omalizumab |
| O Patient has previously had a complete response* to 6 and O Patient has relapsed after cessation of omalizumab th | |

Note: *Inadequate response defined as less than 50% reduction in baseline UAS7 and DLQI score, or an increase in Urticaria Control Test (UCT) score of less than 4 from baseline. Patient is to be reassessed for response after 4 doses of omalizumab. Complete response is defined as UAS7 less than or equal to 6 and DLQI less than or equal to 5; or UCT of 16. Relapse of chronic urticaria on stopping prednisone/ciclosporin does not justify the funding of omalizumab.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| | |

Siltuximab

and

| Re-a | TATION assessment required after 6 months requisites (tick boxes where appropriate) Prescribed by, or recommended by a haematologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. Patient has severe HHV-8 negative idiopathic multicentric Castleman's Disease and Treatment with an adequate trial of corticosteroids has proven ineffective and Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks |
|------|---|
| Re-a | NTINUATION assessment required after 12 months requisites (tick box where appropriate) O Prescribed by, or recommended by a haematologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by |

the Health NZ Hospital.

The treatment remains appropriate and the patient has sustained improvement in inflammatory markers and functional status

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Obinutuzumab

| INITIATION Re-assessment required after 6 months |
|---|
| Prerequisites (tick boxes where appropriate) |
| O Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. |
| The patient has progressive Binet stage A, B or C CD20+ chronic lymphocytic leukaemia requiring treatment The patient is obinutuzumab treatment naive and The patient is not eligible for full dose FCR due to comorbidities with a score > 6 on the Cumulative Illness Rating Scale (CIRS) or reduced renal function (creatinine clearance < 70mL/min) and Patient has adequate neutrophil and platelet counts* unless the cytopenias are a consequence of marrow infiltration by CLL and Patient has good performance status Obinutuzumab to be administered at a maximum cumulative dose of 8,000 mg and in combination with chlorambucil for a maximum of 6 cycles Note: Chronic lymphocytic leukaemia includes small lymphocytic lymphoma. Comorbidity refers only to illness/impairment other than CLL induced illness/impairment in the patient. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms an higher ECOG (2 or 3) is acceptable where treatment with obinutuzumab is expected to improve symptoms and improve ECOG score to < 2. * greater than or equal to 1.5 × 10⁹/L |
| INITIATION – follicular / marginal zone lymphoma Re-assessment required after 9 months Prerequisites (tick boxes where appropriate) |
| or O Patient has follicular lymphoma O Patient has marginal zone lymphoma |
| and Patient is refractory to or has relapsed within 12 months of a rituximab containing combined chemo-immunotherapy regimen* and Patient has an ECOG performance status of 0-2 and Patient has been previously treated with no more than four chemotherapy regimens and Obinutuzumab to be administered at a maximum dose of 1000 mg for a maximum of 6 cycles in combination with chemotherapy* |
| Note: * includes unapproved indications |
| CONTINUATION – follicular / marginal zone lymphoma |

Re-assessment required after 24 months

Prerequisites (tick boxes where appropriate)

()Patient has no evidence of disease progression following obinutuzumab induction therapy and \bigcirc Obinutuzumab to be administered at a maximum of 1000 mg every 2 months for a maximum of 2 years and O Obinutuzumab to be discontinued at disease progression

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| | |

Pertuzumab

| Re-a | INITIATION Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) | | | | | | | |
|------|--|---|--|--|--|--|--|--|
| | (and | O The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology) | | | | | | |
| | | or | O Patient is chemotherapy treatment naive | | | | | |
| | | | O Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer | | | | | |
| | and (and | О | The patient has good performance status (ECOG grade 0-1) | | | | | |
| | and | О | Pertuzumab to be administered in combination with trastuzumab | | | | | |
| | O Pertuzumab maximum first dose of 840 mg, followed by maximum of 420 mg every 3 weeks and | | | | | | | |
| | O Pertuzumab to be discontinued at disease progression | | | | | | | |
| Re-a | CONTINUATION Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) | | | | | | | |
| | | an | O The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology) | | | | | |
| | | | O The cancer has not progressed at any time point during the previous 12 months whilst on pertuzumab and trastuzumab | | | | | |
| | or | an | O Patient has signs of disease progression | | | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Cetuximab

| | head and neck cancer, locally advanced s (tick boxes where appropriate) | | | | |
|---|---|--|--|--|--|
| and | Patient has locally advanced, non-metastatic, squamous cell cancer of the head and neck | | | | |
| 0 | Cisplatin is contraindicated or has resulted in intolerable side effects | | | | |
| and | Patient has an ECOG performance score of 0-2 | | | | |
| and | To be administered in combination with radiation therapy | | | | |
| INITIATION – colorectal cancer, metastatic Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) | | | | | |
| 0 | Patient has metastatic colorectal cancer located on the left side of the colon (see Note) | | | | |
| and O and | There is documentation confirming disease is RAS and BRAF wild-type | | | | |

O Patient has an ECOG performance score of 0-2 and

O Patient has not received prior funded treatment with cetuximab and

O Cetuximab is to be used in combination with chemotherapy

 $\odot\,$ Chemotherapy is determined to not be in the best interest of the patient based on clinician assessment

CONTINUATION – colorectal cancer, metastatic Re-assessment required after 6 months Prerequisites (tick box where appropriate)

or

O No evidence of disease progression

Note: Left-sided colorectal cancer comprises of the distal one-third of the transverse colon, the splenic flexure, the descending colon, the sigmoid colon, or the rectum.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIB | ER | | PATIENT: |
|-------|------------------------|----------------------|----------------|--|
| Name | | | | |
| Ward: | | | | NHI: |
| Aflib | erce | pt | | |
| Re-as | ssessr quisi | nent tes (| requ tick b | ge Related Macular Degeneration ired after 3 months oxes where appropriate) |
| and | | | | by, or recommended by an ophthalmologist or nurse practitioner, or in accordance with a protocol or guideline that has been y the Health NZ Hospital. |
| | | and | or | Wet age-related macular degeneration (wet AMD) Polypoidal choroidal vasculopathy Choroidal neovascular membrane from causes other than wet AMD |
| | | | | O The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab O There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart |
| | | and | Ο | There is no structural damage to the central fovea of the treated eye Patient has not previously been treated with ranibizumab for longer than 3 months |
| | or | or | 0 0 | Patient has current approval to use ranibizumab for treatment of wAMD and was found to be intolerant to ranibizumab within 3 months Patient has previously* (*before June 2018) received treatment with ranibizumab for wAMD and disease was stable while on treatment |
| Re-as | ssessr equisi | nent tes (| requ tick b | Vet Age Related Macular Degeneration ired after 12 months oxes where appropriate) |
| and | | | | by, or recommended by an ophthalmologist or nurse practitioner, or in accordance with a protocol or guideline that has been y the Health NZ Hospital. |

| Documented | benefit | must | be demo | nstrated | to | continue |
|------------|---------|------|---------|----------|----|----------|
| | | | | | | |

Patient's vision is 6/36 or better on the Snellen visual acuity score

There is no structural damage to the central fovea of the treated eye

I confirm that the above details are correct:

 \bigcirc

and

and

Signed: Date:

Page 357

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|--|
| Name: | Name: |
| Ward: | NHI: |
| Aflibercept - continued | |
| INITIATION – Diabetic Macular Oedema Re-assessment required after 4 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by an ophthalmologist or nurse praendorsed by the Health NZ Hospital. and O Patient has centre involving diabetic macular oedema (DMO) and O Patient's disease is non responsive to 4 doses of intravitreal b and O Patient has reduced visual acuity between 6/9 – 6/36 with fun and O Patient has DMO within central OCT (ocular coherence tomog and | ictional awareness of reduction in vision |
| There is no centre-involving sub-retinal fibrosis or foveal atrop | shy |
| CONTINUATION – Diabetic Macular Oedema Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by an ophthalmologist or nurse pra endorsed by the Health NZ Hospital. | actitioner, or in accordance with a protocol or guideline that has been |
| There is stability or two lines of Snellen visual acuity gain and There is structural improvement on OCT scan (with reduction and Patient's vision is 6/36 or better on the Snellen visual acuity s | |
| There is no centre-involving sub-retinal fibrosis or foveal atrop and After each consecutive 12 months treatment with aflibercent | nation has retrialled with at least one injection of bevacizumab and had |

no response

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | SCRIE | BER | PATIENT: | | |
|---|-----------------|------|--|--|--|
| Name | e: | | Name: | | |
| Ward | : | | NHI: | | |
| Secu | ıkinı | uma | ıb | | |
| | | | severe chronic plaque psoriasis, second-line biologic | | |
| | | | t required after 4 months (tick boxes where appropriate) | | |
| O Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Hospital. | | | | | |
| | and | 0 | The patient has had an initial Special Authority approval for adalimumab or etanercept, or has trialled infliximab in a Health NZ Hospital, for severe chronic plaque psoriasis | | |
| | | | O The patient has experienced intolerable side effects from adalimumab, etanercept or infliximab | | |
| | | or | O The patient has received insufficient benefit from adalimumab, etanercept or infliximab | | |
| | and | 0 | A Psoriasis Area and Severity Index (PASI) assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course | | |
| | and | 0 | The most recent PASI or DQLI assessment is no more than 1 month old at the time of application | | |
| | TIA 11 1 | | | | |
| Re-a | ssess | smen | ON – severe chronic plaque psoriasis, second-line biologic t required after 6 months (tick boxes where appropriate) | | |
| (and | F | | bribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ | | |
| | | or | O Patient's PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab | | |
| | | | O Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab | | |
| | and | 0 | Secukinumab to be administered at a maximum dose of 300 mg monthly | | |

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. For more details, refer to Section H of the Pharmaceutic | cal |
|---|-----|
| Schedule. For community funding, see the Special Authority Criteria. | |

| PRESCRIBER | PATIENT: | | | | |
|--|---|--|--|--|--|
| Name: | Name: | | | | |
| Ward: | NHI: | | | | |
| Secukinumab - continued | | | | | |
| INITIATION – severe chronic plaque psoriasis, first-line biologic Re-assessment required after 4 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a dermatologist, or in accordance Hospital. and O Patient has "whole body" severe chronic plaque psoriasis 10, where lesions have been present for at least 6 months from the time of initial of the face, been present for at least 6 months from the time of initial diagnosis, and will least 6 months from the time of initial diagnosis, and will and O Patient has tried, but had an inadequate response (see Note) following (at maximum tolerated doses unless contraindicated doses unless contraindicated of the face of th | or palm of a hand or sole of a foot, where the plaque or plaques have al diagnosis plaque psoriasis where the plaques or lesions have been present for at the a Dermatology Life Quality Index (DLQI) score greater than 10 to, or has experienced intolerable side effects from, at least three of the to; phototherapy, methotrexate, ciclosporin, or acitretin QI) assessment has been completed for at least the most recent prior the north following cessation of each prior treatment course month old at the time of application "Inadequate response" is defined as: for whole body severe chronic plaque on treatment but no longer than 1 month following cessation of the most oot, genital or flexural areas, at least 2 of the 3 PASI symptom sub scores or the face, palm of a hand or sole of a foot the skin area affected is 30% or | | | | |
| or secukinumab Patient has a Dermatology Quality of Life Index (Index (| 75% or more in the skin area affected, or sustained at this level, as | | | | |
| O Secukinumab to be administered at a maximum dose of 300 | ng monthly | | | | |

and

and

 \bigcirc

HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | SCR | IBER | | | PATIENT: | | | | |
|------|---|-------------|---------------|--|---|--|--|--|--|
| Name | e: | | | | Name: | | | | |
| Ward | : | | | | NHI: | | | | |
| Seci | Jkir | านทา | ab - a | continued | | | | | |
| | | | | osing spondylitis, second-line biologic ired after 3 months | | | | | |
| Prer | equi | isites | (tick b | ooxes where appropriate) | | | | | |
| and | C | Pres Hos | | by, or recommended by a rheumatologist, or in accordance | ce with a protocol or guideline that has been endorsed by the Health NZ | | | | |
| | O The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis and | | | | | | | | |
| | | or | 0 | The patient has experienced intolerable side effects from | a reasonable trial of adalimumab and/or etanercept | | | | |
| | | | 0 | Following 12 weeks of adalimumab and/or etanercept tra and/or etanercept for ankylosing spondylitis | eatment, the patient did not meet the renewal criteria for adalimumab | | | | |
| | | | | | | | | | |
| Re-a | isses | ssme | nt requ | nkylosing spondylitis, second-line biologic ired after 6 months poxes where appropriate) | | | | | |
| | С | Pres | cribed | by, or recommended by a rheumatologist, or in accordance | ce with a protocol or guideline that has been endorsed by the Health NZ | | | | |

|) | Prescribed by, or recommended by a rheumatologist, or in a | ccordance | with a prot | tocol or guideline | that has been | endorsed by the | Health NZ |
|---|--|-----------|-------------|--------------------|---------------|-----------------|--|
| | Hospital. | | | | | | |
| | | | | | | | |
| | ر | | | | | | Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Hospital. |

| Ο | Following 12 weeks initial treatment of secukinumab treatment, BASDAI has improved by 4 or more points from pre-secukinumab |
|---|---|
| | baseline on a 10 point scale, or by 50%, whichever is less |

Physician considers that the patient has benefitted from treatment and that continued treatment is appropriate

Secukinumab to be administered at doses no greater than 300 mg monthly

I confirm that the above details are correct:

Signed: Date:

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting | . For more details, refer to Section H of the Pharmaceutical |
|---|--|
| Schedule. For community funding, see the Special Authority Criteria. | |

| R | | PATIENT: |
|-------------------------|--|---|
| | | Name: |
| /ard: NHI: | | |
| nab - c | continued | |
| ient requ es (tick b | uired after 6 months boxes where appropriate) | ance with a protocol or guideline that has been endorsed by the Health NZ |
| O | Patient has had an initial Special Authority approval fo | r adalimumab, etanercept or infliximab for psoriatic arthritis |
| or | O Patient has received insufficient benefit from ada | alimumab, etanercept or infliximab to meet the renewal criteria for |
| and O and O | Patient has tried and not responded to at least three m weekly or a maximum tolerated dose Patient has tried and not responded to at least three m | nonths of oral or parenteral methotrexate at a dose of at least 20 mg nonths of sulfasalazine at a dose of at least 2 g per day or leflunomide at |
| or | | olled and active disease in at least 15 swollen, tender joints olled and active disease in at least four joints from the following: wrist, |
| and or or | application O Patient has an elevated erythrocyte sedimentation | an 15 mg/L measured no more than one month prior to the date of this on rate (ESR) greater than 25 mm per hour ntly receiving prednisone therapy at a dose of greater than 5 mg per day |
| | nab - c - psoria ent reques escribed spital. or and or and or and or and or and or and or | nab - continued - psoriatic arthritis ent required after 6 months es (tick boxes where appropriate) escribed by, or recommended by a rheumatologist, or in accorda spital. O Patient has had an initial Special Authority approval fo and O Patient has experienced intolerable side effects or Patient has received insufficient benefit from ada adalimumab, etanercept or infliximab for psoriati O Patient has had severe active psoriatic arthritis for six O Patient has tried and not responded to at least three m weekly or a maximum tolerated dose and O O Patient has persistent symptoms of poorly control elbow, knee, ankle, and either shoulder or hip and O O Patient has a C-reactive protein level greater tha application |

| | \cap | |
|----|------------|--|
| | \bigcirc | Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician |
| or | 0 | The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior secukinumab treatment in the opinion of the treating physician |

I confirm that the above details are correct:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Trastuzumab emtansine

| \mathbf{O} | Patient has early breast cancer expressing HER2 IHC3+ or ISH+ |
|--------------|---|
| and | Documentation of pathological invasive residual disease in the breast and/or axiliary lymph nodes following completion of surgery |
| and | |
| \mathbf{O} | Patient has completed systemic neoadjuvant therapy with trastuzumab and chemotherapy prior to surgery |
| | Disease has not progressed during neoadjuvant therapy |
| | Patient has left ventricular ejection fraction of 45% or greater |
| | Adjuvant treatment with trastuzumab emtansine to be commenced within 12 weeks of surgery |
| and | Trastuzumab emtansine to be discontinued at disease progression |
| and O | Total adjuvant treatment duration must not exceed 42 weeks (14 cycles) |

Prerequisites (tick boxes where appropriate)

| (and | С | Patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology) |
|-----------------|---------------|---|
| and (| С | Patient has previously received trastuzumab and chemotherapy, separately or in combination |
| | or | O The patient has received prior therapy for metastatic disease* |
| | | O The patient developed disease recurrence during, or within six months of completing adjuvant therapy* |
| and (and | С | Patient has a good performance status (ECOG 0-1) |
| | | O Patient does not have symptomatic brain metastases |
| | or | O Patient has brain metastases and has received prior local CNS therapy |
| and | \subset | |
| | or | O Patient has not received prior funded trastuzumab emtansine or trastuzumab deruxtecan treatment |
| | | O Patient has discontinued trastuzumab deruxtecan due to intolerance |
| | | The cancer did not progress while on trastuzumab deruxtecan |
| and | $\overline{}$ | |
| (| J | Treatment to be discontinued at disease progression |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|--|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |
| Trastuzumab emtansine - continued | | | |
| CONTINUATION – metastatic breast cancer Re-assessment required after 6 months | | | |
| Prerequisites (tick boxes where appropriate) | | | |
| O The cancer has not progressed at any time point during the previous approval period whilst on trastuzumab emtansine and | | | |
| O Treatment to be discontinued at disease progression | | | |
| Note: *Note: Prior or adjuvant therapy includes anthracycline, other chemotherapy, biological drugs, or endocrine therapy. | | | |

I confirm that the above details are correct:

RS2133 - Rituximab

| ABO-incompatible organ transplant - INITIATION | 372 |
|---|----------|
| ANCA associated vasculitis - INITIATION | |
| ANCA associated vasculitis - CONTINUATION | |
| Antibody-mediated organ transplant rejection - INITIATION | 372 |
| B-cell acute lymphoblastic leukaemia/lymphoma* - INITIATION | |
| CD20+ low grade or follicular B-cell NHL - INITIATION | 377 |
| CD20+ low grade or follicular B-cell NHL - CONTINUATION | |
| Chronic lymphocytic leukaemia - INITIATION | |
| Chronic lymphocytic leukaemia - CONTINUATION | 368 |
| Membranous nephropathy - INITIATION | 378 |
| Membranous nephropathy - CONTINUATION | 378 |
| Neuromyelitis Optica Spectrum Disorder (NMOSD) - INITIATION | 374 |
| Neuromyelitis Optica Spectrum Disorder (NMOSD) - CONTINUATION | 374 |
| Severe Refractory Myasthenia Gravis - INITIATION | 375 |
| Severe Refractory Myasthenia Gravis - CONTINUATION | 375 |
| Severe antisynthetase syndrome - INITIATION | |
| Severe antisynthetase syndrome - CONTINUATION | |
| Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS) - INI | TIATION |
| 373 | |
| Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS) - CON | TINUATIO |
| 373 | |
| Steroid resistant nephrotic syndrome (SRNS) - INITIATION | |
| Steroid resistant nephrotic syndrome (SRNS) - CONTINUATION | |
| Aggressive CD20 positive NHL - INITIATION | |
| Aggressive CD20 positive NHL - CONTINUATION | 367 |
| Anti-NMDA receptor autoimmune encephalitis - INITIATION | |
| Anti-NMDA receptor autoimmune encephalitis - CONTINUATION | 377 |
| Desensitisation prior to transplant - INITIATION | 379 |
| Graft versus host disease - INITIATION | 376 |
| Haemophilia with inhibitors - INITIATION | |
| Haemophilia with inhibitors - CONTINUATION | 365 |
| Immune thrombocytopenic purpura (ITP) - INITIATION | 369 |
| Immune thrombocytopenic purpura (ITP) - CONTINUATION | |
| Immunoglobulin G4-related disease (IgG4-RD*) - INITIATION | |
| Immunoglobulin G4-related disease (IgG4-RD*) - CONTINUATION | |
| Indolent low-grade lymphomas or bairy cell leukaemia* - INITIATION | 366 |
| Indolent, low-grade lymphomas or hairy cell leukaemia* - CONTINUATION | |
| Pemiphigus* - INITIATION | 379 |
| Pemiphigus* - CONTINUATION | 380 |
| Post-transplant - INITIATION | 365 |
| Post-transplant - CONTINUATION | 365 |
| Pure red cell aplasia (PRCA) - INITIATION | |
| Pure red cell aplasia (PRCA) - CONTINUATION | |
| Severe chronic inflammatory demyelinating polyneuropathy - INITIATION | |
| Severe chronic inflammatory demyelinating polyneuropathy - CONTINUATION | 376 |
| Severe cold haemagglutinin disease (CHAD) - INITIATION | 368 |
| Severe cold haemagglutinin disease (CHAD) - CONTINUATION | 368 |
| Thrombotic thrombocytopenic purpura (TTP) - INITIATION | 370 |
| Thrombotic thrombocytopenic purpura (TTP) - CONTINUATION | 370 |
| Treatment refractory systemic lupus erythematosus (SLE) - INITIATION | 372 |
| Treatment refractory systemic lupus erythematosus (SLE) - CONTINUATION | 372 |
| Warm autoimmune haemolytic anaemia (warm AIHA) - INITIATION | |
| Warm autoimmune haemolytic anaemia (warm AIHA) - CONTINUATION | 369 |
| | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| RESCRIBER PATIENT: | | | |
|--|------|--|--|
| ame: Name: | | | |
| Ward: | NHI: | | |
| Rituximab (Riximyo) | | | |
| INITIATION – haemophilia with inhibitors Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and | | | |
| O Patient has mild congenital haemophilia complicated by inhibit or O or O or O or O Patient has severe congenital haemophilia complicated by inhibit or O Patient has acquired haemophilia | | | |
| CONTINUATION – haemophilia with inhibitors Prerequisites (tick boxes where appropriate) | | | |
| Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ and O Patient was previously treated with rituximab for haemophilia with inhibitors and O An initial response lasting at least 12 months was demonstrated and O Patient now requires repeat treatment | | | |
| INITIATION – post-transplant Prerequisites (tick boxes where appropriate) | | | |
| O The patient has B-cell post-transplant lymphoproliferative disorder* and O To be used for a maximum of 8 treatment cycles Note: Indications marked with * are unapproved indications. | | | |
| CONTINUATION – post-transplant Prerequisites (tick boxes where appropriate) | | | |
| The patient has had a rituximab treatment-free interval of 12 m and The patient has B-cell post-transplant lymphoproliferative disor and To be used for no more than 6 treatment cycles | | | |
| Note: Indications marked with * are unapproved indications. | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | | |
|---|---|--|--|--|
| Name: Name: | | | | |
| Nard: NHI: | | | | |
| Rituximab (Riximyo) - continued | | | | |
| INITIATION – indolent, low-grade lymphomas or hairy cell leukaemia* Re-assessment required after 9 months Prerequisites (tick boxes where appropriate) | | | | |
| To be used for a maximum of 6 treatment cycles | ukaemia* with relapsed disease following prior chemotherapy | | | |
| or O The patient has indolent, low grade lymphoma or hairy cell leukaemia* requiring first-line systemic chemotherapy and O To be used for a maximum of 6 treatment cycles | | | | |
| Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal z indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant. | one and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved | | | |
| CONTINUATION – indolent, low-grade lymphomas or hairy cell leukaemia* Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) | | | | |
| The patient has had a rituximab treatment-free interval of 12 months or more and The patient has indolent, low-grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy and To be used for no more than 6 treatment cycles | | | | |
| Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant. | | | | |
| INITIATION – aggressive CD20 positive NHL Prerequisites (tick boxes where appropriate) | | | | |
| C The patient has treatment naive aggressive CD20 posi and C To be used with a multi-agent chemotherapy regimen g and C To be used for a maximum of 8 treatment cycles | | | | |
| or The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy and To be used for a maximum of 6 treatment cycles Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia. | | | | |

I confirm that the above details are correct:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|---|--|--|--|
| Name:Name: | | | |
| Ward: NHI: | | | |
| Rituximab (Riximyo) - continued | | | |
| CONTINUATION – aggressive CD20 pos Prerequisites (tick boxes where appropria | | | |
| | | | |
| The patient has had a rituz | O The patient has had a rituximab treatment-free interval of 12 months or more and _ | | |
| O The patient has relapsed refractory/aggressive CD20 positive NHL and | | | |
| O To be used with a multi-agent chemotherapy regimen given with curative intent | | | |
| To be used for a maximum | of 4 treatment cycles | | |
| Note: 'Aggressive CD20 positive NHL' incl | udes large B-cell lymphoma and Burkitt's lymphoma/leukaemia. | | |
| INITIATION – Chronic lymphocytic leuk | aemia | | |
| Re-assessment required after 12 months Prerequisites (tick boxes where appropriation | ate) | | |
| | | | |
| and | e Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment | | |
| O The patient is rituxin | nab treatment naive | | |
| or | O The patient is chemotherapy treatment naive | | |
| | O The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment | | |
| | ent has had a treatment-free interval of 12 months or more if previously treated with fludarabine and | | |
| cycloph | osphamide chemotherapy | | |
| O The patient's diseas | e has relapsed and rituximab treatment is to be used in combination with funded venetoclax | | |
| and | | | |
| and | ormance status | | |
| O The patient does no | t have chromosome 17p deletion CLL | | |
| \sim | is to be used in combination with funded venetoclax for relapsed/refractory chronic lymphocytic leukaemia | | |
| and Dituring to be administed | | | |
| 6 treatment cycles | red in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of | | |
| | nt receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration), ax | | |
| Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to < 2. | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|--|--|--|--|
| Name: | Name: | | |
| /ard:NHI: | | | |
| Rituximab (Riximyo) - continued | | | |
| CONTINUATION – Chronic lymphocytic leukaemia Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) | nent is to be used in combination with funded venetoclax | | |
| The patient's disease has relapsed following no n and The patient has had an interval of 36 months or n and The patient does not have chromosome 17p dele and | nore than one prior line of treatment with rituximab for CLL nore since commencement of initial rituximab treatment tion CLL darabine and cyclophosphamide (orally or dose equivalent intravenous | | |
| and C Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. | | | |
| INITIATION - severe cold haemagglutinin disease (CHAD) Re-assessment required after 8 weeks Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and | | | |
| Patient has cold haemagglutinin disease* and Patient has severe disease which is characterized by symptoms and | natic anaemia, transfusion dependence or disabling circulatory It of 375 mg/m2 of body surface area per week for a total of 4 weeks | | |
| Note: Indications marked with * are unapproved indications. | | | |
| CONTINUATION – severe cold haemagglutinin disease (CHAD) Re-assessment required after 8 weeks Prerequisites (tick boxes where appropriate) | | | |
| and Hospital. | ce with a protocol or guideline that has been endorsed by the Health NZ ekly for 4 weeks) have proven ineffective and treatment with higher | | |
| or $ \begin{array}{c} $ | | | |

Note: Indications marked with * are unapproved indications.

| July 202 | 25 | RESTRICTION | NS CHECKLIST |
|------------------|---|---|--|
| | | o determine if a patient meets the restrictions for funding in the numerity funding, see the Special Authority Criteria. | he hospital setting . For more details, refer to Section H of the Pharmaceutical |
| PRESC | RIBER | | PATIENT: |
| Name: | | | Name: |
| Ward: | | | NHI: |
| Rituxi | mab (Rixi | imyo) - <i>continued</i> | |
| Re-ass | sessment re juisites (tio) Prescrib | | ce with a protocol or guideline that has been endorsed by the Health NZ |
| | and \bigcirc \bigcirc $\overset{\circ}{\overset{\circ}{\overset{\circ}{\overset{\circ}{\overset{\circ}{\overset{\circ}{\overset{\circ}{\overset{\circ}$ | atient has warm autoimmune haemolytic anaemia* ne of the following treatments has been ineffective: steroids 5 mg prednisone daily), cytotoxic agents (e.g. cyclophospha | 6 (including if patient requires ongoing steroids at doses equivalent to amide monotherapy or in combination), intravenous immunoglobulin at of 375 mg/m2 of body surface area per week for a total of 4 weeks |
| Note: I | Indications | marked with * are unapproved indications. | |
| Re-ass Prereq | essment re juisites (tio) Prescrib Hospital O Pr do or (and (and | L · · · · | |
| INITIA Re-ass | TION – imr sessment re juisites (tio | mune thrombocytopenic purpura (ITP) equired after 8 weeks ck boxes where appropriate) bed by, or recommended by a haematologist, or in accordance | ce with a protocol or guideline that has been endorsed by the Health NZ |
| | or | | platelet count of less than or equal to 20,000 platelets per microlitre platelet count of 20,000 to 30,000 platelets per microlitre and significant |
| a | and or or | Treatment with steroids and splenectomy have been ine Treatment with steroids has been ineffective and splene Other treatments including steroids have been ineffective | |
| a | and O Th | ne total rituximab dose used would not exceed the equivaler | nt of 375 mg/m2 of body surface area per week for a total of 4 weeks |

Note: Indications marked with * are unapproved indications.

I confirm that the above details are correct:

| Signad | Data: |
|---------|-----------|
| Signed. | Dale. |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|--|---|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Rituximab (Riximyo) - continued | | |
| CONTINUATION – immune thrombocytopenic purpura (ITP) Re-assessment required after 8 weeks Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a haematologist, or in a Hospital. | accordance with a protocol or guideline that has been endorsed by the Health NZ | |
| and Previous treatment with lower doses of rituximab (10 doses (375 mg/m ² weekly for 4 weeks) is now plann or | 0 mg weekly for 4 weeks) have proven ineffective and treatment with higher ed | |
| Patient was previously treated with rituximab for and An initial response lasting at least 12 months wand Patient now requires repeat treatment | | |
| Note: Indications marked with * are unapproved indications. | | |
| and Hospital. | accordance with a protocol or guideline that has been endorsed by the Health NZ equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks | |
| or or | ura* and has experienced progression of clinical symptoms or persistent ocytopenic purpura* with neurological or cardiovascular pathology | |
| Note: Indications marked with * are unapproved indications. | | |
| CONTINUATION – thrombotic thrombocytopenic purpura (TTP) Re-assessment required after 8 weeks Prerequisites (tick boxes where appropriate) | | |
| O Prescribed by, or recommended by a haematologist, or in a Hospital. | accordance with a protocol or guideline that has been endorsed by the Health NZ | |
| Patient was previously treated with rituximab for thronand An initial response lasting at least 12 months was de and Patient now requires repeat treatment | | |
| O The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks | | |
| Note: Indications marked with * are unapproved indications. | | |

Page 371

| Schedule. For community funding, see the Special Authority Criteria. | |
|--|---|
| PRESCRIBER | PATIENT: |
| Name: | Name: |
| Ward: | NHI: |
| Rituximab (Riximyo) - continued | |
| INITIATION – pure red cell aplasia (PRCA) Re-assessment required after 6 weeks Prerequisites (tick box where appropriate) | |
| O Prescribed by, or recommended by a haematologist, or in a Hospital. and O Patient has autoimmune pure red cell aplasia* associated v Note: Indications marked with * are unapproved indications. | accordance with a protocol or guideline that has been endorsed by the Health NZ with a demonstrable B-cell lymphoproliferative disorder |
| CONTINUATION – pure red cell aplasia (PRCA) Re-assessment required after 6 weeks Prerequisites (tick box where appropriate) | |
| Hospital. | accordance with a protocol or guideline that has been endorsed by the Health NZ |
| Patient was previously treated with rituximab for pure red ca demonstrated an initial response lasting at least 12 months Note: Indications marked with * are unapproved indications. | ell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder and |
| INITIATION – ANCA associated vasculitis Re-assessment required after 8 weeks Prerequisites (tick boxes where appropriate) | |
| O Patient has been diagnosed with ANCA associated va | asculitis* |
| and The total rituximab dose would not exceed the equiva and | alent of 375 mg/m ² of body-surface area per week for a total of 4 weeks |
| O Induction therapy with daily oral or pulse intrave disease after at least 3 months | enous cyclophosphamide has failed to achieve significant improvement of |
| O Patient has previously had a cumulative dose o cyclophosphamide would result in a cumulative or | of cyclophosphamide >15 g or a further repeat 3 month induction course of e dose >15 g |
| O Cyclophosphamide and methotrexate are contra or | raindicated |
| O Patient is a female of child-bearing potential or | |
| O Patient has a previous history of haemorrhagic | cystitis, urological malignancy or haematological malignancy |
| Note: Indications marked with * are unapproved indications. | |
| CONTINUATION – ANCA associated vasculitis Re-assessment required after 8 weeks Prerequisites (tick boxes where appropriate) | |
| O Patient has been diagnosed with ANCA associated va | asculitis* |
| and O Patient has previously responded to treatment with rit and | tuximab but is now experiencing an acute flare of vasculitis |
| | alent of 375 mg/m ² of body-surface area per week for a total of 4 weeks |

Note: Indications marked with * are unapproved indications.

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. | For more details, refer to Section H of the Pharmaceutical |
|--|--|
| Schedule. For community funding, see the Special Authority Criteria. | |

| PRESCRIBER | PATIENT: | | | |
|---|--|--|--|--|
| Name: | Name: | | | |
| Ward: | NHI: | | | |
| Rituximab (Riximyo) - continued | | | | |
| INITIATION – treatment refractory systemic lupus erythematosus (SLE) Prerequisites (tick boxes where appropriate) | | | | |
| Prescribed by, or recommended by a rheumatologist or nephrologist the Health NZ Hospital. and | t, or in accordance with a protocol or guideline that has been endorsed by | | | |
| The patient has severe, immediately life- or organ-threatening | | | | |
| The disease has proved refractory to treatment with steroids a and | a dose of at least 1 mg/kg | | | |
| The disease has relapsed following prior treatment for at least mofetil and high dose cyclophosphamide, or cyclophosphamic and | t 6 months with maximal tolerated doses of azathioprine, mycophenolate de is contraindicated | | | |
| Maximum of four 1000 mg infusions of rituximab | | | | |
| Note: Indications marked with * are unapproved indications. | | | | |
| CONTINUATION – treatment refractory systemic lupus erythematosus (SLE) Prerequisites (tick boxes where appropriate) Prescribed by, or recommended by a rheumatologist or nephrologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and Patient's SLE* achieved at least a partial response to the previous round of prior rituximab treatment and Patient's SLE* achieved at least a partial response to the previous round of prior rituximab treatment Maximum of two 1000 mg infusions of rituximab Note: Indications marked with * are unapproved indications. | | | | |
| INITIATION – Antibody-mediated organ transplant rejection Prerequisites (tick box where appropriate) | | | | |
| O Patient has been diagnosed with antibody-mediated organ transplar Note: Indications marked with * are unapproved indications. | nt rejection* | | | |
| INITIATION – ABO-incompatible organ transplant Prerequisites (tick box where appropriate) | | | | |
| O Patient is to undergo an ABO-incompatible solid organ transplant* Note: Indications marked with * are unapproved indications. | | | | |
| | | | | |

| Use this checklist to determine if a patient meets the restrictions for funding in Schedule. For community funding, see the Special Authority Criteria. | the hospital setting . For more details, refer to Section H of the Pharmaceutical |
|--|--|
| PRESCRIBER | PATIENT: |
| Name: | Name: |
| Ward: | NHI: |
| Rituximab (Riximyo) - continued | |
| | e with a protocol or guideline that has been endorsed by the Health NZ |
| Hospital. | |
| O Patient is a child with SDNS* or FRNS* and | |
| | been ineffective or associated with evidence of steroid toxicity |
| O Treatment with ciclosporin for at least a period of 3 months h | as been ineffective and/or discontinued due to unacceptable side effects |
| Treatment with mycophenolate for at least a period of 3 mont | hs with no reduction in disease relapses |
| O The total rituximab dose used would not exceed the equivale | nt of 375 mg/m ² of body surface area per week for a total of 4 weeks |
| Note: Indications marked with a * are unapproved indications. | |
| Re-assessment required after 8 weeks Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a nephrologist, or in accordanc Hospital. and | e with a protocol or guideline that has been endorsed by the Health NZ |
| O Patient who was previously treated with rituximab for nephrot | ic syndrome* |
| and O Treatment with rituximab was previously successful and has relapsed and the patient now requires repeat treatment and | demonstrated sustained response for > 6 months, but the condition has |
| \sim | nt of 375 mg/m ² of body surface area per week for a total of 4 weeks |
| Note: Indications marked with a * are unapproved indications. | |
| Hospital. | e with a protocol or guideline that has been endorsed by the Health NZ |
| and O Patient is a child with SRNS* where treatment with steroids a and O Treatment with tacrolimus for at least 3 months has been ine | |
| and Genetic causes of nephrotic syndrome have been excluded and The total rituring data used would not exceed the equivale | $rt of 0.75$, ma/m^2 of body surface area particularly for a total of 4 was be |
| Note: Indications marked with a * are unapproved indications. | nt of 375 mg/m ² of body surface area per week for a total of 4 weeks |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIBER | | PATIENT: |
|------|-----------------------|--|--|
| Name | lame: Name: | | |
| Ward | Vard: NHI: | | |
| Ritu | kimab (F | Riximyo) - <i>continued</i> | |
| Re-a | ssessmen equisites | | with a protocol or guideline that has been endorsed by the Health NZ |
| | and and | condition has relapsed and the patient now requires repeat tre | emonstrated sustained response for greater than 6 months, but the |
| Re-a | ssessmen | Neuromyelitis Optica Spectrum Disorder (NMOSD) t required after 6 months (tick boxes where appropriate) | |
| | and | weekly for four weeks | late |
| | | | |
| Re-a | ssessmen | DN – Neuromyelitis Optica Spectrum Disorder (NMOSD) t required after 2 years (tick boxes where appropriate) One of the following dose regimens is to be used: 2 doses of weekly for four weeks The patients has responded to the most recent course of rituxi The patient has not received rituximab in the previous 6 month | |

I confirm that the above details are correct:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER PATI | | ER | PATIENT: | |
|-----------------|----------|-------------|--|--|
| Name: Name: | | | Name: | |
| Ward: | rd: NHI: | | | |
| Rituxi | mal | b (R | Riximyo) - <i>continued</i> | |
| Re-ass | sessr | men | Severe Refractory Myasthenia Gravis t required after 2 years (tick boxes where appropriate) | |
| and | | resc osp | cribed by, or recommended by a neurologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ ital. | |
| a | (and | С | One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart | |
| | | or | O Treatment with corticosteroids and at least one other immunosuppressant for at least a period of 12 months has been ineffective | |
| | | | O Treatment with at least one other immunosuppressant for a period of at least 12 months and | |
| | | | O Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects | |
| | | or or | cribed by, or recommended by a neurologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ ital. One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart. An initial response lasting at least 12 months was demonstrated O The patient has relapsed despite treatment with corticosteroids and at least one other immunosuppressant for a period of at least 12 months. O The patient's myasthenia gravis has relapsed despite treatment with at least one immunosuppressant for a period of at least 12 months. O Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects. | |
| Re-ass | sessr | men | Severe antisynthetase syndrome t required after 12 months (tick boxes where appropriate) | |
| a | and |)) | Patient has confirmed antisynthetase syndrome Patient has severe, immediately life or organ threatening disease, including interstitial lung disease | |
| a | and | | O Treatment with at least 3 immunosuppressants (oral steroids, cyclophosphamide, methotrexate, mycophenolate, ciclosporin, azathioprine) has not be effective at controlling active disease | |
| | | or | O Rapid treatment is required due to life threatening complications | |
| a | and | С | Maximum of four 1,000 mg infusions of rituximab | |

| 041y 2020 | n Eo mio none | |
|---------------------------------|---|---|
| | slist to determine if a patient meets the restrictions for funding in the community funding, see the Special Authority Criteria. | hospital setting. For more details, refer to Section H of the Pharmaceutical |
| PRESCRIBER | 3 | PATIENT: |
| Name: | | lame: |
| Ward: | | IHI: |
| Rituximab (| (Riximyo) - continued | |
| CONTINUATI | ION – Severe antisynthetase syndrome | |
| | ent required after 12 months s (tick boxes where appropriate) | |
| O | Patient's disease has responded to the previous rituximab treatr strength and pulmonary function | nent with demonstrated improvement in inflammatory markers, muscle |
| and O and | The patient has not received rituximab in the previous 6 months | |
| | Maximum of two cycles of 2 × 1,000 mg infusions of rituximab g | ven two weeks apart |
| | - graft versus host disease s (tick boxes where appropriate) | |
| and | Patient has refractory graft versus host disease following transp | ant |
| and | Treatment with at least 3 immunosuppressants (oral steroids, circontrolling active disease | closporin, tacrolimus, mycophenolate, sirolimus) has not be effective at |
| | The total rituximab dose used would not exceed the equivalent of | of 375 mg/m ² of body surface area per week for a total of 4 weeks |
| Prerequisites O Pres Hosp | ent required after 6 months s (tick boxes where appropriate) scribed by, or recommended by a neurologist, or in accordance wit spital. | h a protocol or guideline that has been endorsed by the Health NZ |
| and O and | Patient has severe chronic inflammatory demyelinating polyneur | opathy (CIPD) |
| | O Treatment with steroids and intravenous immunoglo active disease | bulin and/or plasma exchange has not been effective at controlling |
| | | namide, ciclosporin, tacrolimus, mycophenolate) has not been |
| o | O Rapid treatment is required due to life threatening complic | ations |
| and | One of the following dose regimens is to be used: 375 mg/m2 o weekly for four weeks, or two 1,000 mg doses given two weeks | f body surface area per week for a total of four weeks, or 500 mg once apart |
| Re-assessme | ION – severe chronic inflammatory demyelinating polyneuropa ent required after 6 months s (tick boxes where appropriate) | athy |
| Ο | Patient's disease has responded to the previous rituximab treatr compared to baseline | nent with demonstrated improvement in neurological function |
| and O and | The patient has not received rituximab in the previous 6 months | |
| 0 | One of the following dose regimens is to be used: 375 mg/m2 o weekly for four weeks, or two 1,000 mg doses given two weeks | f body surface area per week for a total of four weeks, or 500 mg once apart |

I confirm that the above details are correct:

| Signed: | . Date: |
|---------|---------|
|---------|---------|

| | | cklist to determine if a patient meets the restrictions for funding or community funding, see the Special Authority Criteria. | g in the hospital setting . For more details, refer to Section H of the Pharmaceutica |
|---------------------|-------------------------------------|--|--|
| PRE | SCRIBE | ER | PATIENT: |
| Name: | | | Name: |
| Nard | ł: | | NHI: |
| Ritu | ximab | 0 (Riximyo) - <i>continued</i> | |
| INIT Re-a | TIATION assessm requisit | I – anti-NMDA receptor autoimmune encephalitis ment required after 6 months tes (tick boxes where appropriate) | ance with a protocol or guideline that has been endorsed by the Health NZ |
| and | Ho | ospital. | |
| | and | D Patient has severe anti-NMDA receptor autoimmune enc | ephalitis |
| | | O Treatment with steroids and intravenous imm active disease and | nunoglobulin and/or plasma exchange has not been effective at controlling |
| | | effective at controlling active disease | ophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been |
| | | O Rapid treatment is required due to life threatening | complications |
| | and | One of the following dose regimens is to be used: 375 m weekly for four weeks, or two 1,000 mg doses given two | ng/m2 of body surface area per week for a total of four weeks, or 500 mg once weeks apart |
| Re-a Prer | assessm r equisit O Pr | ATION – anti-NMDA receptor autoimmune encephalitis ment required after 6 months tes (tick boxes where appropriate) rescribed by, or recommended by a neurologist, or in accorda ospital. | nce with a protocol or guideline that has been endorsed by the Health NZ |
| and | and | D Patient's disease has responded to the previous rituxima | b treatment with demonstrated improvement in neurological function |
| | C | ${\sf O}$ The patient has not received rituximab in the previous 6 r | months |
| | and | The patient has experienced a relapse and now requires | further treatment |
| | and | One of the following dose regimens is to be used: 375 m weekly for four weeks, or two 1,000 mg doses given two | ng/m2 of body surface area per week for a total of four weeks, or 500 mg once weeks apart |
| | | | |
| Re-a | assessm | I – CD20+ low grade or follicular B-cell NHL ment required after 9 months tes (tick boxes where appropriate) | |
| Re-a | assessm requisit | nent required after 9 months tes (tick boxes where appropriate) | II NHL with relapsed disease following prior chemotherapy |
| Re-a | assessm requisit | nent required after 9 months tes (tick boxes where appropriate) O The patient has CD20+ low grade or follicular B-ce | II NHL with relapsed disease following prior chemotherapy |
| Re-a | assessm requisit | nent required after 9 months tes (tick boxes where appropriate) O The patient has CD20+ low grade or follicular B-ce and | |

| Use this checklist to determine if a patient meets the restrictions for funding in Schedule. For community funding, see the Special Authority Criteria. | the hospital setting . For more details, refer to Section H of the Pharmaceutical |
|--|--|
| PRESCRIBER | PATIENT: |
| Name: | Name: |
| Ward: | NHI: |
| Rituximab (Riximyo) - continued | |
| CONTINUATION – CD20+ low grade or follicular B-cell NHL | |
| Re-assessment required after 24 months Prerequisites (tick boxes where appropriate) | |
| A Rituximab is to be used for maintenance in CD20+ low grade chemotherapy and | e or follicular B-cell NHL following induction with first-line systemic |
| O Patient is intended to receive rituximab maintenance therapy 12 cycles) | for 2 years at a dose of 375 mg/m2 every 8 weeks (maximum of |
| INITIATION – Membranous nephropathy Re-assessment required after 6 weeks Prerequisites (tick boxes where appropriate) | |
| measures (see Note) | |
| CONTINUATION – Membranous nephropathy Re-assessment required after 6 weeks Prerequisites (tick boxes where appropriate) | |
| O Patient was previously treated with rituximab for membranou and | s nephropathy* |
| O Treatment with rituximab was previously successful, but treatment | It the condition has relapsed, and the patient now requires repeat |
| O Patient achieved partial response to treatment and req | uires repeat treatment (see Note) |
| and O The total rituximab dose used would not exceed the equivale | ent of 375 mg/m2 of body surface area per week for a total of 4 weeks |
| Note: a) Indications marked with * are unapproved indications. | |
| b) High risk of progression to end-stage kidney disease defined as > 5g/day | r proteinuria. |
| c) Conservative measures include renin-angiotensin system blockade, bloo dyslipidaemia, and anticoagulation agents unless contraindicated or the | d-pressure management, dietary sodium and protein restriction, treatment of patient has experienced intolerable side effects. |
| d) Partial response defined as a reduction of proteinuria of at least 50% from | n baseline, and between 0.3 grams and 3.5 grams per 24 hours. |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIE | IBER | PATIENT: |
|------------------------|--|---|
| Name: | | Name: |
| Ward: | | NHI: |
| Rituxima | ab (Riximyo) - continued | |
| | ON – B-cell acute lymphoblastic leukaemia/lymphoma* | |
| | ssment required after 2 years isites (tick boxes where appropriate) | |
| and | O Patient has newly diagnosed B-cell acute lymphoblastic leukae | emia/lymphoma* |
| and | O Treatment must be in combination with an intensive chemother | apy protocol with curative intent |
| | O The total rituximab dose would not exceed the equivalent of 37 | 5 mg/m2 per dose for a maximum of 18 doses |
| Note: Indi | dications marked with * are unapproved indications. | |
| Re-assess | ON – desensitisation prior to transplant ssment required after 6 weeks isites (tick boxes where appropriate) | |
| and | Patient requires desensitisation prior to mismatched allogenic Patient would receive no more than two doses at 375 mg/m2 or | |
| Note: Indi | dications marked with * are unapproved indications. | |
| Re-assess Prerequis | | alist, or in accordance with a protocol or guideline that has been endorsed |
| and | by the Health NZ Hospital. | |
| | O Patient has severe rapidly progressive pemphigus | |
| | O Is used in combination with systemic corticosteroids (20 and | mg/day) |
| | O Skin involvement is at least 5% body surface area | sal erosions) or diffuse gingivitis or confluent large erosions |
| | or O Involvement of two or more mucosal sites | |
| or | | |
| | O Patient has pemphigus and | |
| | \sim | m systemic corticosteroids (20 mg/day) in combination with a steroid |
| Note: Indi | dications marked with * are unapproved indications. | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|---|
| Name: | Name: |
| Ward: | NHI: |
| Rituximab (Riximyo) - continued | |
| CONTINUATION – pemiphigus* Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) | |
| O Prescribed by, or recommended by a dermatologist or relevant speci by the Health NZ Hospital. | alist, or in accordance with a protocol or guideline that has been endorsed |
| O Patient has experienced adequate clinical benefit from rituxima ulceration and reduction in corticosteroid requirement and | ab treatment, with improvement in symptoms and healing of skin |
| O Patient has not received rituximab in the previous 6 months | |
| Note: Indications marked with * are unapproved indications. | |
| INITIATION – immunoglobulin G4-related disease (IgG4-RD*) Re-assessment required after 6 weeks Prerequisites (tick boxes where appropriate) | |
| O Patient has confirmed diagnosis of IgG4-RD* | |
| O Treatment with corticosteroids and/or disease modifying lowering corticosteroid dose below 5 mg per day (predn | anti-rheumatic drugs for at least 3 months has been ineffective in isone equivalent) without relapse anti-rheumatic drugs is contraindicated or associated with evidence of |
| toxicity or intolerance | |
| and O Total rituximab dose used should not exceed a maximum of tw | o 1000 mg infusions of rituximab given two weeks apart |
| Note: Indications marked with * are unapproved indications. | |
| CONTINUATION – immunoglobulin G4-related disease (IgG4-RD*) Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) | |
| but the condition has relapsed | uccessful and patient's disease has demonstrated sustained response, |
| O Patient is receiving maintenance treatment for IgG4-RD* | • |
| and O Rituximab re-treatment not to be given within 6 months of prev and | |
| O Maximum of two 1000 mg infusions of rituximab given two wee | eks apart |
| Note: Indications marked with * are unapproved indications. | |
| | |


| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting | . For more details, | refer to Section H of the | Pharmaceutical |
|---|---------------------|---------------------------|----------------|
| Schedule. For community funding, see the Special Authority Criteria. | | | |

| ESCRIBER | PATIENT: |
|--|---|
| me: | Name: |
| ırd: | NHI: |
| polizumab | |
| ITIATION – Severe eosinophilic asthma e-assessment required after 12 months rerequisites (tick boxes where appropriate) | |
| O Prescribed by, or recommended by a respiratory physician or endorsed by the Health NZ Hospital. | r clinical immunologist, or in accordance with a protocol or guideline that has been |
| O Patient must be aged 12 years or older and | |
| | sthma documented by a respiratory physician or clinical immunologist |
| Conditions that mimic asthma eg. vocal cord dysfunctions | ion, central airway obstruction, bronchiolitis etc. have been excluded |
| Patient has a blood eosinophil count of greater than 0.8 | 5 × 10 [°] 9 cells/L in the last 12 months |
| of fluticasone propionate) plus long acting beta-2 agon therapy regimen, unless contraindicated or not tolerate | including inhaled corticosteroids (equivalent to at least 1000 mcg per day nist, or budesonide/formoterol as part of the single maintenance and reliever ed |
| and O Patient has had at least 4 exacerbations needing defined as either documented use of oral corticol | g systemic corticosteroids in the previous 12 months, where an exacerbation is steroids for at least 3 days or parenteral corticosteroids |
| | pids of at least the equivalent of 10 mg per day over the previous 3 months |
| and O Treatment is not to be used in combination with subsidi | lised benralizumab |
| O Patient has an Asthma Control Test (ACT) score of 10 and oral corticosteroid dose must be made at the time response to treatment | or less. Baseline measurements of the patient's asthma control using the ACT of application, and again at around 52 weeks after the first dose to assess |
| and O Patient has not previously received an anti-IL5 bi | iological therapy for their severe eosinophilic asthma |
| O Patient was refractory or intolerant to previ | ious anti-IL5 biological therapy |
| | ent with previous anti-IL5 biological therapy and discontinued within |
| | |

CONTINUATION – Severe eosinophilic asthma Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

| \cup | Prescribed by, or recommended by a respiratory physician or clinical immunologist, or in accordance with a protocol or guideline that has been |
|--------|--|
| | endorsed by the Health NZ Hospital. |
| nd | |



Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|---|
| Name: | Name: |
| Ward: | NHI: |
| Mepolizumab - continued | |
| INITIATION – eosinophilic granulomatosis with polyangiitis Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) | |
| The patient has eosinophilic granulomatosis with polyangiitis and The patient has trialled and not received adequate benefit from contraindicated to all): azathioprine, cyclophosphamide, leflue and | m at least one of the following for at least three months (unless nomide, methotrexate, mycophenolate, or rituximab |
| | ee months and is unable to maintain disease control at doses below |
| CONTINUATION – eosinophilic granulomatosis with polyangiitis Re-assessment required after 12 months Prerequisites (tick box where appropriate) O Patient has no evidence of clinical disease progression | |

I confirm that the above details are correct:

RS2063 - Adalimumab (Amgevita)

| Arthritis - oligoarticular course juvenile idiopathic - INITIATION | 392 |
|--|-----|
| Arthritis - oligoarticular course juvenile idiopathic - CONTINUATION | |
| Arthritis - polyarticular course juvenile idiopathic - INITIATION | |
| Arthritis - polyarticular course juvenile idiopathic - CONTINUATION | |
| Arthritis - psoriatic - INITIATION | |
| Arthritis - psoriatic - CONTINUATION | |
| Arthritis - rheumatoid - INITIATION | |
| Arthritis - rheumatoid - CONTINUATION | |
| Behcet's disease - severe - INITIATION | |
| Crohn's disease - adults - INITIATION | |
| Crohn's disease - adults - CONTINUATION | |
| Crohn's disease - children - INITIATION | |
| Crohn's disease - children - CONTINUATION | |
| Crohn's disease - fistulising - INITIATION | |
| Crohn's disease - fistulising - CONTINUATION | |
| Hidradenitis suppurativa - INITIATION | |
| Hidradenitis suppurativa - CONTINUATION | |
| Ocular inflammation - chronic - INITIATION | |
| Ocular inflammation - chronic - CONTINUATION | |
| Ocular inflammation - severe - INITIATION | |
| Ocular inflammation - severe - CONTINUATION | |
| Plaque psoriasis - severe chronic - INITIATION | |
| Plaque psoriasis - severe chronic - CONTINUATION | |
| Still's disease - adult-onset (AOSD) - INITIATION | |
| Ankylosing spondylitis - INITIATION | |
| Ankylosing spondylitis - CONTINUATION | |
| Inflammatory bowel arthritis - axial - INITIATION | |
| Inflammatory bowel arthritis - axial - CONTINUATION | |
| Inflammatory bowel arthritis – peripheral - INITIATION | |
| Inflammatory bowel arthritis – peripheral - CONTINUATION | |
| Inflammatory bowel arthritis – peripheral - CONTINUATION Pyoderma gangrenosum - INITIATION Ulcerative colitis - INITIATION | |
| Ulcerative colitis - INITIATION | |
| Ulcerative colitis - CONTINUATION | |
| Undifferentiated spondyloarthiritis - INITIATION | |
| Undifferentiated spondyloarthiritis - CONTINUATION | |
| |) |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Adalimumab (Amgevita)

INITIATION – Behcet's disease - severe Prerequisites (tick boxes where appropriate)

O Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

| | and (| С | The p | patient has severe Behcet's disease* that is significantly impacting the patient's quality of life |
|-------|-------|---------|-------|---|
| | | | 0 | The patient has severe ocular, neurological, and/or vasculitic symptoms and has not responded adequately to one or more treatment(s) appropriate for the particular symptom(s) |
| | | or | 0 | The patient has severe gastrointestinal, rheumatological and/or mucocutaneous symptoms and has not responded adequately to two or more treatments appropriate for the particular symptom(s) |
| lote: | Indic | atio | ns ma | rrked with * are unapproved indications. |

INITIATION – Hidradenitis suppurativa

| Re-assessment required | after 4 | months |
|------------------------|---------|--------|
| | | |

Prerequisites (tick boxes where appropriate)

| (and | | Preso Hosp | cribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ ital. |
|----------|-----|---------------|---|
| | | O | Patient has hidradenitis suppurativa Hurley Stage II or Hurley Stage III lesions in distinct anatomic areas |
| | anc | O | Patient has tried, but had an inadequate response to at least a 90 day trial of systemic antibiotics or patient has demonstrated intolerance to or has contraindications for systemic antibiotics |
| | anc | Ο | Patient has 3 or more active lesions |
| | | 0 | The patient has a DLQI of 10 or more and the assessment is no more than 1 month old at time of application |
| | | | |

| | | | ON – Hidradenitis suppurativa nt required after 2 years |
|---|----------|----------|--|
| F | Prere | quisites | s (tick boxes where appropriate) |
| a | (Ind | | scribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health Hospital. |
| | | Ο | The patient has a reduction in active lesions (e.g. inflammatory nodules, abscesses, draining fistulae) of 25% or more from baseline |
| | | and | The patient has a DLQI improvement of 4 or more from baseline |

I confirm that the above details are correct:

| Use this checklist to determine if a patient meets the restrictions for funding in th Schedule. For community funding, see the Special Authority Criteria. | e hospital setting . For more details, refer to Section H of the Pharmaceutical |
|---|--|
| PRESCRIBER | PATIENT: |
| Name: | Name: |

Ward: NHI:

Adalimumab (Amgevita) - continued

INITIATION – Plaque psoriasis - severe chronic Re-assessment required after 4 months **Prerequisites** (tick boxes where appropriate) O Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ

| | (| С | Patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis | | | | |
|----|-----------------|--------|--|--|--|--|--|
| | and | or | Patient has experienced intolerable side effects Patient has received insufficient benefit to meet the renewal criteria for etanercept for severe chronic plaque psoriasis | | | | |
| or | | | | | | | |
| | | or | Patient has "whole body" severe chronic plaque psoriasis with a (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis Patient has severe chronic localised genital or flexural plaque psoriasis where the plaques or lesions have been present for at least 6 months from the time of initial diagnosis, and with a Dermatology Life Quality Index (DLQI) score greater than 10 | | | | |
| | and (and | С С | Patient has tried, but had an inadequate response to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin A PASI assessment or (DLQI) assessment has been completed for at least the most recent prior treatment course but no longer than 1 month following cessation of each prior treatment course and is no more than 1 month old at the time of application | | | | |

| I confirm that the above details are correct | t: |
|--|----|
|--|----|

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | | |
|--|----------|--|--|--|
| Name: | Name: | | | |
| Ward: | NHI: | | | |
| Adalimumab (Amgevita) - continued | | | | |
| CONTINUATION – Plaque psoriasis - severe chronic Re-assessment required after 2 years Prerequisites (tick boxes where appropriate) | | | | |

| | and | or | O The patient has experienced a 75% or more reduction in PASI score, or is sustained at this level, when compared with the pre-treatment baseline value O The patient has a DLQI improvement of 5 or more, when compared with the pre-treatment baseline value |
|--|-----|--|---|
| or | | | |
| O Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment and | | Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment | |
| | | or | O The patient has experienced a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values O The patient has experienced a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value |
| or | | $\overline{)}$ | Detient had covere obvious locational conital or flavoural plague populacia at the start of tractment |
| | and | | Patient had severe chronic localised genital or flexural plaque psoriasis at the start of treatment |
| | | or | O The patient has experienced a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value |
| | | | O Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing adalimumab |

| INITIATION – pyoderma gangrenosum | | | | | | | | |
|---|--|--|--|--|--|--|--|--|
| Prerequisites (tick boxes where appropriate) | | | | | | | | |
| O Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | | | | | | |
| Patient has pyoderma gangrenosum* Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response | | | | | | | | |
| Note: Indications marked with * are unapproved indications. | | | | | | | | |
| | | | | | | | | |

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. For more details, refer to Section H of the Pharmaceutical |
|---|
| Schedule. For community funding, see the Special Authority Criteria. |
| |

| PRESC | RIBE | R PATIENT: |
|--------|---------------------------|---|
| Name: | | Name: |
| Ward: | | NHI: |
| Adalir | num | ab (Amgevita) - continued |
| Re-ass | sessm quisite | - Crohn's disease - adults ent required after 6 months es (tick boxes where appropriate) |
| and | | escribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health Hospital. |
| é | ر _ and | Patient has severe active Crohn's disease |
| | | O Patient has a CDAI score of greater than or equal to 300 or HBI score of greater than or equal to 10 |
| | | O Patient has extensive small intestine disease affecting more than 50 cm of the small intestine |
| | | O Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection or |
| | | O Patient has an ileostomy or colostomy and has intestinal inflammation |
| | and | Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and corticosteroids |
| | quisite | ent required after 2 years es (tick boxes where appropriate) escribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health Hospital. |
| and | or | CDAI score has reduced by 100 points from the CDAI score, or HBI score has reduced 3 points, from when the patient was initiated on adalimumab |
| | or Or | CDAI score is 150 or less, or HBI is 4 or less |
| | С | The patient has demonstrated an adequate response to treatment, but CDAI score and/or HBI score cannot be assessed |
| Re-ass | sessm quisite) Pre | - Crohn's disease - children ent required after 6 months es (tick boxes where appropriate) escribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health Hospital. |
| | and | Paediatric patient has active Crohn's disease |
| | | O Patient has a PCDAI score of greater than or equal to 30 O Patient has extensive small intestine disease |
| | and | Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and corticosteroids |

| RES | CRIBE | 3 | PATIENT: |
|----------|------------------------------|--|--|
| | | | |
| | | | |
| | | | NUI. |
| | | ab (Amgevita) - continued ION – Crohn's disease - children | |
| Re-a | ssessme | ent required after 2 years s (tick boxes where appropriate) | |
| (and | | scribed by, or recommended by any relevant practitic Hospital. | oner, or in accordance with a protocol or guideline that has been endorsed by the Health |
| | or C | PCDAI score has reduced by 10 points from the P | CDAI score when the patient was initiated on adalimumab |
| | or | PCDAI score is 15 or less | |
| | C | The patient has demonstrated an adequate respon | nse to treatment but PCDAI score cannot be assessed |
| and | NZ | Hospital. Patient has confirmed Crohn's disease O Patient has one or more complex externally O Patient has one or more rectovaginal fistula(O Patient has complex peri-anal fistula | |
| Re-a | ssessme equisite O Pre | Hospital. The number of open draining fistulae have decrea | oner, or in accordance with a protocol or guideline that has been endorsed by the Health sed from baseline by at least 50% i all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment |

I confirm that the above details are correct:

or

or

HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | SCRIE | BER | | | PATIENT: | |
|------|--|----------------|--------|-------|---|-------------------------------|
| Name | ə: | | | | Name: | |
| Ward | : | | | | NHI: | |
| Adal | limu | mab | (An | nge | ngevita) - continued | |
| | | | | | r inflammation - chronic ired after 4 months | |
| Prer | equis | sites (| tick b | oxe | oxes where appropriate) | |
| and | | Presc NZ Ho | | | by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that ha I. | s been endorsed by the Health |
| and | or | 0 | The p | oatie | patient has had an initial Special Authority approval for infliximab for chronic ocular inflammation | |
| | | and | 0 | | Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants wit loss | h a severe risk of vision |
| | | | or | С | O Patient is 18 years or older and treatment with at least two other immunomodulatory agents ha | s proven ineffective |
| | | | or | С | O Patient is under 18 years and treatment with methotrexate has proven ineffective or is not toler | ated at a therapeutic dose |
| | | | | C | O Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achievin methotrexate | |
| | | | | | | |
| Re-a | CONTINUATION – Ocular inflammation - chronic Re-assessment required after 2 years Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health | | | | | |
| and | | NZ Ho | | | | |
| | O The patient has had a good clinical response following 12 weeks' initial treatment | | | | | |

Following each 2 year treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema)

Following each 2 year treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old

I confirm that the above details are correct:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | | | | | | PATIENT: | |
|--|---|----------------|----------|-----|--------------|---|--|
| Name: | | | | | | | |
| Ward | : | | | | | NHI: | |
| Adal | limu | ımab | (Ai | ng | evi | ita) - continued | |
| INITIATION – Ocular Re-assessment requ Prerequisites (tick b | | | | | d af | fter 4 months | |
| (and | 0 | Presc NZ Ho | | | or | recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health | |
| | or | 0 | Patie | ent | nas | had an initial Special Authority approval for infliximab for severe ocular inflammation | |
| | | and | O L | Pa | atie | nt has severe, vision-threatening ocular inflammation requiring rapid control | |
| | | | or or | | \mathbf{c} | Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms Patient developed new inflammatory symptoms while receiving high dose steroids | |
| | | | | OI | (|) | Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms |
| Re-a | CONTINUATION – Ocular inflammation - severe Re-assessment required after 2 years Prerequisites (tick boxes where appropriate) | | | | | | |
| O Prescribed NZ Hospit | | | | | or | recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health | |
| | or | Ο | The | pat | ent | t has had a good clinical response following 3 initial doses | |
| | or | | Nom | end | latu | each 2 year treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis ure (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of oid macular oedema) | |

Following each 2 year treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old

I confirm that the above details are correct:

()

Page 391

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting . | For more details, refer to Section H of the Pharmaceutical |
|--|--|
| Schedule. For community funding, see the Special Authority Criteria. | |

| PRESCRIBER | PATIENT: |
|--|---|
| Name: | Name: |
| Ward: | NHI: |
| Adalimumab (Amgevita) - continued | |
| | nce with a protocol or guideline that has been endorsed by the Health NZ |
| Hospital. and O Patient has had an initial Special Authority approval for and O The patient has experienced intolerable side effect or O The patient has received insufficient benefit to me | ts |
| or Patient has a confirmed diagnosis of ankylosing spondy and Patient has low back pain and stiffness that is relieved by and Patient has bilateral sacroiliitis demonstrated by radiolog and Patient has not responded adequately to treatment with a regular exercise regimen for ankylosing spondylitis and | by exercise but not by rest |
| BASMI measures: a modified Schober's test of let than or equal to 10 cm (mean of left and right) O Patient has limitation of chest expansion by at lea gender and O A BASDAI of at least 6 on a 0-10 scale completed after | e in the sagittal and the frontal planes as determined by the following iss than or equal to 4 cm and lumbar side flexion measurement of less st 2.5 cm below the average normal values corrected for age and er the 3 month exercise trial, but prior to ceasing any previous a old at the time of application |
| CONTINUATION – ankylosing spondylitis Re-assessment required after 2 years Prerequisites (tick box where appropriate) O Prescribed by or recommended by any relevant practitioner, or in any second s | coordance with a protocol or quideline that has been endorsed by the Health |

Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

For applications where treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less

and

 \bigcirc

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | SCRIE | BER | PATIENT: |
|--------------|---------------------------|---|--|
| Name | ə: | | Name: |
| Ward | : | | NHI: |
| Ada | limu | mab | (Amgevita) - continued |
| INIT Re-a | IATIO assess requis |)N – A sment sites (Presc | The patient has experienced intolerable side effects Patient has received insufficient benefit to meet the renewal criteria for oligoarticular course JIA To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance Patient has had oligoarticular course JIA for 6 months duration or longer |
| Re-a | assess requis | sment sites (Presci | N – Arthritis - oligoarticular course juvenile idiopathic required after 2 years (tick boxes where appropriate) ribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health |
| and | or | 0 | Following initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline |
| | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | SCRIE | BER | | PATIENT: | |
|------|---|-----------------|----------|--|--|
| Name | ə: | | | Name: | |
| Ward | : | | | NHI: | |
| Ada | limu | mab | (An | gevita) - continued | |
| Re-a | issess | sment | requ | s - polyarticular course juvenile idiopathic red after 6 months exes where appropriate) | |
| and | | | | by, or recommended by a named specialist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed h NZ Hospital. | |
| | | and | O | Patient has had an initial Special Authority approval for etanercept for polyarticular course juvenile idiopathic arthritis (JIA) Patient has experienced intolerable side effects Patient has received insufficient benefit to meet the renewal criteria for polyarticular course JIA | |
| | or | and | Ο | To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance Patient has had polyarticular course JIA for 6 months duration or longer | |
| | | | or or | At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose) Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose) Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate | |
| Re-a | CONTINUATION – Arthritis - polyarticular course juvenile idiopathic Re-assessment required after 2 years Prerequisites (tick boxes where appropriate) | | | | |
| (| | Presci NZ Ho | | by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health | |

O Following initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline

On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline

and

or

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting | . For more details, refer to Section H of the Pharmaceutical |
|---|--|
| Schedule. For community funding, see the Special Authority Criteria. | |

| PRES | SCRIB | ER | | PATIENT: |
|------|-------------------------------|----------------------------------|----------------------|--|
| Name | ame: Name: | | | |
| Ward | : | | | NHI: |
| Adal | limur | nab | (An | ngevita) - continued |
| Re-a | assess equis O F | ment r ites (ti | requi ck b bed | is - psoriatic ired after 6 months oxes where appropriate) by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ |
| | | (and | C | Patient has had an initial Special Authority approval for etanercept or secukinumab for psoriatic arthritis |
| | | | or | O Patient has experienced intolerable side effects O Patient has received insufficient benefit to meet the renewal criteria for psoriatic arthritis |
| | or | (and (and (and | С С С | Patient has had active psoriatic arthritis for six months duration or longer Patient has tried and not responded to at least three months of methotrexate at a maximum tolerated dose (unless contraindicated) Patient has tried and not responded to at least three months of sulfasalazine or leflunomide at maximum tolerated doses (unless contraindicated) |
| | | | or | Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen joints Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip |
| | | and | or or | Patient has CRP level greater than 15 mg/L measured no more than one month prior to the date of this application Patient has an elevated ESR greater than 25 mm per hour ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months |
| Re-a | assess requis | ment r ites (ti | equi ck b bed | rthritis - psoriatic ired after 2 years oxes where appropriate) by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health I. |
| | or (| re F | espo Patier | wing initial treatment, the patient has at least a 50% decrease in swollen joint count from baseline and a clinically significant onse in the opinion of the physician nt demonstrates at least a continuing 30% improvement in swollen joint count from baseline and a clinically significant response opinion of the treating physician |

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. For | or more details, refer to Section H of the Pharmaceutical |
|--|---|
| Schedule. For community funding, see the Special Authority Criteria. | |

| PRESCRI | BER | | PATIENT: |
|----------|---------------------------|-----------------------|--|
| Name: | | | Name: |
| Ward: | | | NHI: |
| Adalimu | ımab | (An | ngevita) - continued |
| Re-asses | ssment sites (t | requ ick b ibed | is - rheumatoid ired after 6 months oxes where appropriate) by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ |
| | and | or | The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis O The patient has experienced intolerable side effects O The patient has received insufficient benefit from etanercept to meet the renewal criteria for rheumatoid arthritis |
| or | and and and | 0 0 0 | Patient has had rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance Patient has tried and not responded to at least three months of methotrexate at a maximum tolerated dose (unless contraindicated) Patient has tried and not responded to at least three months of methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate at maximum tolerated doses (unless contraindicated) |
| | and | or | Patient has tried and not responded to at least three months of methotrexate in combination with the maximum tolerated dose of ciclosporin Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with methotrexate Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen joints |
| Re-asses | sment | requ | Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip rthritis - rheumatoid ired after 2 years oxes where appropriate) |
| | SILES (I | | aves milele appropriate) |

| (and | O Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the NZ Hospital. | | |
|----------|--|---|---|
| | or | 0 | Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician |
| | U | 0 | On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician |

I confirm that the above details are correct:

| Signed: [| Date: |
|-----------|-------|
|-----------|-------|

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. For more details, refer to Section H of the Pharmaceutical |
|---|
| Schedule. For community funding, see the Special Authority Criteria. |
| |

| PRES | CRIB | ER PATIENT: |
|-------|----------|---|
| Name | : | Name: |
| Ward: | | NHI: |
| Adali | imur | nab (Amgevita) - continued |
| | equisi | N – Still's disease - adult-onset (AOSD) ites (tick boxes where appropriate) |
| and | | Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. |
| | | O The patient has had an initial Special Authority approval for etanercept and/or tocilizumab for (AOSD) |
| | | O Patient has experienced intolerable side effects from etanercept and/or tocilizumab |
| | | O Patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab |
| | or | |
| | | O Patient diagnosed with AOSD according to the Yamaguchi criteria and |
| | | O Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, NSAIDs and methotrexate |
| | | O Patient has persistent symptoms of disabling poorly controlled and active disease |
| Prere | equisi | ment required after 6 months ites (tick boxes where appropriate) Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health IZ Hospital. |
| and | (and | O Patient has active ulcerative colitis |
| | | O Patient's SCCAI score is greater than or equal to 4 |
| | | O Patient's PUCAI score is greater than or equal to 20 |
| | and (| Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and systemic corticosteroids |
| | (| O Surgery (or further surgery) is considered to be clinically inappropriate |
| | TINU | ATION – ulcerative colitis |
| | | ment required after 2 years i tes (tick boxes where appropriate) |
| and | | Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health IZ Hospital. |
| | (or | The SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on biologic therapy |
| | . (| O The PUCAI score has reduced by 10 points or more from the PUCAI score when the patient was initiated on biologic therapy |

| Forn July 2 | n RS2 025 | 2063 | | HOSPITAL MEDICINES LIST Page 39 RESTRICTIONS CHECKLIST | | |
|----------------|---------------------------|--|--|---|----------|--|
| | | | determine if a patient meets the restrictions for funding in a unity funding, see the Special Authority Criteria. | the hospital setting . For more details, refer to Section H of the Pharmace | eutical | |
| PRES | CRIBE | R | | PATIENT: | | |
| Name | : | | | Name: | | |
| Ward: | | | | NHI: | | |
| Adal | imum | nab (A | mgevita) - continued | | | |
| Re-a | ssessm | nent requ | ferentiated spondyloarthiritis uired after 6 months boxes where appropriate) | | | |
| and |) Pr | | | nce with a protocol or guideline that has been endorsed by the Health NZ | <u>-</u> | |
| | and | | ent has undifferentiated peripheral spondyloarthritis* with t, elbow, knee, ankle, and either shoulder or hip | active peripheral joint arthritis in at least four joints from the following: | | |
| | and | | ent has tried and not responded to at least three months rated doses (unless contraindicated) | of each of methotrexate, sulphasalazine and leflunomide, at maximum | | |
| | | or O | | d no more than one month prior to the date of this application | | |
| | | or O | ESR and CRP not measured as patient is currently rec | sured no more than one month prior to the date of this application eiving prednisone therapy at a dose of greater than 5 mg per day and | | |
| | | | has done so for more than three months arked with * are unapproved indications. | | | |
| Re-a | ssessm equisit O Pr | nent requ i es (tick | | ccordance with a protocol or guideline that has been endorsed by the He | ealth | |
| | or | | owing initial treatment, the patient has at least a 50% dec ionse to treatment in the opinion of the physician | rease in active joint count from baseline and a clinically significant | | |
| | | | patient demonstrates at least a continuing 30% improver onse in the opinion of the treating physician | nent in active joint count from baseline and a clinically significant | | |
| Re-a | ssessm equisit O Pr | nent requ es (tick rescribed ospital. | nmatory bowel arthritis – axial uired after 6 months boxes where appropriate) d by, or recommended by a rheumatologist, or in accorda ent has a diagnosis of active ulcerative colitis or active C | nce with a protocol or guideline that has been endorsed by the Health NZ rohn's disease | <u>z</u> | |
| | and and |) Patie | ent has axial inflammatory pain for six months or more | | | |
| | and |) Patie | ent is unable to take NSAIDs | | | |
| | C |) Patie | ent has unequivocal sacroiliitis demonstrated by radiolog | cal imaging or MRI | | |
| | and | | ent has not responded adequately to prior treatment cons siotherapist | sisting of at least 3 months of an exercise regime supervised by a | | |
| | and | | ASDAI of at least 6 on a 0-10 scale completed after the 3 tment | month exercise trial, but prior to ceasing any previous pharmacological | | |

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting . For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria. | | | | |
|--|--|--|--|--|
| PRESCRIBER | PATIENT: | | | |
| Name: | Name: | | | |
| Ward: | NHI: | | | |
| Adalimumab (Amgevita) - continued | | | | |
| CONTINUATION – inflammatory bowel arthritis – axial Re-assessment required after 2 years | | | | |
| Prerequisites (tick box where appropriate) | | | | |
| O Prescribed by, or recommended by any relevant practitioner, or in NZ Hospital. | accordance with a protocol or guideline that has been endorsed by the Health | | | |
| | or more points from pre-treatment baseline on a 10 point scale, or an | | | |
| INITIATION – inflammatory bowel arthritis – peripheral Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) | | | | |
| | lance with a protocol or guideline that has been endorsed by the Health NZ | | | |
| Patient has a diagnosis of active ulcerative colitis or active (and | | | | |
| and Patient has active arthritis in at least four joints from the foll | owing: hip, knee, ankle, subtalar, tarsus, forefoot, wrist, elbow, shoulder, | | | |
| O Patient has tried and not experienced a response to at lease dose (unless contraindicated) | t three months of methotrexate, or azathioprine at a maximum tolerated | | | |
| and Patient has tried and not experienced a response to at lease contraindicated) and | t three months of sulphasalazine at a maximum tolerated dose (unless | | | |
| O Patient has a CRP level greater than 15 mg/L measur | red no more than one month prior to the date of this application | | | |
| O Patient has an ESR greater than 25 mm per hour | | | | |
| | eceiving prednisone therapy at a dose of greater than 5 mg per day and | | | |
| | | | | |
| CONTINUATION – inflammatory bowel arthritis – peripheral Re-assessment required after 2 years Prerequisites (tick boxes where appropriate) | | | | |
| NZ Hospital. | accordance with a protocol or guideline that has been endorsed by the Health | | | |
| and O Following initial treatment, the patient has at least a 50% de response to treatment in the opinion of the physician or | ecrease in active joint count from baseline and a clinically significant | | | |

O Patient demonstrates at least a continuing 30% improvement in active joint count from baseline in the opinion of the treating physician

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |

Palivizumab

| (and | F C | Paliviz | umab | o to be administered during the annual RSV season |
|----------|-----|---------|-------------------------|--|
| | | and | $\overline{\mathbf{O}}$ | Infant was born in the last 12 months Infant was born at less than 32 weeks zero days' gestation |
| | or | and | O | Child was born in the last 24 months |
| | | | or | O Child has severe lung, airway, neurological or neuromuscular disease that requires ongoing ventilatory/respiratory support (see Note A) in the community |
| | | | | and C Child has haemodynamically significant heart disease and C Child has unoperated simple congenital heart disease with significant left to right shunt (see Note B) or O Child has unoperated or surgically palliated complex congenital heart disease or |
| | | | | O Child has severe pulmonary hypertension (see Note C) or O Child has moderate or severe left ventricular (LV) failure (see Note D) |
| | | | or | O Child has severe combined immune deficiency, confirmed by an immunologist, but has not received a stem cell |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIB | ER | | PATIENT: |
|-----------------------|---------------------------|---|---|
| Name: | | | Name: |
| Ward: | | | NHI: |
| Palivizun | nab | - contii | nued |
| CONTINUA Re-assess | ATION iment ites (t | N require tick bo> Palivizu Child w | ed after 6 months xes where appropriate) umab to be administered during the annual RSV season vas born in the last 24 months Child has severe lung, airway, neurological or neuromuscular disease that requires ongoing ventilatory/respiratory support (see Note A) in the community O Child has haemodynamically significant heart disease or O Child has unoperated simple congenital heart disease with significant left to right shunt (see Note B) or O Child has unoperated or surgically palliated complex congenital heart disease |
| | or or | Oc | O Child has severe pulmonary hypertension (see Note C) or O Child has moderate or severe left ventricular (LV) failure (see Note D) Child has severe combined immune deficiency, confirmed by an immunologist, but has not received a stem cell transplant Child has inborn errors of immunity (see Note E) that increase susceptibility to life-threatening viral respiratory infections, confirmed by an immunologist |

Note:

- a) Ventilatory/respiratory support includes those on home oxygen, CPAP/VPAP and those with tracheostomies in situ managed at home
- b) Child requires/will require heart failure medication, and/or child has significant pulmonary hypertension, and/or infant will require surgical palliation/definitive repair within the next 3 months
- c) Mean pulmonary artery pressure more than 25 mmHg
- d) LV Ejection Fraction less than 40%
- e) Inborn errors of immunity include, but are not limited to, IFNAR deficiencies

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Gemtuzumab ozogamicin

INITIATION Prerequisites (tick boxes where appropriate) () Patient has not received prior chemotherapy for this condition and Patient has de novo CD33-positive acute myeloid leukaemia and Patient does not have acute promyelocytic leukaemia and Gemtuzumab ozogamicin will be used in combination with standard anthracycline and cytarabine (AraC) and Patient is being treated with curative intent and Patient's disease risk has been assessed by cytogenetic testing to be good or intermediate and Patient must be considered eligible for standard intensive remission induction chemotherapy with standard anthracycline and cytarabine (AraC) and Gemtuzumab ozogamicin to be funded for one course only (one dose at 3 mg per m² body surface area or up to 2 vials of 5 mg as separate doses)

Note: Acute myeloid leukaemia excludes acute promyelocytic leukaemia and acute myeloid leukaemia that is secondary to another haematological disorder (eg myelodysplasia or myeloproliferative disorder).

| SCRIBE | ER | | PATIENT: |
|----------|------|--|---|
| ie: | | | Name: |
| d: | | | NHI: |
| ralizu | ma | ıb | |
| | | Severe eosinophilic asthma | |
| | | t required after 12 months (tick boxes where appropriate) | |
| requisit | les | (lick boxes where appropriate) | |
| | | ribed by, or recommended by a respiratory physician or clin rsed by the Health NZ Hospital. | ical immunologist, or in accordance with a protocol or guideline that has been |
| and |) | Patient must be aged 12 years or older | |
| and |) | Patient must have a diagnosis of severe eosinophilic asthm | a documented by a respiratory physician or clinical immunologist |
| and |) | | central airway obstruction, bronchiolitis etc. have been excluded |
| and | | Patient has a blood eosinophil count of greater than 0.5×1 | 0 ⁹ cells/L in the last 12 months |
| | ر | | uding inhaled corticosteroids (equivalent to at least 1000 mcg per day of budesonide/formoterol as part of the anti-inflammatory reliever therapy plus ed |
| and | or | defined as either documented use of oral corticoster | temic corticosteroids in the previous 12 months, where an exacerbation is bids for at least 3 days or parenteral corticosteroids of at least the equivalent of 10 mg per day over the previous 3 months |
| and |) | Treatment is not to be used in combination with subsidised | mepolizumab |
| and | C | Patient has an Asthma Control Test (ACT) score of 10 or le and oral corticosteroid dose must be made at the time of an response to treatment | ss. Baseline measurements of the patient's asthma control using the ACT oplication, and again at around 52 weeks after the first dose to assess |
| | or | O Patient has not previously received an anti-IL5 biolog | ical therapy for their severe eosinophilic asthma |
| | | | anti-IL5 biological therapy vith previous anti-IL5 biological therapy and discontinued within |
| | | 12 months of commencing treatment | |
| | | | |
| assessn | nen | N – Severe eosinophilic asthma t required after 2 years | |
| requisit | es | (tick boxes where appropriate) | |
| () D. | resc | ribed by, or recommended by a respiratory physician or clin | ical immunologist, or in accordance with a protocol or guideline that has bee |

 $O\,$ Exacerbations have been reduced from baseline by 50% as a result of treatment with benralizumab

O Reduction in continuous oral corticosteroid use by 50% or by 10 mg/day while maintaining or improving asthma control

and

or

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |

Ustekinumab

| INITIATION – Crohn's disease - adults Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) |
|--|
| Patient is currently on treatment with ustekinumab commenced prior to 1 February 2023 and met all remaining criteria (criterion 2) below at the time of commencing treatment |
| O Patient has active Crohn's disease |
| O Patient has had an initial approval for prior biologic therapy for Crohn's disease and has experienced intolerable side effects or insufficient benefit to meet renewal criteria |
| O Patient meets the initiation criteria for prior biologic therapies for Crohn's disease and O Other biologics for Crohn's disease are contraindicated |
| |
| CONTINUATION – Crohn's disease - adults Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) |
| CDAI score has reduced by 100 points, or HBI score has reduced by 3 points, from when the patient was initiated on biologic therapy or |
| CDAI score is 150 or less, or HBI is 4 or less |
| or O The patient has experienced an adequate response to treatment, but CDAI score and/or HBI score cannot be assessed |
| and Ustekinumab to be administered at a dose no greater than 90 mg every 8 weeks |
| INITIATION – Crohn's disease - children* Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) |
| O Patient is currently on treatment with ustekinumab commenced prior to 1 February 2023 and met all remaining criteria (criterion 2) below at the time of commencing treatment |
| O Patient has active Crohn's disease |
| O Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria |
| Patient meets the initiation criteria for prior biologic therapies for Crohn's disease and Other biologics for Crohn's disease are contraindicated |
| |
| Note: Indication marked with * is an unapproved indication. |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | | |
|--|--|--|--|--|
| Name: | Name: | | | |
| Ward: | NHI: | | | |
| Ustekinumab - continued | | | | |
| CONTINUATION – Crohn's disease - children* Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) | | | | |
| O PCDAI score has reduced by 10 points from when or O PCDAI score is 15 or less or O The patient has experienced an adequate response | the patient was initiated on biologic therapy se to treatment, but CDAI score cannot be assessed | | | |
| and O Ustekinumab to administered at a dose no greater than the second s | 90 mg every 8 weeks | | | |
| Note: Indication marked with * is an unapproved indication. | | | | |
| or below at the time of commencing treatment O Patient has active ulcerative colitis and O Patient has had an initial approval for prior b effects or insufficient benefit to meet renewa | nenced prior to 1 February 2023 and met all remaining criteria (criterion 2) piologic therapy for ulcerative colitis and has experienced intolerable side al criteria prior biologic therapies for ulcerative colitis | | | |
| O Other biologics for ulcerative colitis are | e contraindicated | | | |
| CONTINUATION – ulcerative colitis Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) | | | | |
| or | e from the SCCAI score since initiation on biologic therapy om the PUCAI score since initiation on biologic therapy* | | | |
| and Ustekinumab will be used at a dose no greater than 90 r | ng intravenously every 8 weeks | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |

Vedolizumab

| INITIATION – Crohn's disease - adults Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) | | | | | | |
|--|---|----------|---|---|--|--|
| | O Patient has active Crohn's disease | | | | | |
| | | | 0 | Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria (unless contraindicated) | | |
| | | or or | 0 | Patient has a CDAI score of greater than or equal to 300, or HBI score of greater than or equal to 10 | | |
| | | or | Ο | Patient has extensive small intestine disease affecting more than 50 cm of the small intestine | | |
| | | or | 0 | Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection | | |
| | and | | 0 | Patient has an ileostomy or colostomy, and has intestinal inflammation | | |
| | and | | 0 | Patient has tried but experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids | | |
| | | or or | Ο | Patient has experienced intolerable side effects from immunomodulators and corticosteroids | | |
| | | | Ο | Immunomodulators and corticosteroids are contraindicated | | |
| Re-as | CONTINUATION – Crohn's disease - adults Re-assessment required after 2 years Prerequisites (tick boxes where appropriate) | | | | | |
| | | | 0 | CDAI score has reduced by 100 points, or HBI score has reduced by 3 points, from when the patient was initiated on biologic therapy | | |
| | | or or | Ο | CDAI score is 150 or less, or HBI is 4 or less | | |
| | | | Ο | The patient has experienced an adequate response to treatment, but CDAI score and/or HBI score cannot be assessed | | |
| | and | _ | | | | |

Vedolizumab to administered at a dose no greater than 300 mg every 8 weeks

 \bigcirc

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | | |
|-------------------------|----------|--|--|--|
| Name: | Name: | | | |
| Ward: | NHI: | | | |
| Vedolizumab - continued | | | | |

| Re-a | ssess | men | Crohn's disease - children* t required after 6 months (tick boxes where appropriate) |
|---|--|--|---|
| | Paediatric patient has active Crohn's disease | | Paediatric patient has active Crohn's disease |
| | | | O Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria (unless contraindicated) |
| | | or | O Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30 |
| | or O Patient has extensive small intestine disease | | |
| | and O Patient has tried but experienced an inadequate response to (including lack of initial response and/or loss of initial respo | | O Patient has tried but experienced an inadequate response to (including lack of initial response and/or loss of initial response) |
| or O Petiant has superiors and intelevable side affects from immunemedulators and certicesteroids | | from prior therapy with immunomodulators and corticosteroids O Patient has experienced intolerable side effects from immunomodulators and corticosteroids | |
| | | or | O Immunomodulators and corticosteroids are contraindicated |
| Note | : India | catio | n marked with * is an unapproved indication. |
| Re-a | ssess | men | DN – Crohn's disease - children* t required after 2 years (tick boxes where appropriate) |
| | | | O PCDAI score has reduced by 10 points from when the patient was initiated on biologic therapy |
| | | or or | O PCDAI score is 15 or less |
| | | | O The patient has experienced an adequate response to treatment, but CDAI score cannot be assessed |

 $m O\,$ Vedolizumab to administered at a dose no greater than 300mg every 8 weeks

Note: Indication marked with * is an unapproved indication.

and

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Vedolizumab - continued

| INITIATION – ulcerative colitis Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) | | | | |
|--|---|-----|---|--|
| · | Patient has active ulcerative colitis | | | |
| | | | O Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria (unless contraindicated) | |
| | | or | O Patient has a SCCAI score is greater than or equal to 4 | |
| | | | O Patient's PUCAI score is greater than or equal to 20* | |
| a | and O Patient has tried but experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids | | | |
| | | or | O Patient has experienced intolerable side effects from immunomodulators and corticosteroids | |
| | | | O Immunomodulators and corticosteroids are contraindicated | |
| Note: Indication marked with * is an unapproved indication. | | | | |
| Re-asse | essr | men | N – ulcerative colitis t required after 2 years (tick boxes where appropriate) | |
| | or O The SCCAI score has reduced by 2 points or more from the SCCAI score since initiation on biologic therapy O The PUCAI score has reduced by 10 points or more from the PUCAI score since initiation on biologic therapy * | | O The SCCAI score has reduced by 2 points or more from the SCCAI score since initiation on biologic therapy | |
| | | | O The PUCAI score has reduced by 10 points or more from the PUCAI score since initiation on biologic therapy * | |
| a | nd (| С | Vedolizumab will be used at a dose no greater than 300 mg intravenously every 8 weeks | |

Note: Indication marked with * is an unapproved indication.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Brentuximab

| Re-assessmer | relapsed/refractory Hodgkin lymphoma nt required after 6 months (tick boxes where appropriate) | |
|--------------------------|--|--|
| | O Patient has relapsed/refractory CD30-positive Hodgkin lymphoma after two or more lines of chemotherapy and O Patient is ineligible for autologous stem cell transplant | |
| or | O Patient has relapsed/refractory CD30-positive Hodgkin lymphoma and O Patient has previously undergone autologous stem cell transplant | |
| and and and and | Patient has not previously received funded brentuximab vedotin Response to brentuximab vedotin treatment is to be reviewed after a maximum of 6 treatment cycles Brentuximab vedotin to be administered at doses no greater than 1.8 mg/kg every 3 weeks | |
| Re-assessmer | DN – relapsed/refractory Hodgkin lymphoma ht required after 9 months (tick boxes where appropriate) | |
| and and | O Treatment remains clinically appropriate and the patient is benefitting from treatment and treatment is being tolerated | |
| Re-assessmer | anaplastic large cell lymphoma ht required after 9 months (tick boxes where appropriate) | |
| and and | Patient has relapsed/refractory CD30-positive systemic anaplastic large cell lymphoma Patient has an ECOG performance status of 0-1 | |

Patient has not previously received brentuximab vedotin

Response to brentuximab vedotin treatment is to be reviewed after a maximum of 6 treatment cycles

Brentuximab vedotin to be administered at doses no greater than 1.8 mg/kg every 3 weeks

)

and

and

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRE | SCRIBER | | PATIENT: | |
|--|---|--------------------------------|--|--|
| Name | ə: | | Name: | |
| Ward | : | | NHI: | |
| Brer | ntuxima | b - continued | | |
| CONTINUATION – anaplastic large cell lymphoma Re-assessment required after 9 months | | | | |
| Prer | equisites | (tick boxes where appropriate) | | |
| | O Patient has achieved a partial or complete response to brentuximab vedotin after 6 treatment cycles | | ximab vedotin after 6 treatment cycles | |
| and Treatment remains clinically appropriate and the patient is benefitting from treatment and treatment is being tolerated and Patient is to receive a maximum of 16 total cycles of brentuximab vedotin treatment | | | efitting from treatment and treatment is being tolerated | |
| | | | nab vedotin treatment | |

| Form RS2005 July 2025 | HOSPITAL MEDICINES LIST Page 4 RESTRICTIONS CHECKLIST |
|--|--|
| | e if a patient meets the restrictions for funding in the hospital setting . For more details, refer to Section H of the Pharmaceutical ding, see the Special Authority Criteria. |
| PRESCRIBER | PATIENT: |
| Name: | Name: |
| Ward: | NHI: |
| Trastuzumab (Herzum | a) |
| INITIATION – early breast of Re-assessment required afte Prerequisites (tick boxes w | er 12 months here appropriate) |
| and | has early breast cancer expressing HER-2 IHC 3+ or ISH + (including FISH or other current technology imulative dose of 106 mg/kg (12 months' treatment) |
| and O The pa | er 12 months |
| or O | The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer The patient discontinued lapatinib within 3 months due to intolerable side effects and the cancer did not progress whilst on lapatinib He cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab |
| and or and and | O Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer |
| or O Patien | zumab to be discontinued at disease progression t has previously discontinued treatment with trastuzumab in the metastatic setting for reasons other than severe toxicity hase progression |

O Disease has not progressed during previous treatment with trastuzumab

O Patient has signs of disease progression

Note: * For patients with relapsed HER-2 positive disease who have previously received adjuvant trastuzumab for early breast cancer

and

and

Page 411

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| _ | |

Trastuzumab (Herzuma) - continued

| (and | \mathbf{C} | The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology) |
|----------|--------------|---|
| ſ | | O The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer |
| | or | O The patient discontinued lapatinib within 3 months due to intolerable side effects and the cancer did not progress whilst on lapatinib |
| and | | 2 |
| | or | O Trastuzumab will not be given in combination with pertuzumab |
| | | Trastuzumab to be administered in combination with pertuzumab Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer The patient has good performance status (ECOG grade 0-1) |
| and | C | Trastuzumab to be discontinued at disease progression |
| | TIO | N – metastatic breast cancer |

| | U. O | The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology) |
|----|-----------|--|
| | and O and | The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab |
| | | Trastuzumab to be discontinued at disease progression |
| or | | |
| | and | Patient has previously discontinued treatment with trastuzumab for reasons other than severe toxicity or disease progression |
| | Ο | Patient has signs of disease progression |
| | and | Disease has not progressed during previous treatment with trastuzumab |

INITIATION – gastric, gastro-oesophageal junction and oesophageal cancer Re-assessment required after 12 months Prerequisites (tick boxes where appropriate)

riciequisites (lick boxes where appropriate,

 \bigcirc

and

The patient has locally advanced or metastatic gastric, gastro-oesophageal junction or oesophageal cancer expressing HER-2 IHC 2+ FISH+ or IHC3+ (or other current technology)

O Patient has an ECOG score of 0-2

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | | PATIENT: | |
|--|--|----------|--|
| Name: | | Name: | |
| Ward: | | NHI: | |
| Trastuzumab (Herzuma) - continued | | | |
| CONTINUATION – gastric, gastro-oesophageal junction and oesophageal cancer Re-assessment required after 12 months | | | |
| Prerequisites (tick boxes where appropriate) | | | |
| O The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab | | | |
| O Trastuzumab to be discontinued at disease progression | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Trastuzumab deruxtecan

| Re-a | | smer | t required after 6 months (tick boxes where appropriate) |
|------|------------|------|--|
| | and | 0 | Patient has metastatic breast cancer expressing HER-2 IHC3+ or ISH+ (including FISH or other current technology) |
| | and and | 0 | Patient has previously received trastuzumab and chemotherapy, separately or in combination |
| | | or | O The patient has received prior therapy for metastatic disease |
| | | | O The patient developed disease recurrence during, or within six months of completing adjuvant therapy |
| | and and | 0 | Patient has a good performance status (ECOG 0-1) |
| | and | Ο | Patient has not received prior funded trastuzumab deruxtecan treatment |
| | | Ο | Treatment to be discontinued at disease progression |
| Re-a | | smer | ON It required after 6 months (tick boxes where appropriate) |
| | and | 0 | The cancer has not progressed at any time point during the previous approval period whilst on trastuzumab deruxtecan |

O Treatment to be discontinued at disease progression

Note: Prior or adjuvant therapy includes anthracycline, other chemotherapy, biological drugs, or endocrine therapy.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Bevacizumab

| Re-assessment | Patient has preserved liver function (Child-Pugh A) Transarterial chemoembolisation (TACE) is unsuitable |
|--------------------------------|---|
| and | O Patient has an ECOG performance status of 0-2 |
| Re-assessment Prerequisites | VN – unresectable hepatocellular carcinoma t required after 6 months (tick box where appropriate) vidence of disease progression |
| Re-assessmen | advanced or metastatic ovarian cancer t required after 4 months (tick boxes where appropriate) |

| | O The patient has previously untreated advanced (FIGO Stage IIIB or IIIC) epithelial ovarian, fallopian tube, or primary |
|--------|--|
| | peritoneal cancer |
| | O Debulking surgery is inappropriate |
| | or |
| | O The cancer is sub-optimally debulked (maximum diameter of any gross residual disease greater than 1cm) |
| and | |
| \sim | Bevacizumab to be administered at a maximum dose of 15 mg/kg every three weeks |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|-----------------------------------|
| Name: | Name: |
| Ward: | NHI: |
| Bevacizumab - continued | |
| CONTINUATION – advanced or metastatic ovarian cancer Re-assessment required after 4 months | |
| Prerequisites (tick box where appropriate) O No evidence of disease progression | |
| INITIATION – Recurrent Respiratory Papillomatosis Re-assessment required after 12 months | |
| Prerequisites (tick boxes where appropriate) | |
| Maximum of 6 doses | |
| O The patient has recurrent respiratory papillomatosis and | |
| O The treatment is for intra-lesional administration | |
| CONTINUATION – Recurrent Respiratory Papillomatosis Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) | |
| Maximum of 6 doses | |
| The treatment is for intra-lesional administration | |
| O There has been a reduction in surgical treatments or disease | regrowth as a result of treatment |
| INITIATION – Ocular Conditions Prerequisites (tick boxes where appropriate) | |
| O Ocular neovascularisation | |
| O Exudative ocular angiopathy | |
| | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| | |

Inotuzumab ozogamicin

or

and

INITIATION

| and | 0 | Patient has relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia/lymphoma, including minimal residual disease |
|------|-------------|--|
| and | 0 | Patient has ECOG performance status of 0-2 |
| | | O Patient has Philadelphia chromosome positive B-Cell ALL |
| | | and O Patient has previously received a tyrosine kinase inhibitor |
| | or | |
| | | O Patient has received one prior line of treatment involving intensive chemotherapy |
| and | 0 | Treatment is to be administered for a maximum of 3 cycles |
| TINU | ATIO | Treatment is to be administered for a maximum of 3 cycles |
| TINU | ATIO | Treatment is to be administered for a maximum of 3 cycles |

O Patient has experienced complete remission with incomplete haematological recovery

O Treatment with inotuzumab ozogamicin is to cease after a total duration of 6 cycles

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|----------|
| Name: | Name: |
| Ward: | NHI: |
| Basiliximab | |
| INITIATION | |
| Prerequisites (tick box where appropriate) | |
| ${ m O}~$ For use in solid organ transplants | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESC | RIB | ER | | PATIENT: |
|------------------|---------------------------------|----------------------------|--------------------|---|
| Name: | | | | Name: |
| Ward: | | | | NHI: |
| Rituxi | mal | o (Mal | othe | ra) |
| Re-ass Prerec | sessr quisi t) Pi | nent re tes (tio | equ ck b bed | atoid arthritis - prior TNF inhibitor use red after 4 months oxes where appropriate) by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ |
| and | | and | or | The patient has had an initial community Special Authority approval for at least one of etanercept and/or adalimumab for rheumatoid arthritis O The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept O Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for rheumatoid arthritis |
| á | and | | | |
| | and | or (|)) | Rituximab to be used as an adjunct to methotrexate or leflunomide therapy Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used |
| | | Ом | axir | num of two 1,000 mg infusions of rituximab given two weeks apart |

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting . For more details, refer to Section H of the Pharmaceutica Schedule. For community funding, see the Special Authority Criteria. |
|---|
| |

| | ER | R PATIENT: | |
|----------|-------------|---|---|
| e: | | Name: | |
| : | | NHI: | |
| xima | b (N | (Mabthera) - continued | |
| | | - rheumatoid arthritis - TNF inhibitors contraindicated | |
| | | ent required after 4 months es (tick boxes where appropriate) | |
| | | escribed by, or recommended by a rheumatologist, or in accordance with a protocol or gui | ideline that has been endersed by the Health N |
| | | spital. | idenne that has been endorsed by the freath ha |
| (and | С | Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated | |
| (| С | Patient has had severe and active erosive rheumatoid arthritis (either confirmed by rac citrullinated peptide (CCP) antibody positive) for six months duration or longer | diology imaging, or the patient is cyclic |
| and (| С | Patient has tried and not responded to at least three months of oral or parenteral mether maximum tolerated dose | notrexate at a dose of at least 20 mg weekly or a |
| and (| | Patient has tried and not responded to at least three months of oral or parenteral meth | |
| and | | hydroxychloroquine sulphate (at maximum tolerated doses) | |
| | or | O Patient has tried and not responded to at least three months of oral or parentera maximum tolerated dose of cyclosporin | al methotrexate in combination with the |
| | | O Patient has tried and not responded to at least three months of oral or parentera gold | al methotrexate in combination with intramuscula |
| | or | O Patient has tried and not responded to at least three months of therapy at the m in combination with oral or parenteral methotrexate | aximum tolerated dose of leflunomide alone or |
| and | \subset | | |
| | or | O Patient has persistent symptoms of poorly controlled and active disease in at lea | ast 20 swollen, tender joints |
| | | O Patient has persistent symptoms of poorly controlled and active disease in at lea knee, ankle, and either shoulder or hip | ast four joints from the following: wrist, elbow, |
| and | \subseteq | | |
| | or | O Patient has a C-reactive protein level greater than 15 mg/L measured no more that application | than one month prior to the date of this |
| | | O C-reactive protein levels not measured as patient is currently receiving predniso day and has done so for more than three months | one therapy at a dose of greater than 5 mg per |
| and | | | |
| | or | O Rituximab to be used as an adjunct to methotrexate or leflunomide therapy | |
| | | O Patient is contraindicated to both methotrexate and leflunomide, requiring rituxin | nab monotherapy to be used |
| and (| C | Maximum of two 1,000 mg infusions of rituximab given two weeks apart | |
| | | | |
| | | | |
| | | | |

| | BER | | | PATIENT: | | | |
|---|---------------|------------------------------|---|--|--|--|---|
| : | | | | Name: | | | |
| | | | | NHI: | | | |
| kima | ab (N | /labthe | era) - continued | | | | |
| ssess | smen | it requ | heumatoid arthritis - re-treatment in 'partial responuired after 4 months boxes where appropriate) | Iders' to rituximab | | | |
| | Preso Hosp | | by, or recommended by a rheumatologist, or in accord | ance with a protocol or guideline that has been endorsed by the Health NZ | | | |
| | or | 0 | At 4 months following the initial course of rituximab in count from baseline and a clinically significant respon | fusions the patient had between a 30% and 50% decrease in active joint use to treatment in the opinion of the physician | | | |
| | or | 0 | At 4 months following the second course of rituximab from baseline and a clinically significant response to t | o infusions the patient had at least a 50% decrease in active joint count treatment in the opinion of the physician | | | |
| | | 0 | | ses of rituximab infusions, the patient demonstrates at least a continuing and a clinically significant response to treatment in the opinion of the | | | |
| and A Rituximab re-treatment not to be given within 6 months of the previous course of treatment and O Rituximab to be used as an adjunct to methotrexate or leflunomide therapy | | | | | | | |
| | | | | | | | O Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used |
| and | Ο | Махі | imum of two 1,000 mg infusions of rituximab given two | weeks apart | | | |
| ssess equis | smen sites | it requ (tick t cribed | heumatoid arthritis - re-treatment in 'responders' to uired after 4 months boxes where appropriate) by, or recommended by a rheumatologist, or in accord | o rituximab dance with a protocol or guideline that has been endorsed by the Health NZ | | | |
| ŀ | | 0 | At 4 months following the initial course of rituximab in baseline and a clinically significant response to treatm | fusions the patient had at least a 50% decrease in active joint count from nent in the opinion of the physician | | | |
| ŀ | or | | | urses of rituximab infusions, the patient demonstrates at least a continuing and a clinically significant response to treatment in the opinion of the | | | |
| | | 0 | physician | | | | |
| and | 0 | Ritux | | ne previous course of treatment | | | |
| and | 0 | Ritux | physician kimab re-treatment not to be given within 6 months of the Rituximab to be used as an adjunct to methotrexate o | · | | | |

RS1922 - Adalimumab (Humira - Alternative brand)

| Arthritis - polyarticular course juvenile idiopathic - INITIATION | 430 |
|--|-----|
| Arthritis - polyarticular course juvenile idiopathic - INTHATON | |
| Arthritis - psoriatic - INITIATION | |
| Arthritis - psoriatic - CONTINUATION | 431 |
| Arthritis – oligoarticular course juvenile idiopathic - INITIATION | 429 |
| Arthritis – oligoarticular course juvenile idiopathic - CONTINUATION | 430 |
| Arthritis – rheumatoid - INITIATION | |
| Arthritis – rheumatoid - CONTINUATION | |
| Behcet's disease - severe - INITIATION | |
| Behcet's disease - severe - CONTINUATION | |
| Crohn's disease - adult - INITIATION | |
| Crohn's disease - adult - CONTINUATION | |
| Crohn's disease - children - INITIATION | |
| Crohn's disease - children - CONTINUATION | |
| Crohn's disease - fistulising - INITIATION | |
| Crohn's disease - fistulising - CONTINUATION | |
| Hidradenitis suppurativa - INITIATION | |
| Hidradenitis suppurativa - CONTINUATION | |
| Ocular inflammation – chronic - INITIATION | |
| Ocular inflammation – chronic - CONTINUATION | |
| Ocular inflammation - severe - INITIATION | |
| Ocular inflammation – severe - CONTINUATION | |
| Psoriasis - severe chronic plaque - INITIATION | |
| Psoriasis - severe chronic plaque - CONTINUATION | |
| Pyoderma gangrenosum - INITIATION | |
| Pyoderma gangrenosum - CONTINUATION | |
| Still's disease - adult-onset (AOSD) - INITIATION | |
| Still's disease – adult-onset (AOSD) - CONTINUATION | |
| Ankylosing spondylitis - INITIATION | |
| Ankylosing spondylitis - CONTINUATION | |
| | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | | |
|---|--|--|--|--|
| Name: | Name: | | | |
| Ward: | NHI: | | | |
| Adalimumab (Humira - Alternative brand) | | | | |
| | practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health | | | |
| NZ Hospital. | | | | |
| O Patient has developed symptoms of lo | ble side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment oss of disease control following a minimum of 4 weeks treatment with adalimumab s loss of disease response to a change in treatment regimen | | | |
| and Patient has received a maximum of 6 months treatment with Amgevita and Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication and Adalimumab to be administered at doses no greater than 40 mg every 14 days | | | | |
| CONTINUATION – Behcet's disease – severe Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by any relevant p NZ Hospital. | practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health | | | |
| O The patient has had a good clinical response and O Adalimumab to be administered at doses no | se to treatment with measurably improved quality of life o greater than 40 mg every 14 days | | | |
| INITIATION – Hidradenitis suppurativa Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a dermatologio or guideline that has been endorsed by the Health and | st or Practitioner on the recommendation of a dermatologist, or in accordance with a protocol n NZ Hospital. | | | |
| O The patient has experienced intoleration or O Patient has developed symptoms of lo (Amgevita) and clinician attributes this and O Patient has received a maximum of 6 month and O | ole side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment oss of disease control following a minimum of 4 weeks treatment with adalimumab is loss of disease response to a change in treatment regimen ons treatment with Amgevita rity approval for the Humira brand of adalimumab for this indication | | | |
| O Adalimumab to be administered at doses no | o greater than 40 mg every 7 days. Fortnightly dosing has been considered | | | |

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. | For more details, refer to Section H of the Pharmaceutical |
|--|--|
| Schedule. For community funding, see the Special Authority Criteria. | |

| PRESCRIBER | PATIENT: |
|---|---|
| Name: | Name: |
| Ward: | NHI: |
| Adalimumab (Humira - Alternative brand) - continued | |
| CONTINUATION – Hidradenitis suppurativa Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) | |
| O Prescribed by, or recommended by a dermatologist or Practitioner or or guideline that has been endorsed by the Health NZ Hospital. | n the recommendation of a dermatologist, or in accordance with a protocol |
| | ry nodules, abscesses, draining fistulae) of 25% or more from baseline |
| and Adalimumab is to be administered at doses no greater than 40 | |
| INITIATION – Psoriasis - severe chronic plaque Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) | |
| O Prescribed by, or recommended by a dermatologist or Practitioner or or guideline that has been endorsed by the Health NZ Hospital. | n the recommendation of a dermatologist, or in accordance with a protocol |
| or | m adalimumab (Amgevita) following a minimum of 4 weeks treatment trol following a minimum of 4 weeks treatment with adalimumab esponse to a change in treatment regimen |
| and O Patient has received a maximum of 6 months treatment with A and | Amgevita |
| O Patient has previously had a Special Authority approval for the and O Adalimumab to be administered at doses no greater than 40 r | |

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. | . For more details, refer to Section H of the Pharmaceutical |
|--|--|
| Schedule. For community funding, see the Special Authority Criteria. | |

| PRES | CRIB | ER | PATIENT: |
|-------|--------------------------------|---|--|
| Name | : | | Name: |
| Ward: | | | NHI: |
| Adal | imun | nab | (Humira - Alternative brand) - continued |
| Re-a | ssessr equisi P | ment tes (t rescr | N – Psoriasis - severe chronic plaque required after 6 months tick boxes where appropriate) ibed by, or recommended by a dermatologist or Practitioner on the recommendation of a dermatologist, or in accordance with a protocol deline that has been endorsed by the Health NZ Hospital. |
| | | | Patient had "whole body" severe chronic plaque psoriasis at the start of treatment and Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value Following each prior adalimumab treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value |
| | | or | O Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment and O Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values O Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value |
| Re-a | ssessr equisi O P | I – P y nent tes (t | Adalimumab to be administered at doses no greater than 40 mg every 14 days yoderma gangrenosum required after 6 months tick boxes where appropriate) ibed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ al. |
| | and | or O I | O The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment O Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen Patient has received a maximum of 6 months treatment with Amgevita |
| | and | | Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication A maximum of 8 doses |

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. | For more details, refer to Section H of the Pharmaceutical |
|--|--|
| Schedule. For community funding, see the Special Authority Criteria. | |

| PRESCRIB | ER PATIENT: |
|-------------------------|--|
| Name: | |
| Ward: | NHI: |
| Adalimur | nab (Humira - Alternative brand) - continued |
| Re-assess Prerequisi | ATION – Pyoderma gangrenosum ment required after 6 months ites (tick boxes where appropriate) Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ dospital. |
| Re-assess Prerequisi | N – Crohn's disease - adult ment required after 6 months ites (tick boxes where appropriate) Prescribed by, or recommended by a gastroenterologist or Practitioner on the recommendation of a gastroenterologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. |
| and (and (| O The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita O Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen O Patient has Crohn's and is considered to be at risk of disease destabilisation if there were to be a change to current treatment O Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication O Adalimumab to be administered at doses no greater than 40 mg every 14 days |
| Re-assess | ATION – Crohn's disease - adult ment required after 6 months ites (tick boxes where appropriate) |
| | Prescribed by, or recommended by a gastroenterologist or Practitioner on the recommendation of a gastroenterologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. |
| and | O CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab or O CDAI score is 150 or less or O The patient has demonstrated an adequate response to treatment, but CDAI score cannot be assessed |
| | O Adalimumab to be administered at doses no greater than 40 mg every 14 days |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|--|
| Name: | Name: |
| Ward: | NHI: |
| Adalimumab (Humira - Alternative brand) - continued | |
| and protocol or guideline that has been endorsed by the Health NZ Hosp and O The patient has experienced intolerable side effects from and a maximum of 6 months treatment with Amgevita O Patient has developed symptoms of loss of disease con | er on the recommendation of a gastroenterologist, or in accordance with a ital. n adalimumab (Amgevita) following a minimum of 4 weeks treatment, trol following a minimum of 4 weeks treatment, and a maximum of s this loss of disease response to a change in treatment regimen |
| | |
| CONTINUATION – Crohn's disease - children Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a gastroenterologist or Practition protocol or guideline that has been endorsed by the Health NZ Hosp and O PCDAI score has reduced by 10 points from the PCDAI or O PCDAI score is 15 or less or O The patient has demonstrated an adequate response to and O Adalimumab to be administered at doses no greater than 40 m | score when the patient was initiated on adalimumab treatment, but PCDAI score cannot be assessed |
| INITIATION – Crohn's disease - fistulising Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a gastroenterologist or Practition protocol or guideline that has been endorsed by the Health NZ Hosp and | er on the recommendation of a gastroenterologist, or in accordance with a ital. |
| or O Patient has developed symptoms of loss of disease con 6 months treatment with Amgevita and clinician attribute | |

| | Signed: | Date: |
|--|---------|-------|
|--|---------|-------|

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. For more details, refer to Section H of the Pharmaceutic | al |
|---|----|
| Schedule. For community funding, see the Special Authority Criteria. | |

| PRES | SCRIE | BER | PATIENT: | | | |
|---|--|--|--|--|--|--|
| Name | e: | | Name: | | | |
| Ward | : | | NHI: | | | |
| Adalimumab (Humira - Alternative brand) - continued | | | | | | |
| CONTINUATION – Crohn's disease - fistulising Re-assessment required after 6 months | | | | | | |
| Prer | equis | sites | k boxes where appropriate) | | | |
| and | | ed by, or recommended by a gastroenterologist or Practitioner on the recommendation of a gastroenterologist, or in accordance with a or guideline that has been endorsed by the Health NZ Hospital. | | | | |
| | | or | The number of open draining fistulae have decreased from baseline by at least 50% | | | |
| | | | O There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain | | | |
| | and | 0 | dalimumab to be administered at doses no greater than 40 mg every 14 days | | | |
| INITIATION – Ocular inflammation – chronic Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been end NZ Hospital. | | | | | | |
| and | and | or | P The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita P Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with Amgevita, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen P Patient has uveitis and is considered to be at risk of vision loss if they were to change treatment | | | |
| | and | 0 | atient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication dalimumab to be administered at doses no greater than 40 mg every 14 days | | | |
| CONTINUATION – Ocular inflammation – chronic Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) | | | | | | |
| and | O Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Hea NZ Hospital. | | | | | |
| | and | or or | The patient has had a good clinical response following 12 weeks' initial treatment Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema) Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old | | | |
| O Adalimumab to be administered at doses no greater than 40 mg every 14 days | | | | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIE | BER | | F | PATIENT: | | | |
|--|---|--|--|--|--|--|--|
| Name: | | | | Name: | | | |
| Ward: | | | | NHI: | | | |
| Adalimu | mak | o (Hu | mira - Alternative brand) - continued | | | | |
| _ | | | r inflammation – severe ired after 12 months | | | | |
| Prerequis | Prerequisites (tick boxes where appropriate) | | | | | | |
| and | O Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | | | | |
| The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks and a maximum of 6 months treatment with Amgevita | | | | adalimumab (Amgevita) following a minimum of 4 weeks treatment, | | | |
| | | 0 | | ol following a minimum of 4 weeks treatment with Amgevita, and a cian attributes this loss of disease response to a change in treatment | | | |
| | or | Ο | Patient has uveitis and is considered to be at risk of vision | loss if they were to change treatment | | | |
| and O Patient has previously had a Special Authority approval for the Humira brand of adalimumab for the | | nt has previously had a Special Authority approval for the F | Humira brand of adalimumab for this indication | | | | |
| | Adalimumab to be administered at doses no greater than 40 mg every 14 days | | | | | | |
| CONTINUATION – Ocular inflammation – severe Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Healt NZ Hospital. | | | | | | | |
| | or | 0 | The patient has had a good clinical response following 3 i | initial doses | | | |
| | or | 0 | Following each 12-month treatment period, the patient has Uveitis Nomenclature (SUN) criteria < $\frac{1}{2}$ + anterior chamber resolution of uveitic cystoid macular oedema) | s had a sustained reduction in inflammation (Standardisation of er or vitreous cells, absence of active vitreous or retinal lesions, or | | | |
| | U | 0 | Following each 12-month treatment period, the patient has to < 10mg daily, or steroid drops less than twice daily if un | s a sustained steroid sparing effect, allowing reduction in prednisone ider 18 years old | | | |
| and | Adalimumab to be administered at doses no greater than 40 mg every 14 days | | | | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | | | | |
|---|--|--|--|--|--|--|
| Name: | Name: | | | | | |
| Ward: | NHI: | | | | | |
| Adalimumab (Humira - Alternative brand) - continued | | | | | | |
| INITIATION – ankylosing spondylitis Re-assessment required after 6 months | | | | | | |
| Prerequisites (tick boxes where appropriate) | | | | | | |
| | Prescribed by, or recommended by a rheumatologist or Practitioner on the recommendation of a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | | | |
| or | m adalimumab (Amgevita) following a minimum of 4 weeks treatment | | | | | |
| O Patient has developed symptoms of loss of disease co (Amgevita) | ntrol following a minimum of 4 weeks treatment with adalimumab | | | | | |
| and O Patient has received a maximum of 6 months treatment with and | Amgevita | | | | | |
| O Patient has previously had a Special Authority approval for th | e Humira brand of adalimumab for this indication | | | | | |
| Adalimumab to be administered at doses no greater than 40 | mg every 14 days | | | | | |
| Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a rheumatologist or Practitioner on the recommendation of a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | | | | |
| improvement in BASDAI of 50%, whichever is less | more points from pre-treatment baseline on a 10 point scale, or an | | | | | |
| Adalimumab to be administered at doses no greater than 40 | mg every 14 days | | | | | |
| INITIATION – Arthritis – oligoarticular course juvenile idiopathic Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) | | | | | | |
| O Prescribed by, or recommended by a named specialist or rheumate by the Health NZ Hospital. | ologist, or in accordance with a protocol or guideline that has been endorsed | | | | | |
| or | m adalimumab (Amgevita) following a minimum of 4 weeks treatment ntrol following a minimum of 4 weeks treatment with adalimumab response to a change in treatment regimen | | | | | |
| and O Patient has received a maximum of 6 months treatment with and O Patient has previously had a Special Authority approval for th | | | | | | |
| | | | | | | |

| Form RS1922 July 2025 | HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST | | | | | |
|--|---|---------------------------------|--|--|--|--|
| Use this checklist to determine if a patient meets the restricti Schedule. For community funding, see the Special Authority | ions for funding in the hospital setting . For more details, refer to y Criteria. | Section H of the Pharmaceutical | | | | |
| PRESCRIBER | PATIENT: | | | | | |
| Name: | Name: | | | | | |
| Ward: | NHI: | | | | | |
| Adalimumab (Humira - Alternative brand) - co | ontinued | | | | | |
| CONTINUATION – Arthritis – oligoarticular course juve Re-assessment required after 6 months Prerequisites (tick box where appropriate) | anile idiopathic | | | | | |
| O Prescribed by, or recommended by a named spe by the Health NZ Hospital. | ecialist or rheumatologist, or in accordance with a protocol or guid | teline that has been endorsed | | | | |
| O For patients that demonstrate at least a continuin assessment from baseline | ng 30% improvement in active joint count and continued improve | ment in physician's global | | | | |
| INITIATION – Arthritis - polyarticular course juvenile id Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) | liopathic | | | | | |
| O Prescribed by, or recommended by a named spe by the Health NZ Hospital. | ecialist or rheumatologist, or in accordance with a protocol or guid | Jeline that has been endorsed | | | | |
| O The patient has experienced intolera | able side effects from adalimumab (Amgevita) following a minimu | m of 4 weeks treatment | | | | |
| | O Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen | | | | | |
| and O Patient has received a maximum of 6 mont and | | | | | | |
| Patient has previously had a Special Author | prity approval for the Humira brand of adalimumab for this indicat | ion | | | | |
| CONTINUATION – Arthritis - polyarticular course juven Re-assessment required after 6 months Prerequisites (tick box where appropriate) | nile idiopathic | | | | | |
| O Prescribed by, or recommended by a named spe by the Health NZ Hospital. | ecialist or rheumatologist, or in accordance with a protocol or guid | deline that has been endorsed | | | | |
| | ng 30% improvement in active joint count and continued improve | ment in physician's global | | | | |
| INITIATION – Arthritis - psoriatic Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a named spe | ecialist or rheumatologist, or in accordance with a protocol or guid | deline that has been endorsed | | | | |
| and by the Health NZ Hospital. | able side effects from adalimumab (Amgevita) following a minimu |] | | | | |
| | loss of disease control following a minimum of 4 weeks treatment is loss of disease response to a change in treatment regimen | nt with adalimumab | | | | |
| and O Patient has received a maximum of 6 months treatment with Amgevita and | | | | | | |
| \square | prity approval for the Humira brand of adalimumab for this indicat | ion | | | | |

Adalimumab to be administered at doses no greater than 40 mg every 14 days

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIBE | PATIENT: | | | | |
|---|--|---|--|--|--|--|
| Name: | | Name: | | | | |
| Ward: | | NHI: | | | | |
| Adali | mum | ab (Humira - Alternative brand) - continued | | | | |
| Re-as | CONTINUATION – Arthritis - psoriatic Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a named specialist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed | | | | | |
| and | by | he Health NZ Hospital. The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician | | | | |
| | and | Adalimumab to be administered at doses no greater than 40 mg every 14 days | | | | |
| Re-as | sessn | - Arthritis – rheumatoid ent required after 6 months s (tick boxes where appropriate) | | | | |
| O Prescribed by, or recommended by a rheumatologist or Practitioner on the recommendation of a rheumatologist, or in accordance protocol or guideline that has been endorsed by the Health NZ Hospital. | | | | | | |
| | | O The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment O Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen | | | | |
| | and and | Patient has received a maximum of 6 months treatment with Amgevita | | | | |
| | and | Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication | | | | |
| | | O Adalimumab to be administered at doses no greater than 40 mg every 14 days | | | | |
| | | Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response | | | | |
| CONTINUATION – Arthritis – rheumatoid Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) | | | | | | |
| and | | scribed by, or recommended by a rheumatologist or Practitioner on the recommendation of a rheumatologist, or in accordance with a tocol or guideline that has been endorsed by the Health NZ Hospital. | | | | |
| | and | The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician | | | | |
| | | Adalimumab to be administered at doses no greater than 40 mg every 14 days Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain | | | | |
| | | an adequate response | | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|---|--|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |
| Adalimumab (Humira - Alternative brand) - continued | | | |
| INITIATION – Still's disease – adult-onset (AOSD) Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a rheumatologist or Practitioner protocol or guideline that has been endorsed by the Health NZ Hosp and | | | |
| O The patient has experienced intolerable side effects from | n adalimumab (Amgevita) following a minimum of 4 weeks treatment trol following a minimum of 4 weeks treatment with adalimumab esponse to a change in treatment regimen | | |
| and | Patient has received a maximum of 6 months treatment with Amgevita Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication | | |
| CONTINUATION – Still's disease – adult-onset (AOSD) | | | |

Re-assessment required after 6 months **Prerequisites** (tick box where appropriate)

and

Freiequisites (lick box where appropriate)

O Prescribed by, or recommended by a rheumatologist or Practitioner on the recommendation of a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

The patient has demonstrated a sustained improvement in inflammatory markers and functional status

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | SCR | IBER | | PATIENT: |
|--|-----------|------|--|------------------------------------|
| Name | ə: | | | Name: |
| Ward | : | | | NHI: |
| Abc | Abciximab | | | |
| INITIATION Prerequisites (tick boxes where appropriate) | | | (tick boxes where appropriate) | |
| | | 0 | For use in patients with acute coronary syndromes undergoing | percutaneous coronary intervention |
| | or | Ο | For use in patients undergoing intra-cranial intervention | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRI | IBER | PATIENT: | |
|---|--|---|--|
| Name: | | Name: | |
| Ward: | | NHI: | |
| Nivolum | nab | | |
| Re-asses | ON – unresectable or metastatic melanoma ssment required after 4 months isites (tick boxes where appropriate) Prescribed by, or recommended by a relevant specialist or any rele accordance with a protocol or guideline that has been endorsed by | evant practitioner on the recommendation of a relevant specialist, or in / the Health NZ Hospital. | |
| The individual has metastatic or unresectable melanoma (excluding uveal) stage III or IV and Baseline measurement of overall tumour burden is documented clinically and radiologically and The individual has ECOG performance 0-2 and The individual has not received funded pembrolizumab | | | |
| | or O The individual has received an initial Special Aut within 12 weeks of starting treatment due to intol and O The cancer did not progress while the individual | | |
| and | O The individual has been diagnosed in the metastatic or or O The individual did not receive treatment in the perioper or O The individual received treatment in the perioper and | rative setting with a PD-1/PD-L1 inhibitor | |

()The individual did not experience disease recurrence within six months of completing perioperative treatment with a PD-1/PD-L1 inhibitor

and

| ESCRIBER | | | PATIENT: |
|-----------------------------------|--|---|---|
| | | | Name: |
| : | | | NHI: |
| luma | ab - co | ntinued | |
| assessr r equisi O P | ment re i tes (tic Prescrib | | r any relevant practitioner on the recommendation of a relevant specialist, or in |
| a | ccorda | nce with a protocol or guideline that has been end | lorsed by the Health NZ Hospital. |
| | | O The individual's disease has had a compor O The individual's disease has had a parti or O The individual has stable disease | |
| or | and | Response to treatment in target lesions has be treatment period | een determined by comparable radiologic assessment following the most recent |
| | and and | progression The individual has signs of disease progression Disease has not progressed during previous to | |
| | | | |
| issessr equisi P | ment re ites (tic Prescrib | - unresectable or metastatic melanoma, more quired after 4 months k boxes where appropriate) ed by, or recommended by a relevant specialist or nee with a protocol or guideline that has been end e individual has been on treatment for more than | r any relevant practitioner on the recommendation of a relevant specialist, or in lorsed by the Health NZ Hospital. |
| | | O The individual's disease has had a or O The individual's disease has had a or O The individual has stable disease | |
| | | $\overline{\mathbf{O}}$ | has been determined by comparable radiologic or clinical assessment following |
| | | O The individual has previously discontinu progression | ed treatment with nivolumab for reasons other than severe toxicity or disease |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Nivolumab - continued

| or |) Pa | tient i | is currently on treatment with nivolumab and met all remaining criteria prior to commencing treatment |
|----|-----------------|---------|---|
| | С |) т | ne patient has metastatic renal cell carcinoma |
| | and |) т | ne patient is treatment naive |
| | and |) т | ne patient has ECOG performance status 0-2 |
| | and C and |) т | ne disease is predominantly of clear cell histology |
| | | (| D The patient has sarcomatoid histology |
| | | or (| D Haemoglobin levels less than the lower limit of normal |
| | | or (| Corrected serum calcium level greater than 10 mg/dL (2.5 mmol/L) |
| | | or (| O Neutrophils greater than the upper limit of normal |
| | | or (| O Platelets greater than the upper limit of normal |
| | | or (| O Interval of less than 1 year from original diagnosis to the start of systemic therapy |
| | 1 | or (| C Karnofsky performance score of less than or equal to 70 |

INITIATION – renal cell carcinoma, second line Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

| C | Patient has metastatic renal-cell carcinoma |
|-----|--|
| and | The disease is of predominant clear-cell histology |
| and | Patient has ECOG performance status 0-2 |
| and | Patient has documented disease progression following one or two previous regimens of antiangiogenic therapy |
| and | Patient has not previously received a funded immune checkpoint inhibitor |
| and | Nivolumab is to be used as monotherapy at a maximum dose of 240 mg every 2 weeks (or equivalent) and discontinued at disease progression |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | | | | | PATIENT: |
|------------|-----------------|--------|---|---|---|
| Name | : | | | | Name: |
| Ward: | | | | | NHI: |
| Nivol | uma | ıb - | cont | inued | |
| Re-as | sessi | men | t requ | enal cell carcinoma ired after 4 months poxes where appropriate) | |
| | or | | Patient's disease has had a complete response to treatment Patient's disease has had a partial response to treatment Patient has stable disease | | |
| | and (and | С С | Nivo | vidence of disease progression lumab is to be used as monotherapy at a maximum dose o ression | of 240 mg every 2 weeks (or equivalent) and discontinued at disease |

RS2134 - Pembrolizumab

| MSI-H/dMMR advanced colorectal cancer - INITIATION | |
|--|--|
| MSI-H/dMMR advanced colorectal cancer - CONTINUATION | |
| Urothelial carcinoma - INITIATION | |
| Urothelial carcinoma - CONTINUATION | |
| Breast cancer, advanced - INITIATION | |
| Breast cancer, advanced - CONTINUATION | |
| Head and neck squamous cell carcinoma - INITIATION | |
| Head and neck squamous cell carcinoma - CONTINUATION | |
| Non-small cell lung cancer first-line combination therapy - INITIATION | |
| Non-small cell lung cancer first-line combination therapy - CONTINUATION | |
| Non-small cell lung cancer first-line monotherapy - INITIATION | |
| Non-small cell lung cancer first-line monotherapy - CONTINUATION | |
| Relapsed/refractory Hodgkin lymphoma - INITIATION | |
| Relapsed/refractory Hodgkin lymphoma - CONTINUATION | |
| Stage III or IV resectable melanoma - neoadjuvant - INITIATION | |
| Stage III or IV resectable melanoma - neoadjuvant - CONTINUATION | |
| Stage III or IV resected melanoma - adjuvant - INITIATION | |
| Stage III or IV resected melanoma - adjuvant - CONTINUATION | |
| Unresectable or metastatic melanoma - INITIATION | |
| Unresectable or metastatic melanoma, less than 24 months on treatment - CONTINUATION | |
| Unresectable or metastatic melanoma, more than 24 months on treatment - CONTINUATION | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Pembrolizumab | |

| | INITIATION – stage III or IV resectable melanoma - neoadjuvant Re-assessment required after 4 months | | | | | |
|-----|---|-----------|--|--|--|--|
| | Prerequisites (tick boxes where appropriate) | | | | | |
| and | O Prescribed by, or recommended by a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | | | |
| | or | O The | individual is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment | | | |
| | | and | The individual has resectable stage IIIB, IIIC, IIID or IV melanoma (excluding uveal) (see note) | | | |
| | | 0 | The individual has not received prior funded systemic treatment in the perioperative setting for their stage IIIB, IIIC, IIID or IV melanoma | | | |
| | | and O and | Treatment must be prior to complete surgical resection | | | |
| | | and | Pembrolizumab must be administered as monotherapy | | | |
| | | and | The individual has ECOG performance score 0-2 | | | |
| | | | Pembrolizumab to be administered at a fixed dose of 200 mg every 3 weeks (or equivalent) | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | SCRI | BER | | PATIENT: | |
|---|---|------------|--|---|--|
| Name | : | | | Name: | |
| Ward | | | | NHI: | |
| Pem | brol | lizumab | - continued | | |
| Re-a | sses | sment requ | tage III or IV resectable melanoma - neoadjuvant ired after 4 months oxes where appropriate) | | |
| O Prescribed by, or recommended by a relevant specialist or any relevant practitioner on the recommendation of a relevant special accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | | | |
| | | and | The individual has received neoadjuvant treatment with | an immune checkpoint inhibitor | |
| | or | 0 | The individual meets initiation criteria for pembrolizumat | o for stage III or IV resected melanoma – adjuvant | |
| | 01 | and | The individual has received neoadjuvant and adjuvant tr | eatment with an immune checkpoint inhibitor | |
| | | 0 | The individual meets continuation criteria for pembrolizu | mab for stage III or IV resected melanoma – adjuvant | |
| | or | () and | The individual has received neoadjuvant and adjuvant tr | eatment with an immune checkpoint inhibitor | |
| | | and | The individual has metastatic or unresectable melanoma | a (excluding uveal) stage III or IV | |
| | or | 0 | The individual meets initiation criteria for pembrolizumat | o for unresectable or metastatic melanoma | |
| | U | and | The individual has received neoadjuvant and adjuvant tr | eatment with an immune checkpoint inhibitor | |
| | | and | The individual has received treatment with an immune c | heckpoint inhibitor for unresectable or metastatic melanoma | |
| | | Ο | The individual meets continuation criteria for pembrolizu | mab for unresectable or metastatic melanoma | |
| Note | : | | | | |
| a) S | a) Stage IIIB, IIIC, IIID or IV melanoma defined as per American Joint Committee on Cancer (AJCC) 8th Edition | | | | |

b) Initiating treatment within 13 weeks of complete surgical resection means either 13 weeks after resection (primary or lymphadenectomy) or 13 weeks prior to the scheduled date of the resection (primary or lymphadenectomy)

I confirm that the above details are correct:

Signed: Date:

Page 441

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIE | BER | | PATIENT: | | |
|----------|--|-------------|---|---|--|--|
| Name | : | | | Name: | | |
| Ward: | | | | NHI: | | |
| Pem | brol | lizumal | b - continued | | | |
| | | | ge III or IV resected melanoma - adjuvant quired after 4 months | | | |
| Prere | equis | sites (ticl | k boxes where appropriate) | | | |
| (and | O Prescribed by, or recommended by a relevant specialist or any relevant accordance with a protocol or guideline that has been endorsed by the | | | | | |
| | or | O Th | e individual is currently on treatment with pembrolizumab a | nd met all remaining criteria prior to commencing treatment | | |
| | | and | ${\sf O}$ The individual has resected stage IIIB, IIIC, IIID or IV me | elanoma (excluding uveal) (see note a) | | |
| | | C | O Adjuvant treatment with pembrolizumab is required | | | |
| | | and | D The individual has not received prior funded systemic tre | eatment in the adjuvant setting for stage IIIB, IIIC, IIID or IV melanoma | | |
| | | and | D Treatment must be in addition to complete surgical resea | ction | | |
| | | and | Treatment must be initiated within 13 weeks of complete recovery (see note b) | e surgical resection, unless delay is necessary due to post-surgery | | |
| | | and and | Pembrolizumab must be administered as monotherapy | | | |
| | | | The individual has ECOG performance score 0-2 | | | |
| | | and | Pembrolizumab to be administered at a fixed dose of 20 | 0 mg every 3 weeks (or equivalent) | | |
| Note | Note: | | | | | |

a) Stage IIIB, IIIC, IIID or IV melanoma defined as per American Joint Committee on Cancer (AJCC) 8th Edition

b) Initiating treatment within 13 weeks of complete surgical resection means 13 weeks after resection (primary or lymphadenectomy)

| I confirm that the above of | details are correct: |
|-----------------------------|----------------------|
|-----------------------------|----------------------|

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | | P/ | ATIENT: | |
|------------|-------|-------------------|--|--|
| Name | e: | | Na | ame: |
| Ward | : | | Ni | Ні: |
| Pem | broli | izumab | - continued | |
| Re-a | ssess | sment requ | stage III or IV resected melanoma - adjuvant nired after 4 months poxes where appropriate) | |
| (and | J F | Prescribed | | practitioner on the recommendation of a relevant specialist, or in Health NZ Hospital. |
| | | and and | No evidence of disease recurrence Pembrolizumab must be administered as monotherapy | |
| | | and | total treatment course, including any systemic neoadjuvant | e or at completion of 12 months total treatment course (equivalent to |
| | or | and and and | The individual has received adjuvant treatment with an imm The individual has metastatic or unresectable melanoma (e The individual meets initiation criteria for pembrolizumab fo | excluding uveal) stage III or IV |
| | or | and and | The individual has received adjuvant treatment with an imm The individual has received treatment with an immune check | ckpoint inhibitor for unresectable or metastatic melanoma |
| | | | The individual meets continuation criteria for pembrolizuma | ID TOR UNRESECTABLE OF METASTATIC MEIANOMA |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|---|--|--|--|
| Name: Name: | | | |
| Ward: | NHI: | | |
| Pembrolizumab - continued | | | |
| INITIATION – unresectable or metastatic melanoma Re-assessment required after 4 months Prerequisites (tick boxes where appropriate) | | | |
| O Prescribed by, or recommended by a relevant specialist or any relevant accordance with a protocol or guideline that has been endorsed by t and | | | |
| The individual has metastatic or unresectable melanoma (excland) Baseline measurement of overall tumour burden is documenter and The individual has ECOG performance 0-2 The individual has not received funded nivolumab The individual has received an initial Special Auth 12 weeks of starting treatment due to intolerance The cancer did not progress while the individual weight of the individual has received an initial Special Auth 12 weeks of starting treatment due to intolerance | ed clinically and radiologically | | |
| and | tive setting with a PD-1/PD-L1 inhibitor | | |

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting | . For more details, refer to Section H of the Pharmaceutical |
|---|--|
| Schedule. For community funding, see the Special Authority Criteria. | |

| PATIENT: | RESCRIBER | PRES | |
|---|--|--------------|--|
| Name: | lame: Name: | | |
| NHI: | lard: | Ward | |
| | embrolizuma | Pem | |
| appropriate) | Re-assessment re Prerequisites (tio | Re-a | |
| nmended by a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist, or in ocol or guideline that has been endorsed by the Health NZ Hospital. | accorda | and | |
| individual's disease has had a complete response to treatment individual's disease has had a partial response to treatment individual has stable disease to treatment in target lesions has been determined by comparable radiologic assessment following the most recent beriod | or (and | | |
| ual has signs of disease progression as not progressed during previous treatment with pembrolizumab | and | | |
| | CONTINUATION Re-assessment re Prerequisites (tio | Re-a | |
| nmended by a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist, or in ocol or guideline that has been endorsed by the Health NZ Hospital. | accorda | (and | |
| as been on treatment for more than 24 months | O T | | |
| The individual's disease has had a complete response to treatment The individual's disease has had a partial response to treatment The individual has stable disease ponse to treatment in target lesions has been determined by comparable radiologic or clinical assessment following nost recent treatment period treatment remains clinically appropriate and the individual is benefitting from the treatment individual has previously discontinued treatment with pembrolizumab for reasons other than severe toxicity or ase progression individual has signs of disease progression ase has not progressed during previous treatment with pembrolizumab | or | | |
| months appropriate) Inmended by a relevant specialist or any relevant practitioner on the recommendation of a relevant special cool or guideline that has been endorsed by the Health NZ Hospital. Its been on treatment for more than 24 months The individual's disease has had a complete response to treatment The individual's disease has had a partial response to treatment The individual has stable disease bonse to treatment in target lesions has been determined by comparable radiologic or clinical assessmost recent treatment period treatment remains clinically appropriate and the individual is benefitting from the treatment individual has previously discontinued treatment with pembrolizumab for reasons other than severe to ase progression individual has signs of disease progression | Re-assessment roprerequisites (tide) Prescribut accordation and Transformed Tr | Re-a Prer | |

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| RESCRIBER PATIENT: | | |
|---|--|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Pembrolizumab - continued | | |
| INITIATION – non-small cell lung cancer first-line monotherapy Re-assessment required after 4 months Prerequisites (tick boxes where appropriate) | | |
| O Prescribed by, or recommended by a medical oncologist or any release accordance with a protocol or guideline that has been endorsed by and | vant practitioner on the recommendation of a medical oncologist, or in the Health NZ Hospital. | |
| O Patient has locally advanced or metastatic, unresectable, non and | -small cell lung cancer | |
| O Patient has not had chemotherapy for their disease in the pall | iative setting | |
| O Patient has not received prior funded treatment with an immu | ne checkpoint inhibitor for NSCLC | |
| EGFR or ALK tyrosine kinase unless not possible to ascertain | tion confirming that the disease does not express activating mutations of | |
| and O Pembrolizumab to be used as monotherapy and | | |
| O There is documentation confirming the disease express validated test unless not possible to ascertain | es PD-L1 at a level greater than or equal to 50% as determined by a | |
| O There is documentation confirming the disease ex by a validated test unless not possible to ascertain | xpresses PD-L1 at a level greater than or equal to 1% as determined | |
| | interest of the patient based on clinician assessment | |
| and O Patient has an ECOG 0-2 | | |
| O Pembrolizumab to be used at a maximum dose of 200 mg eve | ery three weeks (or equivalent) for a maximum of 16 weeks | |
| Baseline measurement of overall tumour burden is documente | ed clinically and radiologically | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIBER | PATIENT: |
|----------|------------|---|
| Name | : | Name: |
| Ward: | | NHI: |
| Pem | brolizu | mab - continued |
| Re-a | ssessmer | DN – non-small cell lung cancer first-line monotherapy tt required after 4 months (tick boxes where appropriate) |
| (and | | cribed by, or recommended by a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist, or in rdance with a protocol or guideline that has been endorsed by the Health NZ Hospital. |
| | or | O Patient's disease has had a complete response to treatment |
| | or | Patient's disease has had a partial response to treatment Patient has stable disease |
| | and | Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period |
| | and and | No evidence of disease progression |
| | and | The treatment remains clinically appropriate and patient is benefitting from treatment |
| | and _ | Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) |
| | | Treatment with pembrolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks) |
| Re-a | ssessmer | non-small cell lung cancer first-line combination therapy nt required after 4 months (tick boxes where appropriate) |
| (and | | cribed by, or recommended by a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist, or in rdance with a protocol or guideline that has been endorsed by the Health NZ Hospital. |
| | | Patient has locally advanced or metastatic, unresectable, non-small cell lung cancer |
| | and | The patient has not had chemotherapy for their disease in the palliative setting |
| | and | Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC |
| | and | For patients with non-squamous histology there is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain |
| | and | Pembrolizumab to be used in combination with platinum-based chemotherapy |
| | and | Patient has an ECOG 0-2 |
| | and | Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks |
| | | Baseline measurement of overall tumour burden is documented clinically and radiologically |

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting . For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria. | | | | |
|--|----------|--|--|--|
| PRESCRIBER | PATIENT: | | | |
| Name: | Name: | | | |

Pembrolizumab - continued

| Re-a | sses | smen | t requ | non-small cell lung cancer first-line combination therapy nired after 4 months poxes where appropriate) |
|------------------|------------|-------|--------|--|
| (and | С | Preso | ribed | by, or recommended by a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist, or in e with a protocol or guideline that has been endorsed by the Health NZ Hospital. |
| | | | Ο | Patient's disease has had a complete response to treatment |
| | | or | Ο | Patient's disease has had a partial response to treatment |
| | | or | Ο | Patient has stable disease |
| | and and | 0 | | ponse to treatment in target lesions has been determined by comparable radiologic assessment following the most recent ment period |
| | and | Ο | No e | vidence of disease progression |
| | and | Ο | The | treatment remains clinically appropriate and patient is benefitting from treatment |
| | and | Ο | Pem | brolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) |
| | and | 0 | | tment with pembrolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed y 3 weeks) |
| Prer (and | С | Preso | ribed | boxes where appropriate) by, or recommended by a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist, or in e with a protocol or guideline that has been endorsed by the Health NZ Hospital. |
| | or | 0 | Patie | ent is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment |
| | | | or | O Patient has recurrent or de novo unresectable, inoperable locally advanced triple-negative breast cancer (that does not express ER, PR or HER2 IHC3+ or ISH+ [including FISH or other technology]) |
| | | | | O Patient has recurrent or de novo metastatic triple-negative breast cancer (that does not express ER, PR or HER2 IHC3+ or ISH+ [including FISH or other technology] |
| | | an | d O | Patient is treated with palliative intent |
| | | an | Q | Patient's cancer has confirmed PD-L1 Combined Positive Score (CPS) is greater than or equal to 10 |
| | | an | Ο | Patient has received no prior systemic therapy in the palliative setting |
| | | an | Ο | Patient has an ECOG score of 0-2 |
| | | an | Ο | Pembrolizumab is to be used in combination with chemotherapy |
| | | an | Ο | Baseline measurement of overall tumour burden is documented clinically and radiologically |
| | | an | Ö | Pembrolizumab is to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks |

| Signed: | | Date: | |
|---------|--|-------|--|
|---------|--|-------|--|

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | SCRIB | ER | PATIENT: |
|------|-----------------|-------|---|
| Name | ə: | | Name: |
| Ward | : | | NHI: |
| Pem | broli | izun | nab - continued |
| Re-a | assess | men | DN – breast cancer, advanced t required after 6 months (tick boxes where appropriate) |
| and | | | cribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health ospital. |
| | | or | O Patient's disease has had a complete response to treatment |
| | | or | O Patient's disease has had a partial response to treatment |
| | | | O Patient has stable disease |
| | and (and | О | No evidence of disease progression |
| | (and | 0 | Response to treatment in target lesions has been determined by a comparable radiologic assessment following the most recent treatment period |
| | and | Ο | Pembrolizumab is to be used at a maximum dose of 200 mg every three weeks (or equivalent) |
| | (| 0 | Treatment with pembrolizumab is to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks) |
| Re-a | assess | men | nead and neck squamous cell carcinoma t required after 4 months (tick boxes where appropriate) |
| and | Р a | Presc | cribed by, or recommended by a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist, or in rdance with a protocol or guideline that has been endorsed by the Health NZ Hospital. |
| - | (or | О | Patient is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment |
| | | and | O Patient has recurrent or metastatic head and neck squamous cell carcinoma of mucosal origin (excluding nasopharyngeal carcinoma) that is incurable by local therapies |
| | | and | O Patient has not received prior systemic therapy in the recurrent or metastatic setting |
| | | and | O Patient has a positive PD-L1 combined positive score (CPS) of greater than or equal to 1 |
| | | and | O Patient has an ECOG performance score of 0-2 |
| | | | O Pembrolizumab to be used in combination with platinum-based chemotherapy |
| | | | or O Pembrolizumab to be used as monotherapy |
| | | and | Pembrolizumab is to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIB | ER | | PATIENT: |
|----------|-----------------------------|---------------------------------|-------------------------------------|--|
| Name | Name: | | | Name: |
| Ward: | | | | NHI: |
| Pem | broli | izun | nab | - continued |
| Re-a | ssess | ment | requ | ead and neck squamous cell carcinoma ired after 4 months oxes where appropriate) |
| (and | | | ribed ospita | by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health I. |
| | | or or | 0 0 0 | Patient's disease has had a complete response to treatment Patient's disease has had a partial response to treatment Patient has stable disease |
| | and (and (and | 0 | Peml Treat | vidence of disease progression prolizumab is to be used at a maximum dose of 200 mg every three weeks (or equivalent) ment with pembrolizumab is to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed v 3 weeks) |
| Re-a | ssess equisi | ites (Presc | t requ (tick b ribed dance | /dMMR advanced colorectal cancer ired after 4 months oxes where appropriate) by, or recommended by a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist, or in e with a protocol or guideline that has been endorsed by the Health NZ Hospital. dual is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment O Individual has deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer |
| | | anc anc anc anc anc | | O Individual has deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) unresectable colorectal cancer Individual is treated with palliative intent Individual has not previously received funded treatment with pembrolizumab for MSI-H/dMMR advanced colorectal cancer Individual has an ECOG performance score of 0-2 Baseline measurement of overall tumour burden is documented clinically and radiologically Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks |

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESC | RIBER PATIENT: |
|-------------------|--|
| Name: | Name: |
| Ward: | NHI: |
| Pemb | rolizumab - continued |
| Re-ass Prerect | NUATION – MSI-H/dMMR advanced colorectal cancer essment required after 4 months juisites (tick boxes where appropriate) Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. No evidence of disease progression Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) and Treatment with pembrolizumab is to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks) |
| Re-ass | FION – Urothelial carcinoma essment required after 4 months juisites (tick boxes where appropriate) |
| and | Prescribed by, or recommended by a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. |
| c | O Patient is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment |
| | O Patient has inoperable locally advanced (T4) or metastatic urothelial carcinoma and |
| | O Patient has an ECOG performance score of 0-2 and |
| | O Patient has documented disease progression following treatment with chemotherapy and |
| | O Pembrolizumab to be used as monotherapy at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks |
| | |
| Re-ass | NUATION – Urothelial carcinoma essment required after 4 months uisites (tick boxes where appropriate) |
| and | Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. |
| | O Patient's disease has had a complete response to treatment |
| | or O Patient's disease has had a partial response to treatment |
| | or O Patient has stable disease |
| | O No evidence of disease progression |
| | O Pembrolizumab is to be used as monotherapy at a maximum dose of 200 mg every three weeks (or equivalent) |
| | O Treatment with pembrolizumab is to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks) |

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESC | RIBER | PATIENT: |
|-------|-------|----------|
| Name: | | Name: |
| Ward: | | NHI: |

Pembrolizumab - continued

| Re-assessmen | relapsed/refractory Hodgkin lymphoma It required after 4 months (tick boxes where appropriate) | |
|--------------|---|--|
| | cribed by, or recommended by a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist, or in rdance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | |
| or O | Individual is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment | |
| | O Individual has relapsed/refractory Hodgkin lymphoma after two or more lines of chemotherapy | |
| | O Individual is ineligible for autologous stem cell transplant | |
| | or O Individual has relapsed/refractory Hodgkin lymphoma and has previously undergone an autologous stem cell transplant | |
| and | O Individual has not previously received funded pembrolizumab for relapsed/refractory Hodgkin lymphoma | |
| | O Pembrolizumab to be administered at doses no greater than 200 mg once every 3 weeks | |
| Re-assessmen | DN – relapsed/refractory Hodgkin lymphoma It required after 6 months (tick boxes where appropriate) | |
| | cribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health lospital. | |
| and | Patient has received a partial or complete response to pembrolizumab | |
| | Treatment with pembrolizumab is to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed | |

Treatment with pembrolizumab is to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks)

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Durvalumab | |

INITIATION – Non-small cell lung cancer Re-assessment required after 4 months Prerequisites (tick boxes where appropriate) () Patient has histologically or cytologically documented stage III, locally advanced, unresectable non-small cell lung cancer (NSCLC) or Patient has histologically or cytologically documented stage IIb (T1N2a only), locally advanced, unresectable non-small cell lung cancer (NSCLC) and) Patient has received two or more cycles of platinum-based chemotherapy concurrently with definitive radiation therapy and Patient has no disease progression following the second or subsequent cycle of platinum-based chemotherapy with definitive radiation therapy treatment and Patient has a ECOG performance status of 0 or 1 and Patient has completed last radiation dose within 8 weeks of starting treatment with durvalumab and ()Patient must not have received prior PD-1 or PD-L1 inhibitor therapy for this condition and Durvalumab is to be used at a maximum dose of no greater than 10 mg/kg every 2 weeks or Durvalumab is to be used at a flat dose of 1500 mg every 4 weeks and () Treatment with durvalumab to cease upon signs of disease progression

CONTINUATION – Non-small cell lung cancer Re-assessment required after 4 months

| | ~ | |
|----------|----|--|
| (and | C | The treatment remains clinically appropriate and the patient is benefitting from treatment |
| (| | O Durvalumab is to be used at a maximum dose of no greater than 10 mg/kg every 2 weeks |
| | or | O Durvalumab is to be used at a flat dose of 1500 mg every 4 weeks |
| and (| С | Treatment with durvalumab to cease upon signs of disease progression |
| and (| С | Total continuous treatment duration must not exceed 12 months |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIBE | ER | BER PATIENT: | |
|----------|------------|--------------|--|--------------------------------|
| Name | Name: | | | |
| Ward | Vard: NHI: | | | |
| Atez | olizuı | ma | ımab | |
| ΙΝΙΤΙ | ATION | – r | N – non-small cell lung cancer second line monotherapy | |
| | | | ment required after 4 months | |
| Prer | equisit | es | ites (tick boxes where appropriate) | |
| (and | | | Prescribed by, or recommended by a medical oncologist or any relevant practitioner on the recommendation of accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | a medical oncologist, or in |
| | and |) | O Patient has locally advanced or metastatic non-small cell lung cancer | |
| | and |) | O Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC | |
| | and |) | O For patients with non-squamous histology there is documentation confirming that the disease does not ex EGFR or ALK tyrosine kinase unless not possible to ascertain | press activating mutations of |
| | (|) | O Patient has an ECOG 0-2 | |
| | and |) | m O Patient has documented disease progression following treatment with at least two cycles of platinum-base | ed chemotherapy |
| | and |) | m O Atezolizumab is to be used as monotherapy at a dose of 1200 mg every three weeks (or equivalent) for a | maximum of 16 weeks |
| | and | $\mathbf{)}$ | O Baseline measurement of overall tumour burden is documented clinically and radiologically | |
| | | | |) |
| | | | ATION – non-small cell lung cancer second line monotherapy ment required after 4 months | |
| | | | ites (tick boxes where appropriate) | |
| (and | | | Prescribed by, or recommended by a medical oncologist or any relevant practitioner on the recommendation of accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | a medical oncologist, or in |
| | | | O Patient's disease has had a complete response to treatment | |
| | | or | O Patient's disease has had a partial response to treatment | |
| | | or | or O Patient has stable disease | |
| | and | | |] |
| | C |) | O Response to treatment in target lesions has been determined by comparable radiologic assessment follow treatment period | ving the most recent |
| | and |) | O No evidence of disease progression | |
| | and |) | m O The treatment remains clinically appropriate and patient is benefitting from treatment | |
| | and |) | m O Atezolizumab to be used at a maximum dose of 1200 mg every three weeks (or equivalent) | |
| | and |) | O Treatment with atezolizumab to cease after a total duration of 24 months from commencement (or equiva 3 weeks) | alent of 35 cycles dosed every |

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |

Atezolizumab - continued

| or (| С г | Patient is currently on treatment with atezolizumab and met all remaining criteria prior to commencing treatment |
|------|-----|--|
| | (| O Patient has locally advanced or metastatic, unresectable hepatocellular carcinoma |
| | and | O Patient has preserved liver function (Child-Pugh A) |
| | and | \sim |
| | and | O Transarterial chemoembolisation (TACE) is unsuitable |
| | | O Patient has not received prior systemic therapy for the treatment of hepatocellular carcinoma |
| | | or O Patient received funded lenvatinib before 1 March 2025 |
| | | O Patient has experienced treatment-limiting toxicity from treatment with lenvatinib |
| | | O No disease progression since initiation of lenvatinib |
| | and | O Patient has an ECOG performance status of 0-2 |
| | and | O To be given in combination with bevacizumab |

Re-assessment required after 6 months **Prerequisites** (tick box where appropriate)

(lick box where appropriate)

O No evidence of disease progression

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Ipilimumab

| or C |) The | ne patient is currently on treatment with ipilimumab and met all remaining criteria prior to commencing treatment |
|------|----------|---|
| | C | D The patient has metastatic renal cell carcinoma |
| | and C | D The patient is treatment naive |
| | and C | The patient has ECOG performance status 0-2 |
| | and C | D The disease is predominantly of clear cell histology |
| c | and | O The patient has sarcomatoid histology |
| | C | or O Haemoglobin levels less than the lower limit of normal |
| | | O Corrected serum calcium level greater than 10 mg/dL (2.5 mmol/L) |
| | | or O Neutrophils greater than the upper limit of normal |
| | | or O Platelets greater than the upper limit of normal |
| | | or O Interval of less than 1 year from original diagnosis to the start of systemic therapy |
| | C | or O Karnofsky performance score of less than or equal to 70 |

| | y 2025 HOSPITAL MEI | |
|-------|---|--|
| Use t | e this checklist to determine if a patient meets the restrictions for funding in the nedule. For community funding, see the Special Authority Criteria. | |
| PRE | ESCRIBER | ATIENT: |
| Nam | me: N | lame: |
| Ward | rd: N | IHI: |
| Eve | erolimus | |
| Re-a | ITIATION e-assessment required after 3 months erequisites (tick boxes where appropriate) O Prescribed by, or recommended by a neurologist or oncologist, or in ad Health NZ Hospital. | |
| | e-assessment required after 12 months rerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a neurologist or oncologist, or in ac Health NZ Hospital. | ecordance with a protocol or guideline that has been endorsed by the |
| | O Documented evidence of SEGA reduction or stabilisation by MR and O The treatment remains appropriate and the patient is benefiting and O Everolimus to be discontinued at progression of SEGAs | |
| Re-a | ITIATION – renal cell carcinoma e-assessment required after 4 months rerequisites (tick boxes where appropriate) | |
| | The patient has metastatic renal cell carcinoma The disease is of predominant clear-cell histology The patient has documented disease progression following The patient has an ECOG performance status of 0-2 Everolimus is to be used in combination with lenvatinib | g one previous line of treatment |

or

O Patient has received funded treatment with nivolumab for the second line treatment of metastatic renal cell carcinoma and

Patient has experienced treatment limiting toxicity from treatment with nivolumab \mathbf{O}

Everolimus is to be used in combination with lenvatinib

Ο There is no evidence of disease progression

CONTINUATION – renal cell carcinoma Re-assessment required after 4 months

and

and

Prerequisites (tick box where appropriate)

O There is no evidence of disease progression

| Signed: Date: | |
|---------------|--|
|---------------|--|

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. | For more details, refer to Section H of the Pharmaceutical |
|--|--|
| Schedule. For community funding, see the Special Authority Criteria. | |

| PATIENT: | |
|--|--|
| Name: | |
| NHI: | |
| | |
| | |
| atment as defined by refractory rejection; or intolerant to calcineurin inhibitor | |
| | |
| | |
| | |
| | |
| | |
| | |
| mation* protherapy and surgery therapy and surgery are not considered clinically appropriate r to consideration of surgery alformation multi-disciplinary team persion 1.1 (see Note) | |
| ons* | |
| se or a partial response to treatment, or patient has stable disease ally and disease response to treatment has been clearly documents in | |
| | |

| Signed: Date: . | |
|-----------------|--|
|-----------------|--|

| PRESCRIBER | PATIENT: |
|--|---|
| Name: | Name: |
| Nard: | NHI: |
| Sirolimus - continued | |
| INITIATION – renal angiomyolipoma(s) associated with tuberous Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a nephrologist or urolog Health NZ Hospital. and O Patient has tuberous sclerosis complex* | s sclerosis complex* |
| and Evidence of renal angiomyolipoma(s) measuring 3 cm | n or greater and that have shown interval growth |
| CONTINUATION – renal angiomyolipoma(s) associated with tube Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) | erous sclerosis complex* |
| and Demonstrated stabilisation or improvement in renal fu | emorrhage or significant adverse effects to sirolimus treatment |
| Note: Indications marked with * are unapproved indications |) |
| Hospital. | osis complex* |
| and O Patient has epilepsy with a background of documente | ed tuberous sclerosis complex* |
| | y, or the patient has experienced unacceptable side effects from, optimal g: sodium valproate, topiramate, levetiracetam, carbamazepine, lamotrigine, |
| | y, or the patient has experienced unacceptable side effects from, optimal ing: sodium valproate, topiramate, levetiracetam, carbamazepine, lamotrigine, Note) |
| and O Seizures have a significant impact on quality of life and O Patient has been assessed and surgery is considered benefit from mTOR inhibitor treatment prior to surgery | d inappropriate for this patient, or the patient has been assessed and would |

 \bigcirc

and

HOSPITAL MEDICINES LIST **RESTRICTIONS CHECKLIST**

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | | |
|--|----------|--|--|--|
| Name: | Name: | | | |
| Ward: | NHI: | | | |
| Sirolimus - continued | | | | |
| CONTINUATION – refractory seizures associated with tuberous sclerosis complex* Re-assessment required after 12 months | | | | |

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a neurologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

Demonstrated significant and sustained improvement in seizure rate (e.g. 50% reduction in seizure frequency) or severity and/or patient quality of life compared with baseline prior to starting sirolimus treatment Note: Indications marked with * are unapproved indications

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|----------|
| Name: | Name: |
| Ward: | NHI: |
| Bacillus calmette-guerin (BCG) | |
| | |
| Prerequisites (tick box where appropriate) | |
| O For use in bladder cancer | |

RS2120 - Upadacitinib

| Atopic dermatitis - INITIATION | 462 |
|---|-----|
| Atopic dermatitis - CONTINUATION | |
| Crohn's disease - adult - INITIATION | |
| Crohn's disease - adult - CONTINUATION | |
| Crohn's disease - children - INITIATION | |
| Crohn's disease – children - CONTINUATION | |
| Rheumatoid Arthritis - CONTINUATION | |
| Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept) - INITIATION | |
| Ulcerative colitis - INITIATION | |
| Ulcerative colitis - CONTINUATION | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Upadacitinib

| | ~ | |
|--|--------------|---|
| (and |) | The individual has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis |
| | or | O The individual has experienced intolerable side effects with adalimumab and/or etanercept |
| | | O The individual has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that the do not meet the renewal criteria for rheumatoid arthritis |
| and | | O Rituximab is not clinically appropriate |
| | or | O The individual is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor |
| | or | |
| | | O The individual has been started on rituximab for rheumatoid arthritis in a Health NZ Hospital and |
| | | O The individual has experienced intolerable side effects with rituximab |
| | | Or At four months following the initial course of rituximab the individual has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis |
| | | |
| | es (| required after 6 months (tick boxes where appropriate) Following 6 months' initial treatment, the individual has experienced at least a 50% decrease in active joint count from baseline |
| | ies (| (tick boxes where appropriate) |
| or or | bes (| (tick boxes where appropriate) Following 6 months' initial treatment, the individual has experienced at least a 50% decrease in active joint count from baseline On subsequent reapplications, the individual has experienced at least a continuing 30% improvement in active joint count from |
| quisite or TION sessm quisite | ies (| (tick boxes where appropriate) Following 6 months' initial treatment, the individual has experienced at least a 50% decrease in active joint count from baseline On subsequent reapplications, the individual has experienced at least a continuing 30% improvement in active joint count from baseline topic dermatitis required after 6 months (tick boxes where appropriate) |
| quisit or TION sessin quisit or | ces (| (tick boxes where appropriate) Following 6 months' initial treatment, the individual has experienced at least a 50% decrease in active joint count from baseline On subsequent reapplications, the individual has experienced at least a continuing 30% improvement in active joint count from baseline topic dermatitis required after 6 months (tick boxes where appropriate) Individual is currently on treatment with upadacitinib for atopic dermatitis and met all remaining criteria prior to commencing treatment O Individual has moderate to severe atopic dermatitis, severity as defined by an Eczema Area and Severity Index (EASI) score of greater than or equal to 16 or a Dermatology Life Quality Index (DLQI) score of greater than or equal to 10 |
| or TION sessm quisit | and | (tick boxes where appropriate) Following 6 months' initial treatment, the individual has experienced at least a 50% decrease in active joint count from baseline On subsequent reapplications, the individual has experienced at least a continuing 30% improvement in active joint count from baseline topic dermatitis required after 6 months (tick boxes where appropriate) Individual has moderate to severe atopic dermatitis, severity as defined by an Eczema Area and Severity Index (EASI) score of greater than or equal to 16 or a Dermatology Life Quality Index (DLQI) score of greater than or equal to 10 Individual has received insufficient benefit from topical therapy (including topical corticosteroids or topical calcineurin inhibitors for a 28-day trial within the last 6 months, unless contraindicated to all |
| quisiti | and | tick boxes where appropriate) Following 6 months' initial treatment, the individual has experienced at least a 50% decrease in active joint count from baseline On subsequent reapplications, the individual has experienced at least a continuing 30% improvement in active joint count from baseline topic dermatitis required after 6 months tick boxes where appropriate) Individual is currently on treatment with upadacitinib for atopic dermatitis and met all remaining criteria prior to commencing treatme Individual has moderate to severe atopic dermatitis, severity as defined by an Eczema Area and Severity Index (EASI) score of greater than or equal to 16 or a Dermatology Life Quality Index (DLQI) score of greater than or equal to 10 Individual has received insufficient benefit from topical therapy (including topical corticosteroids or topical calcineurin inhibitors for a 28-day trial within the last 6 months, unless contraindicated to all Individual has trialled and received insufficient benefit from at least one systemic therapy for a minimum of three months (eg ciclosporin, azathioprine, methotrexate or mycophenolate mofetil), unless contraindicated to all |
| or ATION assessm quisit | and | tick boxes where appropriate) Following 6 months' initial treatment, the individual has experienced at least a 50% decrease in active joint count from baseline On subsequent reapplications, the individual has experienced at least a continuing 30% improvement in active joint count from baseline topic dermatitis required after 6 months tick boxes where appropriate) Individual is currently on treatment with upadacitinib for atopic dermatitis and met all remaining criteria prior to commencing treatment of Individual has moderate to severe atopic dermatitis, severity as defined by an Eczema Area and Severity Index (EASI) score of greater than or equal to 16 or a Dermatology Life Quality Index (DLQI) score of greater than or equal to 10 Individual has received insufficient benefit from topical therapy (including topical corticosteroids or topical calcineurin inhibitors for a 28-day trial within the last 6 months, unless contraindicated to all |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|--|--|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Upadacitinib - continued | | |
| CONTINUATION – Atopic dermatitis Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) O Individual has received a 75% or greater reduction in EASI sco upadacitinib or O Individual has received a DLQI improvement of 4 or more as c | ore (EASI 75) as compared to baseline EASI prior to commencing ompared to baseline DLQI prior to commencing upadacitinib | |
| INITIATION – Crohn's disease – adult Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) | | |
| Individual is currently on treatment with upadacitinib for Crohn's disease and met all remaining criteria prior to commencing treatment or or Individual has active Crohn's disease and Individual has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria or Individual meets the initiation criteria for prior biologic therapies for Crohn's disease and O Individual meets the initiation criteria for prior biologic therapies for Crohn's disease O ther biologic therapies for Crohn's disease are contraindicated | | |
| CONTINUATION – Crohn's disease – adult Re-assessment required after 2 years Prerequisites (tick boxes where appropriate) | | |
| O CDAI score has reduced by 100 points from the CDAI score w or O or O O CDAI score has reduced by 3 points from when individual was in or O O CDAI score is 150 or less or O HBI score is 4 or less or O The individual has experienced an adequate response to treat | nitiated on biologic therapy | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|--|
| Name: | Name: |
| Ward: | NHI: |
| Upadacitinib - continued | |
| INITIATION – Crohn's disease – children Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) | |
| O Individual is currently on treatment with upadacitinib for Crohr | n's disease and met all remaining criteria prior to commencing treatment |
| Child has active Crohn's disease | |
| O Child has had an initial approval for prior biologic effects or insufficient benefit to meet renewal crite | therapy for Crohn's disease and has experienced intolerable side ria |
| Child meets the initiation criteria for prior bio | ologic therapies for Crohn's disease |
| O Other biologic therapies for Crohn's disease | e are contraindicated |
| | |
| CONTINUATION – Crohn's disease – children Re-assessment required after 2 years Prerequisites (tick boxes where appropriate) | |
| O PCDAI score has reduced by 10 points from when the child w | as initiated on treatment |
| or O PCDAI score is 15 or less | |
| O The child has experienced an adequate response to treatment, but PCDAI score cannot be assessed | |
| Note: Indications marked with * are unapproved indications. | |
| INITIATION – Ulcerative colitis Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) | |
| O Individual is currently on treatment with upadacitinib for ulcera | ative colitis and met all remaining criteria prior to commencing treatment |
| Individual has active ulcerative colitis | |
| | |

or Individual has had an initial approval for prior biologic therapy for ulcerative colitis and has experienced intolerable side effects or insufficient benefit to meet renewal criteria
O Individual meets the initiation criteria for prior biologic therapies for ulcerative colitis
and
O Other biologic therapies for ulcerative colitis are contraindicated

CONTINUATION – Ulcerative colitis Re-assessment required after 2 years

or O

Prerequisites (tick boxes where appropriate)

O The SCCAI score has reduced by 2 points or more from the SCCAI score when the individual was initiated on treatment

PUCAI score has reduced by 10 points or more from the PUCAI score when the individual was initiated on treatment

| | Signed: | Date: |
|--|---------|-------|
|--|---------|-------|

Respiratory System and Allergies

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | | | | PATIENT: | | | |
|---|-----|---|---|--|--|--|--|
| Name: | | | | Name: | | | |
| Ward: | | | | NHI: | | | |
| Icatibant | | | | | | | |
| INITIATION Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a clinical immunologist or relevant specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | | | | | |
| | and | | Supply for anticipated emergency treatment of laryngeal/oro-pharyngeal or severe abdominal attacks of acute hereditary angioedema (HAE) for patients with confirmed diagnosis of C1-esterase inhibitor deficiency | | | | |
| | 0 | Ō | The patient has undergone product training and has agreed up | oon an action plan for self-administration | | | |

CONTINUATION

Re-assessment required after 12 months Prerequisites (tick box where appropriate)

O The treatment remains appropriate and the patient is benefiting from treatment

or

HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | | | |
|---|---|--|--|--|--|
| Name: | Name: | | | | |
| Ward: | NHI: | | | | |
| Adrenaline | | | | | |
| INITIATION – anaphylaxis Prerequisites (tick boxes where appropriate) | | | | | |
| O Patient has experienced a previous anaphylactic reaction which | ch has resulted in presentation to a hospital or emergency department | | | | |

Patient has been assessed to be at significant risk of anaphylaxis by a relevant practitioner

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | | | | |
|---|------------|--|--|--|--|--|
| Name: | Name: | | | | | |
| Ward: | NHI: | | | | | |
| Bee venom | | | | | | |
| INITIATION Prerequisites (tick boxes where appropriate) | | | | | | |
| ARST or skin test positive | | | | | | |
| O Patient has had severe generalised reaction to the sensiti | sing agent | | | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | SCRIBER | | PATIENT: |
|---|---------|--|----------|
| Name |): | | Name: |
| Ward: | | | NHI: |
| Раре | er wasp | venom | |
| INITIATION Prerequisites (tick boxes where appropriate) | | (tick boxes where appropriate) | |
| | and | RAST or skin test positive | |
| | | Patient has had severe generalised reaction to the sensitising | agent |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|----------|
| Name: | Name: |
| Ward: | NHI: |
| Yellow jacket wasp venom | |
| INITIATION Prerequisites (tick boxes where appropriate) | |
| ARAST or skin test positive | |
| O Patient has had severe generalised reaction to the sensitising | agent |

| Form | RS1518 |
|---------|---------------|
| July 20 | 25 |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |

Long-acting muscarinic antagonists with long-acting beta-adrenoceptor agonists

| INITIATION Re-assessment required after 2 years Prerequisites (tick boxes where appropriate) | | | | |
|--|--|--|--|--|
| O Patient has been stabilised on a long acting muscarinic antagonist and | | | | |
| O The prescriber considers that the patient would receive additional benefit from switching to a combination product | | | | |
| CONTINUATION Re-assessment required after 2 years | | | | |
| Prerequisites (tick boxes where appropriate) | | | | |
| O Patient is compliant with the medication and | | | | |
| O Patient has experienced improved COPD symptom control (prescriber determined) | | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Fluticasone furoate with umeclidinium and vilanterol

| Ind | | | |
|-----|--|--|--|
| | O Patient is currently receiving an inhaled corticosteroid with long acting beta-2 agonist (ICS/LABA) or a long acting muscarinic antagonist with long acting beta-2 agonist (LAMA/LABA) | | |
| | a | Clinical criteria: | |
| | | O Patient has a COPD Assessment Test (CAT) score greater than 10 | |
| | | or O Patient has had 2 or more exacerbations in the previous 12 months | |
| | | O Patient has had one exacerbation requiring hospitalisation in the previous 12 months | |
| | | or O Patient has had an eosinophil count greater than or equal to 0.3 × 10°9 cells/L in the previous 12 months | |
| or | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |

Budesonide with glycopyrronium and eformoterol

| Ind | | |
|-----|--|--|
| | O Patient is currently receiving an inhaled corticosteroid with long acting beta-2 agonist (ICS/LABA) or a long acting muscarinic antagonist with long acting beta-2 agonist (LAMA/LABA) | |
| | and | Clinical criteria: |
| | | O Patient has a COPD Assessment Test (CAT) score greater than 10 |
| | | or O Patient has had 2 or more exacerbations in the previous 12 months or |
| | | O Patient has had one exacerbation requiring hospitalisation in the previous 12 months or |
| | | O Patient has had an eosinophil count greater than or equal to 0.3 × 10 [^] 9 cells/L in the previous 12 months |
| or | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Pirfenidone

| INITIATION - idiopathic pulmonary fibrosis Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) Image: the preservibed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and Image: the preservibed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist and Pirfenidone is to be discontinued at disease progression (See Notes) and Pirfenidone is not to be used in combination with subsidised nintedanib or Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance or Patient has previously received nintedanib, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib) CONTINUATION - idiopathic pulmonary fibrosis Re-assessment required after 12 months Prerequisite (ick boxes where appropriate) or Prescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and Prescribed by, or recommended by a resp | | | | | |
|---|--|--|--|--|--|
| Prescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist Proceed vital capacity is between 50% and 90% predicted Pirfenidone is to be discontinued at disease progression (See Notes) Pirfenidone is not to be used in combination with subsidised nintedanib or Patient has previously received nintedanib, but discontinued nintedanib or Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance or Patient has previously received nintedanib, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib) | Re-assessment required after 12 months | | | | |
| NZ Hospital. And Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist and Proceed vital capacity is between 50% and 90% predicted and Pirfenidone is to be discontinued at disease progression (See Notes) and Pirfenidone is not to be used in combination with subsidised nintedanib and Pirfenidone is not to be used in combination with subsidised nintedanib and Patient has previously received treatment with nintedanib or Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance or Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance or Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance or Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance or Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance or Patient has previously received nintedanib, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib) CONTINUATION – idiopathic pulmonary fibrosis Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) Prescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and Pirfenidone is not to be used in combination with subsidised nintedanib and Pirfenidone is not to be used in combination with subsidised nintedanib | Prerequisites (tick boxes where appropriate) | | | | |
| and Forced vital capacity is between 50% and 90% predicted and Pirfenidone is to be discontinued at disease progression (See Notes) and Pirfenidone is not to be used in combination with subsidised nintedanib and Pirfenidone is not to be used in combination with subsidised nintedanib or Patient has not previously received treatment with nintedanib or Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance or Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance or Patient has previously received nintedanib, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib) CONTINUATION - idiopathic pulmonary fibrosis Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) Prescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and Pirfenidone is not to be used in combination with subsidised nintedanib | NZ Hospital. | | | | |
| CONTINUATION - idiopathic pulmonary fibrosis Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) Prescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | | | |
| and Pirfenidone is not to be used in combination with subsidised nintedanib and Or Or Patient has not previously received treatment with nintedanib or Or Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance or Or Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance or Or Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance or Patient has previously received nintedanib, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib) CONTINUATION – idiopathic pulmonary fibrosis Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) Or Prescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and Or Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment and Or Pirfenidone is not to be used in combination with subsidised nintedanib | O Forced vital capacity is between 50% and 90% predicted | | | | |
| and O The patient has not previously received treatment with nintedanib or O Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance or O Patient has previously received nintedanib, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib) CONTINUATION – idiopathic pulmonary fibrosis Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and O Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment and O Pirfenidone is not to be used in combination with subsidised nintedanib | | | | | |
| or Or Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance or Or Patient has previously received nintedanib, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib) CONTINUATION - idiopathic pulmonary fibrosis Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) Or Prescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and Or Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment and Or Pirfenidone is not to be used in combination with subsidised nintedanib | | | | | |
| Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance Patient has previously received nintedanib, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib) CONTINUATION - idiopathic pulmonary fibrosis Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) Prescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and Pirfenidone is not to be used in combination with subsidised nintedanib | | | | | |
| or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib) CONTINUATION - idiopathic pulmonary fibrosis Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and O Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment and O Pirfenidone is not to be used in combination with subsidised nintedanib | O Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance | | | | |
| Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and O Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment and O Pirfenidone is not to be used in combination with subsidised nintedanib and O D D D D D D D D D D D D D D D D D D | | | | | |
| Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and O Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment and O Pirfenidone is not to be used in combination with subsidised nintedanib and O D D D D D D D D D D D D D D D D D D | | | | | |
| Prescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment and Pirfenidone is not to be used in combination with subsidised nintedanib | | | | | |
| and NZ Hospital. | Prerequisites (tick boxes where appropriate) | | | | |
| and O Pirfenidone is not to be used in combination with subsidised nintedanib and O | NZ Hospital. | | | | |
| O Pirfenidone is not to be used in combination with subsidised nintedanib and | | | | | |
| O Pirfenidone is to be discontinued at disease progression (See Note) | O Pirfenidone is not to be used in combination with subsidised nintedanib | | | | |
| | O Pirfenidone is to be discontinued at disease progression (See Note) | | | | |

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Nintedanib

| Re-a | INITIATION – idiopathic pulmonary fibrosis Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) | | | | |
|----------|--|--|--|--|--|
| (and | O Prescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed NZ Hospital. | | | | |
| | (and | O Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist | | | |
| | (and | O Forced vital capacity is between 50% and 90% predicted | | | |
| | (and | \sim | | | |
| | and | | | | |
| | | O The patient has not previously received treatment with pirfenidone or | | | |
| | | Patient has previously received pirfenidone, but discontinued pirfenidone within 12 weeks due to intolerance Or Patient has previously received pirfenidone, but the patient's disease has not progressed (disease progression defined as 10%) | | | |
| | | or more decline in predicted FVC within any 12 month period since starting treatment with pirfenidone) | | | |
| | | | | | |
| Re-a | ssess | ATION – idiopathic pulmonary fibrosis sment required after 12 months sites (tick boxes where appropriate) | | | |
| (and | | Prescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | |
| | (and | O Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment | | | |
| | (and | O Nintedanib is not to be used in combination with subsidised pirfenidone | | | |
| | (| O Nintedanib is to be discontinued at disease progression (See Note) | | | |

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | | | | P, | ATIENT: |
|------------|-----------------|----------------------|-------|---|--|
| Name: | | | | N | ame: |
| Ward: | | | | N | НІ: |
| lvaca | ftor | | | | |
| | Эр | tes (resc | ribed | boxes where appropriate) by, or recommended by a respiratory specialist or paediatric by the Health NZ Hospital. | cian, or in accordance with a protocol or guideline that has been |
| | (and | С | Patie | ent has been diagnosed with cystic fibrosis | |
| | | or | 0 | Patient must have G551D mutation in the cystic fibrosis tra 1 allele | nsmembrane conductance regulator (CFTR) gene on at least |
| | | | Ο | Patient must have other gating (class III) mutation (G1244E in the CFTR gene on at least 1 allele | E, G1349D, G178R, G551S, S1251N, S1255P, S549N and S549R) |
| | and (| | | ents must have a sweat chloride value of at least 60 mmol/L ction system | by quantitative pilocarpine iontophoresis or by Macroduct sweat |
| | and (and | С | Treat | tment with ivacaftor must be given concomitantly with standa | ard therapy for this condition |
| | (| | | ent must not have an acute upper or lower respiratory infection iotics) for pulmonary disease in the last 4 weeks prior to con | on, pulmonary exacerbation, or changes in therapy (including nmencing treatment with ivacaftor |
| | and (and | С | The c | dose of ivacaftor will not exceed one tablet or one sachet twi | ce daily |
| | | С | Appli | icant has experience and expertise in the management of cy | stic fibrosis |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |

Elexacaftor with tezacaftor, ivacaftor and ivacaftor

INITIATION

| equisi | ites | (tick b | poxes where appropriate) |
|----------|------|---------|--|
| (and | С | Patie | ent has been diagnosed with cystic fibrosis |
| and (| С | Patie | ent is 6 years of age or older |
| | | 0 | Patient has two cystic fibrosis-causing mutations in the cystic fibrosis transmembrane regulator (CFTR) gene (one from each parental allele) |
| | or | 0 | Patient has a sweat chloride value of at least 60 mmol/L by quantitative pilocarpine iontophoresis or by Macroduct sweat collection system |
| and | _ | | |
| | | Ο | Patient has a heterozygous or homozygous F508del mutation |
| | or | Ο | Patient has a G551D mutation or other mutation responsive in vitro to elexacaftor/tezacaftor/ivacaftor (see note a) |
| and (| С | The | treatment must be the sole funded CFTR modulator therapy for this condition |
| and (| С | Treat | ment with elexacaftor/tezacaftor/ivacaftor must be given concomitantly with standard therapy for this condition |
| : | | | |
| | | | s are listed in the Food and Drug Administration (FDA) Trikafta prescribing information a.gov/fdalabel/services/spl/set-ids/f354423a-85c2-41c3-a9db-0f3aee135d8d/spl-doc |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Dornase alfa

| INITIATION – cystic fibrosis Re-assessment required after 12 months | | | |
|--|--|--|--|
| Prerequisites (tick boxes where appropriate) | | | |
| O Prescribed by, or recommended by a respiratory physician or paediatrician, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | |
| O Patient has a confirmed diagnosis of cystic fibrosis | | | |
| O Patient has previously undergone a trial with, or is currently being treated with, hypertonic saline and | | | |
| O Patient has required one or more hospital inpatient respiratory admissions in the previous 12 month period or | | | |
| O Patient has had 3 exacerbations due to CF, requiring oral or intravenous (IV) antibiotics in in the previous 12 month period or | | | |
| O Patient has had 1 exacerbation due to CF, requiring oral or IV antibiotics in the previous 12 month period and a Brasfield score of < 22/25 | | | |
| O Patient has a diagnosis of allergic bronchopulmonary aspergillosis (ABPA) | | | |
| CONTINUATION – cystic fibrosis Prerequisites (tick box where appropriate) O Prescribed by, or recommended by a respiratory physician or paediatrician, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and O The treatment remains appropriate and the patient continues to benefit from treatment | | | |
| INITIATION – significant mucus production Re-assessment required after 4 weeks Prerequisites (tick boxes where appropriate) | | | |
| Patient is an in-patient and The mucus production cannot be cleared by first line chest techniques | | | |
| INITIATION – pleural emphyema Re-assessment required after 3 days Prerequisites (tick boxes where appropriate) | | | |
| O Patient is an in-patient and _ | | | |
| O Patient diagnoses with pleural emphyema | | | |

Sensory Organs

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Dexamethasone

| | ATIO | N – I | Diabetic macular oedema | | |
|---|---------|---------------|--|--|--|
| Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) | | | | | |
| FIEle | quis | nes | (lick boxes where appropriate) | | |
| (and | | Preso Hosp | cribed by, or recommended by an ophthalmologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ ital. | | |
| | and | 0 | Patients have diabetic macular oedema with pseudophakic lens | | |
| | and | 0 | Patient has reduced visual acuity of between 6/9 – 6/48 with functional awareness of reduction in vision | | |
| | | or | O Patient's disease has progressed despite 3 injections with bevacizumab | | |
| | | | O Patient is unsuitable or contraindicated to treatment with anti-VEGF agents | | |
| | and | 0 | Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year | | |
| Re-as | sess | mer | DN – Diabetic macular oedema t required after 12 months (tick boxes where appropriate) | | |
| and | | Preso Hosp | cribed by, or recommended by an ophthalmologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ ital. | | |
| | and | 0 | Patient's vision is stable or has improved (prescriber determined) | | |
| | | 0 | Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year | | |
| | | | | | |
| | | | Nomen of child bearing age with diabetic macular oedema t required after 12 months | | |
| | | | (tick boxes where appropriate) | | |
| and | | Preso Hosp | cribed by, or recommended by an ophthalmologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ ital. | | |
| | and | 0 | Patients have diabetic macular oedema | | |
| | and and | 0 | Patient has reduced visual acuity of between 6/9 – 6/48 with functional awareness of reduction in vision | | |
| | and | 0 | Patient is of child bearing potential and has not yet completed a family | | |
| | | 0 | Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRIBER | | PATIENT: | |
|-------|--|------------------|---|----------|
| Name | : | | Name: | |
| Ward: | | | NHI: | |
| Dexa | metha | sone - continued | | |
| Re-a | ssessme equisites | | dema ance with a protocol or guideline that has been endorsed by the Health NZ | |
| | Patient's vision is stable or has improved (prescriber determined) and Patient is of child bearing potential and has not yet completed a family and Dexamethasone implants are to be administered not more frequently than once every 4 m of 3 implants per eye per year | | | a family |

Various

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |

Deferasirox

| Re-a | INITIATION Re-assessment required after 2 years Prerequisites (tick boxes where appropriate) | | | | | |
|------|--|--|--|--|--|--|
| and | Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. | | | | | |
| | and | The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia Deferasirox is to be given at a daily dose not exceeding 40 mg/kg/day | | | | |
| | | O Treatment with maximum tolerated doses of deferiprone monotherapy or deferiprone and desferrioxamine combination therapy have proven ineffective as measured by serum ferritin levels, liver or cardiac MRI T2* O Treatment with deferiprone has resulted in severe persistent vomiting or diarrhoea O Treatment with deferiprone has resulted in arthritis O Treatment with deferiprone is contraindicated due to a history of agranulocytosis (defined as an absolute neutrophil count (ANC) of < 0.5 cells per μL) or recurrent episodes (greater than 2 episodes) of moderate neutropenia (ANC 0.5 - 1.0 cells per μL) | | | | |
| Re-a | isses equi: | ATION ment required after 2 years ites (tick boxes where appropriate) | | | | |
| and | Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and | | | | | |
| | or | For the first renewal following 2 years of therapy, the treatment has been tolerated and has resulted in clinical improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels For subsequent renewals, the treatment has been tolerated and has resulted in clinical stability or continued improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels | | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|-------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Deferiprone | |
| INITIATION | |

Prerequisites (tick box where appropriate)

O Patient has been diagnosed with chronic iron overload due to congenital inherited anaemia or acquired red cell aplasia

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|---|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |
| Povidone-iodine - Vaginal tab 200 mg | | | |
| INITIATION | | | |
| Prerequisites (tick box where appropriate) | | | |
| O Rectal administration pre-prostate biopsy | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|--|
| Name: | Name: |
| Ward: | NHI: |
| Chlorhexidine with cetrimide | |
| INITIATION Re-assessment required after 3 months Prerequisites (tick boxes where appropriate) O Patient has burns that are greater than 30% of total body surface and O For use in the perioperative preparation and cleansing of large and O The use of 30 ml ampoules is impractical due to the size of th | e burn areas requiring debridement/skin grafting |
| | |

Re-assessment required after 3 months Prerequisites (tick box where appropriate)

O The treatment remains appropriate for the patient and the patient is benefiting from the treatment

Special Foods

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Carbohydrate

| | INITIATION – Use as an additive Prerequisites (tick boxes where appropriate) | | | | |
|----|---|--|--|--|--|
| or | 0 | Cystic fibrosis | | | |
| or | Ο | Chronic kidney disease | | | |
| or | Ο | Cancer in children | | | |
| or | Ο | Cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years | | | |
| or | Ο | Faltering growth in an infant/child | | | |
| or | Ο | Bronchopulmonary dysplasia | | | |
| or | \bigcirc | Premature and post premature infant | | | |
| or | \bigcirc | | | | |
| | | Inborn errors of metabolism | | | |
| | | Use as a module | | | |

Prerequisites (tick box where appropriate)

O For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | SCRI | BER | | PATIENT: |
|------|----------|-----|---|---|
| Name | : | | | Name: |
| Ward | | | | NHI: |
| Fat | | | | |
| | | | Use as an additive (tick boxes where appropriate) | |
| | | 0 | Patient has inborn errors of metabolism | |
| | or | Ο | Faltering growth in an infant/child | |
| | or | Ο | Bronchopulmonary dysplasia | |
| | or | Ο | Fat malabsorption | |
| | or | Ο | Lymphangiectasia | |
| | or or | Ο | Short bowel syndrome | |
| | | Ο | Infants with necrotising enterocolitis | |
| | or | Ο | Biliary atresia | |
| | or | Ο | For use in a ketogenic diet | |
| | or | Ο | Chyle leak | |
| | or | Ο | Ascites | |
| | or | Ο | Patient has increased energy requirements, and for whom | dietary measures have not been successful |

INITIATION – Use as a module

Prerequisites (tick box where appropriate)

O For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk. Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

| Signed Date |
|-------------|
|-------------|

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|----------|
| Name: | Name: |
| Ward: | NHI: |
| Protein | |
| INITIATION – Use as an additive Prerequisites (tick boxes where appropriate) | |
| or O High protein needs | |
| NITIATION – Use as a module | |

Prerequisites (tick box where appropriate)

O For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk. Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|---------------------------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Carbohydrate and fat sunnlement | | |

arbohydrate and fat supplement

| (and | С | Infar | ant or child aged four years or under | |
|----------|----|-------|---------------------------------------|--|
| | | Ο | Cystic fibrosis | |
| | or | Ο | Cancer in children | |
| | or | Ο | D Faltering growth | |
| | or | Ο | D Bronchopulmonary dysplasia | |
| | or | Ο | Premature and post premature infants | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CR | IBER | PATIENT: |
|----------------|----|---|----------|
| Name | : | | Name: |
| Ward: | | | NHI: |
| Meta | bo | lic Products | |
| INITI Prere | | ON isites (tick boxes where appropriate) | |
| | | O For the dietary management of inherited metabolic disease | |
| | or | O Patient has adrenoleukodystrophy | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCF | RIBER | PATIENT: |
|---------|-------|----------|
| Name: . | | Name: |
| Ward: | | NHI: |

Diabetic Products

| INITI Prere | | | (tick boxes where appropriate) |
|----------------|----|---|--|
| | | Ο | For patients with type I or type II diabetes suffering weight loss and malnutrition that requires nutritional support |
| | or | Ο | For patients with pancreatic insufficiency |
| | or | Ο | For patients who have, or are expected to, eat little or nothing for 5 days |
| | or | Ο | For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism |
| | or | 0 | For use pre- and post-surgery |
| | or | Ο | For patients being tube-fed |
| | or | 0 | For tube-feeding as a transition from intravenous nutrition |
| | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|---------------------------------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Elemental and Semi-Elemental Products | | |

| INITI. Prere | | | (tick boxes where appropriate) | |
|-----------------|----|---|---|--|
| | | 0 | Malabsorption | |
| | or | Ο | Short bowel syndrome | |
| | or | Ο | Enterocutaneous fistulas | |
| | or | Ο | Eosinophilic enteritis (including oesophagitis) | |
| | or | Ο | Inflammatory bowel disease | |
| | or | Ο | Acute pancreatitis where standard feeds are not tolerated | |
| | or | Ο | Patients with multiple food allergies requiring enteral feeding | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | | PATIENT: |
|--|---|---|
| Name: | | Name: |
| Ward: | | NHI: |
| Fat-modified feed | | |
| INITIATION Prerequisites (tick boxes where appropriate) O Patient has metabolic disorder or O Patient has a chyle leak or Modified as a modular feed, r Pharmaceutical Schedule, for | ers of fat metabolism nade from at least one nutrient me | odule and at least one further product listed in Section D of the |

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|----------|
| Name: | Name: |
| Ward: | NHI: |
| Hepatic Products | |
| INITIATION Prerequisites (tick box where appropriate) | |
| O For children (up to 18 years) who require a liver transplant | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|-----------------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| High Calaria Braduata | |

High Calorie Products

| ATIO equis | | k boxes where appropriate) |
|---------------|-----|---|
| | O | tient is fluid volume or rate restricted |
| or or | 0 | tient requires low electrolyte |
| | and | O Cystic fibrosis O Any condition causing malabsorption Or O Faltering growth in an infant/child O Increased nutritional requirements |
| | | Patient has substantially increased metabolic requirements |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRE | SCRIB | ER | | | PATIENT: |
|------|-------------------|----------|-----|---|----------|
| Name | ə: | | | | Name: |
| Ward | : | | | | NHI: |
| High | n pro | tein | ent | eral feed | |
| | IATIOI requisi | ites | | poxes where appropriate) | |
| | and | | The | patient has a high protein requirement | |
| | | or | Ο | Patient has liver disease | |
| | | | Ο | Patient is obese (BMI > 30) and is undergoing surgery | |
| | | or or | Ο | Patient is fluid restricted | |

O Patient's needs cannot be more appropriately met using high calorie product

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |

Extensively hydrolysed formula

INITIATION Prerequisites (tick boxes where appropriate) Cows' milk formula is inappropriate due to severe intolerance or allergy to its protein content and Soy milk formula has been reasonably trialled without resolution of symptoms or Soy milk formula is considered clinically inappropriate or contraindicated or () Severe malabsorption or Short bowel syndrome or Intractable diarrhoea or Biliary atresia or Cholestatic liver diseases causing malsorption or Cystic fibrosis or () Proven fat malabsorption or Severe intestinal motility disorders causing significant malabsorption or ()Intestinal failure or For step down from Amino Acid Formula Note: A reasonable trial is defined as a 2-4 week trial, or signs of an immediate IgE mediated allergic reaction. CONTINUATION

Prerequisites (tick boxes where appropriate)

 \bigcirc

and

An assessment as to whether the infant can be transitioned to a cows' milk protein or soy infant formula has been undertaken

The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|---------------|
| Name: | Name: |
| Ward: | NHI: |
| Preterm formula | |
| INITIATION Prerequisites (tick box where appropriate) | |
| O For infants born before 33 weeks' gestation or weighing less than 1. | 5 kg at birth |

Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|---|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |
| Paediatric oral/enteral feed 1 kcal/ml | | | |
| INITIATION – Fluid restricted or volume intolerance with faltering growth | | | |

Prerequisites (tick boxes where appropriate)

or

and

The patient is fluid restricted or volume intolerant

The patient has increased nutritional requirements due to faltering growth ()

) Patient is under 18 months old and weighs less than 8kg

Note: 'Volume intolerant' patients are those who are unable to tolerate an adequate volume of infant formula to achieve expected growth rate. These patients should have first trialled appropriate clinical alternative treatments, such as concentrating, fortifying and adjusting the frequency of feeding.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Enteral liquid peptide formula

INITIATION Prerequisites (tick boxes where appropriate) () Patient has impaired gastrointestinal function and either cannot tolerate polymeric feeds, or polymeric feeds are unsuitable and () Severe malabsorption or Short bowel syndrome or Intractable diarrhoea or Biliary atresia or Cholestatic liver diseases causing malabsorption or Cystic fibrosis or Proven fat malabsorption or Severe intestinal motility disorders causing significant malabsorption or Intestinal failure or O The patient is currently receiving funded amino acid formula and The patient is to be trialled on, or transitioned to, an enteral liquid peptide formula and () A semi-elemental or partially hydrolysed powdered feed has been reasonably trialled and considered unsuitable or For step down from intravenous nutrition Note: A reasonable trial is defined as a 2-4 week trial. CONTINUATION Prerequisites (tick boxes where appropriate) An assessment as to whether the patient can be transitioned to a cows milk protein or soy infant formula or extensively hydrolysed formula has been undertaken and

The outcome of the assessment is that the patient continues to require an enteral liquid peptide formula

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |

Amino acid formula

INITIATION Prerequisites (tick boxes where appropriate) C Extensively hydrolysed formula has been reasonably trialled for 2-4 weeks and is inappropriate due to documented severe intolerance or allergy or malabsorption or C History of anaphylaxis to cows' milk protein formula or dairy products or C Eosinophilic oesophagitis or C Ultra-short gut or C Severe Immune deficiency

CONTINUATION

and

and

and

and

| Prerequisites | (tick boxes | where | appropriate) |) |
|---------------|-------------|-------|--------------|---|
|---------------|-------------|-------|--------------|---|

An assessment as to whether the infant can be transitioned to a cows' milk protein, soy, or extensively hydrolysed infant formula has been undertaken
 The outcome of the assessment is that the infant continues to require an amino acid infant formula

 \bigcirc Amino acid formula is required for a nutritional deficit

INITIATION – patients who are currently funded under RS1502 or SA1557

Re-assessment required after 3 months **Prerequisites** (tick boxes where appropriate)

Patient has a valid initiation or renewal approval for extensively hydrolysed formula (RS1502)

Patient is unable to source funded Aptamil powder at this time

The approval only applies to funded dispensings of Neocate Gold and Neocate Syneo

Note: This criteria is short term funding to cover an out-of-stock situation on some extensively hydrolysed formula powder funded under Hospital Restriction RS1502. There is no continuation criteria under this criterion.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|------------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| High fat formula | | |

INITIATION

Prerequisites (tick box where appropriate)

()For patients with intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Ward: | NHI: | |

Paediatric Products

| IITIATI rerequ | | s (tick b | poxes where appropriate) |
|-------------------|--------|------------|---|
| an | O d | Child | d is aged one to ten years |
| | ο | 0 | The child is being fed via a tube or a tube is to be inserted for the purposes of feeding |
| | | Ο | Any condition causing malabsorption |
| | 0 | Ο | Faltering growth in an infant/child |
| | 0 | \bigcirc | Increased nutritional requirements |
| | 0 | \bigcirc | The child is being transitioned from TPN or tube feeding to oral feeding |
| | 0 | Ó | The child has eaten, or is expected to eat, little or nothing for 3 days |
| | | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|----------|
| Name: | Name: |
| Ward: | NHI: |
| Low electrolyte oral feed | |
| INITIATION Prerequisites (tick box where appropriate) | |
| O For children (up to 18 years) with acute or chronic kidney disease | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|----------|
| Name: | Name: |
| Ward: | NHI: |
| Low electrolyte oral feed | |
| INITIATION Prerequisites (tick box where appropriate) | |
| O For patients with acute or chronic kidney disease | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|----------|
| Name: | Name: |
| Ward: | NHI: |
| Preoperative carbohydrate feed 0.5 kcal/ml | |

INITIATION

Prerequisites (tick box where appropriate)

O Maximum of 400 ml as part of an Enhanced Recovery After Surgery (ERAS) protocol 2 to 3 hours before major abdominal surgery

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|---------------------|
| Name: | Name: |
| Ward: | NHI: |
| High arginine oral feed 1.4 kcal/ml | |
| INITIATION Prerequisites (tick box where appropriate) | |
| m O Three packs per day for 5 to 7 days prior to major gastrointestinal, h | ead or neck surgery |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|----------------|----------|
| Name: | Name: |
| Ward: | NHI: |
| Standard Feeds | |

| For | patients with malnutrition, defined as any of the following: |
|----------------|--|
| | O BMI < 18.5 |
| 0 | O Greater than 10% weight loss in the last 3-6 months |
| 0 | O BMI < 20 with greater than 5% weight loss in the last 3-6 months |
| | |
| or | |
| Ο | For patients who have, or are expected to, eat little or nothing for 5 days |
| or O | For patients who have, or are expected to, eat little or nothing for 5 days For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism |
| Ο | For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism |
| or O | For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as |
| or () or () | For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism |
| or () or () | For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism For use pre- and post-surgery |

Vaccines

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |

Diphtheria, tetanus, pertussis and polio vaccine

| | Ο | A single dose for children up to the age of 7 who have completed primary immunisation |
|----------|---|---|
| or or | 0 | A course of up to four vaccines is funded for catch up programmes for children (to the age of 10 years) to complete full primary immunisation |
| 01 | Ο | An additional four doses (as appropriate) are funded for (re-)immunisation for patients post HSCT, or chemotherapy; pre- or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens |
| or | 0 | Five doses will be funded for children requiring solid organ transplantation |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine

| INITIATION Prerequisites (tick boxes where appropriate) | | | | |
|---|----|---|---|--|
| | | 0 | Up to four doses for children under the age of 10 years for primary immunisation | |
| | or | 0 | An additional four doses (as appropriate) for (re-)immunisation of children under the age of 18 years post haematopoietic stem cell transplantation | |
| | or | Ο | An additional four doses (as appropriate) for (re-)immunisation of children under the age of 10 years who are post chemotherapy; pre or post splenectomy; undergoing renal dialysis and other severely immunosuppressive regimens | |
| | or | 0 | Up to five doses for children under the age of 10 years receiving solid organ transplantation | |
| | | | | |

Note: A course of up-to four vaccines is funded for catch up programmes for children (up to and under the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|--|--|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Bacillus calmette-guerin vaccine | | |
| INITIATION Prerequisites (tick boxes where appropriate) | | |
| For infants at increased risk of tuberculosis defined as: | | |
| O Living in a house or family with a person with current or past history of TB | | |
| And O Having one or more household members or carers who within the last 5 years lived in a country with a rate of TB > or equal to 40 per 100,000 for 6 months or longer | | |
| and During their first 5 years will be living 3 months or longer in a d | country with a rate of TB $>$ or equal to 40 per 100 000 | |

Note: A list of countries with high rates of TB are available at http://www.health.govt.nz/tuberculosis (Search for Downloads) or www.bcgatlas.org/index.php

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |

Diphtheria, tetanus and pertussis vaccine

INITIATION Prerequisites (tick boxes where appropriate) () A single dose for pregnant women in the second or third trimester of each pregnancy; or or A single dose for parents or primary caregivers of infants admitted to a Neonatal Intensive Care Unit or Specialist Care Baby Unit for more than 3 days, who had not been exposed to maternal vaccination at least 14 days prior to birth; or or A course of up to four doses is funded for children from age 7 up the age of 18 years inclusive to complete full primary immunisation or An additional four doses (as appropriate) are funded for (re-)immunisation for patients post haematopoietic stem cell transplantation or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens or A single dose for vaccination of patients aged from 65 years old or A single dose for vaccination of patients aged from 45 years old who have not had 4 previous tetanus doses or For vaccination of previously unimmunised or partially immunised patients or For revaccination following immunosuppression or For boosting of patients with tetanus-prone wounds

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | SCRI | BER | | PATIENT: |
|------|--|-------|--|--|
| Name | e: | | | Name: |
| Ward | | | | NHI: |
| Haer | nop | ohilu | s influenzae type B vaccine | |
| | sses | smen | t required after 1 dose (tick boxes where appropriate) | |
| | ~ | Ο | For primary vaccination in children | |
| | An additional dose (as appropriate) is funded for (re-)immunisation for patients post haematopoietic stem cell transplantation, or chemotherapy; functional asplenic; pre or post splenectomy; pre- or post solid organ transplant, pre- or post cochlear implants, renal dialysis and other severely immunosuppressive regimens | | | |
| | | 0 | For use in testing for primary immunodeficiency diseases, on t | he recommendation of an internal medicine physician or paediatrician |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |

Meningococcal (A, C, Y and W-135) conjugate vaccine

INITIATION Prerequisites (tick boxes where appropriate) () Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant or One dose for close contacts of meningococcal cases of any group or One dose for person who has previously had meningococcal disease of any group or A maximum of two doses for bone marrow transplant patients or A maximum of two doses for person pre and post-immunosuppression* or () Person is aged between 13 and 25 years, inclusive and \bigcirc One dose for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons or ()One dose for individuals who turn 13 years of age while living in boarding school hostels

Note: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly. *Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|------------|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |

Meningococcal (A, C, Y and W-135) conjugate vaccine

Note: infants from 6 weeks to less than 6 months of age require a 2+1 schedule, infants from 6 months to less than 12 months of age require a 1+1 schedule. Refer to the Immunisation Handbook for recommended booster schedules with meningococcal ACWY vaccine. *Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

| Use this checklist to determine if a patient meets the restrictions for funding in the h Schedule. For community funding, see the Special Authority Criteria. | spital setting . For more details, refer to Section H of the Pharmaceutical |
|--|---|
| PRESCRIBER PA | FIENT: |
| Name: Na | ne: |
| Ward: NH | l: |
| Pneumococcal (PCV13) conjugate vaccine | |
| INITIATION – Primary course for previously unvaccinated children aged und Re-assessment required after 3 doses Prerequisites (tick box where appropriate) O A primary course of three doses for previously unvaccinated children up | |
| INITIATION – High risk individuals who have received PCV10 Re-assessment required after 2 doses Prerequisites (tick box where appropriate) O Two doses are funded for high risk individuals (over the age of 12 month primary course of PCV10 | s and under 18 years) who have previously received two doses of the |
| INITIATION – High risk children aged under 5 years Re-assessment required after 4 doses Prerequisites (tick boxes where appropriate) O Up to an additional four doses (as appropriate) are funded for the and | re)immunisation of high-risk children aged under 5 years |
| On immunosuppressive therapy or radiation therapy, vaccination Primary immune deficiencies Primary immune deficiencies HIV infection Renal failure, or nephrotic syndrome Reriand failure, or nephrotic syndrome Are immune-suppressed following organ transplantation (incomposed for Cochlear implants or intracranial shunts Cerebrospinal fluid leaks | nd who are on an equivalent daily dosage of prednisone of 2 mg/kg n a total daily dosage of 20 mg or greater |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|---|---|--|
| Name: | Name: | |
| | Nalle. | |
| Ward: | | |
| Pneumococcal (PCV13) conjugate vaccine - continued | | |
| INITIATION – High risk individuals 5 years and over Re-assessment required after 4 doses Prerequisites (tick box where appropriate) | | |
| O Up to an additional four doses (as appropriate) are funded for the (re-)immunisation of individuals 5 years and over with HIV, pre or post haematopoietic stem cell transplantation, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post- solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, intracranial shunts, cerebrospinal fluid leaks or primary immunodeficiency | | |
| INITIATION – Testing for primary immunodeficiency diseases Prerequisites (tick box where appropriate) | | |
| O For use in testing for primary immunodeficiency diseases, on the red | commendation of an internal medicine physician or paediatrician | |
| Note: Please refer to the Immunisation Handbook for the appropriate schedu | le for catch up programmes | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. | For more details, refer to Section H of the Pharmaceutical |
|--|--|
| Schedule. For community funding, see the Special Authority Criteria. | |

| PRESCRIBE | R | PATIENT: | |
|--|--|--|--|
| Name: | Name: | | |
| Ward: | Ward: NHI: | | |
| Pneumoco | occal | (PPV23) polysaccharide vaccine | |
| Re-assessm Prerequisite O Fo as | ent rec es (tick r patie plenia, | n risk patients quired after 3 doses < box where appropriate) nts with HIV, for patients post haematopoietic stem cell transplant, or chemotherapy; pre- or post-splenectomy; or with functional , pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary deficiency | |
| Re-assessm | ent ree | n risk children quired after 2 doses < boxes where appropriate) | |
| and |) Pat | tient is a child under 18 years for (re-)immunisation | |
| | С | On immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response | |
| | or C | With primary immune deficiencies | |
| | O With HIV infection | | |
| | or O With renal failure, or nephrotic syndrome | | |
| | or O Who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant) | | |
| | or O With cochlear implants or intracranial shunts | | |
| | or O With cerebrospinal fluid leaks | | |
| | or C or | Receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater | |
| | O With chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy) | | |
| | O Pre term infants, born before 28 weeks gestation | | |
| | or C | With cardiac disease, with cyanosis or failure | |
| | or C | With diabetes | |
| | or C | With Down syndrome | |
| | or C | Who are pre-or post-splenectomy, or with functional asplenia | |
| | | | |

INITIATION – Testing for primary immunodeficiency diseases Prerequisites (tick box where appropriate)

O For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|---|----------|
| Name: | Name: |
| Ward: | NHI: |
| Salmonella typhi vaccine | |
| INITIATION Prerequisites (tick box where appropriate) | |
| ${ m O}~$ For use during typhoid fever outbreaks | |

and

or

HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

| Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. | For more details, refer to Section H of the Pharmaceutical |
|--|--|
| Schedule. For community funding, see the Special Authority Criteria. | |

| RESCRIBE | 3 | PATIENT: |
|------------|---|---|
| lame: | | Name: |
| Vard: | | NHI: |
| leningoc | occal B multicomponent vaccine | |
| | - Primary immunisation for children up to 12 months of age ent required after 3 doses | 9 |
| | s (tick boxes where appropriate) | |
| or | Three doses for children up to 12 months of age (inclusive) f | or primary immunisation |
| | Up to three doses (dependent on age at first dose) for a cate (inclusive) for primary immunisation, from 1 March 2023 to 3 | ch-up programme for children from 13 months to 59 months of age 1 August 2025 |
| | | pre- and post-splenectomy and for patients with functional or anatomic |
| or C | asplenia, HIV, complement deficiency (acquired or inherited)Up to two doses for close contacts of meningococcal cases of the splene of the | |
| or or | Up to two doses for person who has previously had meningo | pecoccal disease of any group |
| or | Up to two doses for bone marrow transplant patients | |
| C | Up to two doses for person pre- and post-immunosuppression | on* |
| | Person is and between 12 and 25 years (inclusive) | |
| Re-assessm | Person is aged between 13 and 25 years (inclusive) ent required after 2 doses s (tick boxes where appropriate) | |
| C | Person is aged between 13 and 25 years (inclusive) | |

O Two doses for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, Youth Justice residences, or prisons

O Two doses for individuals who turn 13 years of age while living in boarding school hostels

Note: *Immunosuppression due to corticosteroid or other immunosuppressive therapy must be for a period of greater than 28 days.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | SCRI | BER | | PATIENT: |
|----------------|-------|-------|---|----------|
| Name | : | | | Name: |
| Ward: | | | | NHI: |
| Нера | atiti | s A v | vaccine | |
| INITI Prere | | | (tick boxes where appropriate) | |
| | _ | 0 | Two vaccinations for use in transplant patients | |
| | or | Ο | Two vaccinations for use in children with chronic liver disease | |
| | or | 0 | One dose of vaccine for close contacts of known hepatitis A ca | ases |

Use this checklist to determine if a patient meets the restrictions for funding in the hospital setting. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Hepatitis B recombinant vaccine

INITIATION Prerequisites (tick boxes where appropriate) () For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers or For children born to mothers who are hepatitis B surface antigen (HBsAg) positive or For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination or ()For HIV positive patients or For hepatitis C positive patients or For patients following non-consensual sexual intercourse or For patients prior to planned immunosuppression for greater than 28 days or () For patients following immunosuppression or For solid organ transplant patients or For post-haematopoietic stem cell transplant (HSCT) patients or Following needle stick injury or For dialysis patients or For liver or kidney transplant patients

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |

Hepatitis B recombinant vaccine

INITIATION Prerequisites (tick boxes where appropriate) () For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers or For children born to mothers who are hepatitis B surface antigen (HBsAg) positive or For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination or ()For HIV positive patients or For hepatitis C positive patients or For patients following non-consensual sexual intercourse or For patients prior to planned immunosuppression for greater than 28 days or () For patients following immunosuppression or For solid organ transplant patients or For post-haematopoietic stem cell transplant (HSCT) patients or Following needle stick injury

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCR | IBER | PATIENT: | | | |
|----------|---|-------------------------------|--|--|--|
| Name: . | | Name: | | | |
| Ward: | | NHI: | | | |
| Influen | za vaccine Inj 60 mcg in 0.5 ml syringe (quadrivalen | t vaccine) | | | |
| | INITIATION – People over 65 Prerequisites (tick box where appropriate) O The patient is 65 years of age or over | | | | |
| | INITIATION – cardiovascular disease Prerequisites (tick boxes where appropriate) | | | | |
| or | O Congestive heart failure | | | | |
| or | O Congenital heart disease | | | | |
| Note: hy | Cerebro-vascular disease //pertension and/or dyslipidaemia without evidence of end-organ disea | ise is excluded from funding. | | | |

INITIATION – chronic respiratory disease

 \bigcirc

or

Prerequisites (tick boxes where appropriate)

Asthma, if on a regular preventative therapy

O Other chronic respiratory disease with impaired lung function

Note: asthma not requiring regular preventative therapy is excluded from funding.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |

Influenza vaccine Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) - continued

| | | Ο | Diabetes |
|-----|----------|---------------|--|
| | or | 0 | Chronic renal disease |
| | or | 0 | Any cancer, excluding basal and squamous skin cancers if not invasive |
| | or | Ο | Autoimmune disease |
| | or | Ο | Immune suppression or immune deficiency |
| | or | Ο | HIV |
| | or | Ο | Transplant recipient |
| | or | Ο | Neuromuscular and CNS diseases/ disorders |
| | or | Ο | Haemoglobinopathies |
| | or | Ο | Is a child on long term aspirin |
| | or | Ο | Has a cochlear implant |
| | or or | Ο | Errors of metabolism at risk of major metabolic decompensation |
| | | Ο | Pre and post splenectomy |
| | or or | Ο | Down syndrome |
| | or | Ο | Is pregnant |
| | 01 | 0 | Is a child 4 years of age or under (inclusive) who has been hospitalised for respiratory illness or has a history of significant respiratory illness |
| r (| | Patie Hosp | ents in a long-stay inpatient mental health care unit or who are compulsorily detained long-term in a forensic unit within a Publi ital |
| ION | – S | eriou | us mental health conditions or addiction |

 or
 O
 Schizophrenia

 or
 O
 Major depressive disorder

 or
 O
 Bipolar disorder

 or
 O
 Schizoaffective disorder

 or
 O
 Schizoaffective disorder

 or
 O
 Person is currently accessing secondary or tertiary mental health and addiction services

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | SCRI | BER | | PATIENT: |
|------|----------|------------|---|----------|
| Name | e: | | | Name: |
| Ward | : | | | NHI: |
| Mea | sles | s, mı | imps and rubella vaccine | |
| Re-a | sses | smen | irst dose prior to 12 months t required after 3 doses (tick boxes where appropriate) | |
| | or or | 0 0 | For primary vaccination in children For revaccination following immunosuppression | |
| | | \bigcirc | For any individual susceptible to measles, mumps or rubella | |
| Re-a | isses | smen | irst dose after 12 months t required after 2 doses (tick boxes where appropriate) | |
| | or | 0 0 | For primary vaccination in children For revaccination following immunosuppression | |
| | | 0 | For any individual susceptible to measles, mumps or rubella | |

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | |
|---|----------|--|
| Name: | Name: | |
| Ward: | NHI: | |
| Poliomyelitis vaccine | | |
| INITIATION Re-assessment required after 3 doses Prerequisites (tick boxes where appropriate) O For partially vaccinated or previously unvaccinated individuals or O For revaccination following immunosuppression | 3 | |

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | | PATIENT: |
|--|---|---|
| Name: | | Name: |
| Ward: | | NHI: |
| Varicella vacc | ine [Chickenpox vaccine] | |
| Re-assessment ro Prerequisites (tio | imary vaccinations required after 1 dose ck boxes where appropriate) any infant born on or after 1 April 2016 | r after 1 July 2017, who have not previously had a varicella infection |
| | chickenpox) | a ater 1 duy 2017, who have not previously had a varicella infection |
| | h er conditions required after 2 doses ck boxes where appropriate) | |
| fr or or or or (or (| or non-immune patients: With chronic liver disease who may in future be candidat With deteriorating renal function before transplantation Prior to solid organ transplant Prior to any elective immunosuppression* For post exposure prophylaxis who are immune competer | |
| or or or or or or or or or or or or or | here the household contact has no clinical history of varicella | by, on advice of their specialist moderate immunosuppression on advice of HIV specialist netabolic decompensation, with no clinical history of varicella compromised, or undergoing a procedure leading to immune compromise history of varicella and who are severely immunocompromised or |
| Note: * immunos | suppression due to steroid or other immunosuppressive thera | py must be for a treatment period of |

greater than 28 days

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|------------|----------|
| Name: | Name: |
| Ward: | NHI: |

Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV]

| INITIATION – Children aged 14 years and under Re-assessment required after 2 doses Prerequisites (tick box where appropriate) | |
|---|--|
| O Children aged 14 years and under | |

| | | O Maximum of three doses for people aged 15 years and over | , |
|----------|-----|--|---|
| and (| С | The person has recurrent respiratory papillomatosis | |
| and (| C C | The person has not previously had an HPV vaccine | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: |
|--|----------|
| Name: | Name: |
| Ward: | NHI: |
| Rotavirus oral vaccine | |
| INITIATION Re-assessment required after 2 doses | |
| Prerequisites (tick boxes where appropriate) | |
| First dose to be administered in infants aged under 14 weeks | of age |
| No vaccination being administered to children aged 24 weeks | or over |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | CRI | BER | | PATIENT: | |
|---|----------|-------|--|---|--|
| Name | : | | | Name: | |
| Ward: | | | | NHI: | |
| Varic | ella | a zos | ster vaccine [shingles vaccine] | | |
| Re-as | sses | smen | beople aged 18 years and over (Shingrix) t required after 2 doses (tick boxes where appropriate) | | |
| O Pre- and post-haematopoietic stem cell transplant or cellular therapy | | | | | |
| | or or | Ο | Pre- or post-solid organ transplant | | |
| | or | Ο | Haematological malignancies | | |
| | or | 0 | People living with poorly controlled HIV infection | | |
| | ~ " | 0 | Planned or receiving disease modifying anti-rheumatic drugs (polymyalgia rheumatica, systemic lupus erythematosus or rhe | DMARDs – targeted synthetic, biologic, or conventional synthetic) for umatoid arthritis | |
| | or | Ο | End stage kidney disease (CKD 4 or 5); | | |
| | or | Ο | Primary immunodeficiency | | |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|---------------------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |
| COVID-19 vaccine | | | |
| INITIATION – initial dose | | | |

Prerequisites (tick box where appropriate)

m O Up to three doses for previously unvaccinated children aged 6 months – 4 years at high risk of severe illness

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRES | SCR | IBER | | PATIENT: |
|-------|-----|-------|--|-----------|
| Name | e: | | | Name: |
| Ward: | : | | | NHI: |
| cov | ID- | 19 va | accine | |
| | | | nitial dose (tick boxes where appropriate) | |
| | | Ο | One dose for previously unvaccinated children aged 5-11 year | s old |
| | or | 0 | Up to three doses for immunocompromised children aged 5-11 | years old |

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | PATIENT: | | |
|------------|----------|--|--|
| Name: | Name: | | |
| Ward: | NHI: | | |

COVID-19 vaccine

| _ |
|---|

INITIATION – additional dose

Prerequisites (tick box where appropriate)

O One additional dose every 6 months for people aged 30 years and over, additional dose is given at least 6 months after last dose

CONTINUATION – additional dose

Prerequisites (tick box where appropriate)

O One additional dose every 6 months for people aged 30 years and over, additional dose is given at least 6 months after last dose

I confirm that the above details are correct:

Signed: Date:

Index of form numbers

| | Ajmaline79 |
|------------------|--|
| RS1007 | Levosimendan |
| R51008 | Hydralazine hydrochloride - Tab 25 mg |
| | Rasburicase |
| RS1027 | Omeprazole - Tab dispersible 10 mg and 20 mg |
| RS1028 | Diazoxide |
| RS1035 | Levocarnitine19 |
| RS1041 | Amikacin |
| RS1043 | Streptomycin sulphate |
| | Ertapenem |
| RS1046 | Imipenem with cilastatin |
| RS1047 | Meropenem140 |
| | Ceftazadime |
| | Cefepime |
| RS1053 RS1054 | Piperacillin with tazobactam |
| | Ciprofloxacin |
| RS1059 | Tigecycline |
| RS1061 | Clindamycin |
| | Colistin sulphomethate [Colestimethate]166 |
| RS1063 | Daptomycin |
| RS1064 | Fusidic acid |
| | Linezolid |
| RS1067 | Sulphadiazine |
| | Teicoplanin |
| | Vancomycin |
| RS1071 | Amphotericin B - Inj (liposomal) 50 mg vial |
| | Fluconazole |
| | Caspofungin |
| | Clofazimine |
| RS1078 | Dapsone |
| RS1079 | Cycloserine |
| RS1080 | Ethambutol hydrochloride |
| | Para-aminosalicylic Acid |
| RS1085 | Pyrazinamide |
| | Rifabutin |
| | Rifampicin |
| RS1088 | Albendazole |
| | Artemether with lumefantrine |
| RS1091 | Artesunate |
| RS1093 | Chloroquine phosphate |
| | Mefloquine hydrochloride |
| | Nitazoxanide203 |
| | Pentamidine isethionate |
| RS1097 | Primaquine phosphate |
| | Pyrimethamine |
| | Sodium stibogluconate |
| | Spiramycin |
| | Cidofovir |
| | Foscarnet sodium |
| | Ganciclovir |
| | Interferon gamma 218 Bee venom 468 |
| | Paper wasp venom |
| | Yellow jacket wasp venom |
| RS1125 | Betamethasone valerate with clioquinol |
| | Methyl aminolevulinate hydrochloride |
| | Terbutaline |
| | Finasteride |
| | Potassium citrate |
| RS1143 | Teriparatide |
| RS1145 | Capsaicin238 |
| | Paracetamol |
| | Aprepitant |
| | Hyoscine hydrobromide - Patch 1.5 mg 242 Buprenorphine with naloxone 265 |
| | |

| - BC1174 | |
|--|--|
| 101170 | Naltrexone hydrochloride262 |
| RS1175 | Sodium hyaluronate |
| RS1176 | Alpha tocopheryl acetate |
| RS1178 | Multivitamins – Powder |
| | Bivalirudin |
| | Danaparoid |
| | Defibrotide |
| R51103 | |
| R51184 | Fondaparinux sodium |
| RS1188 | Filgrastim73 |
| RS1202 | Abciximab |
| RS1203 | Basiliximab |
| RS1206 | Bacillus calmette-guerin (BCG) |
| | Carbohydrate and fat supplement |
| R\$1214 | Standard Feeds |
| D01010 | Diahatia Draduata 400 |
| R51215 | Diabetic Products |
| | Elemental and Semi-Elemental Products |
| | Hepatic Products |
| RS1224 | Preterm formula |
| | High fat formula |
| | Low electrolyte oral feed |
| R\$1228 | Low electrolyte oral feed |
| DC1001 | High arginine oral feed 1.4 kcal/ml |
| R51231 | |
| RS1233 | Bacillus calmette-guerin vaccine |
| | Salmonella typhi vaccine |
| RS1261 | L-ornithine L-aspartate |
| | Captopril - Oral liq 5 mg per ml76 |
| BS1266 | Adenosine - Inj 3 mg per ml, 10 ml vial78 |
| R\$1276 | Propylthiouracil |
| DC1077 | Aztreonam, Chloramphenicol |
| no12// | Aztreonam, Chioramphenicor |
| RS1279 | Flucytosine |
| RS1281 | Isoniazid185 |
| RS1282 | lsoniazid with rifampicin181 |
| RS1283 | Ivermectin |
| | Methoxyflurane |
| BS1297 | Sodium chloride – Inj74 |
| Re1207 | Mafenide acetate |
| | |
| R51301 | Liothyronine sodium - Tab 20 mcg |
| | Oxandrolone - Tab 2.5 mg118 |
| BS1307 | Ocaltamivir 014 |
| 1101007 | Oseltamivir |
| | |
| RS1309 | Capsaicin232 |
| RS1309 RS1315 | Capsaicin |
| RS1309 RS1315 RS1316 | Capsaicin 232 Fosfomycin 160 Amphotericin B - Inj 50 mg vial 169 |
| RS1309 RS1315 RS1316 RS1317 | Capsaicin 232 Fosfomycin 160 Amphotericin B - Inj 50 mg vial 169 High Calorie Products 497 |
| RS1309 RS1315 RS1316 RS1317 RS1322 | Capsaicin 232 Fosfomycin 160 Amphotericin B - Inj 50 mg vial 169 High Calorie Products 497 Pivmecillinam 161 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 | Capsaicin 232 Fosfomycin 160 Amphotericin B - Inj 50 mg vial 169 High Calorie Products 497 Pivmecillinam 161 High protein enteral feed 498 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1330 | Capsaicin 232 Fosfomycin 160 Amphotericin B - Inj 50 mg vial 169 High Calorie Products 497 Pivmecillinam 161 High protein enteral feed 498 Biotin 21 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1330 | Capsaicin 232 Fosfomycin 160 Amphotericin B - Inj 50 mg vial 169 High Calorie Products 497 Pivmecillinam 161 High protein enteral feed 498 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1330 RS1331 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1330 RS1331 RS1332 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1330 RS1331 RS1332 RS1351 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1320 RS1331 RS1332 RS1351 RS1354 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg485 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1330 RS1331 RS1332 RS1351 RS1354 RS1369 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg215Zanamivir - Powder for inhalation 5 mg215 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1330 RS1331 RS1332 RS1351 RS1354 RS1369 RS1370 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg485Zanamivir - Powder for inhalation 5 mg215Sugammadex230 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1330 RS1331 RS1332 RS1351 RS1354 RS1369 RS1370 RS1387 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg485Zanamivir - Powder for inhalation 5 mg215Sugammadex230Diphtheria, tetanus, pertussis and polio vaccine512 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1330 RS1331 RS1354 RS1354 RS1369 RS1370 RS1387 RS1398 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg485Zanamivir - Powder for inhalation 5 mg215Sugammadex230Diphtheria, tetanus, pertussis and polio vaccine512Poliomyelitis vaccine530 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1330 RS1331 RS1354 RS1354 RS1369 RS1370 RS1387 RS1398 RS1410 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg485Zanamivir - Powder for inhalation 5 mg215Sugammadex230Diphtheria, tetanus, pertussis and polio vaccine512Poliomyelitis vaccine530Ketoconazole - Tab 200 mg167 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1330 RS1331 RS1354 RS1354 RS1369 RS1370 RS1387 RS1398 RS1410 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg485Zanamivir - Powder for inhalation 5 mg215Sugammadex230Diphtheria, tetanus, pertussis and polio vaccine512Poliomyelitis vaccine530Ketoconazole - Tab 200 mg167 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1330 RS1331 RS1354 RS1354 RS1369 RS1370 RS1387 RS1398 RS1410 RS1415 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg485Zanamivir - Powder for inhalation 5 mg215Sugammadex230Diphtheria, tetanus, pertussis and polio vaccine512Poliomyelitis vaccine530Ketoconazole - Tab 200 mg167Preoperative carbohydrate feed 0.5 kcal/ml508 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1330 RS1331 RS1332 RS1351 RS1354 RS1370 RS1387 RS1398 RS1410 RS1415 RS1416 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg485Zanamivir - Powder for inhalation 5 mg215Sugammadex230Diphtheria, tetanus, pertussis and polio vaccine512Poliomyelitis vaccine530Ketoconazole - Tab 200 mg167Preoperative carbohydrate feed 0.5 kcal/ml508Rifaximin10 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1330 RS1331 RS1332 RS1354 RS1354 RS1356 RS1370 RS1387 RS1398 RS1410 RS1415 RS1416 RS1417 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg485Zanamivir - Powder for inhalation 5 mg215Sugammadex230Diphtheria, tetanus, pertussis and polio vaccine512Poliomyelitis vaccine530Ketoconazole - Tab 200 mg167Preoperative carbohydrate feed 0.5 kcal/ml508Rifaximin10Ferric carboxymaltose35 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1330 RS1331 RS1332 RS1351 RS1354 RS1369 RS1370 RS1387 RS1398 RS1410 RS1415 RS1416 RS1417 RS1427 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg485Zanamivir - Powder for inhalation 5 mg215Sugammadex230Diphtheria, tetanus, pertussis and polio vaccine512Poliomyelitis vaccine530Ketoconazole - Tab 200 mg167Preoperative carbohydrate feed 0.5 kcal/ml508Rifaximin10Ferric carboxymaltose35Midodrine81 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1330 RS1331 RS1332 RS1331 RS1332 RS1351 RS1354 RS1369 RS1370 RS1387 RS1398 RS1410 RS1415 RS1416 RS1417 RS1427 RS1435 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg215Sugammadex230Diphtheria, tetanus, pertussis and polio vaccine512Poliomyelitis vaccine530Ketoconazole - Tab 200 mg167Preoperative carbohydrate feed 0.5 kcal/ml508Rifaximin10Ferric carboxymaltose35Midodrine81Tobramycin Solution for inhalation 60 mg per ml, 5 ml135 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1330 RS1331 RS1332 RS1351 RS1354 RS1369 RS1370 RS1387 RS1398 RS1410 RS1415 RS1417 RS1427 RS1435 RS1435 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg235Zanamivir - Powder for inhalation 5 mg215Sugammadex230Diphtheria, tetanus, pertussis and polio vaccine512Poliomyelitis vaccine530Ketoconazole - Tab 200 mg167Preoperative carbohydrate feed 0.5 kcal/ml508Rifaximin10Ferric carboxymaltose35Midodrine81Tobramycin Solution for inhalation 60 mg per ml, 5 ml135Rivastigmine261 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1330 RS1331 RS1332 RS1351 RS1354 RS1369 RS1370 RS1387 RS1398 RS1410 RS1415 RS1417 RS1427 RS1435 RS1435 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg215Sugammadex230Diphtheria, tetanus, pertussis and polio vaccine512Poliomyelitis vaccine530Ketoconazole - Tab 200 mg167Preoperative carbohydrate feed 0.5 kcal/ml508Rifaximin10Ferric carboxymaltose35Midodrine81Tobramycin Solution for inhalation 60 mg per ml, 5 ml135 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1330 RS1331 RS1331 RS1351 RS1354 RS1369 RS1370 RS1387 RS1398 RS1410 RS1415 RS1416 RS1417 RS1435 RS1444 RS1435 RS1444 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg245Zanamivir - Powder for inhalation 5 mg215Sugammadex230Diphtheria, tetanus, pertussis and polio vaccine512Poliomyelitis vaccine530Ketoconazole - Tab 200 mg167Preoperative carbohydrate feed 0.5 kcal/ml508Rifaximin10Ferric carboxymaltose35Midodrine81Tobramycin Solution for inhalation 60 mg per ml, 5 ml135Rivastigmine261Deferasirox483 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1330 RS1331 RS1331 RS1351 RS1351 RS1354 RS1350 RS1351 RS1354 RS1356 RS1410 RS1415 RS1416 RS1417 RS1427 RS1435 RS1444 RS1445 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg485Zanamivir - Powder for inhalation 5 mg215Sugammadex230Diphtheria, tetanus, pertussis and polio vaccine512Poliomyelitis vaccine530Ketoconazole - Tab 200 mg167Preoperative carbohydrate feed 0.5 kcal/ml508Rifaximin10Ferric carboxymaltose35Midodrine81Tobramycin Solution for inhalation 60 mg per ml, 5 ml135Rivastigmine261Deferasirox483Deferiprone484 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1330 RS1331 RS1332 RS1351 RS1354 RS1354 RS1354 RS1354 RS1354 RS1354 RS1410 RS1415 RS1416 RS1417 RS1427 RS1435 RS1446 RS1446 RS1446 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg485Zanamivir - Powder for inhalation 5 mg215Sugammadex230Diphtheria, tetanus, pertussis and polio vaccine512Poliomyelitis vaccine530Ketoconazole - Tab 200 mg167Preoperative carbohydrate feed 0.5 kcal/ml508Rifaximin10Ferric carboxymaltose35Midodrine81Tobramycin Solution for inhalation 60 mg per ml, 5 ml135Rivastigmine261Deferasirox483Deferiprone484Ceftaroline484 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1320 RS1331 RS1332 RS1351 RS1354 RS1354 RS1354 RS1354 RS1354 RS1410 RS1415 RS1416 RS1417 RS1427 RS1436 RS1446 RS1446 RS1446 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg485Zanamivir - Powder for inhalation 5 mg215Sugammadex230Diphtheria, tetanus, pertussis and polio vaccine512Poliomyelitis vaccine530Ketoconazole - Tab 200 mg167Preoperative carbohydrate feed 0.5 kcal/ml508Rifaximin10Ferric carboxymaltose35Midodrine81Tobramycin Solution for inhalation 60 mg per ml, 5 ml135Rivastigmine261Deferasirox483Deferiprone484Ceftaroline144Carbohydrate488 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1320 RS1331 RS1332 RS1351 RS1354 RS1354 RS1354 RS1354 RS1354 RS1354 RS1354 RS1354 RS1410 RS1415 RS1416 RS1417 RS1425 RS1446 RS1446 RS1446 RS1446 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg485Zanamivir - Powder for inhalation 5 mg215Sugammadex230Diphtheria, tetanus, pertussis and polio vaccine512Poliomyelitis vaccine530Ketoconazole - Tab 200 mg167Preoperative carbohydrate feed 0.5 kcal/ml508Rifaximin10Ferric carboxymaltose35Midodrine81Tobramycin Solution for inhalation 60 mg per ml, 5 ml135Rivastigmine261Deferasirox483Deferiprone484Ceftaroline488Fat488Fat489 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1330 RS1331 RS1332 RS1354 RS1354 RS1354 RS1356 RS1356 RS1356 RS1356 RS1356 RS1356 RS1356 RS1416 RS1417 RS1427 RS1436 RS1446 RS1446 RS14468 RS1468 RS1468 RS1468 RS1468 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg485Zanamivir - Powder for inhalation 5 mg215Sugammadex230Diphtheria, tetanus, pertussis and polio vaccine512Poliomyelitis vaccine530Ketoconazole - Tab 200 mg167Preoperative carbohydrate feed 0.5 kcal/ml508Rifaximin10Ferric carboxymaltose35Midodrine81Tobramycin Solution for inhalation 60 mg per ml, 5 ml135Rivastigmine261Deferasirox483Deferiprone484Ceftaroline144Carbohydrate488Fat489Protein490 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1322 RS1331 RS1332 RS1331 RS1332 RS1331 RS1332 RS1351 RS1354 RS1356 RS1357 RS1396 RS1370 RS1387 RS1416 RS1417 RS1427 RS1446 RS1446 RS1446 RS1446 RS1446 RS1446 RS1446 RS1446 RS1446 RS1446 RS1446 RS1446 RS1446 RS1469 RS1469 RS1469 RS1470 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg485Zanamivir - Powder for inhalation 5 mg215Sugammadex230Diphtheria, tetanus, pertussis and polio vaccine512Poliomyelitis vaccine530Ketoconazole - Tab 200 mg167Preoperative carbohydrate feed 0.5 kcal/ml508Rifaximin10Ferric carboxymaltose35Midodrine81Tobramycin Solution for inhalation 60 mg per ml, 5 ml135Rivastigmine261Deferasirox483Deferiprone484Fat-modified feed490Fat-modified feed490 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1322 RS1331 RS1332 RS1331 RS1332 RS1331 RS1332 RS1351 RS1354 RS1356 RS1357 RS1396 RS1370 RS1387 RS1416 RS1417 RS1427 RS1446 RS1446 RS1446 RS1446 RS1446 RS1446 RS1446 RS1446 RS1446 RS1446 RS1446 RS1446 RS1446 RS1469 RS1469 RS1469 RS1470 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg485Zanamivir - Powder for inhalation 5 mg215Sugammadex230Diphtheria, tetanus, pertussis and polio vaccine512Poliomyelitis vaccine530Ketoconazole - Tab 200 mg167Preoperative carbohydrate feed 0.5 kcal/ml508Rifaximin10Ferric carboxymaltose35Midodrine81Tobramycin Solution for inhalation 60 mg per ml, 5 ml135Rivastigmine261Deferasirox483Deferiprone484Ceftaroline144Carbohydrate488Fat489Protein490 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1322 RS1331 RS1332 RS1331 RS1332 RS1331 RS1332 RS1331 RS1332 RS1336 RS1351 RS1356 RS1416 RS1417 RS1427 RS1446 RS1447 RS146 RS1446 RS1447 RS146 RS1446 RS1447 RS146 RS1446 RS1447 RS146 RS1446 RS1447 RS146 RS1477 RS146 RS1477 RS146 RS1477 RS146 RS1477 RS146 RS1477 RS146 RS14777 RS1477 RS1777 RS1777 RS1777 RS17777 RS17777777777 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg485Zanamivir - Powder for inhalation 5 mg215Sugammadex230Diphtheria, tetanus, pertussis and polio vaccine512Poliomyelitis vaccine530Ketoconazole - Tab 200 mg167Preoperative carbohydrate feed 0.5 kcal/ml508Rifaximin10Ferric carboxymaltose35Midodrine81Tobramycin Solution for inhalation 60 mg per ml, 5 ml135Rivastigmine261Deferasirox483Deferiprone484Fat489Fat489Fat489Fat-modified feed495Paediatric Products505 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1320 RS1331 RS1332 RS1331 RS1332 RS1331 RS1332 RS1331 RS1332 RS1330 RS1330 RS1330 RS1330 RS1330 RS1340 RS1410 RS1415 RS1444 RS1445 RS1446 RS1469 RS1470 RS1473 RS1475 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg485Zanamivir - Powder for inhalation 5 mg215Sugammadex230Diphtheria, tetanus, pertussis and polio vaccine512Poliomyelitis vaccine530Ketoconazole - Tab 200 mg167Preoperative carbohydrate feed 0.5 kcal/ml508Rifaximin10Ferric carboxymaltose35Midodrine81Tobramycin Solution for inhalation 60 mg per ml, 5 ml135Rivastigmine261Deferasirox483Deferiprone484Carbohydrate489Protein489Protein489Protein489Protein480Fat489Protein490Fat-modified feed490Paediatric Products505Tobramcyin136 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1322 RS1331 RS1332 RS1331 RS1332 RS1331 RS1332 RS1331 RS1332 RS1330 RS1330 RS1330 RS1330 RS1340 RS1417 RS1427 RS1460 RS1440 RS1470 RS1475 RS1475 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg485Zanamivir - Powder for inhalation 5 mg215Sugammadex230Diphtheria, tetanus, pertussis and polio vaccine512Poliomyelitis vaccine530Ketoconazole - Tab 200 mg167Preoperative carbohydrate feed 0.5 kcal/ml508Rifaximin10Ferric carboxymaltose35Midodrine81Tobramycin Solution for inhalation 60 mg per ml, 5 ml135Rivastigmine261Deferasirox483Deferiprone484Ceftaroline144Carbohydrate489Protein490Fat-modified feed495Paediatric Products505Tobramcyin136Measles, mumps and rubella vaccine529 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1322 RS1331 RS1332 RS1331 RS1332 RS1331 RS1332 RS1331 RS1332 RS1330 RS1337 RS1398 RS1410 RS1415 RS1416 RS1417 RS1446 RS1446 RS1446 RS1446 RS1446 RS1446 RS1446 RS1446 RS1446 RS1447 RS1468 RS1475 RS1475 RS1475 RS1475 RS1475 | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg485Zanamivir - Powder for inhalation 5 mg215Sugammadex230Diphtheria, tetanus, pertussis and polio vaccine512Poliomyelitis vaccine530Ketoconazole - Tab 200 mg167Preoperative carbohydrate feed 0.5 kcal/ml508Rifaximin10Ferric carboxymaltose35Midodrine81Tobramycin Solution for inhalation 60 mg per ml, 5 ml135Rivastigmine261Deferiprone488Fat489Protein499Protein499Paediatric Products505Tobramcyin136Measles, mumps and rubella vaccine529Multivitamin and mineral supplement40 |
| RS1309 RS1315 RS1316 RS1317 RS1322 RS1327 RS1320 RS1331 RS1331 RS1332 RS1331 RS1351 RS1351 RS1354 RS1351 RS1359 RS1350 RS1351 RS1359 RS1350 RS1350 RS1350 RS1350 RS1350 RS1350 RS1350 RS1470 RS1446 RS1446 RS1447 RS1469 RS1475 RS1475 RS1477 RS1478 RS1477 RS1478 RS1477 RS1478 RS1477 RS1478 RS1477 RS1478 RS1477 RS1478 RS1477 RS1478 RS1477 RS1478 RS1477 RS1478 RS1477 RS1478 RS1477 RS1478 RS1477 RS1478 RS1477 RS1478 RS1477 RS1478 RS1477 RS1478 RS1477 RS1478 RS1477 RS | Capsaicin232Fosfomycin160Amphotericin B - Inj 50 mg vial169High Calorie Products497Pivmecillinam161High protein enteral feed498Biotin21Pyridoxal-5-phosphate22Aprotinin49Riluzole234Povidone-iodine - Vaginal tab 200 mg485Zanamivir - Powder for inhalation 5 mg215Sugammadex230Diphtheria, tetanus, pertussis and polio vaccine512Poliomyelitis vaccine530Ketoconazole - Tab 200 mg167Preoperative carbohydrate feed 0.5 kcal/ml508Rifaximin10Ferric carboxymaltose35Midodrine81Tobramycin Solution for inhalation 60 mg per ml, 5 ml135Rivastigmine261Deferasirox483Deferiprone484Ceftaroline144Carbohydrate489Protein490Fat-modified feed495Paediatric Products505Tobramcyin136Measles, mumps and rubella vaccine529 |

| | Icatibant | | | | Coenzyme Q10 | |
|---------|---|------------|-----|------|---|-------------|
| | Extensively hydrolysed formula | | | | Riboflavin | |
| | Long-acting muscarinic antagonists with long-acting beta-adr | | | | Taurinesodium picosulfate | |
| | s Haemophilus influenzae type B vaccine | | | | Febuxostat | |
| | Siltuximab | | | | Cabergoline | |
| | Ledipasvir with sofosbuvir | | | | Tacrolimus Ointment | |
| | Idarucizumab | | | | Vigabatrin | |
| | Plerixafor | | RS1 | 867 | Amino acid formula | |
| | dursulfase | | | | Rosuvastatin | |
| | Aminolevulinic acid hydrochloride | | - | | Ranibizumab | |
| RS1566 | Ivabradine | 80 | | | Aflibercept | |
| | Roxithromycin tab dispersible 50 mg | | | | Nicotine | |
| | Melatonin Pneumococcal (PPV23) polysaccharide vaccine | | | | Abiraterone acetate | |
| | Rotavirus oral vaccine | | | | COVID-19 treatments Taliglucerase alfa | |
| | Varicella vaccine [Chickenpox vaccine] | | | | Non-Nucleoside Reverse Transcriptase Inhibitors | |
| | Etoricoxib | | | | Nucleoside Reverse Transcriptase Inhibitors | |
| | Azithromycin | | | | Protease Inhibitors | |
| RS1603 | Paromomycin | 137 | RS1 | 901 | Strand Transfer Inhibitors | 207 |
| RS1606 | Dexamethasone | | | | Emtricitabine with tenofovir disoproxil | |
| | Laronidase | | | | Remdesivir | |
| | Paediatric oral/enteral feed 1 kcal/ml | | | | Obinutuzumab | |
| | Multivitamins - Cap | | | | Benralizumab | |
| | Alpha tocopheryl | | | | Adalimumab (Humira - Alternative brand) | |
| | Mercaptopurine Hepatitis A vaccine | | | | Gemtuzumab ozogamicin Olaparib | |
| | Eplerenone | | | | Copper chloride | |
| | Eltrombopag | | | | Selenium | |
| | Omalizumab | | | | Tolvaptan | |
| | Epoetin alfa | | | | Cinacalcet | |
| RS1661 | Époetin beta | 45 | RS1 | 932 | Paliperidone palmitate | 245 |
| | Raloxifene | | | | Pneumococcal (PCV13) conjugate vaccine | |
| | Nonacog gamma | | | | Nusinersen | |
| | Rurioctocog alfa pegol [Recombinant factor VIII] | | | | Ustekinumab | |
| | Chlorhexidine with cetrimide | | | | Vedolizumab | |
| | Eftrenonacog alfa | | | | Adrenaline | |
| | Lysine acetylsalicylate Bevacizumab | | | | Risdiplam Bedaguiline | |
| | Dexrazoxane | | | | bosentan | |
| | Calcium carbonate | | | | sildenafil (Vedafil) | |
| | Nicardipine hydrochloride | | | | Epoprostenol | |
| | Varenicline | | | | lloprost | |
| RS1703 | Ranitidine | | | | Lacosamide | |
| | Eptacog alfa | | | | Stiripentol | |
| | Factor eight inhibitor bypassing fraction | | | | Sirolimus | |
| | Moroctocog alfa [Recombinant factor VIII] | | | | Alprostadil | |
| R51/0/ | Octocog alfa [Recombinant factor VIII] (Advate) Octocog alfa [Recombinant factor VIII] (Kogenate FS) | | | | Multiple Sclerosis Temozolomide | |
| R\$1700 | Clarithromycin | 146 | | | Pertuzumab | |
| | Alectinib | | | | Multiple Sclerosis | |
| | Budesonide | | | | Emicizumab | |
| | Ruxolitinib | | | | Brentuximab | |
| RS1732 | Fulvestrant | 310 | RS2 | 2005 | Trastuzumab (Herzuma) | 410 |
| RS1743 | Pegfilgrastim | | | | Nilotinib | |
| | Eptifibatide | | | 2013 | Influenza vaccine Inj 60 mcg in 0.5 ml syringe (quadrivaler | nt vaccine) |
| | Sucrose | | 527 | | | |
| | Ticagrelor | | | | Sacubitril with valsartan | |
| R01//5 | Enteral liquid peptide formula Pimecrolimus | 502 100 | | | Olanzapine Meningococcal (A, C, Y and W-135) conjugate vaccine | |
| | Rituximab | | | | Meningococcal B multicomponent vaccine | |
| | Dornase alfa | | | | Menningococcar b multicomponent vaccine | |
| | Pegaspargase | | RS2 | 2026 | Trientine | |
| | Diphtheria, tetanus and pertussis vaccine | | | | Niraparib | |
| | Alglucosidase Alfa | | RS2 | 2028 | Fluticasone furoate with umeclidinium and vilanterol | 472 |
| | Betaine | | | | Midostaurin | |
| | Galsulfase | | | | Palbociclib (Ibrance) | |
| | Sapropterin dihydrochloride | | | | Meningococcal (A, C, Y and W-135) conjugate vaccine | |
| | Sodium phenylbutyrate Valganciclovir | | | | Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 5 | |
| | Nintedanib | | | | Varicella zoster vaccine [shingles vaccine] | |
| | Pirfenidone | | | | COVID-19 vaccine | |
| | lvacaftor | | | | COVID-19 vaccine | |
| RS1826 | Somatropin | 123 | | | COVID-19 vaccine | |
| | Pegylated interferon alfa-2a | | | | Bortezomib | |
| | Lapatinib | | | | Lenalidomide | |
| R\$1831 | Carglumic Acid | 29 | RS2 | 2045 | Pomalidomide | 278 |

INDEX OF FORM NUMBERS

| RS2047 Metabolic Products 492 RS2098 Lervatinib 289 RS2049 Hepatitis B recombinant vaccine 526 RS2100 Long-acting Somatostatin Analogues 311 RS2050 Hepatitis B recombinant vaccine 525 RS2100 Long-acting Somatostatin Analogues 311 RS2050 Ipiptheria, tetanus, pertussis, polio, hepatitis B and haemophilus RS2104 Ceftazidime with avbactam 141 RS2052 Posaconazole 174 RS2106 Methylphenidate hydrochloride 259 RS2050 Diazepam 249 RS2106 Modalinii 292 RS2055 Dasatinib 300 RS2108 Crizotinib 292 RS2055 Dasatinib 300 RS2110 Exrotinib 292 RS2055 Pastatinib 300 RS2110 Exrotinib 292 RS2056 Dasatinib 300 RS2110 Exrotinib 302 RS2057 Methylnaltrexone bromide 16 RS2109 Sunitinib 302 RS2068 Aripiprazole 244 RS2111 Bevacizumab 414 RS2068 Bendamustine hydrochloride 267 RS2114 Eixacaftor with tezacaftor, iwacaftor and iwacaftor 475 RS2068 Adalimumab (Amgevita) 354 RS2116 Azacitidine <th>RS2046 Thalidomide</th> <th>RS2097 Denosumab</th> <th></th> | RS2046 Thalidomide | RS2097 Denosumab | |
|--|---|---|-----|
| RS2050 Hepatitis B recombinant vaccine .525 RS2100 Long-acting Somatostatin Analogues .311 RS2051 Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus RS2103 Ursodeoxycholic acid .15 Influenzae type B vaccine .513 RS2104 Ceftazidime with avibactam .141 RS2052 Posaconazole .174 RS2105 Methylphenidate hydrochloride .259 RS2055 Dasatinib .292 RS2106 Modafinil .292 RS2056 Dasatinib .300 RS2108 Crizotinib .292 RS2058 Aripiprazole .248 RS2110 Tacrolinus .314 RS2069 Paliperidone .244 RS2110 Tacrolinus .314 RS2061 Bendamustine hydrochloride .267 RS2114 Devazizumab coggamicin .414 RS2062 Etancept .316 RS2116 Intuzumab coggamicin .416 RS2064 Cetuximab .355 RS2116 Intuitib .275 RS2068 Propagliflozin, Empagliflozin with metformin hydrochloride .16 .275 RS2064 Cetuximab .355 RS2116 Intuitib .275 RS2068 Erancept .316 RS2121 Noutrinib .375 | | | |
| RS2051 Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus RS2103 Ursodeoxycholic acid 15 influenzae type B vaccine 513 RS2104 Ceftazidime with avibactam 141 RS2052 Voriconazole 174 RS2104 Ceftazidime with avibactam 141 RS2053 Voriconazole 172 RS2106 Modafinil 259 RS2054 Diazepam 249 RS2107 Avitinib 293 RS2055 Methylphenidate hydrochloride 293 RS2057 Methylnaltrexone bromide 16 RS2058 Aripiprazole 248 RS2100 Sutinib 302 RS2050 Risperidone 244 RS2111 Tacrolimus 314 RS2060 Risperidone 244 RS2112 Inotuzumab ozogamicin 414 RS2062 Risperidone 247 RS2114 Elexacator with tezacaftor, ivacaftor and ivacaftor 477 RS2062 Risperidone 247 RS2114 Elexacator with tezacaftor, ivacaftor and ivacaftor 477 RS2063 Adalimumab (Amgevita) 384 RS2116 Azacituline 269 RS2064 Cetuximab 355 RS2117 Ibrutinib 275 RS2070 Lisdexamfetamine dimesilate 268 RS21210 Vpadacitinib 368 RS2070 Everolimus 462 <t< td=""><td></td><td></td><td></td></t<> | | | |
| influenzae type B vaccine 513 RS2104 Ceftazidime with avibactam 141 RS2052 Posaconazole 174 RS2105 Methylphenidate hydrochloride 257 RS2054 Diazepam 249 RS2106 Modafinil 257 RS2055 Dasatinib 300 RS2108 Critinib 292 RS2055 Arbitylnaltrexone bromide 16 RS2109 Critinib 302 RS2056 Arbitylnaltrexone bromide 16 RS2109 Sunitinib 302 RS2056 Destinib 302 RS2107 Axitinib 302 RS2056 Arbitylnaltrexone bromide 16 RS2109 Sunitinib 302 RS2056 Diazepam 244 RS2110 Tacrolimus 314 RS2056 Arbitylnaltrexone bromide 247 RS2111 Brotuzumab cogamicin 416 RS2062 Etanercept 316 RS2114 Elexacaftor with tezacaftor, ivacaftor and ivacaftor 477 RS2062 Etanercept 316 RS2114 Elexacaftor with tezacaftor, ivacaftor and ivacaftor 477 RS2062 Etanercept 316 RS2119 Brotuinumab 455 RS2017 Lidetaxinfetamine dimesilate 268 RS2119 Brotuinab 455 RS2017 Lidetaxinfetamine dimesilate 268 RS2119 Brotuinab | | | |
| RS2052 Posaconazole 174 RS2105 Methylphenidate hydrochloride 259 RS2053 Voriconazole 172 RS2106 Modafinii 257 RS2054 Diazepam 249 RS2107 Axitinib 293 RS2055 Dasatinib 300 RS2108 Crizotinib 293 RS2055 Arbiprazole 248 RS2110 Tacrolimus 302 RS2058 Arbiprazole 248 RS2110 Tacrolimus 314 RS2050 Risperidone 244 RS2111 Bevacizumab 414 RS2062 Etanercept RS2114 Elexacaftor with tezacaftor, ivacaftor and ivacaftor 417 RS2063 Adalimumab (Amgevita) 384 RS2115 Ipilimumab 455 RS2064 Etanercept 316 RS2115 Ipilimumab 269 RS2064 Cetuximab 356 RS2116 Azacitidine 269 RS2064 Demogenita 348 RS2118 Venetoclax 271 RS2070 Lisdexamfetamine dimesitate 258 RS2121 Norunib 358 RS2071 Dexampletamine sulphate 260 RS2122 Indixinab 362 RS2078 Erolinib 301 RS2124 Inflixinab 329 | RS2051 Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus | | |
| RS2053 Voriconazole 172 RS2106 Modafinil 257 RS2054 Diazepam 249 RS2107 Axitinib 293 RS2055 Dasatinib 300 RS2108 Crizotinib 293 RS2057 Methylnaltrexone bromide 16 RS2109 Crizotinib 293 RS2058 Aripiprazole 248 RS2110 Tacrolimus 314 RS2060 Risperidone 244 RS2111 Bevacizumab 314 RS2061 Bendamustine hydrochloride 267 RS2114 Elexacaftor with tezacaftor, ivacaftor and ivacaftor 477 RS2062 Etanercept 316 RS2115 Ipilimumab 415 455 RS2064 Cetuximab 355 RS2116 Elexacaftor with tezacaftor, ivacaftor and ivacaftor 477 RS2064 Cetuximab 355 RS2116 Elexacaftor iultimib 275 RS2069 Empagliflozin; Empagliflozin with metformin hydrochloride 14 RS2110 Elexamfetamine dimesilate 258 RS2070 Lisdexamfetamine dimesilate 268 RS2119 Secukinumab 358 RS2071 Dexamphetamine dimesilate 268 RS21219 Secukinumab 358 RS2076 Everolimus 456 RS2121 Ambrisentan | influenzae type B vaccine513 | | |
| RS2054 Diazepam 249 RS2107 Axitinib 292 RS2055 Dasatinib 300 RS2108 Crizotinib 293 RS2057 Methylnaltrexone bromide 16 RS2109 Sunitinib 302 RS2058 Aripiprazole 248 RS2110 Tacrolimus 314 RS2059 Paliperidone 244 RS2111 Bevacizumab 414 RS2060 Risperidone 247 RS2112 Inctruzumab ozogamicin 416 RS2062 Etanercept 316 RS2116 Tacrolimus 415 RS2063 Adalimumab (Amgevita) 384 RS2116 Azacitidine 269 RS2064 Cetuximab 358 RS2119 Ventorial 271 RS2070 Lisdexamfetamine dimesilate 258 RS2119 Venetoclax 271 RS2076 Everolimus 462 RS2120 Upadacitinib 462 RS2076 Everolimus 456 RS2121 Morismab 329 RS2076 Everolimus 456 RS21210 Cupadacitinib 462 RS2076 Everolimus 456 RS2121 Morismab 329 RS2079 Gefitinib 306 RS2124 Infliximab 329 RS208 | RS2052 Posaconazole174 | RS2105 Methylphenidate hydrochloride | 259 |
| RS2055 Dasatinib 300 RS2108 Crizotinib 293 RS2057 Methylnaltrexone bromide 16 RS2109 Sunitinib 302 RS2058 Aripiprazole 248 RS2110 Tacrolimus 314 RS2050 Risperidone 244 RS2111 Bevacizumab 414 RS2060 Risperidone 247 RS2111 Bevacizumab 414 RS2061 Bendamustine hydrochloride 267 RS2112 Inotuzumab ozogamicin 416 RS2062 Etanercept 316 RS2116 Azacitor with tezacaftor, ivacaftor and ivacaftor 477 RS2063 Adalimumab (Arngevita) 384 RS2116 Azacitidine 269 RS2064 Cetuximab 355 RS2117 Ibrutinib 275 RS2069 Empagliflozin, Empagliflozin with metformin hydrochloride 14 RS2119 Secukinumab 358 RS2070 Lisdexamfetamine dimesilate 268 RS2120 Upadacitinib 368 RS2076 Everolimus 456 RS2121 Ambrisentan 393 RS2076 Everolimus 456 RS2121 Ambrisentan 393 RS2070 Gefitinib 301 RS2126 Nivolumab 343 RS2080 Osimertnib | | | |
| RS2057 Methylnaltrexone bromide 16 RS2109 Sunitinib 302 RS2058 Aripiprazole 248 RS2110 Tacrolimus 314 RS2059 Paliperidone 244 RS2111 Bevacizumab 414 RS2061 Bendamustine hydrochloride 267 RS2112 Inotuzumab ozogamicin 416 RS2062 Etanercept 316 RS2115 Ipilimumab 455 RS2063 Adalimumab (Amgevita) 384 RS2116 Azacitidine 269 RS2064 Cetuximab 355 RS2117 Ibrutinib 275 RS2065 Empagliflozin; Empagliflozin with metformin hydrochloride 14 RS2118 Venetoclax 271 RS2070 Lisdexamfetamine dimesilate 258 RS2119 Secukinumab 355 RS2071 Dexamphetamine sulphate 260 RS2124 Infliximab 329 RS2073 Erlotinib 301 RS2124 Infliximab 329 RS2074 Everolimus 456 RS2125 Tocilizumab 343 RS2075 Erlotinib 301 RS2124 Infliximab 329 RS2076 Everolimus 456 RS21210 Upadacitinib 462 RS2079 Gefitinib 301 RS2124 Infliximab 329 RS2079 Gefitinib 391 <td>RS2054 Diazepam249</td> <td></td> <td></td> | RS2054 Diazepam249 | | |
| RS2058 Aripiprazole 248 RS2110 Tacrolimus 314 RS2059 Paliperidone 244 RS2111 Bevacizumab 414 RS2060 Risperidone 247 RS2112 Intouzumab ozogamicin 416 RS2061 Bendamustine hydrochloride 267 RS2114 Elexacaftor with tezacaftor, ivacaftor and ivacaftor 477 RS2062 Etanercept 316 RS2115 Ipilimumab 455 RS2063 Adalimumab (Amgevita) 384 RS2116 Azacitidine 269 RS2064 Cetuximab 355 RS2117 Ibrutnib 275 RS2069 Empagliflozin; Empagliflozin with metformin hydrochloride 14 RS2119 Secutinumab 358 RS2071 Lesdexamfetamine dimesilate 258 RS2119 Secutinumab 358 RS2076 Everolimus 456 RS2120 Upadacitinib 462 RS2078 Erlotinib 301 RS2124 Infliximab 329 RS2078 Erlotinib 301 RS2126 Nivolumab 343 RS2080 Osimertin | | | |
| RS2059 Paiperidone 244 RS2111 Bevacizumab 414 RS2060 Risperidone 247 RS2112 Inotuzumab ozogamicin 416 RS2061 Bendamustine hydrochloride 267 RS2114 Elexacaftor with tezacaftor, ivacaftor and ivacaftor 477 RS2062 Etanercept 316 RS2115 Ipilimumab 455 RS2063 Adalimumab (Amgevita) 384 RS2116 Azacitidine 269 RS2064 Cetuximab 355 RS2117 Ibrutinib 275 RS2069 Empagliflozin; Empagliflozin with metformin hydrochloride 14 RS2120 Upadacitinib 271 RS2070 Lisdexamfetamine dimesilate 258 RS2120 Upadacitinib 352 RS2076 Everolimus 456 RS2120 Upadacitinib 362 RS2078 Erlotinib 301 RS2124 Infliximab 329 RS2079 Gefitinib 306 RS2125 Tocilizumab 343 RS2080 Osimertinib 399 RS2126 Nivolumab 434 RS2081 Palivizumab 399 RS2124 Infliximab 329 RS2081 Palivizumab 399 RS2125 Tocilizumab 343 RS2081 Palivizumab 399 RS2126 Nivolumab 343 RS2081 Palivizuma | RS2057 Methylnaltrexone bromide16 | | |
| RS2060 Risperidone 247 RS2112 Inotuzumab ozogamicin 416 RS2061 Bendamustine hydrochloride 267 RS2114 Elexacaftor with tezacaftor, ivacaftor and ivacaftor 477 RS2062 Etanercept 316 RS2115 Iplimumab 455 RS2063 Adalmumab (Amgevita) 384 RS2116 Azacitidine 269 RS2064 Cetuximab 355 RS2117 Ibrutinib 275 RS2070 Lisdexamfetamine dimesilate 258 RS2119 Secukinumab 358 RS2071 Dexamphetamine sulphate 260 RS2120 Upadacitinib 358 RS2078 Erlotinib 301 RS2121 Morisentan 93 RS2079 Gefitinib 300 RS2125 Tocilizumab 343 RS2081 Palivizumab 399 RS2128 Dulglutide 12 RS2082 Trastuzumab deruxtecan 413 RS2128 Dulglutide 12 RS2084 Durvalumab 452 RS2130 Dabrafenib 294 RS2084 Pacopanib 305 | RS2058 Aripiprazole | | |
| RS2061 Bendamustine hydrochloride 267 RS2114 Elexacaftor with tezacaftor, ivacaftor and ivacaftor 477 RS2062 Etanercept 316 RS2115 Ipilimumab 455 RS2063 Adalimumab (Amgevita) 384 RS2116 Azacitidine 269 RS2064 Cetuximab 355 RS2117 Ibrutinib 275 RS2070 Lisdexamfetamine dimesilate 258 RS2119 Secukinumab 271 RS2070 Lisdexamfetamine sulphate 260 RS2120 Upadacitinib 355 RS2076 Everolimus 456 RS2120 Upadacitinib 462 RS2078 Erlotinib 301 RS2122 Upadacitinib 329 RS2080 Osimertinib 306 RS2126 Nivolumab 343 RS2081 Palivizumab 399 RS2128 Dulaglutide 12 RS2083 Trastuzumab deruxtecan 413 RS2129 Moxifloxacin 152 RS2084 Durvalumab 452 RS2130 Dabrafenib 294 RS2085 Budesonide with glycopyrronium and eformoterol 473 RS213 Rituximab 297 RS2089 Pazopanib 305 RS213 Rituximab 305 | RS2059 Paliperidone | | |
| RS2062 Etanercept 316 RS2115 Ipilimumab 455 RS2063 Adalimumab (Amgevita) 384 RS2116 Azacitidine 269 RS2064 Cetuximab 355 RS2117 Ibrutinib 275 RS2069 Empagliflozin; Empagliflozin with metformin hydrochloride 14 RS2118 Venetoclax 271 RS2070 Lisdexamfetamine dimesilate 258 RS2119 Secukinumab 358 RS2071 Dexamphetamine sulphate 260 RS2120 Upadacitinib 358 RS2078 Erlotinib 301 RS2124 Infliximab 462 RS2079 Gefitinib 301 RS2125 Tocilizumab 329 RS2080 Osimertinib 306 RS2126 Nivolumab 343 RS2081 Palivizumab 399 RS2128 Dulaglutide 12 RS2083 Trastuzumab deruxtecan 413 RS2130 Dabrafenib 152 RS2084 Durvalumab 452 RS2131 Ribociclib 294 RS2085 Budesonide with glycopyrronium and eformoterol 473 RS2132 Trastuzimab 294 RS2089 Pazopanib 305 RS2133 Rituximab 365 | | | |
| RS2063 Adalimumab (Amgevita) 384 RS2116 Azacitidine 269 RS2064 Cetuximab 355 RS2117 Ibrutinib 275 RS2069 Empagliflozin; Empagliflozin with metformin hydrochloride 14 RS2118 Venetoclax 271 RS2070 Lisdexamfetamine dimesilate 258 RS2119 Secukinumab 358 RS2071 Dexamphetamine sulphate 260 RS2120 Upadacitinib 462 RS2076 Everolimus 456 RS2121 Ambrisentan 93 RS2078 Erlotinib 301 RS2124 Infliximab 329 RS2080 Osimertinib 291 RS2126 Nivolumab 434 RS2081 Palivizumab 399 RS2128 Dulaglutide 12 RS2083 Trastuzumab deruxtecan 413 RS2130 Dabrafenib 294 RS2084 Durvalumab 452 RS2131 Ribociclib 294 RS2084 Durvalumab 452 RS2131 Ribociclib 298 RS2084 Parainab 452 RS2131 Ribociclib 294 RS2085 Budesonide with glycopyrronium and eformoterol 473 RS2132 Trametinib 297 RS2084 Parapaib 305 RS2133 Rituximab 365 <td>RS2061 Bendamustine hydrochloride267</td> <td>RS2114 Elexacaftor with tezacaftor, ivacaftor and ivacaftor</td> <td>477</td> | RS2061 Bendamustine hydrochloride267 | RS2114 Elexacaftor with tezacaftor, ivacaftor and ivacaftor | 477 |
| RS2064 Cetuximab355RS2117 Ibrutinib275RS2069 Empagliflozin; Empagliflozin with metformin hydrochloride14RS2118 Venetoclax271RS2070 Lisdexamfetamine dimesilate258RS2119 Secukinumab358RS2071 Dexamphetamine sulphate260RS2120 Upadacitinib462RS2076 Everolimus456RS2121 Ambrisentan93RS2078 Erlotinib301RS2124 Infliximab329RS2080 Osimertinib306RS2125 Tocilizumab343RS2081 Palivizumab291RS2128 Nivolumab434RS2082 Trastuzumab deruxtecan413RS2129 Moxifloxacin12RS2083 Trastuzumab emtansine362RS2130 Dabrafenib294RS2084 Durvalumab452RS2131 Ribociclib288RS2085 Budesonide with glycopyrronium and eformoterol473RS2132 Trametinib297RS2089 Pazopanib305RS2133 Rituximab365 | | | |
| RS2069 Empagliflozin; Empagliflozin with metformin hydrochloride14RS2118 Venetoclax271RS2070 Lisdexamfetamine dimesilate258RS2119 Secukinumab358RS2071 Dexamphetamine sulphate260RS2120 Upadacitinib462RS2076 Everolimus456RS2121 Ambrisentan93RS2078 Erlotinib301RS2124 Infliximab329RS2080 Osimertinib291RS2125 Tocilizumab343RS2081 Palivizumab399RS2128 Dulaglutide12RS2083 Trastuzumab deruxtecan413RS2130 Dabrafenib294RS2084 Durvalumab452RS2131 Ribociclib298RS2085 Budesonide with glycopyrronium and eformoterol473RS2132 Rituximab297RS2089 Pazopanib305RS2133 Rituximab365 | | | |
| RS2070 Lisdexamfetamine dimesilate258RS2119 Secukinumab358RS2071 Dexamphetamine sulphate260RS2120 Upadacitinib462RS2076 Everolimus456RS2121 Ambrisentan93RS2078 Erlotinib301RS2124 Infliximab329RS2079 Gefitinib306RS2125 Tocilizumab343RS2080 Osimertinib291RS2126 Nivolumab434RS2081 Palivizumab399RS2128 Dulaglutide12RS2083 Trastuzumab deruxtecan413RS2129 Moxifloxacin152RS2084 Durvalumab362RS2130 Dabrafenib294RS2084 Durvalumab452RS2131 Ribociclib288RS2085 Budesonide with glycopyrronium and eformoterol473RS2132 Traetinib297RS2089 Pazopanib305RS2133 Rituximab365 | | | |
| RS2071 Dexamphetamine sulphate 260 RS2120 Upadacitinib 462 RS2076 Everolimus 456 RS2121 Ambrisentan 93 RS2078 Erlotinib 301 RS2124 Infliximab 329 RS2079 Gefitinib 306 RS2125 Tocilizumab 343 RS2080 Osimertinib 291 RS2126 Nivolumab 434 RS2081 Palivizumab 399 RS2128 Dulaglutide 12 RS2083 Trastuzumab deruxtecan 413 RS2129 Moxifloxacin 152 RS2084 Durvalumab 362 RS2130 Dabrafenib 294 RS2085 Budesonide with glycopyrronium and eformoterol 473 RS2132 Trametinib 287 RS2085 Pazopanib 305 RS2133 Rituximab 365 | RS2069 Empagliflozin; Empagliflozin with metformin hydrochloride14 | | |
| RS2076 Everolimus456RS2121 Ambrisentan93RS2078 Erlotinib301RS2124 Infliximab329RS2079 Gefitinib306RS2125 Tocilizumab343RS2080 Osimertinib291RS2126 Nivolumab434RS2081 Palivizumab399RS2128 Dulaglutide12RS2083 Trastuzumab deruxtecan413RS2129 Moxifloxacin152RS2084 Durvalumab362RS2130 Dabrafenib294RS2084 Durvalumab452RS2131 Ribociclib288RS2085 Budesonide with glycopyrronium and eformoterol473RS2132 Traettinib297RS2089 Pazopanib305RS2133 Rituximab365 | | | |
| RS2078 Erlotinib301RS2124 Infliximab329RS2079 Gefitinib306RS2125 Tocilizumab343RS2080 Osimertinib291RS2126 Nivolumab434RS2081 Palivizumab399RS2128 Dulaglutide12RS2082 Trastuzumab deruxtecan413RS2129 Moxifloxacin152RS2083 Trastuzumab emtansine362RS2130 Dabrafenib294RS2084 Durvalumab452RS2131 Ribociclib288RS2085 Budesonide with glycopyrronium and eformoterol473RS2132 Trametinib297RS2089 Pazopanib305RS2133 Rituximab365 | RS2071 Dexamphetamine sulphate | RS2120 Upadacitinib | 462 |
| RS2079 Gefitinib306RS2125 Tocilizumab343RS2080 Osimertinib291RS2126 Nivolumab434RS2081 Palivizumab399RS2128 Dulaglutide12RS2082 Trastuzumab deruxtecan413RS2129 Moxifloxacin152RS2083 Trastuzumab emtansine362RS2130 Dabrafenib294RS2084 Durvalumab452RS2131 Ribociclib288RS2085 Budesonide with glycopyrronium and eformoterol473RS2132 Trametinib297RS2089 Pazopanib305RS2133 Rituximab365 | RS2076 Everolimus | | |
| RS2080 Osimertinib291RS2126 Nivolumab434RS2081 Palivizumab399RS2128 Dulaglutide12RS2082 Trastuzumab deruxtecan413RS2129 Moxifloxacin152RS2083 Trastuzumab emtansine362RS2130 Dabrafenib294RS2084 Durvalumab452RS2131 Ribociclib288RS2085 Budesonide with glycopyrronium and eformoterol473RS2132 Trametinib297RS2089 Pazopanib305RS2133 Rituximab365 | RS2078 Erlotinib | RS2124 Infliximab | 329 |
| RS2081 Palivizumab399RS2128 Dulaglutide12RS2082 Trastuzumab deruxtecan413RS2129 Moxifloxacin152RS2083 Trastuzumab emtansine362RS2130 Dabrafenib294RS2084 Durvalumab452RS2131 Ribociclib288RS2085 Budesonide with glycopyrronium and eformoterol473RS2132 Trametinib297RS2089 Pazopanib305RS2133 Rituximab365 | RS2079 Gefitinib | RS2125 Tocilizumab | 343 |
| RS2082 Trastuzumab deruxtecan413RS2129 Moxifloxacin152RS2083 Trastuzumab emtansine362RS2130 Dabrafenib294RS2084 Durvalumab452RS2131 Ribociclib288RS2085 Budesonide with glycopyrronium and eformoterol473RS2132 Trametinib297RS2089 Pazopanib305RS2133 Rituximab365 | RS2080 Osimertinib | RS2126 Nivolumab | 434 |
| RS2083 Trastuzumab emtansine362RS2130 Dabrafenib294RS2084 Durvalumab452RS2131 Ribociclib288RS2085 Budesonide with glycopyrronium and eformoterol473RS2132 Trametinib297RS2089 Pazopanib305RS2133 Rituximab365 | RS2081 Palivizumab | RS2128 Dulaglutide | 12 |
| RS2084 Durvalumab452RS2131 Ribociclib288RS2085 Budesonide with glycopyrronium and eformoterol473RS2132 Trametinib297RS2089 Pazopanib305RS2133 Rituximab365 | RS2082 Trastuzumab deruxtecan | | |
| RS2085 Budesonide with glycopyrronium and eformoterol473RS2132 Trametinib297RS2089 Pazopanib305RS2133 Rituximab365 | RS2083 Trastuzumab emtansine | | |
| RS2089 Pazopanib | | | |
| RS2089 Pazopanib | RS2085 Budesonide with glycopyrronium and eformoterol | RS2132 Trametinib | 297 |
| RS2096 Liraglutide 13 RS2134 Pembrolizumab 439 | RS2089 Pazopanib | | |
| | RS2096 Liraglutide | RS2134 Pembrolizumab | 439 |

Index of titles

| Abciximab (RS1202) | 433 | Clindamycin (RS1061) | 164 |
|--|---|--|--|
| Abiraterone acetate (RS1888) | 308 | Clofazimine (RS1077) | |
| Adalimumab (Amgevita) (RS2063) | 384 | Coenzyme Q10 (RS1832) | |
| Adalimumab (Humira - Alternative brand) (RS1922) | | Colistin sulphomethate [Colestimethate] (RS1062) | |
| Adenosine - Inj 3 mg per ml, 10 ml vial (RS1266) | | Copper chloride (RS1928) | 34 |
| Adrenaline (RS1944) | | Crizotinib (RS2108) | 293 |
| Aflibercept (RS1872) | | Cycloserine (RS1079) | |
| Ajmaline (RS1001) | 79 | Dabrafenib (RS2130) | |
| Albendazole (RS1088) | | Danaparoid (RS1182) | |
| Alectinib (RS1712) | 285 | Dapsone (RS1078) | |
| Alglucosidase Alfa (RS1793) | 24 | Daptomycin (RS1063) | 155 |
| Alpha tocopheryl (RS1632) | 43 | Dasatinib (RS2055) | |
| Alpha tocopheryl acetate (RS1176) | | Deferasirox (RS1444) | |
| Alprostadil (RS1992) | | Deferiprone (RS1445) | |
| Aluminium chloride (RS1500) | | Defibrotide (RS1183) | |
| Ambrisentan (RS2121) | | Denosumab (RS2097) | |
| Amikacin (RS1041) | | Dexamethasone (RS1606) | 480 |
| Amino acid formula (RS1867) | | Dexamphetamine sulphate (RS2071) | |
| Aminolevulinic acid hydrochloride (RS1565) | | Dexrazoxane (RS1695) | |
| Amphotericin B - Inj (liposomal) 50 mg vial (RS1071) | | Diabetic Products (RS1215) | 493 |
| Amphotericin B - Inj 50 mg vial (RS1316) | | Diazepam (RS2054) | |
| Aprepitant (RS1154) | | Diazoxide (RS1028) | |
| Aprotinin (RS1332) | | Diphtheria, tetanus and pertussis vaccine (RS1790) | |
| Aripiprazole (RS2058) | 248 | Diphtheria, tetanus, pertussis and polio vaccine (RS1387) | |
| Artemether with lumefantrine (RS1090) | 192 | Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus in | |
| Artesunate (RS1091) | | type B vaccine (RS2051) | |
| Atezolizumab (RS2099) | | Dornase alfa (RS1787) | |
| Atovaquone with proguanil hydrochloride (RS1092) | | Dulaglutide (RS2128) | |
| Axitinib (RS2107) | | Durvalumab (RS2084) | 452 |
| Azacitidine (RS2116) | | Edrophonium chloride (RS1015) | 224 |
| Azithromycin (RS1598) | | Eftrenonacog alfa (RS1684) | 60 |
| Aztreonam, Chloramphenicol (RS1277) | | Elemental and Semi-Elemental Products (RS1216) | |
| Bacillus calmette-guerin (BCG) (RS1206) | 460 | Elexacaftor with tezacaftor, ivacaftor and ivacaftor (RS2114) | |
| Bacillus calmette-guerin vaccine (RS1233) | | Eltrombopag (RS1648) | |
| Basiliximab (RS1203) | | Emicizumab (RS1998) | |
| Bedaquiline (RS1977) | | Empagliflozin; Empagliflozin with metformin hydrochloride (RS2069) | |
| Bee venom (RS1117) | | Emtricitabine with tenofovir disoproxil (RS1902) | |
| Bendamustine hydrochloride (RS2061) | | Enteral liquid peptide formula (RS1775) | |
| Benralizumab (RS1920) | | Eplerenone (RS1640) Epoetin alfa (RS1660) | |
| Betaine (RS1794) Betamethasone valerate with clioquinol (RS1125) | 100 | Epoetin beta (RS1661) | |
| Bevacizumab (RS1691) | | Epoprostenol (RS1984) | |
| Bevacizumab (RS2111) | | Eptacog alfa (RS1704) | |
| Biotin (RS1330) | | Eptifibatide (RS1759) | |
| Bivalirudin (RS1181) | | Erlotinib (RS2078) | |
| Bortezomib (RS2043) | | Ertapenem (RS1045) | |
| Brentuximab (RS2002) | | Etanercept (RS2062) | |
| Budesonide (RS1723) | | Ethambutol hydrochloride (RS1080) | |
| Budesonide with glycopyrronium and eformoterol (RS2085) | | Etoricoxib (RS1592) | |
| Buprenorphine with naloxone (RS1172) | | Everolimus (RS2076) | |
| COVID-19 treatments (RS1894) | | Extensively hydrolysed formula (RS1502) | |
| COVID-19 vaccine (RS2042) | | Factor eight inhibitor bypassing fraction (RS1705) | |
| COVID-19 vaccine (RS2041) | | Fat (RS1468) | |
| COVID-19 vaccine (RS2040) | | Fat-modified feed (RS1470) | |
| Cabergoline (RS1855) | | Febuxostat (RS1844) | |
| Calcium carbonate (RS1698) | | Ferric carboxymaltose (RS1417) | |
| Capsaicin (RS1309) | | Filgrastim (RS1188) | |
| Capsaicin (RS1145) | | Finasteride (RS1131) | |
| Captopril - Oral liq 5 mg per ml (RS1263) | | Fluconazole (RS1072) | |
| Carbohydrate (RS1467) | | | 176 |
| Carbohydrate and fat supplement (RS1212) | | Flucytosine (RS1279) | |
| | 488 | Flucytosine (RS1279) Fluticasone furoate with umeclidinium and vilanterol (RS2028) | 472 |
| Carglumic Acid (RS1831) | 488 491 | | |
| Caspofungin (RS1076) | 488 491 29 177 | Fluticasone furoate with umeclidinium and vilanterol (RS2028) | 66 |
| | 488 491 29 177 | Fluticasone furoate with umeclidinium and vilanterol (RS2028) Fondaparinux sodium (RS1184) | 66 210 |
| Caspofungin (RS1076) | 488 491 29 177 143 | Fluticasone furoate with umeclidinium and vilanterol (RS2028) Fondaparinux sodium (RS1184) Foscarnet sodium (RS1109) | 66 210 160 |
| Caspofungin (RS1076) Cefepime (RS1049) Ceftaroline (RS1446) Ceftazadime (RS1048) | 488 491 29 177 143 144 142 | Fluticasone furoate with umeclidinium and vilanterol (RS2028) Fondaparinux sodium (RS1184) Foscarnet sodium (RS1109) Fosfomycin (RS1315) | 66 210 160 310 |
| Caspofungin (RS1076) Cefepime (RS1049) Ceftaroline (RS1446) Ceftazadime (RS1048) Ceftazidime with avibactam (RS2104) | 488 491 29 177 143 144 142 141 | Fluticasone furoate with umeclidinium and vilanterol (RS2028) Fondaparinux sodium (RS1184) Foscarnet sodium (RS1109) Fosfomycin (RS1315) Fulvestrant (RS1732) | 66 |
| Caspofungin (RS1076) Cefepime (RS1049) Ceftaroline (RS1446) Ceftazadime (RS1048) Ceftazidime with avibactam (RS2104) Cetuximab (RS2064) | 488 491 29 177 143 144 142 141 355 | Fluticasone furoate with umeclidinium and vilanterol (RS2028) Fondaparinux sodium (RS1184) Foscarnet sodium (RS1109) Fosfomycin (RS1315) Fulvestrant (RS1732) Fusidic acid (RS1064) Galsulfase (RS1795) Ganciclovir (RS1110) | 66 160 310 165 23 211 |
| Caspofungin (RS1076) Cefepime (RS1049) Ceftaroline (RS1446) Ceftazadime (RS1048) Ceftazidime with avibactam (RS2104) Cetuximab (RS2064) Chlorhexidine with cetrimide (RS1683) | 488 491 29 177 143 144 142 141 355 486 | Fluticasone furoate with umeclidinium and vilanterol (RS2028) Fondaparinux sodium (RS1184) Foscarnet sodium (RS1109) Fosfomycin (RS1315) Fulvestrant (RS1732) Fusidic acid (RS1064) Galsulfase (RS1795) Ganciclovir (RS1110) Gefitinib (RS2079) | 66 210 160 165 23 211 23 |
| Caspofungin (RS1076) Cefepime (RS1049) Ceftaroline (RS1446) Ceftazadime (RS1048) Ceftazidime with avibactam (RS2104) Cetuximab (RS2064) Chlorhexidine with cetrimide (RS1683) Chloroquine phosphate (RS1093) | 488 491 29 177 143 144 142 141 355 486 195 | Fluticasone furoate with umeclidinium and vilanterol (RS2028) Fondaparinux sodium (RS1184) Foscarnet sodium (RS1109) Fosfomycin (RS1315) Fulvestrant (RS1732) Fusidic acid (RS1064) Galsulfase (RS1795) Ganciclovir (RS1110) Gefitinib (RS2079) Gemtuzumab ozogamicin (RS1923) | 66 210 160 165 23 211 306 401 |
| Caspofungin (RS1076) Cefepime (RS1049) Ceftaroline (RS1446) Ceftazadime (RS1048) Ceftazidime with avibactam (RS2104) Cetuximab (RS2064) Chlorhexidine with cetrimide (RS1683) Chloroquine phosphate (RS1093) Cidofovir (RS1108) | 488 491 29 177 143 144 142 141 355 486 195 209 | Fluticasone furoate with umeclidinium and vilanterol (RS2028) Fondaparinux sodium (RS1184) Foscarnet sodium (RS1109) Fosfomycin (RS1315) Fulvestrant (RS1732) Fusidic acid (RS1064) Galsulfase (RS1795) Ganciclovir (RS1110) Gefitinib (RS2079) Gemtuzumab ozogamicin (RS1923) Haemophilus influenzae type B vaccine (RS1520) | |
| Caspofungin (RS1076) Cefepime (RS1049) Ceftaroline (RS1049) Ceftazadime (RS1048) Ceftazidime with avibactam (RS2104) Cetuximab (RS2064) Chlorhexidine with cetrimide (RS1683) Chloroquine phosphate (RS1093) Cidofovir (RS1108) Cinacalcet (RS1931) | 488 491 29 177 143 144 144 141 355 486 195 209 119 | Fluticasone furoate with umeclidinium and vilanterol (RS2028) Fondaparinux sodium (RS1184) Foscarnet sodium (RS1109) Fosfomycin (RS1315) Fulvestrant (RS1732) Fusidic acid (RS1064) Galsulfase (RS1795) Ganciclovir (RS1110) Gefitinib (RS2079) Gemtuzumab ozogamicin (RS1923) Haemophilus influenzae type B vaccine (RS1520) Hepatic Products (RS1217) | |
| Caspofungin (RS1076) Cefepime (RS1049) Ceftaroline (RS1446) Ceftazadime (RS1048) Ceftazidime with avibactam (RS2104) Cetuximab (RS2064) Chlorhexidine with cetrimide (RS1683) Chloroquine phosphate (RS1093) Cidofovir (RS1108) | 488 491 29 177 143 144 144 142 486 209 195 209 119 151 | Fluticasone furoate with umeclidinium and vilanterol (RS2028) Fondaparinux sodium (RS1184) Foscarnet sodium (RS1109) Fosfomycin (RS1315) Fulvestrant (RS1732) Fusidic acid (RS1064) Galsulfase (RS1795) Ganciclovir (RS1110) Gefitinib (RS2079) Gemtuzumab ozogamicin (RS1923) Haemophilus influenzae type B vaccine (RS1520) | |

| Hepatitis B recombinant vaccine (RS2049) | 526 | Nilotinib (RS2010) | 283 |
|--|--|---|---|
| High Calorie Products (RS1317) | | Nintedanib (RS1813) | |
| High arginine oral feed 1.4 kcal/ml (RS1231) | | Niraparib (RS2027) | |
| High fat formula (RS1225) | | Nitazoxanide (RS1095) | |
| High protein enteral feed (RS1327) | | Nivolumab (RS2126) | |
| Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vacci | | Non-Nucleoside Reverse Transcriptase Inhibitors (RS1898) | |
| (RS2038) | 532 | Nonacog gamma (RS1679) | |
| Hydralazine hydrochloride - Tab 25 mg (RS1008) | | Nucleoside Reverse Transcriptase Inhibitors (RS1899) | 205 |
| Hyoscine hydrobromide - Patch 1.5 mg (RS1155) | | Nusinersen (RS1938) | |
| Ibrutinib (RS2117) | | Obinutuzumab (RS1919) | |
| Icatibant (RS1501) | | Octocog alfa [Recombinant factor VIII] (Advate) (RS1707) | |
| Idarucizumab (RS1535) | | Octocog alfa [Recombinant factor VIII] (Kogenate FS) (RS1708) | |
| Idursulfase (RS1546) | | Olanzapine (RS2018) | |
| lloprost (RS1985) | | Olaparib (RS1925) | |
| Imipenem with cilastatin (RS1046) | | Omalizumab (RS1652) | 250 |
| Infliximab (RS2124) | | Omeprazole - Tab dispersible 10 mg and 20 mg (RS1027) | 300 |
| | | | |
| Influenza vaccine Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) (| (132013) | Oseltamivir (RS1307) | |
| 527 | 440 | Osimertinib (RS2080) Oxandrolone - Tab 2.5 mg (RS1302) | |
| Inotuzumab ozogamicin (RS2112) | | | |
| Interferon gamma (RS1113) | | Paediatric Products (RS1473) | |
| Ipilimumab (RS2115) | | Paediatric oral/enteral feed 1 kcal/ml (RS1614) | |
| Isoniazid (RS1281) | | Palbociclib (Ibrance) (RS2034) | |
| Isoniazid with rifampicin (RS1282) | | Paliperidone (RS2059) | 244 |
| Itraconazole (RS1073) | | Paliperidone palmitate (RS1932) | |
| Ivabradine (RS1566) | | Palivizumab (RS2081) | |
| Ivacaftor (RS1818) | | Paper wasp venom (RS1118) | |
| Ivermectin (RS1283) | | Para-aminosalicylic Acid (RS1083) | |
| Ketoconazole - Tab 200 mg (RS1410) | | Paracetamol (RS1146) | |
| L-ornithine L-aspartate (RS1261) | | Paromomycin (RS1603) | |
| Lacosamide (RS1988) | | Pazopanib (RS2089) | |
| Lapatinib (RS1828) | | Pegaspargase (RS1788) | |
| Laronidase (RS1607) | | Pegfilgrastim (RS1743) | 72 |
| Ledipasvir with sofosbuvir (RS1528) | 208 | Pegylated interferon alfa-2a (RS1827) | 220 |
| Lenalidomide (RS2044) | | Pembrolizumab (RS2134) | 439 |
| Lenvatinib (RS2098) | | Pentamidine isethionate (RS1096) | |
| Levocarnitine (RS1035) | 19 | Pertuzumab (RS1995) | 354 |
| Levosimendan (RS1007) | | Pimecrolimus (RS1781) | |
| Lincomycin (RS1065) | | Piperacillin with tazobactam (RS1053) | 150 |
| Linezolid (RS1066) | | Pirfenidone (RS1814) | |
| Liothyronine sodium - Tab 20 mcg (RS1301) | | Pivmecillinam (RS1322) | 161 |
| Liraglutide (RS2096) | 13 | Plerixafor (RS1536) | |
| Lisdexamfetamine dimesilate (RS2070) | | Pneumococcal (PCV13) conjugate vaccine (RS1936) | |
| Long-acting Somatostatin Analogues (RS2100) | 211 | Pneumococcal (PPV23) polysaccharide vaccine (RS1587) | |
| | | | |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep | tor agonists | | |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) | tor agonists | Pomalidomide (RS2045) | 278 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) | tor agonists 471 506 | Pomalidomide (RS2045) Posaconazole (RS2052) | 278 174 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) | tor agonists 471 506 507 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) | 278 174 116 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) | tor agonists 471 506 507 | Pomalidomide (RS2045) Posaconazole (RS2052) | 278 174 116 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) | tor agonists | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) | 278 174 116 485 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) | tor agonists | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) | 278 174 116 485 508 500 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) | tor agonists | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) | 278 174 116 485 508 500 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) | tor agonists 471 506 67 67 107 529 196 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) | 278 174 485 508 500 198 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) Mefloquine hydrochloride (RS1094) | tor agonists 471 506 507 67 107 529 196 254 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) Primaquine phosphate (RS1097) | 278 174 116 485 508 500 198 130 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) Mefloquine hydrochloride (RS1094) Melatonin (RS1576) | tor agonists 471 506 507 67 67 67 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) Primaquine phosphate (RS1097) Propylthiouracil (RS1276) | 278 174 116 485 508 500 198 130 130 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) Mefloquine hydrochloride (RS1094) Melatonin (RS1576) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2037) Meningococcal B multicomponent vaccine (RS2020) | tor agonists 471 506 507 67 107 529 196 254 517 518 523 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) Primaquine phosphate (RS1097) Propylthiouracil (RS1276) Protease Inhibitors (RS1900) | 278 174 116 485 508 500 198 130 206 490 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) Mefloquine hydrochloride (RS1094) Melatonin (RS1576) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2037) Meningococcal B multicomponent vaccine (RS2020) Mepolizumab (RS2024) | tor agonists 471 506 507 67 67 107 529 254 517 518 523 381 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) Primaquine phosphate (RS1097) Propylthiouracil (RS1276) Protease Inhibitors (RS1900) Protein (RS1469) Protionamide (RS1084) Pyrazinamide (RS1085) | 278 174 116 485 508 500 198 130 206 490 189 182 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) Mefloquine hydrochloride (RS1094) Melatonin (RS1576) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2037) Meningococcal B multicomponent vaccine (RS2020) | tor agonists 471 506 507 67 67 107 529 254 517 518 523 381 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) Primaquine phosphate (RS1097) Propylthiouracil (RS1276) Protease Inhibitors (RS1900) Protein (RS1469) Protionamide (RS1084) Pyrazinamide (RS1085) Pyridoxal-5-phosphate (RS1331) | 278 174 116 485 508 500 198 130 206 490 189 182 182 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) Mefloquine hydrochloride (RS1094) Melatonin (RS1576) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2037) Meningococcal B multicomponent vaccine (RS2020) Mepolizumab (RS2024) | tor agonists 471 506 507 67 107 529 254 517 518 523 381 270 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) Primaquine phosphate (RS1097) Propylthiouracil (RS1276) Protease Inhibitors (RS1900) Protein (RS1469) Protionamide (RS1084) Pyrazinamide (RS1085) Pyridoxal-5-phosphate (RS1331) Pyrimethamine (RS1098) | 278 174 116 485 508 500 198 130 206 490 189 182 22 22 199 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) Mefloquine hydrochloride (RS1094) Melatonin (RS1576) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2037) Meningococcal B multicomponent vaccine (RS2020) Mepolizumab (RS2024) Mercaptopurine (RS1635) | tor agonists 471 506 507 67 107 529 196 254 517 518 523 381 270 140 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) Primaquine phosphate (RS1097) Propylthiouracil (RS1276) Protease Inhibitors (RS1900) Protein (RS1469) Protionamide (RS1084) Pyrazinamide (RS1085) Pyridoxal-5-phosphate (RS1331) | 278 174 116 485 508 500 198 130 206 490 189 182 22 22 199 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) Mefloquine hydrochloride (RS1094) Melatonin (RS1576) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2037) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2037) Meningococcal B multicomponent vaccine (RS2020) Mepolizumab (RS2024) Mercaptopurine (RS1635) Meropenem (RS1047) Methabolic Products (RS2047) | tor agonists 471 506 507 67 107 529 196 254 517 518 523 381 270 140 492 236 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) Primaquine phosphate (RS1097) Propylthiouracil (RS1276) Protease Inhibitors (RS1900) Protein (RS1469) Protionamide (RS1084) Pyrazinamide (RS1084) Pyrazinamide (RS1085) Pyridoxal-5-phosphate (RS1331) Pyrimethamine (RS1098) Quinine dihydrochloride (RS1099) | 278 174 116 485 508 500 198 130 206 490 189 182 222 199 200 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) Mefloquine hydrochloride (RS1094) Melatonin (RS1576) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2037) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2037) Meningococcal B multicomponent vaccine (RS2020) Mepolizumab (RS2024) Mercaptopurine (RS1635) Meropenem (RS1047) Methabolic Products (RS2047) | tor agonists 471 506 507 67 107 529 196 254 517 518 523 381 270 140 492 236 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) Primaquine phosphate (RS1097) Propylthiouracil (RS1276) Protease Inhibitors (RS1900) Protein (RS1469) Protionamide (RS1084) Pyrazinamide (RS1084) Pyrazinamide (RS1085) Pyridoxal-5-phosphate (RS1331) Pyrimethamine (RS1098) Quinine dihydrochloride (RS1099) Raloxifene (RS1666) | 278 174 116 485 508 500 198 130 206 490 189 189 182 22 22 200 220 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) Mefloquine hydrochloride (RS1094) Melatonin (RS1576) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2037) Meningococcal B multicomponent vaccine (RS2020) Mepolizumab (RS2024) Mercaptopurine (RS1635) Meropenem (RS1047) Metabolic Products (RS2047) Methoxyflurane (RS1292) Methyl aminolevulinate hydrochloride (RS1127) | tor agonists 471 506 507 67 107 529 196 254 517 518 523 381 270 140 492 236 11 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) Primaquine phosphate (RS1097) Propylthiouracil (RS1276) Protease Inhibitors (RS1900) Protein (RS1469) Protionamide (RS1084) Pyrazinamide (RS1084) Pyrimethamine (RS1085) Pyrimethamine (RS1098) Quinine dihydrochloride (RS1099) Raloxifene (RS1666) Ranibizumab (RS1870) | 278 174 116 485 508 500 198 130 206 490 189 182 222 199 200 226 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) Mefloquine hydrochloride (RS1094) Melatonin (RS1576) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2037) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2037) Meningococcal B multicomponent vaccine (RS2020) Mepolizumab (RS2024) Mercaptopurine (RS1635) Meropenem (RS1047) Methabolic Products (RS2047) | tor agonists 471 506 507 67 107 529 196 254 517 518 523 381 270 140 492 236 111 16 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) Primaquine phosphate (RS1097) Propylthiouracil (RS1276) Protease Inhibitors (RS1900) Protein (RS1469) Protionamide (RS1084) Pyrazinamide (RS1084) Pyrazinamide (RS1085) Pyridoxal-5-phosphate (RS1331) Pyrimethamine (RS1098) Quinine dihydrochloride (RS1099) Raloxifene (RS1666) | 278 174 116 485 508 500 198 130 206 490 189 182 222 220 226 226 327 7 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) Mefloquine hydrochloride (RS1094) Melatonin (RS1576) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2037) Meningococcal B multicomponent vaccine (RS2020) Mepolizumab (RS2024) Mercaptopurine (RS1635) Meropenem (RS1047) Metabolic Products (RS2047) Methoxyflurane (RS1292) Methyl aminolevulinate hydrochloride (RS1127) Methylnaltrexone bromide (RS2057) | tor agonists 471 506 507 67 107 529 196 254 517 518 523 381 270 140 492 236 111 16 259 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) Primaquine phosphate (RS1097) Propylthiouracil (RS1276) Protease Inhibitors (RS1900) Protein (RS1469) Protionamide (RS1084) Pyrazinamide (RS1085) Pyridoxal-5-phosphate (RS1331) Pyrimethamine (RS1098) Quinine dihydrochloride (RS1099) Raloxifene (RS1666) Ranibizumab (RS1870) Ranibizumab (RS1703) | 278 174 116 485 508 500 198 130 206 490 189 222 199 200 226 327 7 228 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) Mefloquine hydrochloride (RS1094) Melatonin (RS1576) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2037) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2037) Meningococcal B multicomponent vaccine (RS2020) Mepolizumab (RS2024) Mercaptopurine (RS1635) Meropenem (RS1047) Metabolic Products (RS2047) Methoxyflurane (RS1292) Methyl aminolevulinate hydrochloride (RS1127) Methylphenidate hydrochloride (RS2105) | tor agonists 471 506 507 67 107 529 196 254 517 518 523 381 270 140 492 236 111 16 259 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) Primaquine phosphate (RS1097) Propylthiouracil (RS1276) Protease Inhibitors (RS1900) Protein (RS1469) Protionamide (RS1084) Pyrazinamide (RS1085) Pyridoxal-5-phosphate (RS1331) Pyrimethamine (RS1098) Quinine dihydrochloride (RS1099) Raloxifene (RS1666) Ranibizumab (RS1703) Rasburicase (RS1016) | 278 174 116 485 508 500 198 130 206 490 189 22 199 200 226 227 7 228 7 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) Mefloquine hydrochloride (RS1094) Melatonin (RS1576) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2037) Meningococcal B multicomponent vaccine (RS2020) Mepolizumab (RS2024) Mercaptopurine (RS1635) Meropenem (RS1047) Methoxyflurane (RS1292) Methyl aminolevulinate hydrochloride (RS1127) Methyl aminolevulinate hydrochloride (RS2105) Midodrine (RS1427) | tor agonists 471 506 507 67 107 529 196 254 517 518 523 381 270 140 492 236 111 16 259 81 287 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) Primaquine phosphate (RS1097) Propylthiouracil (RS1276) Protease Inhibitors (RS1900) Protein (RS1469) Protionamide (RS1084) Pyrazinamide (RS1085) Pyridoxal-5-phosphate (RS1331) Pyrimethamine (RS1098) Quinine dihydrochloride (RS1099) Raloxifene (RS1666) Ranibizumab (RS1870) Rasburicase (RS1016) Remdesivir (RS1912) | 278 174 116 485 500 198 130 206 490 189 182 222 199 200 226 327 7 7 228 217 288 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) Mefloquine hydrochloride (RS1094) Melatonin (RS1576) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2037) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2037) Meningococcal B multicomponent vaccine (RS2020) Mepolizumab (RS2024) Mercaptopurine (RS1635) Meropenem (RS1047) Metabolic Products (RS2047) Methoxyflurane (RS1292) Methyl aminolevulinate hydrochloride (RS1127) Methylnaltrexone bromide (RS2057) Methylphenidate hydrochloride (RS2105) Midodrine (RS1427) Midostaurin (RS2033) | tor agonists 471 506 507 67 107 529 196 254 517 518 523 381 270 140 492 236 111 16 259 81 257 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) Primaquine phosphate (RS1097) Propylthiouracil (RS1276) Protease Inhibitors (RS1900) Protein (RS1469) Protionamide (RS1084) Pyrazinamide (RS1085) Pyridoxal-5-phosphate (RS1331) Pyrimethamine (RS1098) Quinine dihydrochloride (RS1099) Raloxifene (RS1666) Ranibizumab (RS1703) Rasburicase (RS1016) Remdesivir (RS1912) Ribociclib (RS2131) | 278 174 116 485 500 198 130 206 490 189 182 222 199 200 226 327 7 228 217 228 217 228 31 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) Mefloquine hydrochloride (RS1094) Melatonin (RS1576) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal B multicomponent vaccine (RS2020) Mepolizumab (RS2024) Mercaptopurine (RS1635) Meropenem (RS1047) Methoxyflurane (RS1292) Methyl aminolevulinate hydrochloride (RS1127) Methylphenidate hydrochloride (RS2105) Midodrine (RS1427) Midostaurin (RS2033) Modafinil (RS2106) Moroctocog alfa [Recombinant factor VIII] (RS1706) | tor agonists 471 506 507 67 107 529 254 517 518 523 381 270 140 492 236 111 111 16 259 81 287 257 55 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) Primaquine phosphate (RS1097) Propylthiouracil (RS1276) Protease Inhibitors (RS1900) Protein (RS1469) Protionamide (RS1084) Pyrazinamide (RS1085) Pyridoxal-5-phosphate (RS1331) Pyrimethamine (RS1098) Quinine dihydrochloride (RS1099) Ranibizumab (RS1870) Rasburicase (RS1016) Remdesivir (RS1912) Ribociclib (RS2131) | 278 174 116 485 508 500 198 130 206 490 189 182 222 199 200 226 327 7 228 217 228 217 288 217 288 217 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) Mefloquine hydrochloride (RS1094) Melatonin (RS1576) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2037) Meningococcal B multicomponent vaccine (RS2020) Mepolizumab (RS2024) Mercaptopurine (RS1635) Meropenem (RS1047) Methoxyflurane (RS1292) Methyl aminolevulinate hydrochloride (RS1127) Methylphenidate hydrochloride (RS2105) Midodrine (RS1427) Midostaurin (RS2033) Modafinil (RS2106) Moroctocog alfa [Recombinant factor VIII] (RS1706) Moxifloxacin (RS2129) | tor agonists 471 506 507 67 107 529 254 517 518 523 381 270 140 492 236 111 111 16 259 81 287 257 55 152 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) Primaquine phosphate (RS1097) Propylthiouracil (RS1276) Protease Inhibitors (RS1900) Protein (RS1469) Protionamide (RS1084) Pyrazinamide (RS1085) Pyridoxal-5-phosphate (RS1331) Pyrimethamine (RS1098) Quinine dihydrochloride (RS1099) Raloxifene (RS1666) Ranibizumab (RS1870) Rasburicase (RS1016) Remdesivir (RS1912) Ribociclib (RS2131) Riboflavin (RS1833) Rifaputin (RS1086) Rifaputin (RS1086) | 278 174 116 485 508 500 198 130 206 490 189 182 222 199 200 226 327 7 228 227 228 31 31 186 31 186 183 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) Mefloquine hydrochloride (RS1094) Melatonin (RS1576) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal B multicomponent vaccine (RS2020) Mepolizumab (RS2024) Mercaptopurine (RS1635) Meropenem (RS1047) Methoxyflurane (RS1292) Methyl aminolevulinate hydrochloride (RS1127) Methylphenidate hydrochloride (RS2105) Midodrine (RS1427) Midostaurin (RS2033) Modafinil (RS2106) Moroctocog alfa [Recombinant factor VIII] (RS1706) | tor agonists 471 506 507 67 107 529 254 517 518 523 381 270 140 492 236 11 11 16 259 81 287 255 55 55 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) Primaquine phosphate (RS1097) Propylthiouracil (RS1276) Protease Inhibitors (RS1900) Protein (RS1469) Protionamide (RS1084) Pyrazinamide (RS1085) Pyridoxal-5-phosphate (RS1331) Pyrimethamine (RS1098) Quinine dihydrochloride (RS1099) Ranibizumab (RS1870) Ranibizumab (RS1870) Rasburicase (RS1016) Remdesivir (RS1912) Ribociclib (RS2131) Ribolavin (RS1833) Rifabutin (RS1086) | 278 174 116 485 508 500 198 130 206 490 189 182 222 199 200 226 327 7 228 217 7 288 31 186 31 186 183 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) Mefloquine hydrochloride (RS1094) Melatonin (RS1576) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal B multicomponent vaccine (RS2020) Mepolizumab (RS2024) Mercaptopurine (RS1635) Meropenem (RS1047) Methoxyflurane (RS1292) Methyl aminolevulinate hydrochloride (RS1127) Methylaltrexone bromide (RS2057) Methylphenidate hydrochloride (RS2105) Midodrine (RS1427) Midostaurin (RS2033) Modafinil (RS2106) Moroctocog alfa [Recombinant factor VIII] (RS1706) Moxifloxacin (RS2129) Multiple Sclerosis (RS1993) Multiple Sclerosis (RS1997) | tor agonists 471 506 507 67 67 529 107 519 254 517 518 523 381 270 140 492 236 111 16 259 81 287 257 55 55 55 52 250 252 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) Primaquine phosphate (RS1097) Propylthiouracil (RS1276) Protease Inhibitors (RS1900) Protionamide (RS1084) Pyrazinamide (RS1085) Pyridoxal-5-phosphate (RS1331) Pyrimethamine (RS1098) Quinine dihydrochloride (RS1099) Raloxifene (RS1666) Ranibizumab (RS1870) Rasburicase (RS1016) Remdesivir (RS1912) Ribociclib (RS2131) Rifabutin (RS1086) Rifampicin (RS1087) Rifampicin (RS1087) Rifampicin (RS1087) Rifaximin (RS1416) Riluzole (RS1351) | 278 174 116 485 508 500 198 130 206 490 189 200 226 327 7 228 217 228 311 186 311 186 183 310 206 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) Mefloquine hydrochloride (RS1094) Melatonin (RS1576) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal B multicomponent vaccine (RS2020) Mepolizumab (RS2024) Mercaptopurine (RS1635) Meropenem (RS1047) Methoxyflurane (RS1292) Methyl aminolevulinate hydrochloride (RS1127) Methylaltrexone bromide (RS2057) Methylphenidate hydrochloride (RS2105) Midodrine (RS1427) Midostaurin (RS2033) Modafinil (RS2106) Moroctocog alfa [Recombinant factor VIII] (RS1706) Moxifloxacin (RS2129) Multiple Sclerosis (RS1993) | tor agonists 471 506 507 67 67 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) Primaquine phosphate (RS1097) Propylthiouracil (RS1276) Protease Inhibitors (RS1900) Protein (RS1469) Protionamide (RS1084) Pyrazinamide (RS1085) Pyridoxal-5-phosphate (RS1331) Pyrimethamine (RS1098) Quinine dihydrochloride (RS1099) Raloxifene (RS1666) Ranibizumab (RS1870) Rasiburicase (RS1016) Remdesivir (RS1912) Ribociclib (RS2131) Riboflavin (RS1833) Rifabutin (RS1086) Rifappicin (RS1087) Rifaximin (RS1416) Rifaximin (RS1416) Riluzole (RS1351) | 278 174 116 485 508 500 198 198 206 206 189 200 226 327 7 228 217 228 217 288 31 186 183 200 226 327 7 228 217 228 217 228 217 228 217 228 217 228 217 228 217 228 217 228 217 228 217 228 217 228 217 228 217 228 217 228 227 227 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) Mefloquine hydrochloride (RS1094) Melatonin (RS1576) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal B multicomponent vaccine (RS2020) Mepolizumab (RS2024) Mercaptopurine (RS1635) Meropenem (RS1047) Methoxyflurane (RS1292) Methyl aminolevulinate hydrochloride (RS1127) Methylaltrexone bromide (RS2057) Methylphenidate hydrochloride (RS2105) Midodrine (RS1427) Midostaurin (RS2033) Modafinil (RS2106) Morofcocg alfa [Recombinant factor VIII] (RS1706) Moxifloxacin (RS2129) Multiple Sclerosis (RS1993) Multiple Sclerosis (RS1997) Multivitamin and mineral supplement (RS1498) | tor agonists 471 506 507 67 107 529 254 517 518 523 381 270 140 492 236 111 16 259 81 111 16 259 81 257 55 152 257 55 152 250 252 40 41 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) Primaquine phosphate (RS1097) Propylthiouracil (RS1276) Protease Inhibitors (RS1900) Protionamide (RS1084) Pyrazinamide (RS1085) Pyridoxal-5-phosphate (RS1331) Pyrimethamine (RS1098) Quinine dihydrochloride (RS1099) Raloxifene (RS1666) Ranibizumab (RS1870) Rasburicase (RS1016) Remdesivir (RS1912) Ribociclib (RS2131) Rifabutin (RS1086) Rifampicin (RS1087) Rifampicin (RS1087) Rifampicin (RS1087) Rifaximin (RS1416) | 278 174 116 485 508 500 198 130 206 490 189 182 222 199 200 226 327 7 228 217 228 217 288 31 186 183 10 234 256 247 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) Mefloquine hydrochloride (RS1094) Melatonin (RS1576) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2037) Meningococcal B multicomponent vaccine (RS2020) Mepolizumab (RS2024) Mercaptopurine (RS1635) Meropenem (RS1047) Methoxyflurane (RS1292) Methyl aminolevulinate hydrochloride (RS1127) Methylphenidate hydrochloride (RS2105) Midodrine (RS1427) Midostaurin (RS2033) Modafinil (RS2106) Moroctocog alfa [Recombinant factor VIII] (RS1706) Moxifloxacin (RS2129) Multiple Sclerosis (RS1993) Multiple Sclerosis (RS1997) Multivitamin and mineral supplement (RS1498) Multivitamin renal (RS1499) | tor agonists 471 506 507 67 107 529 196 254 517 518 523 381 270 140 492 236 111 16 259 81 287 255 55 152 250 252 40 41 38 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) Primaquine phosphate (RS1097) Propylthiouracil (RS1276) Protease Inhibitors (RS1900) Protease Inhibitors (RS1900) Protein (RS1469) Protonamide (RS1084) Pyrazinamide (RS1084) Pyrazinamide (RS1084) Pyrazinamide (RS1088) Quinine dihydrochloride (RS1331) Pyrimethamine (RS1098) Quinine dihydrochloride (RS1099) Raloxifene (RS1666) Ranibizumab (RS1870) Rasiburicase (RS1016) Remdesivir (RS1912) Ribociclib (RS2131) Ribolfavin (RS1833) Rifabutin (RS1086) Rifapicin (RS1087) Rifampicin (RS1087) Rifaximin (RS1416) Riluzole (RS1351) Risperidone (RS2060) | 278 174 116 485 508 500 198 130 206 490 189 182 222 199 200 226 327 7 228 217 228 217 228 217 228 217 228 217 228 217 228 217 228 227 227 228 217 228 227 247 247 244 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) Mefloquine hydrochloride (RS1094) Melatonin (RS1576) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2037) Meningococcal B multicomponent vaccine (RS2020) Mepolizumab (RS2024) Mercaptopurine (RS1635) Meropenem (RS1047) Methoxyflurane (RS1292) Methyl aminolevulinate hydrochloride (RS1127) Methylynaltrexone bromide (RS2057) Methylphenidate hydrochloride (RS2105) Midodrine (RS1427) Midostaurin (RS2033) Modafinil (RS2106) Moroctocog alfa [Recombinant factor VIII] (RS1706) Moxifloxacin (RS2199) Multiple Sclerosis (RS1993) Multiple Sclerosis (RS1997) Multivitamin and mineral supplement (RS1498) Multivitamin renal (RS1499) Multivitamins - Cap (RS1620) | tor agonists 471 506 507 67 107 529 196 254 517 518 523 381 270 140 492 236 111 16 259 81 287 257 55 152 250 252 40 41 38 38 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) Primaquine phosphate (RS1097) Propylthiouracil (RS1276) Protease Inhibitors (RS1900) Protein (RS1469) Protoinamide (RS1084) Pyrazinamide (RS1085) Pyridoxal-5-phosphate (RS1331) Pyrimethamine (RS1098) Quinine dihydrochloride (RS1099) Raloxifene (RS1666) Ranibizumab (RS1703) Rasburicase (RS1016) Remdesivir (RS1912) Ribociclib (RS2131) Riboflavin (RS1833) Rifapticin (RS1086) Rifapticin (RS1087) Rifapticin (RS1087) Rifaximin (RS1416) Riluzole (RS1351) Risperidone (RS2060) Rituximab (RS1785) | 278 174 116 485 500 198 130 206 490 189 182 222 199 200 226 327 77 228 217 228 217 228 31 186 183 183 214 234 234 234 234 234 234 |
| Long-acting muscarinic antagonists with long-acting beta-adrenocep (RS1518) Low electrolyte oral feed (RS1227) Low electrolyte oral feed (RS1228) Lysine acetylsalicylate (RS1689) Mafenide acetate (RS1299) Measles, mumps and rubella vaccine (RS1487) Mefloquine hydrochloride (RS1094) Melatonin (RS1576) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2019) Meningococcal (A, C, Y and W-135) conjugate vaccine (RS2037) Meningococcal B multicomponent vaccine (RS2020) Mepolizumab (RS2024) Mercaptopurine (RS1635) Meropenem (RS1047) Methoxyflurane (RS1292) Methyl aminolevulinate hydrochloride (RS1127) Methylylautrexone bromide (RS2057) Methylphenidate hydrochloride (RS2105) Midodrine (RS1427) Midostaurin (RS2033) Modafinil (RS2106) Moroctocog alfa [Recombinant factor VIII] (RS1706) Moxifloxacin (RS2199) Multiple Sclerosis (RS1993) Multiple Sclerosis (RS1993) Multiple Sclerosis (RS1997) Multivitamin and mineral supplement (RS1498) Multivitamins - Cap (RS1620) Multivitamins - Powder (RS1178) | tor agonists 471 506 507 67 107 529 196 254 517 518 523 381 270 140 492 236 111 16 259 81 287 257 55 152 250 252 250 252 250 40 41 38 39 262 | Pomalidomide (RS2045) Posaconazole (RS2052) Potassium citrate (RS1133) Povidone-iodine - Vaginal tab 200 mg (RS1354) Preoperative carbohydrate feed 0.5 kcal/ml (RS1415) Preterm formula (RS1224) Primaquine phosphate (RS1097) Propylthiouracil (RS1276) Protease Inhibitors (RS1900) Protein (RS1469) Protoinamide (RS1084) Pyrazinamide (RS1085) Pyridoxal-5-phosphate (RS1331) Pyrimethamine (RS1098) Quinine dihydrochloride (RS1099) Raloxifene (RS1666) Ranibizumab (RS1870) Rasburicase (RS1016) Remdesivir (RS1912) Ribociclib (RS2131) Rifabutin (RS1086) Rifabutin (RS1087) Rifabutin (RS1087) Rifabutin (RS1416) Riluzole (RS1351) Risperidone (RS2060) Rituximab (RS1785) Rituximab (RS1785) | 278 174 116 485 500 198 130 206 490 189 182 222 199 200 226 327 77 228 217 288 217 27 288 31 186 183 10 234 256 247 |

| Roxithromycin tab dispersible 50 mg (RS1569) | | Teriparatide (RS1143) | 227 |
|---|-----|--|-----|
| Rurioctocog alfa pegol [Recombinant factor VIII] (RS1682) | | Thalidomide (RS2046) | 280 |
| Ruxolitinib (RS1726) | | Ticagrelor (RS1774) | 69 |
| Sacubitril with valsartan (RS2014) | 77 | Ticarcillin with clavulanic acid (RS1054) | 149 |
| Salmonella typhi vaccine (RS1243) | | Tigecycline (RS1059) | |
| Sapropterin dihydrochloride (RS1796) | | Tobramcyin (RS1475) | |
| Secukinumab (RS2119) | | Tobramycin (RS1044) | 134 |
| Selenium (RS1929) | | Tobramycin Solution for inhalation 60 mg per ml, 5 ml (RS1435) | 135 |
| Siltuximab (RS1525) | | Tocilizumab (RS2125) | |
| Sirolimus (RS1991) | | Tolvaptan (RS1930) | 84 |
| Sodium chloride – İnj (RS1297) | 74 | Trametinib (RS2132) | 297 |
| Sodium hyaluronate (RS1175) | | Trastuzumab (Herzuma) (RS2005) | 410 |
| Sodium phenylbutyrate (RS1797) | 20 | Trastuzumab deruxtecan (RS2082) | 413 |
| Sodium stibogluconate (RS1100) | 201 | Trastuzumab emtansine (RS2083) | 362 |
| Somatropin (RS1826) | 123 | Trientine (RS2026) | |
| Spiramycin (RS1101) | 202 | Upadacitinib (RS2120) | 462 |
| Standard Feeds (RS1214) | 510 | Ursodeoxycholic acid (RS2103) | |
| Stiripentol (RS1989) | 241 | Ustekinumab (RS1942) | 403 |
| Strand Transfer Inhibitors (RS1901) | 207 | Valganciclovir (RS1799) | 212 |
| Streptomycin sulphate (RS1043) | 132 | Vancomycin (RS1069) | 162 |
| Sucrose (RS1763) | | Varenicline (RS1702) | 264 |
| Sugammadex (RS1370) | | Varicella vaccine [Chickenpox vaccine] (RS1591) | 531 |
| Sulphadiazine (RS1067) | 158 | Varicella zoster vaccine [shingles vaccine] (RS2039) | |
| Sunitinib (RS2109) | | Vedolizumab (RS1943) | 405 |
| Tacrolimus (RS2110) | | Venetoclax (RS2118) | 271 |
| Tacrolimus Ointment (RS1859) | 110 | Vigabatrin (RS1865) | 239 |
| Taliglucerase alfa (RS1897) | 27 | Voriconazole (RS2053) | 172 |
| Tamsulosin (RS1132) | 115 | Yellow jacket wasp venom (RS1119) | 470 |
| Taurine (RS1834) | | Zanamivir - Powder for inhalation 5 mg (RS1369) | 215 |
| Teicoplanin (RS1068) | 159 | bosentan (RS1982) | |
| Temozolomide (RS1994) | 279 | sildenafil (Vedafil) (RS1983) | 97 |
| Terbutaline (RS1130) | 113 | sodium picosulfate (RS1843) | 17 |
| | | | |